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Abstract 
The enteric nervous system (ENS) is a complex network of neurons and glia that resides within the bowel 
wall. It rivals the spinal cord in complexity and regulates crucial bowel functions like gastrointestinal 
motility. Dysfunction of the ENS, also called enteric neuropathy, can cause growth failure, abdominal 
distention, and, in some individuals, sepsis and early death. Hirschsprung disease, a developmental 
enteric neuropathy where the ENS is missing from the distal bowel, can be treated with surgical removal 
of the affected bowel segment. However, debilitating bowel problems including dysmotility persist in a 
subset of patients. Treatment options of chronic intestinal pseudo-obstruction (CIPO) are even more 
limited and mostly symptomatic. In CIPO, the ENS develops along the length of the bowel, but bowel 
motility is compromised. Due to the dearth of options, the scientific community is actively trying to 
develop effective therapeutic options to improve enteric neuropathy-related symptoms. Bowel problems 
in CIPO and Hirschsprung disease post-surgery have been attributed to loss or dysfunction of subtypes of 
enteric neurons. Ideally, curative treatment would involve postnatal replacement of the defective ENS or 
supplementation of these missing ENS cell types. Recently developed in vitro differentiation protocols 
that convert human pluripotent stem cells into enteric neurons and glia have made stem cell therapy an 
enticing avenue to pursue. However, we still do not sufficiently understand the nuances of enteric neuron 
subtype fate decisions to direct differentiation of enteric neuron precursors into specific neuron subtypes. 
In chapter 2, I describe our work characterizing the differential expression of transcriptional regulators in 
enteric neuron subtypes during embryonic development and in the adult colonic ENS. We show that the 
transcription factor Tbx3 is required for the development of a normal complement of nitrergic neurons in 
the neonatal ENS. In chapter 3, I describe our work towards designing a high throughput screen that will 
allow us to determine whether transcriptional regulators affect differentiation into cholinergic versus 
nitrergic enteric neuron subtypes. In chapter 4, I describe exciting new work that indicates that postnatal 
treatment of distal colon lacking an enteric nervous system with the neurotrophic factor GDNF can re-
grow a normal, functional ENS in mice. This discovery may lay the foundation for the development of 
adjunct, non-invasive therapeutic options for the treatment of Hirschsprung disease. Lastly, in chapter 5, I 
introduce work towards understanding the function of the epigenetic regulator Bap1 in enteric nervous 
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NOVEL INSIGHTS INTO THE GENETIC AND ENVIRONMENTAL DETERMINANTS OF 
ENTERIC NERVOUS SYSTEM BIOLOGY 
Sabine Schneider 
Robert O. Heuckeroth 
 
The enteric nervous system (ENS) is a complex network of neurons and glia that resides 
within the bowel wall. It rivals the spinal cord in complexity and regulates crucial bowel functions 
like gastrointestinal motility. Dysfunction of the ENS, also called enteric neuropathy, can cause 
growth failure, abdominal distention, and, in some individuals, sepsis and early death. Hirschsprung 
disease, a developmental enteric neuropathy where the ENS is missing from the distal bowel, can 
be treated with surgical removal of the affected bowel segment. However, debilitating bowel 
problems including dysmotility persist in a subset of patients. Treatment options of chronic intestinal 
pseudo-obstruction (CIPO) are even more limited and mostly symptomatic. In CIPO, the ENS 
develops along the length of the bowel, but bowel motility is compromised. Due to the dearth of 
options, the scientific community is actively trying to develop effective therapeutic options to 
improve enteric neuropathy-related symptoms. Bowel problems in CIPO and Hirschsprung disease 
post-surgery have been attributed to loss or dysfunction of subtypes of enteric neurons. Ideally, 
curative treatment would involve postnatal replacement of the defective ENS or supplementation 
of these missing ENS cell types. Recently developed in vitro differentiation protocols that convert 
human pluripotent stem cells into enteric neurons and glia have made stem cell therapy an enticing 
avenue to pursue. However, we still do not sufficiently understand the nuances of enteric neuron 
subtype fate decisions to direct differentiation of enteric neuron precursors into specific neuron 
subtypes. In chapter 2, I describe our work characterizing the differential expression of 
transcriptional regulators in enteric neuron subtypes during embryonic development and in the adult 
colonic ENS. We show that the transcription factor Tbx3 is required for the development of a normal 
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complement of nitrergic neurons in the neonatal ENS. In chapter 3, I describe our work towards 
designing a high throughput screen that will allow us to determine whether transcriptional regulators 
affect differentiation into cholinergic versus nitrergic enteric neuron subtypes. In chapter 4, I 
describe exciting new work that indicates that postnatal treatment of distal colon lacking an enteric 
nervous system with the neurotrophic factor GDNF can re-grow a normal, functional ENS in mice. 
This discovery may lay the foundation for the development of adjunct, non-invasive therapeutic 
options for the treatment of Hirschsprung disease. Lastly, in chapter 5, I introduce work towards 
understanding the function of the epigenetic regulator Bap1 in enteric nervous system development 
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1.1 Abstract 
At the most fundamental level, the bowel facilitates absorption of small molecules, regulates fluid 
and electrolyte flux, and eliminates waste. To successfully coordinate this complex array of 
functions, the bowel relies on the enteric nervous system (ENS), an intricate network of more than 
500 million neurons and supporting glia that are organized into distinct layers or plexi within the 
bowel wall. Neuron and glial diversity, as well as neurotransmitter and receptor expression in the 
ENS, resembles that of the central nervous system. The most carefully studied ENS functions 
include control of bowel motility, epithelial secretion, and blood flow, but the ENS also interacts with 
enteroendocrine cells, influences epithelial proliferation and repair, modulates the intestinal 
immune system, and mediates extrinsic nerve input. Here, we review the many different cell types 
that communicate with the ENS, integrating data about ENS function into a broader view of human 
health and disease. In particular, we focus on exciting new literature highlighting relationships 






Digesting nutrients that fuel our survival requires complex integration of many bowel 
functions and all must run smoothly to maintain a normal quality of life. Food must be broken into 
small particles and chemically digested for nutrient absorption. Indigestible components must 
efficiently pass through the gastrointestinal tract for elimination, while fluid and electrolyte balance 
is maintained. All of these processes occur in the setting of a complex microbiome that aids nutrient 
absorption, but can trigger inflammation and even infection should the system go awry. The 
intestine could not coordinate these functions without the enteric nervous system (ENS), a complex 
network of neurons and glia that reside in the bowel wall and send nerve fibers throughout the 
bowel. Like an orchestra conductor, the ENS is a critical regulator of many processes described 
above and interacts with an astounding array of cell types to facilitate bowel function.  
The ENS is distributed all the way along the bowel in two layers called the myenteric and 
submucosal plexus (1). Each plexus is comprised of diverse enteric neuron and glial cell types that 
interact closely with each other and with other intestinal cells. Myenteric plexus cells cluster into 
ganglia between the outer longitudinal and inner circular smooth muscle of the bowel. Myenteric 
neurons provide the majority of direct innervation to the bowel’s motor apparatus and the final 
output controlling bowel relaxation and contraction. Myenteric neurons interact closely with the 
tissue-resident macrophages (muscularis macrophages) that influence motility. Submucosal plexus 
ganglia reside between muscle and epithelium, where they regulate epithelial secretion and local 
blood flow. Neurons in both plexi respond to input from mucosal enteroendocrine cells and the 
autonomic nervous system. The ENS also interacts with immune and epithelial cells to promote 
barrier function that protects the bowel from pathogens in the gut lumen. Enteric neurons are 
currently classified by function, axon number, direction of axonal projections, synaptic connectivity, 
neurotransmitters, receptors, and electrophysiologic signatures. Approximately 20 enteric neuron 
subtypes and four glial subtypes have been characterized thus far, but a wealth of single cell 
sequencing data is expected to redefine enteric neuron and glial subtypes in the next few years. 
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Many excellent recent reviews detail known ENS circuitry, cell types, transmitters and functions (2-
5)  Instead of duplicating those efforts, our goal is to show how the ENS interacts with non-ENS 
cell types and the implications of these interactions for human disease. 
To facilitate communication, enteric neurons extend an elaborate network of neurites with 
associated glia. These ENS components contact almost all bowel cells including muscle, epithelial 
cells, pacemaker cells (called the interstitial cells of Cajal, (ICC)), blood vessels and immune cells. 
Enteric neurons synapse on each other, but also release neurotransmitters from varicosities along 
neurites to regulate smooth muscle cell (SMC) and ICC activity. The ICC act as pacemakers since 
they have intrinsic slow waves of depolarization and hyperpolarization (6). 
The contractile force for bowel motility is provided by SMC, which must coordinate activity 
to mix luminal contents or move undigested food toward the distal bowel for eventual elimination 
(7). To contract smooth muscle, myenteric plexus excitatory motor neurons project their axons 
predominantly orally. In contrast, inhibitory motor neurons project axons distally and cause smooth 
muscle relaxation. Simultaneous activation of excitatory and inhibitory motor neurons in a bowel 
region causes proximal bowel contraction and distal relaxation, a pattern called peristalsis that is 
frequently observed in the small intestine.  
Additional enteric neuron types control epithelial secretion (secretomotor neurons), 
epithelial secretion and blood vessel dilation (secretomotor/vasodilator neurons), epithelial 
proliferation, or innervate enteroendocrine cells and lymphoid follicles. Enteric neurons also send 
intestinofugal fibers to pancreas, gallbladder, prevertebral sympathetic ganglia, and the central 
nervous system (CNS) (4). Finally, although the ENS can control many aspects of bowel function 
autonomously, in vivo ENS activity is modulated by luminal contents (nutrients and microbes), 
muscularis macrophages, parasympathetic neurons, sympathetic innervation from the celiac, 
superior and inferior mesenteric ganglia, and hormonal signals (e.g., adrenaline, thyroid hormone, 
corticotrophin releasing hormone, oxytocin). Many of these extrinsic signals are influenced by CNS 
activity, explaining how emotional responses like anxiety and fear can alter bowel function. The 
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remainder of this article will explore cell types that interact with the ENS, integrating basic science 
with human disease to explore how ENS function and dysfunction impact human health. 
 
1.3 The ENS interfaces with the SIP syncytium to regulate motility 
ENS interactions with SMC, ICC, and PDGFRα+ cells are critical for bowel motility. Many 
excellent manuscripts describe these interactions in detail (6-8), so here we highlight a few 
important interactions and recent developments. 
Gap junctions connect SMC, ICC, and fibroblast-like PDGFRα+ cells into a multicellular 
syncytium commonly called the “SIP syncytium”, whose name derives from the first letter of each 
cell type (Figure 1.1A) (6). The SIP syncytium receives input from excitatory and inhibitory motor 
neurons whose cell bodies reside within the myenteric plexus. Although SMC were once 
considered the main targets of excitatory and inhibitory ENS motor neurons, neural input onto ICC 
and PDGFRα+ cells is likely also critical for mediating smooth muscle contractility and for 
generating complex motility patterns necessary for life.  
There are at least five types of ICC in the bowel: ICC-MY, located between the circular and 
longitudinal muscle layers, ICC-IM, located within the circular muscle layer in colon and stomach, 
ICC-DMP, between the inner and outer parts of the circular muscle layer of the small intestine, ICC-
SM, on the submucosal surface of the circular muscle layer of colon, and ICC-SS, in the subserosal 
layer (Figure 1.1B). ICC-MY and ICC-SM, the “pacemaker” cells of the bowel, generate rhythmic 
electrical slow waves of depolarization and hyperpolarization that propagate passively to SMC via 
gap junctions and synchronize SMC contraction. This baseline electrical rhythm is present even 
when the ENS is absent. ICC-IM and ICC-DMP are closely associated with nerve varicosities (8) 
and electron microscopy suggests more nerve-ICC-IM contacts than nerve-SMC contacts (9). ICC-






Figure 1.1: The SIP syncytium 
(A) The SIP syncytium is composed of SMCs, ICCs, and PDGFR + cells which receive input from 
ENS varicosities. (B) ICC localization and composition varies with bowel region . Abbreviations: 
ICC-DMP, deep muscular plexus ICC; ICC-IM, intramuscular ICC; ICC-MY, myenteric ICC; ICC-
SM, submucosal ICC. 
 
To determine how ICC contribute to neuromuscular transmission, many early studies 
compared SMC recordings in wild type and ICC-IM-deficient animals during electric field stimulation 
(EFS). Although some investigators observed attenuated excitatory and/or inhibitory junction 
potentials in ICC-depleted smooth muscle, results were inconsistent (9-11). Possible explanations 
for the disparate findings include incomplete absence of ICC in certain model organisms (e.g., 
commonly used W/WV  mouse has inconsistent and incomplete ICC loss (6)), strain and species 
differences, differences in level of tissue pre-contraction or pre-relaxation (12), use of nifedipine 
(422), differences between bowel regions, and developmental changes in innervation or smooth 
muscle reactivity in the absence of ICC. More recent studies test contributions of transduction 
pathways for specific neurotransmitters, often in genetically modified conditional knockout mice 
(10, 12, 13). These studies support the presence of parallel complementary pathways for signal 





Inhibitory junctional potentials (IJPs) recorded from colon smooth muscle are composed of 
a fast purinergic phase that is followed by a slower nitrergic phase (13). The purinergic contribution 
to the IJP is probably mediated by PDGFRα+ cells, which express high levels of the purine receptor 
P2Y1. The ligand for P2Y1 receptors in the bowel was once thought to be adenosine triphosphate 
(ATP), but in recent years β-nicotinamide adenine dinucleotide (β-NAD)  and adenosine 5-
diphosphate-ribose (ADPR) have emerged as more likely candidates (14). Applying β-NAD and 
ADPR to PDGFRα+ cells activates apamin-sensitive small-conductance Ca2+-activated K+ (SK) 
channels, leading to potassium efflux and membrane hyperpolarization (15). The change in 
membrane potential spreads via gap junctions to nearby SMC. Purinergic receptors are also 
expressed on SMC and ICC, but they are unlikely to mediate the strong fast hyperpolarization 
associated with the IJP (14, 16).   
Nitric oxide (NO) is a major signaling molecule in inhibitory motor neurons that acts on both 
ICC and SMC. NO binds and activates nitric oxide-sensitive guanylyl cyclase (NO-GC). Guanylate 
cyclase converts GTP to cGMP, which activates GMP-dependent protein kinase I (PRKG1). 
PRKG1 in turn phosphorylates serines and threonines on many intracellular proteins, causing 
hyperpolarizing via mechanisms that remain incompletely understood. Molecules downstream of 
NO (e.g. NO-GC, Prkg1) have been deleted from subsets of ICC and SMC using conditional 
knockout mice. Although inconsistent findings have been reported, the results suggest that both 
ICC and SMC likely mediate NO signaling (10, 13). Interestingly, one study found that conditionally 
deleting NO-GC from ICC in mouse colon reduced IJP amplitude in response to EFS, but 
conditionally deleting NO-GC from ICC in mouse fundus completely abolished IJPs (13). This 
underscores an important and underemphasized issue in the literature: regulation of ICC, SMC, 
and PDGFRα+ cells by neural signaling may vary considerably depending on bowel region. 
Consistent with this observation, ICC localization and receptor expression differ in various bowel 
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regions (Figure 1.1B). For instance, ICC-MY in stomach do not express the NO-GC subunit 
sGCβ1, whereas most ICC-MY in colon express sGCβ1, and some ICC-MY in colon express 
sGCβ1 at high levels (17).  
A few recent papers suggest that PRKG1-independent (but NO-GC and cGMP dependent) 
NO signal transduction may occur in ICC (18, 19). Pacemaker rhythms in cultured colon ICC were 
slowed by NO donors and cGMP, but not by a PRKG1 inhibitor (18). Small-molecule activation of 
NO-GC decreased spontaneous calcium transients in ICC-DMP in mouse small intestine, but 
PRKG1 inhibition had no effect (19). These findings are difficult to reconcile with data showing 
absent NO-mediated IJPs in Prkg1 conditional knockout mice (10). Possible explanations for the 
discrepancy include failure of the PRKG1 inhibitors to penetrate tissue, or differences between ICC 
subtypes studied. 
Although the literature on how NO affects smooth muscle and ICC are sometimes 
contradictory, NO clearly has strong effects on both ICC and SMC in a guanylate cyclase-
dependent manner. Further research is needed to determine (a) how members of the SIP 
syncytium in various bowel regions differ in receptor expression and response to signaling, (b) how 
innervation of the SIP syncytium differs in each bowel region, and (c) the significance of PRKG1-
independent pathways in NO-mediated responses. Defining these characteristics may elucidate 
molecular mechanisms that generate diverse motility in each bowel region. 
In addition to NO, inhibitory enteric neurons release vasoactive intestinal peptide (VIP) and 
pituitary adenylate cyclase activating peptide (PACAP). These neuropeptides likely signal through 
VIP receptors VIPR1 and VIPR2 and the PACAP receptor ADCYAP1R1, which are expressed on 
ICC and SMC (7). Typically, neuropeptides are released at high stimulus frequencies, so VIP and 
PACAP may play less prominent roles in direct motor neurotransmission than NO (7). In SMC, 
VIP/PACAP signaling is mediated via Gs which activates adenylyl cyclase, cyclic AMP (cAMP), 
and protein kinase A (PKA) (20). This increases Ca2+ transients that should increase the opening 
probability of Ca2+-activated K+ channels, causing membrane hyperpolarization (20).  In ICC, VIP 
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may act via a different pathway. VIP decreases calcium transients dramatically in some ICC, and 
calcium transients increase when a VIP inhibitor is added. These calcium transients likely control 
the activity of calcium-dependent chloride channels (CaCC) which regulate slow waves (19). The 
mechanism behind this response is currently unknown. 
 
 
Figure 1.2: Inhibitory and excitatory motor neurotransmission. 
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(A) Inhibitory neurotransmission involves a combination of purine, NO, and VIP/PACAP signaling. 
(B) The primary neurotransmitters involved in excitatory neuromuscular transmission are 
acetylcholine and tachykinins. Abbreviations: AC, adenylate cyclase; ACh, acetylcholine; 
ADCYAP1R1, pituitary adenylate cyclase-activating polypeptide type 1 receptor; ADPR, ADP-
Ribose; β-NAD, β-Nicotinamide adenine dinucleotide; cAMP, cyclic AMP; cGMP, cyclic GMP; DAG, 
diacylglycerol; GTP, guanosine triphosphate; ER, endoplasmic reticulum; ICC, interstitial cells of 
Cajal; IP3, inositol triphosphate; M2, muscarinic receptor 2; M3, muscarinic receptor 3; NKA, 
neurokinin A; NO, nitric oxide; PACAP, pituitary adenylate cyclase-activating peptide; PKA, protein 
kinase A; PKC, protein kinase C; PRKG1, protein kinase G; PLCβ, phospholipase C beta; sGC, 
soluble guanylate cyclase; SK3, small conductance calcium-activated potassium channel 3; SP, 
substance P; SR, sarcoplasmic reticulum; TACR1, tachykinin receptor 1; TACR2, tachykinin 
receptor 2; VIP, vasoactive intestinal peptide; VIPR, VIP receptors. 
 
Excitatory signaling 
The major excitatory neurotransmitters involved in direct motor neurotransmission are 
acetylcholine (ACh) and tachykinins (neurokinin A (NKA), and substance P (SP)). ACh binds 
muscarinic M2 and M3 receptors on SMC and ICC, while tachykinins bind tachykinin receptor 1 
(TACR1) and tachykinin receptor 2 (TACR2) receptors on SMC and TACR1 on ICC (Figure 1.2B). 
In ICC-DMP, signal transduction via M3 receptors likely occurs through Gq leading to Ca2+ release 
from the endoplasmic reticulum and activation of CaCC such as anoctamin 1 (Ano1). Opening of 
CaCC causes a depolarizing current predicted to enhance the likelihood of action potential 
generation and increase contraction amplitude (21, 22). M2 receptors are also expressed on ICC 
but may play a less important role than M3 receptors (21, 23). In contrast, evidence from knockout 
mice suggests that both M3 and M2 receptors influence SMC contractility (24).  
Like muscarinic signaling in ICC, tachykinin signaling via TACR1 is hypothesized to act via Gq 
signaling coupled to Ca2+ release and CaCC opening. Tachykinin signaling may be more important 
than muscarinic signaling in ICC-DMP. Applying TACR1 receptor antagonists attenuated basal 
Ca2+ transients in small intestine ICC-DMP, suggesting that ICC-DMP are tonically excited by 
tachykinins (21). The same may not be true in colonic ICC, which do not express TACR1 receptor 
as highly (21). In SMC, tachykinin signaling is transduced by both TACR2 and TACR1 receptors 
(25). Second messenger signaling likely occurs through protein kinase C (PKC) and IP3 (7), 




ENS, the SIP syncytium, and bowel motility: putting it all together 
When considering direct neural input to the SIP syncytium, it is important to remember that diverse 
motor patterns are needed for food to be digested and absorbed, and for waste to be eliminated. 
These motility patterns in human small intestine include peristalsis (waves of contraction and 
relaxation that propagate down the bowel), segmentation (alternating contraction and relaxation to 
mix food with digestive enzymes and bile), and the migrating motor complex (MMC) (where strong 
waves of contraction and relaxation propagate down the bowel during phase III to moves luminal 
contents toward distal bowel for elimination). In the colon there are high amplitude propagating 
contractions (HAPC) that move stool over long distances toward the rectum and occur only 
occasionally. Generation and maintenance of these motor patterns requires a complex interplay 
between neural signaling, ICC, PDGFRα+ cells, and SMC. In broad strokes, ICC continually 
produce oscillating electrical slow waves in the bowel that set the rhythm for many motor patterns. 
Slow wave electrical activity propagates from ICC to SMC, generating rhythmic SMC depolarization 
and contraction. Neural signaling onto the SIP syncytium generates and modulates ICC and SMC 
activity to produce the motor patterns described above. Stimuli from the environment alter ENS 
activity to determine which motor patterns should occur at specific times (7). For example, 
segmentation in the small bowel occurs after meals, but phase III MMC predominates once most 
nutrients are absorbed. Although the ENS is not essential for generating some motor patterns, the 
ENS is probably the primary inducer of complex motility patterns needed for survival (26).  
To “decide” what to do, sensory neurons of the ENS (called intrinsic primary afferent neurons, 
IPANs) respond to diverse stimuli including stretch and mucosal distortion (1, 2). Stretch sensing 
is mediated by mechanoreceptors located within the myenteric plexus, which fire in response to 
distention (27). Historically, it has been assumed that stimulation of enterochromaffin (EC) cells in 
the bowel mucosa and the resulting serotonin (5-HT) release onto IPANs play a major role in 
evoking enteric neural reflexes such as the peristaltic reflex. However, recent papers question the 
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importance of serotonin release from EC cells for initiation of motility since mice lacking a critical 
enzyme involved in 5-HT biosynthesis in EC cells (tryptophan hydroxylase 1, or TPH1) survive to 
adulthood and have a normal gastrointestinal transit time (28). Further research has shown these 
mice have larger fecal pellets and aberrant colonic migrating motor complexes (29) suggesting that 
in the absence of 5-HT from EC cells, a higher degree of stretch is required to trigger contractions 
(30).  
We have focused thus far on neurotransmission to the SIP syncytium, but enteric glia also influence 
bowel motility. Female mice lacking enteric glia have reduced gastrointestinal transit time and 
increased CMMC frequency compared to controls. Intriguingly, the same effect was not seen in 
males, suggesting potential glia-intrinsic sex-dependent differences, or sexual dimorphism in glial 
interacting partners (31). Other studies also suggest enteric glia influence bowel motility; for 
instance, mice lacking the glial-specific hemichannel connexin-43 had prolonged colonic transit, 
increased stool water content, and diminished contraction and relaxation amplitude (32). 
Mechanisms behind glial control of motility are not well understood. One hypothesis is that trophic 
factors produced by glia may prevent ENS dysfunction. Another possibility is that enteric glia 
directly modulate ICC slow wave activity (33). 
 
Clinical relevance 
Human bowel motility disorders include life threatening problems like Hirschsprung and 
chronic intestinal pseudo-obstruction (CIPO) syndrome. In these disorders, ENS or SIP syncytium 
function is so disrupted that surgical intervention or intravenous nutrition is often needed for survival 
 
Hirschsprung disease. The ENS forms from neural crest-derived precursor cells (ENCDC) that 
colonize the bowel during first trimester fetal development. In about 1:5000 children, ENCDC never 
reach the distal bowel resulting in a region where the ENS is completely absent. This problem is 
called Hirschsprung disease. In children with Hirschsprung disease, the region of bowel that lacks 
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enteric ganglia (i.e. aganglionic bowel) is tonically contracted and does not have propagated 
motility, leading to functional obstruction. Because aganglionic bowel does not efficiently pass stool 
or air, Hirschsprung disease symptoms include distension, constipation, vomiting, abdominal pain, 
growth failure, and a predisposition to bowel inflammation (called enterocolitis) that may lead to 
death from sepsis. Hirschsprung disease provides absolute proof that the ENS is essential for life, 
since even a small region of aganglionosis can cause serious illness and premature death. Our 
recent review provides more detailed information about Hirschsprung disease symptoms and 
molecular mechanisms (34). 
  
Chronic intestinal pseudo-obstruction syndrome (CIPO). When the ENS is present throughout 
the bowel, but bowel motility does not consistently support survival or growth without at least 
intermittent intravenous nutrition, CIPO is the likely diagnosis. Symptoms of CIPO include repetitive 
episodes of abdominal distension and pain, vomiting, growth failure, and weight loss (89). CIPO 
may occur as a primary disorder, or it may be secondary to complications of another disease. CIPO 
should not be confused with transient bowel motility defects such as ileus (the absence of bowel 
contractions) that commonly accompanies abdominal surgery, pancreatitis, appendicitis or sepsis. 
The etiology of CIPO remains poorly understood, although clues are emerging from human 
and mouse genetics. Because so many cell types, transmitters, and signaling molecules impact 
ENS development and intestinal function, there are likely many underlying causes of CIPO, 
potentially including dysfunction of ENS, SMC, ICC, and/or PDGFRα+ cells. Unfortunately, even 
with advanced genetic tools like whole exome sequencing, causative genetic variants remain poorly 
defined. Only a few genetic causes of CIPO have been identified. These include mutations in the 
genes encoding filamin A (FLNA), DNA polymerase gamma (POLG), and gamma smooth muscle 
actin (ACTG2), leiomodin 1 (LMOD1), myosin heavy chain 11 (MYH11) and myosin light chain 
kinase (MYLK)  (35, 36). Identifying more genetic causes of CIPO is critical as it will undoubtedly 
aid diagnosis. New medicines to treat CIPO are also desperately needed. Available prokinetic 
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medications prevent ACh degradation (e.g. Pyridostigmine), activate 5-HT4 receptors (enhancing 
ACh release from excitatory motor neurons and increasing bowel motility; e.g. Cisapride, 
Tegeserod, Prucalopride), inhibit dopamine receptors (Metoclopramide, Domperidone), activate 
somatostatin receptors (Octreotide) or activate receptors for motilin, a peptide that increases GI 
motility (e.g. Erythromycin). Unfortunately, many of these medicines have serious side effects or 
are only minimally effective at enhancing small bowel motility and resolving symptoms for people 
with serious motility disorders like CIPO (35, 37). 
 
1.4 The ENS and vascular endothelium 
During digestion, blood flow to intestinal mucosa increases as much as 2-fold owing in part 
to dilation of submucosal arterioles. Vasodilation and resulting hyperemia are needed to meet the 
high metabolic demands of the mucosa and to exchange nutrients, water, and solutes across bowel 
epithelium. Neurogenic vasodilation of submucosal arterioles is mediated by extrinsic and intrinsic 
(ENS) innervation. In contrast, vasoconstriction of bowel arterioles is wholly under control of 
extrinsic sympathetic innervation. Here we briefly review ENS control of vasodilation, which has 
been extensively characterized.  
Most studies of submucosal arteriole vasodilation evaluated guinea pig small intestine, 
using varied preparations including isolated submucosa and full thickness intact bowel. These 
studies suggest many triggers for ENS-mediated vasodilation, including gently stroking bowel 
mucosa, distorting the mucosa with puffs of gas, and distending smooth muscle with a balloon. 
Small distortions of the mucosa (stroking, puffing gas) cause EC cells to release 5-HT onto enteric 
nerve terminals expressing 5-HT3 [myenteric IPANS (38)] and 5-HT4, and/or 5-HT1P [submucosal 
IPANs (39)]. Stimulation of these IPANs by 5-HT activates short (1–2 mm) reflex pathways within 
the submucosa, as well as longer reflex pathways that span submucosal and myenteric plexus 
(39). Stretching the bowel activates 5-HT3 and 5-HT4-insensitive mechanotransducers in the 
myenteric plexus (40) and possibly submucosal plexus (41) leading to vasodilation. Mechanical 
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deformation of the gut activates neurites and soma of a large number of mechanosensitive enteric 
neurons within the myenteric plexus (27). These mechanosensitive neurons are multifunctional (i.e. 
they may be afferents, interneurons, or efferents) and their responses to mechanical stimulation 
may be rapid-adapting, slow-adapting, or ultra-slow-adapting (42). 
A final common pathway for ENS-mediated vasodilation in guinea pig small intestine is 
release of ACh onto endothelial cells which activates muscarinic M3 receptors, leading to NO 
release and vasodilation (43). In guinea pig distal colon, substance P and/or VIP release from 
submucosal plexus neurons may contribute to vasodilation (44). The ENS may also stimulate mast 
cells to release the vasodilator histamine directly onto submucosal blood vessels (45) via SP and/or 
calcitonin gene-related peptide (CGRP) (45).  
 
Clinical relevance 
Impaired vascular control has been implicated in a number of inflammatory conditions, 
including necrotizing enterocolitis (NEC) and inflammatory bowel disease (IBD). NEC is a 
dangerous bowel disease in premature neonates, characterized by severe inflammation, ischemic 
necrosis, and sometimes bowel perforation. It is tempting to hypothesize that neuron dysfunction 
may contribute to development of necrotizing enterocolitis, for instance through dysregulation of 
vasodilation that occurs in response to feeding. Indeed, altered microcirculation involving 
constricted arterioles has been demonstrated in NEC (47) and damage to the ENS also occurs with 
NEC (47). However, there is not yet convincing evidence that ENS dysfunction is the primary cause 
of altered blood circulation in babies with NEC. Arguing against this hypothesis, vessel endothelial 
cells from bowel with NEC failed to generate NO in response to ACh, but vessels dilated in 
response to exogenous NO administration, suggesting dysfunction of endothelial cells may be 
paramount (48). This is similar to IBD, where vessel endothelium does not appropriately produce 
NO even when stimulated by ACh (49). Unfortunately, because defects seem intrinsic to endothelial 
cells, neuromodulators (e.g. AChE inhibitors) are unlikely to have therapeutic value in these 
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disorders, although gut derived neural stem cells do appear to prevent NEC-like injury in a rodent 
model (47). 
 
1.5 Epithelial secretion and the ENS 
5-HT released from enteroendocrine cells in response to mucosal stroking not only elicits 
peristalsis and supports vasodilation, but also activates fluid and electrolyte secretion into the gut 
lumen to facilitate digestion. 5-HT activates IPANS that in turn synapse on secretomotor neurons 
that release ACh or VIP. ACh acts via muscarinic receptors and VIP via VIPR1 receptors on crypt 
epithelial cells to increase intracellular Ca2+ (via phospholipase C and IP3) and cAMP (via Gs) 
respectively. Cyclic AMP activates the cystic fibrosis transmembrane regulator (CFTR) chloride 
channel. Calcium activates the HCLCA1 chloride channel inducing more transient chloride flux. 
Movement of chloride into the gut lumen is accompanied by sodium and water. The details of these 
circuits are much better understood than this brief description suggests, and they are beautifully 
described in reviews (50, 51). 
Interestingly, a recent publication has also defined a role for enteric glia in the regulation 
of epithelial ion transport. When glial cells lack the glial-specific hemichannel connexin-43 neuron-
regulated electrogenic ion transport was reduced while transmural conductance and epithelial 
permeability were not significantly changed. Activation of GFAP-expressing glial cells stimulated 
electrogenic ion transport similar to that observed with direct neuronal stimulation. Inhibiting 
neuronal activation with tetrodotoxin only partially reduced glial-induced electrogenic ion transport, 
indicating that the enteric glia interactions with the epithelium do not require neuronal activity (52). 
 
Clinical relevance  
Dysfunctional regulation of epithelial secretion may lead to increased stool water content. 
VIP-producing tumors and SSRI-induced serotonin syndrome cause diarrhea by directly increasing 
neurotransmitters in the ENS circuit that controls epithelial secretion (53). Cholera, Rotavirus, 
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Clostridium difficile, Cryptosporidium, and enterotoxin producing Escherichia coli all cause profuse 
watery diarrhea at least in part by activating ENS circuits (54, 55).  
 
1.6 The ENS, epithelial proliferation and repair 
Bowel epithelium is replaced every few days via proliferation of stem cells and transit-
amplifying cells in the crypt. Newly-generated cells differentiate into absorptive epithelial cells, 
goblet cells, and EC (among other cells types) before being lost via apoptosis. Regulation of 
epithelial proliferation and differentiation is carefully controlled since too little epithelial replacement 
reduces absorptive capacity and too much epithelial proliferation causes cancer. Among other 
regulatory mechanisms, accumulating data suggest the ENS influences epithelial proliferation and 
repair, as well as epithelial barrier function, but that effects of the ENS on bowel epithelium are 
complex. 
For example, chemical ablation of the myenteric plexus with benzalkonium chloride increases 
epithelial proliferation, crypt depth and villus height (56) suggesting inhibitory effects of the ENS on 
epithelial renewal. Consistent with the hypothesis that ENS components reduce epithelial 
proliferation, mice with a hypomorphic ENS because of mutations in the tyrosine kinase receptor 
Ret have enhanced small bowel epithelial proliferation after small bowel resection during the 
adaptive response (57). In contrast, loss of the hepatocyte growth factor receptor Met within the 
ENS leads to reduced epithelial proliferation after dextran sodium sulfate (DSS)-induced bowel 
injury (58). Because Met and Ret are expressed in different subsets of myenteric neurons, these 
observations suggest some enteric neurons enhance and others suppress bowel epithelial 
proliferation depending on context.  
Consistent with this hypothesis, ACh activates muscarinic receptors on intestinal stem or progenitor 
cells to enhance epithelial proliferation (59-62). Neuron-derived serotonin activates 5-HT(2A) 
receptors on cholinergic neurons, enhancing ACh release (63) and also enhancing epithelial 
proliferation. Interestingly, glucagon-like peptide 2 (GLP-2), a potent stimulant for epithelial 
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proliferation, might also work via the ENS since GLP-2 receptors are expressed by enteric neurons, 
but not intestinal epithelium (64). Alternatively, GLP-2 might support epithelial proliferation via 
subepithelial myofibroblasts that express GLP-2 receptor and release IGF-1 in response to GLP-2. 
In support of this hypothesis, IGF-1 is required for GLP-2 intestinotrophic effects and this 
mechanism could bypass the ENS (65). 
In addition to regulating epithelial cell proliferation, enteric neurons appear to enhance 
epithelial barrier function. Co-culture of primary enteric neurons with primary intestinal epithelial 
stem cells, increases expression of tight junction associated protein zona occludens 1 (ZO-1), 
increases transepithelial resistance across the monolayer, and reduces apical to basolateral 
dextran permeability (66). Parallel studies suggest enteric glia may also influence intestinal 
epithelial barrier function (67-70). For these studies, enteric glia were eliminated using a transgenic 
GFAP-Cre driver to induce expression of HSV-TK or using the GFAP promoter to drive expression 
of the neoantigen haemagglutinin. In the former case, treatment with gancyclovir induced cell death 
in any cell that expressed the transgene by conversion of the antiviral agent to a toxic nucleotide 
analog. In the latter case, neoantigen expression led to CD8+-mediated cell death of any 
neoantigen-expressing cell. Eliminating glia in these ways led to massive bowel inflammation. Co-
culture of epithelial cells and glia also changed gene expression (71) in epithelial cells, increasing 
tight junction proteins (like ZO1 and occludin) and decreasing transepithelial permeability in 
cultured epithelial monolayers (69-71). S-nitrosoglutathione was identified as a soluble glial-derived 
factor that increased epithelial barrier function in vitro. This compound drastically reduced the 
development of enterocolitis in vivo after HSV-TK-mediated damage to ENS and epithelium (69). 
Another study found that mucosal glia strongly upregulate their expression of GDNF in states of 
inflammation (72, 73). GDNF reduced epithelial apoptosis in vitro (74, 75) and in a mouse model 
of DSS-colitis, GDNF overexpression increased tight junction protein expression and decreased 
epithelial permeability (76). Collectively these studies provided substantial support for the 
hypothesis that enteric glia enhance epithelial barrier function. Interestingly, enteric glial cell-
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derived GDNF also activates RET on type 3 innate lymphoid cells (ILC3) to induce release of IL-
22, which enhances epithelial expression of genes that reduce bacterial translocation (77). 
Collectively these studies provided substantial support for the hypothesis that enteric glia enhance 
epithelial barrier function. 
Surprisingly, an elegant set of experiments showed that enteric glial cells are not required 
for maintenance of epithelial integrity in mice. The authors eliminated all enteric glia by inducing 
cholera toxin subunit A expression under the control of the PLP1 promoter. In this system, no 
enterocolitis developed, and epithelial cell ultrastructure, proliferation and permeability were 
unaffected despite a dramatic loss of enteric glia. The absence of glia in the setting of DSS-induced 
colitis did not worsen symptom severity or specifically affect transepithelial permeability. Lastly, the 
authors showed that the discrepancy between their study and the previous in vivo studies could be 
explained by the aberrant GFAP-Cre transgene expression in a small number of epithelial cells 
which caused direct injury to the epithelial cell layer after ganciclovir treatment or induction of 
neoantigen expression (31).  
Overall, it is clear the ENS influences intestinal barrier function in a normal physiologic 
state and during inflammation. The exact contributions of the different enteric neuron subtypes and 
of enteric glia have not yet been conclusively elucidated. 
 
1.7 The ENS and macrophages 
Two broad classes of tissue-resident macrophages contribute to intestinal immune 
function. The most abundant macrophage (Mφ) class resides in the lamina propria (LpMφ) directly 
beneath bowel epithelium (78) and are surrounded by dense submucosal neuron projections that 
innervate the epithelial layer. Direct functional interactions between ENS and LpMφ have not yet 
been document, but seem plausible. The second, relatively understudied group called muscularis 
macrophages (MMφ) are very closely associated with the myenteric plexus and emerging literature 
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suggests significant cross-talk and even developmental interdependence between these cell types 
(Figure 1.3).  
 
Figure 1.3: Interaction between muscularis macrophages and enteric neurons. 
(A) Muscularis macrophages support enteric neurons through BMP2 signaling and possibly 
synaptic pruning and clearing of debris. (B) Enteric neurons are a key part of the cholinergic anti-
inflammatory pathway (CAIP) reducing the activation of macrophages through vagal stimulation. 
(C) Activation of muscularis macrophages by ACh decreases macrophage activation and 
decreases production of TNFα.  Abbreviations: α7nAChR, α7 nicotinic acetylcholine receptor; ACh, 
acetylcholine; ATP, adenosine triphosphate; BMP2, bone morphogenetic protein 2; CSF-1, colony 
stimulating factor 1; JAK, Janus kinase; NF-κB, nuclear factor kappa-light-chain-enhancer of 
activated B cells; STAT, signal transducer and activation of stimulation; TNFα, tumor necrosis factor 
alpha; Transcr., transcription.   
 
 
1.8 The ENS depends on MMφ for normal structure and function 
MMφ produce bone morphogenetic protein 2 (BMP2), a morphogen that binds its receptor 
BMPRII on neurons and influences ENS precursor differentiation, neurite fasciculation, and 
ganglion formation (79, 80). Mice lacking MMφ during development have increased numbers of 
enteric neurons and a disorganized ENS. Interestingly, this phenotype is similar what occurs when 
the BMP antagonist noggin is over-expressed in vivo (79, 81). Acute depletion of MMφ from the 
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bowel in adulthood enhanced colon contractility in response to stretch ex vivo, but delayed 
expulsion of a bead by the colon in vivo, suggesting problems with coordinating muscle activity. 
The motility changes were not limited to the colon since gastric emptying was also accelerated two 
days after acute MMφ depletion. The effects of MMφ depletion on ex vivo colon contractility could 
be mimicked by dorsomorphin (a BMP signaling inhibitor) or rescued by adding BMP2. Consistent 
with these observations, nuclear localization of pSMAD1/5/8 (a downstream effector complex for 
BMP signaling) was reduced in enteric neurons from MMφ-depleted bowel. Interestingly, antibiotic 
treatment to reduce luminal microbes reduced bowel MMφ, BMP2 levels, and nuclear pSMAD1/5/8 
in enteric neurons. Antibiotics increased whole-bowel transit time and enhanced colon contractility 
ex vivo, suggesting dysfunctional bowel motility (81).  
Taken together, these results offer strong evidence that enteric neurons rely on BMP2 
produced by MMφ for normal morphology and function. These observations also suggest that 
postnatal acquisition of intestinal microbes critically shapes neuroimmune interactions in the bowel. 
Some authors have suggested that MMφ also contribute to normal ENS morphology by 
phagocytosing neuronal debris (82). This function of MMφ would be similar to that of microglia, the 
tissue-resident macrophages of the brain, which clear apoptotic neurons and eliminate 
unnecessary axons and synaptic connections (i.e. synaptic pruning). Further research is needed 
to determine the extent to which phagocytosis by MMφ shapes the ENS.  
 
 
1.9 Activated MMφ regulate enteric neuron excitability during inflammation 
Activated murine MMφ release chemokines, cytokines (interleukin 1, monocyte 
chemoattractant protein 1, interleukin 6, tumor necrosis factor alpha (TNFα)) and other bioactive 
compounds (NO, prostaglandins) (83, 84). NO regulates neuron excitability and directly relaxes 
SMC, so it is not surprising that increased NO reduces bowel contractility. Some enteric neurons 
also produce TNFα receptors, and TNFα activates neuropeptide Y (NPY) expression. NPY 
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increases bowel epithelial permeability during inflammation (85), suggesting a neuro-immune 
interaction that might be modulated to reduce intestinal inflammation.  
 
1.10 The ENS modulates MMφ activation, and may affect MMφ survival 
Macrophages express many neurotransmitter receptors, including α7 nicotinic 
acetylcholine (α7nAChR), tachykinin, glycine, and P2 purine receptors, all of which may alter MMφ 
function (84). The most well-characterized example of ENS modulation of MMφ is the cholinergic 
anti-inflammatory pathway (CAIP), a circuit involving the vagus, ENS, and MMφ. Stimulating the 
vagus nerve activates cholinergic enteric neurons near MMφ, leading to release of ACh and 
stimulation of α7nAChR on MMφ. This reduces inflammation by decreasing the ATP-induced 
calcium transients in MMφ, decreasing macrophage activation (86) and reducing TNFα production 
by macrophages (87). α7nAChR also activates the Jak2-STAT3 signaling pathway, which likely 
plays a role in attenuating macrophage activation (88). ENS-MMφ signaling is likely not limited to 
ACh-α7nAChR interactions given the large number of neurotransmitter receptors expressed by 
macrophages. Extrinsic nerves also modulate MMφ activation directly through norepinephrine 
signaling onto adrenoreceptor β2, but this pathway is probably independent of the ENS (78). 
Intriguingly, adult enteric neurons express colony stimulating factor 1 (CSF-1), the primary 
survival factor for MMφ (450). Since other CSF-1 expressing cell types had not been identified in 
the bowel, we hypothesized that MMφ rely on CSF-1 produced by enteric neurons for normal 
development. Surprisingly, MMφ appear normal in neonatal bowel even in the absence of an ENS. 
Other intestinal cell types (endothelial cells, ICC) produce CSF-1 perinatally and may be the main 
cells supplying MMφ with CSF-1 in early life (89). Since a considerable ENS development occurs 
after birth, ENS-MMφ interactions likely mature postnatally, and it remains possible that CSF-1 
expressed by neurons is critical for MMφ survival in adulthood. Global knockout models of CSF-1 
(i.e. Csf1op/op mice) lack all MMφ, but thus far conditional depletion of CSF-1 from enteric neurons 
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has not been reported. This experiment would be needed to confirm that ENS-derived CSF-1 
influences adult MMφ number or function. 
 
Clinical relevance 
Post-operative paralytic ileus is a common condition characterized by transiently impaired 
bowel motility after abdominal surgery. Post-operative ileus may be partially mediated by low-grade 
inflammation leading to impairment of muscle contractility. Supporting a role for MMφ in post-
operative ileus, depletion of MMφ by clodronate or genetic MMφ loss in Csf1op/op mice protects 
against post-operative ileus (90). Intriguingly, vagal nerve stimulation reduced inflammation and 
improved post-operative ileus (91). This is likely mediated by the vagal-ENS-MMφ anti-
inflammatory pathway described previously (86). MMφ activation has also been implicated in other 
gastrointestinal motility disorders such as gastroparesis, which also may be helped by vagal 
stimulation. This topic is summarized in a number of excellent recent reviews (83, 84). 
 
1.11 ENS interactions with the microbiome 
After birth, the bowel must grapple with drastic changes as it is exposed to a diverse array 
of microbes seeking to establish themselves within the gut lumen. Microbial colonization occurs 
while the ENS is still maturing, and we now believe these microbes substantially affect ENS 
development. At least two studies have shown reductions in neuron density in the small intestine 
and/or colon of young germ-free (GF) mice compared to age-matched gnotobiotic controls (92, 93). 
Oddly, one study reported an increased proportion of nitrergic myenteric neurons in their 3-day-old 
GF mice (93), while the other study, which used 4-week old GF mice, reported decreased nitrergic 
neuron numbers (92). The cause of this difference is unclear.  
A few mechanisms for microbial effects on ENS development have been proposed. 
Interestingly, enteric neurons and glia express toll-like receptors (TLR), pattern recognition 
receptors that are activated by pathogen associated molecular patterns (PAMPs) as part of the 
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innate immune system. TLRs 3, 4, and 7 are expressed in enteric neurons and glia (94). 
Additionally, TLR2 may be expressed in ENS and in surrounding cells including SMC (95). Global 
deletion of TLR2 reduced the number of nitrergic neurons in colon, and accelerated gastrointestinal 
transit (95). Mice with a global deletion of TLR4, which detects lipopolysaccharide (LPS; a major 
component of gram-negative bacteria) had reduced numbers of nitrergic neurons, slow bowel 
motility, and reduced bowel relaxation in response to EFS. Conditional knockout mice missing 
Myd88 selectively in neurons and glia also had delayed colon transit and reduced nitrergic neurons 
(92) MYD88 is a mediator of TLR4 activity. Finally, a high fat diet, which causes dysbiosis, also 
reduced NO-producing myenteric neuron number and slowed bowel motility in a TLR4-dependent 
fashion (96).  
One possible explanation for these findings is that microbes could activate TLRs on enteric 
glia or mesenchymal cells, leading to release of the RET ligand glial cell line-derived neurotrophic 
factor (GDNF). GDNF provides trophic support for enteric neurons expressing RET and its co-
receptor GDNF Family Receptor alpha 1 (GFRα1) during ENS development (97). In addition, GDNF 
contributes to motility by stimulating the ascending limb of the peristaltic response (98). In support 
of this theory, mice lacking TLR2 had significantly reduced GDNF in muscle. Administering 
recombinant GDNF to these mice subcutaneously for seven days restored neuron numbers and 
reversed dysmotility (95). Some evidence suggests enteric glia produce GDNF in response to 
inflammation (72), making them a plausible intermediary in this pathway, although SMCs or other 
mesenchymal cells could also be involved.  
In addition to developmental effects, the microbiome can affect the ENS in adult life. 
Microbiome composition directly affects mature ENS function by altering electrophysiologic 
properties of neuron subtypes (99) and leading to changes in intestinal motility and neurally-
mediated secretion (100, 101). Furthermore, giving mice antibiotics reduces neuron numbers and 
slows gastrointestinal transit (92). The ENS can also influence the composition of the microbiome. 
In a zebrafish model of HSCR, the pathogenic over-abundance of pro-inflammatory bacterial strains 
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could be corrected simply by restoring ENS function (102). These observations highlight just a few 
of the complex interactions between gut microbes and the ENS; a more detailed description of 
ENS-microbiome interactions can be found in recent reviews (103, 104). 
 
1.12 ENS interactions with the adaptive immune system 
Enteric neuron projections can be found within mucosal lymphoid follicles (Peyer’s 
patches) (105, 106). When lymphocytes from Peyer’s patches were exposed to neuropeptides, 
they significantly increased their proliferation rate and immunoglobulin synthesis (107). This 
suggests the exciting possibility that enteric neurons can directly influence the adaptive immune 
system. For example, the Y1 receptor that binds neuropeptide Y is expressed on monocytes, 
macrophages, lymphocytes, and granulocytes (108). Y1-deficient mice have reduced antigen 
presenting cell function, reduced effector T cells, and reduced production of TNFα and IL-12 by 
macrophages. Similarly, Npy-/- mice have lower TNFα levels and Y1-/- mice resist colitis that 
occurs after epithelial injury with dextran sodium sulfate (DSS) (109). VIP is produced by inhibitory 
motor neurons, descending interneurons and secretomotor neurons of the ENS to control motility 
and epithelial function. The VIP receptor is also expressed by T-cells, where VIP promotes a T-reg 
phenotype (110), by dendritic cells where VIP induces a tolerogenic phenotype (111, 112), and by 
macrophages where VIP inhibits production of TNFα, IL-6 and IL-12p40 (110). These anti-
inflammatory effects of VIP in vitro contrast with the observation that VIP-/- mice are resistant to 
TNBS-induced colitis (113) and LPS-induced endotoxemia (114). The reason for this discrepancy 
is not known.  
 
1.13 ENS interaction with enteroendocrine cells 
Enteroendocrine cells (EEC) are a diverse group of neuroendocrine cells in the bowel 
epithelium that produce hormones and neuropeptides in response to stimulation from the gut 
lumen. The molecules produced by EEC act locally on cells within the mucosa, as well as 
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systemically via the bloodstream (115). Significant cross-talk occurs between EEC and the ENS to 
modulate vasodilation, motility and epithelial secretion. We already alluded to one mechanism by 
which enterochromaffin cells (EC), a subtype of EEC, signal enteric neurons through release of 5-
HT onto nerve terminals. The triggers for 5-HT release are incredibly diverse and include 
mechanical deformation of the mucosa, macromolecules (e.g. glucose, fatty acids, amino acids), 
chemical irritants (e.g. allyl isothiocyanate), injury or stress (e.g. norepinephrine), and changes in 
the bacterial milieu (e.g. butyrate and other short chain fatty acids) (115, 116). In response to 
stimulation, EC activate neurons through the release of 5-HT onto nerve terminals. In addition to 
5-HT, EEC produce neuropeptides such as somatostatin, motilin, VIP, glucagon-like peptide-1 
(GLP-1) and cholecystokinin (CCK), which modulate ENS activity (117-119). It has traditionally 
been assumed that these neuroactive peptides signal in a paracrine manner. However, presynaptic 
and postsynaptic markers have been identified on EC, suggesting that EC communicate with 
nerves via synapse-like structures (116, 120). Even more compelling, monosynaptic transmission 
of modified rabies virus confirms the presence of functional efferent synapses (120). Unfortunately, 
the in vivo data does not address the question of whether the EC form synapses with enteric or 
extrinsic neurons (120). There is a paucity of research regarding EEC-ENS connections and 
particularly efferent ENS signaling onto hormone-producing EEC. Given the similarity in signaling 
molecules and receptors between EECs and the ENS, it seems highly likely that these cells 
communicate through additional pathways that remain to be discovered.  
 
1.14 The ENS, CNS and the autonomic nervous system 
A variety of extrinsic nerves innervate the bowel, including sympathetic nerves, the 
parasympathetic vagus and sacral plexus nerves, and the dorsal root ganglia. Some of these 
nerves interact directly with their targets in the bowel, but they may also mediate their effects 
indirectly by synapsing on enteric neurons. We already mentioned the cholinergic anti-inflammatory 
(CAIP) pathway, where vagal nerve fibers signal ENS intermediaries that then signal macrophages 
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to reduce inflammation. Here we provide a brief overview of other important ENS interactions with 
the autonomic nervous system. Please see the following reviews for a more in-depth discussion of 
this topic (4, 121), 
 
1.15 Sympathetic neuron-ENS interactions 
 Sympathetic nerve endings contact the vast majority of enteric neurons (122), and may 
also activate enteric glia via ATP release (123). Sympathetic nerves indirectly regulate epithelial 
secretion by inhibiting secretomotor neurons in the submucosal plexus. This inhibition is likely tonic 
since transepithelial secretion is greatly enhanced after sympathectomy (122), and acute 
sympathetic inhibition effects on secretion are most apparent when the secretomotor reflex has 
been activated (124, 125).  
The sympathetic nervous system coordinates motility across large segments of bowel. The 
changes in motility are mediated by reflex arcs that involve afferent sensory neurons of the ENS 
and efferent inhibition of enteric neurotransmission by the sympathetic nervous system. These 
reflex arcs may include or bypass the CNS, depending on context. Sympathetic reflexes have been 
worked out in detail and are well described elsewhere (122). 
 
1.16 Parasympathetic-ENS interactions 
Parasympathetic innervation of the upper gastrointestinal tract is exclusively provided by 
the vagus nerve and vagal projections are known to reach as far as the colon. Whether the entire 
bowel is innervated by the vagus nerve is still contested. Evidence suggests that the innervation 
includes the distal colon at least in some animal models (126). The pelvic nerves may provide 
additional parasympathetic innervation to the lower gastrointestinal tract. However, a recent study 
argues that these nerves are actually part of the sympathetic nervous system (127).  
Most enteric ganglia in the small intestine and stomach are innervated by vagal nerve fibers 
(128). The vast majority of vagal nerve fibers are sensory and transmit afferent input to the CNS. It 
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is unclear if afferent vagal signaling to the CNS is directly influenced by the ENS. Vagal-enteric 
(efferent) neurotransmission is predominantly cholinergic, although additional neurotransmitters 
have been identified in preganglionic vagal neurons (catecholamines and NO) and could have an 
auxiliary role (129, 130). Efferent vagal input affects all functions of the ENS, including the 
regulation of bowel motility, epithelial secretion, and vasoconstriction (4). Additionally, the vagus 
nerve mediates anti-inflammatory effects on the bowel through enteric neurons as part of the CAIP 
as described earlier (86).  
 
1.16 Clinical relevance 
The pathways described above confirm bidirectional communication between the ENS and 
CNS that has important effects on bowel function, but the gut also influence the brain, an interaction 
referred to as the “Gut-Brain Axis” (131). An additional intriguing hypothesis is that these pathways 
may lead to CNS disease since protein misfolding events that occur in the ENS could be initiators 
for certain CNS diseases such as Parkinson’s disease (PD). PD involves the prion-like misfolding 
of α-synuclein which aggregates into deposits called Lewy bodies, leading to neurodegeneration 
and dementia. Genetic changes or ingested toxins like the pesticide rotenone could first cause α-
synuclein aggregation in the ENS (132), which then travels to the CNS via the vagus, where they 
induce misfolding of additional α-synuclein to cause the characteristic Lewy body pathology. 
Support for this hypothesis includes the observation that Lewy body-type pathology is found within 
enteric neurons of people with PD (133), bowel symptoms often precede CNS symptoms and 
correlate with disease severity (134), and that α-synuclein aggregates can travel from the bowel to 
the brain via the vagus nerve (135, 136). In humans, truncal vagotomy may reduce PD risk (137, 
138). Similar transit of misfolded protein from the bowel to the brain could also explain the spread 
of prion diseases like kuru, variant Creutzfeldt-Jakob, scrapie, chronic wasting disease and 
spongiform encephalopathy where ingestion of misfolded prion proteins initiates disease 




1.17 ENS and the CNS 
Since the ENS shares many neurotransmitters, receptors, and transcription factors with 
the CNS, it is not surprising that many people with CNS disease also have problems with bowel 
function. People with autism spectrum disorder (ASD) are 3-4 times more likely to have 
gastrointestinal symptoms than unaffected individuals; intriguingly, mutations in chromodomain-
helicase-DNA binding protein 8 (CDH8), haploinsufficiency for the transcription factor TCF4, an 
activating mutation in the sodium-dependent 5-HT transporter (SERT/SLC6A4), and MET 
mutations are all directly linked to ASD and GI motility disorders (58,143-146). Mice expressing 
mutant forms of amyloid precursor protein associated with familial Alzheimer disease accumulate 
amyloid beta in enteric neurons, have a reduced enteric neuron number, dysmotility and increased 
vulnerability to bowel inflammation (147, 148). Mutations in TAR DNA-binding protein 43 (TDP-43) 
that cause familial amyotrophic lateral sclerosis (ALS), may also cause ENS defects, including 
intestinal obstruction in the Prp-TDP43Ala315Thr mouse model (149, 150). There is much more to 
learn about links between ENS and CNS disease. 
 
1.18 Summary 
The enteric neurons and glia richly integrate sensory stimuli to control bowel motility, 
epithelial function, blood flow, and immune system activity. To do this, almost every cell of the 
bowel wall closely interacts with the ENS including smooth muscle, ICC, PDGFRα+ cells, EEC, 
epithelial cells, blood vessels, and many hematopoietic lineages. The ENS also interacts with 
extrinsic sympathetic, parasympathetic and sensory nerves, and is influenced by hormonal signals 
to modulate bowel function to meet systemic needs. Mechanisms and cell types that impact ENS 
activity remain under-investigated. Defining molecular and cellular mechanisms of ENS activity 
promises new approaches to dangerous bowel motility disorders (Hirschsprung disease, CIPO, 
gastroparesis), common and less dangerous motility problems (irritable bowel syndrome, chronic 
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constipation, functional dyspepsia), inflammatory bowel disease, necrotizing enterocolitis, and 
ischemic bowel disease. Given links between gut microbes, bowel motility, epithelial function and 
CNS activity, ENS biology may also provide new approaches to addressing complex problems like 
anxiety, depression, autism, Parkinson’s and ALS, and Alzheimer’s disease as we begin to define 
the interplay along the gut brain axis. 
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Bowel function requires coordinated activity of many enteric neuron subtypes. Clear 
definition of subtype-specific gene expression may facilitate molecular diagnoses for bowel motility 
disorders. Using adult mouse colon RNAseq data from 635 myenteric neurons and 707 E17.5 
neurons, we defined seven adult myenteric neuron subtypes, eight E17.5 neuron subtypes and 
hundreds of differentially- expressed genes. Manually dissected human colon myenteric plexus 
yielded data from 48 neurons, 3798 glia, 5568 smooth muscle, 377 interstitial cells, and 2153 
macrophages. Immunohistochemistry demonstrated differential protein abundance for BNC2, 
PBX3, RBFOX1, TBX2, and TBX3 in enteric neuron subtypes. Conditional Tbx3 loss reduced 
NOS1-expressing myenteric neurons. Differential Gfra1 and Gfra2 expression coupled with calcium 
imaging revealed that GDNF and neurturin acutely and differentially regulate activity of ~50% of 
myenteric neurons with distinct effects on smooth muscle contractions. This insight into enteric 






 The enteric nervous system (ENS) is a network of neurons and glia within the bowel wall 
that controls gut motility, mucosal immunity, epithelial function and proliferation, along with 
vasodilation in response to local and extrinsic stimuli (1–3). Thus, ENS defects can cause 
debilitating bowel dysfunction. Defects include developmental anomalies like Hirschsprung disease 
(HSCR) and primary chronic intestinal pseudo-obstruction. Acquired ENS defects occur in 
achalasia, Parkinson’s disease, Chagas, and probably gastroparesis and irritable bowel syndrome. 
Unfortunately, we currently have limited ability to identify missing or defective ENS cell populations 
in people with bowel dysmotility and available therapies are often ineffective. Even if missing cells 
were identified, neurotransmitters, receptors, and signaling pathways that may be therapeutic 
targets in the ENS are poorly defined. Potential new therapies include stem cell replacement (4), 
trophic factor-induced regeneration (5) and repurposing medicines based on genetic 
polymorphisms that underlie symptoms. Each strategy would benefit from detailed data about ENS 
gene expression. 
Our goal was to use single cell RNAseq in mouse and human enteric neurons to gain new 
insight into enteric neuron subtype identity, regional neuron identity, and to learn more about how 
RET ligands impact neural activity and motility in adult mice. As our studies proceeded, other 
groups described single cell ENS RNAseq data from P21 mouse small bowel (6) and adult mouse 
bowel with or without gut microbes (7). New bioRxiv papers also provide single cell RNAseq data 
from adult mouse and human colon (8), and from E15.5, E18.5, and P21 mouse small bowel (9). 
Each manuscript has a unique focus. These data, along with our analyses, provide the rich tapestry 
of ENS gene expression information needed for progress in diagnosing and treating bowel motility 
disorders. 
The RNA-seq data collectively define 8-12 myenteric neuron types and >20 total enteric 
neuron types, plus 4-7 types of enteric glia, consistent with anatomic and functional analyses over 
decades (2,10–13). Here we focus on distinctions between myenteric nitrergic (nitric oxide 
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producing) and cholinergic (acetylcholine producing) neurons, which comprise >89% of human and 
>95% of mouse myenteric neurons (14,15). We found many cell type-specific ion channels, 
neurotransmitters, adhesion proteins, and signaling pathways supporting functional connectivity, 
and identified >40 differentially expressed transcriptional regulators, including Tbx3, which is 
preferentially expressed in neuronal nitric oxide synthase (NOS1)-producing myenteric neurons. 
Tbx3-/- mice had a 30% reduction in NOS1 neurons. We also found that Pbx3 is preferentially 
expressed in cholinergic neurons, consistent with a report that Pbx3-/- mice have fewer CALB1+ 
cholinergic neurons (9). Further, Pou3f3 marks colon, but not small bowel, neurons from early 
development to adulthood, consistent with distinct ENS organization and function in colon versus 
small bowel.  
An additional major distinction is that nitrergic neurons predominantly express Gfra1, but 
cholinergic neurons express Gfra2 in adult and E17.5 mouse myenteric plexus. GFRA1 and GFRA2 
are cell surface receptors that bind preferentially to glial cell line-derived neurotrophic factor 
(GDNF) and neurturin (NRTN), respectively, and this binding activates RET kinase. RET impacts 
many signaling pathways and has clear trophic effects (16), but if the only purpose of 
GDNF/GFRA1 and of NRTN/GFRA2 signaling was to activate RET, it is unclear why distinct trophic 
factors and co-receptors would be advantageous once development is complete. We thus used 
calcium imaging to test the hypothesis that GDNF and NRTN acutely affect ENS function and bowel 
motility. We discovered strikingly different effects of these trophic factors on GCaMP6s activity in 
enteric neurons. Collectively, our single cell RNAseq data provide highly validated information 
about gene expression in mouse and human ENS and a new foundation for ENS cell classification. 
Our novel observations about TBX3, GDNF/GFRA1, NRTN/GFRA2, POU3F3, and many other 
genes also offer distinct new insights that could facilitate stem cell or trophic factor based therapies 






Single nucleus RNA-sequencing defines mouse distal colon enteric neuron subpopulations  
Isolating ENS cells from adult mouse distal colon was challenging. Many approaches did 
not work well (Supplementary Table 2.1). Ultimately, myenteric plexus nuclei were isolated from 
47-52 day old Wnt1-CreCre/wt; R26R-LSL-H2B-mCherry mice that express the fluorescent nuclear 
protein Histone 2B-mCherry (Supplementary Figure 2.1A-D). Cryosectioning disrupted muscle, 
improving yield. Dounce homogenization released nuclei (Figure 2.1A). 10x Genomics platform 
generated data from 1,520 mCherry+ neuronal (Figure 2.1B) and glial nuclei. Because of low read 
depth we included intronic reads, yielding a mean of 2,970 unique molecular identifiers (UMI, 
number of unique RNA molecules sequenced) and 1,549 genes per cell. 
Using CellRanger and Seurat (17,18), we identified 12 clusters: 4 glial (Plp1+ and Sox10+), 
4 neuronal (Elavl4+), and several non-ENS (6.5% of total), including Pdgfra+ (PDGFRα+ cells), 
Kit+ (interstitial cells of Cajal, ICC), and Actg2+ (smooth muscle cells (SMC); Supplementary 
Figure 2.1E-J). Mean UMI and gene counts were higher for neurons than glia (Neurons: 4,629 UMI 
and 2,217 genes; Glia: 1,780 UMI, 1,069 genes; Figure 2.1C). To refine analyses, we re-clustered 
neuronal groups (Figure 2.1B) and identified 7 clusters (635 neurons total).  
Two neuron groups (Nos1 and Nos2) express Nos1, Vip, and Gal, consistent with known 
co-expression in inhibitory motor neurons and interneurons that have NOS1+/VIP+ nerve terminals 
within circular smooth muscle and myenteric ganglia respectively (13,19). Chat1 cells express 
choline acetyl-transferase (Chat) and preprotachykinin (substance P precursor, Tac1), but not 
proenkephalin (Penk), consistent with excitatory motor neurons or intrinsic sensory neurons 
(20,21). Chat2 cells express Chat, Tac1 and Penk, a combination marking guinea pig ileum 
excitatory motor neurons and ascending interneurons. Chat3 cells express Chat, Tac1, Penk, and 
hepatocyte growth factor receptor Met (Figure 2.1D, E, Supplementary Figure 2.2E). We tested 
if Tac1 and Penk expression could differentiate between motor- and interneurons. 
Immunohistochemistry showed that in circular smooth muscle, 55.3± 8.4% of varicosities 
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containing substance P (SP) do not contain enkephalin (ENK; Supplementary Figure 2.1K-M, S), 
but in myenteric ganglia, ~25% of SP terminals lack ENK and vice versa (Supplementary Figure 
2.1N-P, S). An additional clustered neuron group appeared heterogeneous. We manually divided 
these neurons into Chat4 that express Chat, Penk, and Slc17a6 (encodingVGLUT2) and Calcb that 
express Calcb (Calcitonin Related Polypeptide Beta), Grp (Gastrin releasing peptide) and Nmu 
(Neuromedin U)). We hypothesize that Chat4 are interneurons since VAChT+/VGLUT2+ terminals 
were reported in mouse distal colon myenteric ganglia, but not muscle (22) Chat/Penk/Vglut2 
neurons also express Calb1, a calcium-binding protein in mouse interneurons (13,23,24). To further 
validate Vglut2/Chat co-expression, we bred Vglut2-IRES-Cre;TdTomato x ChAT-L10A-EGFP and 
found 95.9 ± 0.9% of TDTOMATO+ neurons in myenteric plexus co-expressed EGFP 
(Supplementary Figure 2.1T-V). 
Many neurotransmitters (Figure 2.1E; Supplementary Figure 2.2A) and neurotransmitter 
receptors (Figure 2.1F; Supplementary Figure 2.2B) were differentially expressed between 
neuron subgroups, including receptors for acetylcholine, glutamate, serotonin, opioids, and 
purines. Neuron groups also differentially expressed ion channels (Supplementary Figure 
2.2C,D), signaling molecules (Supplementary Figure 2.2E,F), axon guidance molecules, 




Figure 2.1: Adult mouse distal colon myenteric plexus RNAseq defines neuron and glia 
subtypes. 
(A) Single nucleus RNAseq workflow. (B) T-SNE plot of enteric neuron and glial clusters. (C) Violin 
plots for neuron and glia clusters. (D) Feature plots for selected markers highlight neuron subtypes. 
Color shows loge(normalized gene expression). (E, F) Heatmaps show expression of commonly 
used enteric neuron markers with >0 detected reads (E) and neurotransmitter receptors (F). (E-F) 
Colors show loge(normalized mean gene expression). 
 
Single-nucleus sequencing reveals distinct roles for GDNF and NRTN in mouse distal colon. 
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We were particularly intrigued that Gfra1 and Gfra2, preferred receptors for GDNF and 
NRTN respectively, were abundant in glia but differentially expressed in neuron subsets. Gfra2 was 
primarily in Chat+ neurons (Figure 2. 2A-B), consistent with prior studies (25,26). Gfra1 was 
primarily in Nos/Vip/Gal+ neurons. We could not find prior reports of Gfra1-restricted expression in 
adult mouse ENS, so we tested if NOS1 colocalized with GFP in distal colon of Gfrα1Gfp/wt mice that 
express GFP from a Gfra1 locus (27). GFP was in 88.9±1.8% of NOS1+ neurons, 8.8±5.7% of 
NOS1-negative neurons (Figure 2.2D-E), and in S100β+ glia (Supplementary Figure 2.3A) 
consistent with RNAseq. Coupled with the observation that GDNF acts acutely in the ascending 
peristaltic response (28), our data suggest GDNF and NRTN have opposing acute effects on bowel 
contractility, although both activate RET. 
To test this, we recorded myenteric neuron calcium transients in GDNF or NRTN-treated 
full-thickness colon of E2a-Cre;R26R-GCaMP6s mice that express the calcium indicator GCaMP6s 
in all cells (Figure 2.2F-G). We also simultaneously monitored colon movement, an indirect 
measure of muscle tension (29). GDNF and NRTN increased or decreased spontaneous GCaMP6s 
activity in 50% (260/523) of all myenteric neurons (Figure 2.2H-J). Only 8.3% responded to both 
GDNF and NRTN (Figure 2.2I) suggesting most effects are via their preferred receptors, GFRA1 
and GFRA2 respectively. To test this, we identified nitrergic neurons post-hoc in 3 fields. 63% 
(29/48) of neurons responding only to GDNF were nitrergic, while 25% (17/68) NRTN-only 
responders were nitrergic (Supplementary Figure 2.3B-G). The high percentage of non-nitrergic 
neurons responding to GDNF suggested some changes in GCaMP6s activity were due to synaptic 
connectivity. Remarkably, when we added the  voltage-gated sodium channel blocker, tetrodotoxin 
(TTX), only 3-4% of myenteric neurons were GDNF- or NRTN-responsive, and only 7-8% 
responded in the presence of the nicotinic acetylcholine receptor antagonist, hexamethonium, with 
almost no overlap between GDNF- and NRTN-influenced cells (Figure 2.2K-L and 
Supplementary Figure 2.3H-I). This suggests that GDNF and NRTN have direct and indirect 
effects on GCaMP6s activity in distinct myenteric neurons.  
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GDNF also increased myenteric neurons responding to oral electrical field stimulation 
(EFS) by 71.3 ± 17.5% (p=0.0068), but did not affect responses to EFS applied aboral to recorded 
ganglia (p=0.49; Suppl. Fig. 3J-K). In contrast, NRTN did not affect the percentage of EFS-
responsive myenteric neurons, regardless of stimulus location (p=0.116 aboral, p=0.188 oral; 
Supplementary Figure 2.3L-M). GDNF and NRTN both altered which neurons responded to oral 
and/or aboral EFS (data not shown). Further, GDNF robustly increased spontaneous  and oral 
EFS-induced movement in the imaging field (p=0.0230, Supplementary Figure 2.3J,N). NRTN 
decreased movement in 3 of 5 preparations, but this was not statistically significant (Figure 2.2M-
O). These observations suggest that GDNF and NRTN influence distinct myenteric neurons and 




Figure 2.2: GDNF and NRTN acutely influence GCaMP activity of largely non-overlapping 
adult distal colon myenteric neuron populations. 
(A-C) Feature plots show Gfra1 is primarily in Nos1/Vip/Gal neurons (A), Gfra2 is in Chat neurons 
(B), and Ret is in almost all neurons except Chat 3 (C). (D) Whole mount immunohistochemistry 
shows GFP (green) in most NOS1+ (red) neurons of Gfra1Gfp/wt distal colon. White arrowheads, 
GFP+, NOS1+ neurons. Yellow arrowhead, GFP-, NOS1+ neuron. (E) Most NOS1+ neurons are 
GFP+. Most NOS1- neurons are GFP-, consistent with RNAseq (p<0.0001, Student’s t-test, n=3 
mice (Gfra1Gfp/wt)). (F-G) Time-lapse images (top; pixels assigned color based on timing of 
transients; i.e., color=activity) and traces (bottom) of GCaMP6s activity from ROIs on myenteric 
neurons during baseline (left) and after addition of 10 nM GDNF (F) or NRTN (G) (right). (H) Sample 
traces from neurons with activity increased (top) or decreased (bottom) by GDNF (red) or NRTN 
(blue). Baseline (gray) and percent neurons (in parentheses) with increased or decreased activity 
(>2 standard deviation change). (I) Percent neurons responding only to GDNF (red), only to NRTN 
(blue), or both (gray) (P<0.05, one-way ANOVA with Tukey’s multiple comparisons test). (J) Iris 
plot of GDNF and NRTN responsive myenteric neurons (49.7% of total neurons, 260 of 523 total 
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neurons). GDNF (outer circle, red). NRTN (inner circle, blue) (n=5 mice). White, no ligand-induced 
activity change. Light shades indicate decreased activity after ligand addition. Most responsive 
neurons are affected by either GDNF or NRTN, but not both. (K-L) Heatmaps of GCaMP6s activity 
before and after adding the voltage-gated sodium channel blocker tetrodotoxin (TTX) and during 
sequential addition of GDNF and NRTN. Colors indicate GCaMP signal amplitude (red, no activity). 
(K) Heatmap of all neurons  (n=301 neurons, 4 independent colon sections, 1 mouse). Dotted box 
shows GDNF- and NRTN-responsive neurons. (L) Expanded heatmap of 13 neurons that were 
only GDNF-responsive, 11 neurons only NRTN-responsive, and 3 neurons that responded to both. 
(M, N) Sample traces (left) and graph (right) of tissue displacement at baseline and after GDNF (M) 
(P=0.022, ratio paired t-test) or NRTN (N) (P=0.1583, ratio paired t-test). (O) GDNF, but not NRTN,  
enhanced tissue movement (P<0.01, unpaired t-test). (E,I,O) Mean +/- SEM. (D,F,G) Scale 
bar=100 microns. *p<0.05, **<0.01, ****p<0.0001. 
 
Sequencing suggests combinatorial transcription factor codes define neuron subtypes. 
To gain insight into neuronal subtype identity, we examined transcription and splicing 
factors ('regulatory genes') in adult colon myenteric neurons. Some genes that affect ENS subtype 
ratios (e.g. Ascl1, Hand2, and Sox6) were not differentially expressed in adults, but others not yet 
known to affect subtype specification were differentially expressed (e.g. Tbx3, Tlx2, and Zeb2; (30–
32); Figure 2.3A; Supplementary Figure 2.2G). Many other transcription factors had distinct 
expression patterns in neuron subgroups including Pbx3, Etv1, Casz1, Bnc2, and Zfhx3. Consistent 
with data from other nervous system regions (33), few transcription factors were expressed in only 
one neuron subpopulation, suggesting combinatorial codes regulate enteric neuron phenotype 
(Figure 2.3A; Supplementary Figure 2.2G). 
We focused on regulatory genes differentially expressed in cholinergic or nitrergic neurons, 
as most myenteric neurons express Chat or Nos1, but not both. We used ChAT-EGFP-L10A mice 
that reliably express EGFP at high levels in CHAT+ cells, since antibody staining is often weak 
(34). Consistent with RNAseq, SATB1, RBFOX1, and PBX3 immunoreactivity was preferentially in 
Chat-EGFP+ neurons, and TBX3 was primarily in NOS1+ neurons (Figure 2.3B-F; I-L). RNAseq 
also suggested Etv1 enrichment in NOS1+ neurons. To validate this, we treated Etv1-
CreERT2Cre/wt;R26R-TdTomato mice with high-dose tamoxifen to induce TDTOMATO from Etv1+ 
regulatory elements. TDTOMATO was in 56.4±3.6% of NOS1+ and 5.6±0.9% of NOS1- myenteric 
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neurons (Figure 2.3B,H, N). Also consistent with RNAseq, PHOX2B protein had similar abundance 
in Chat-EGFP+ and Chat-EGFP- myenteric neurons (Figure 2.3B,G, M). Distribution of these 
transcription factors between Chat-EGFP+ and NOS1+ neurons is summarized in Figure 2.3O-P. 
These quantitative analyses show substantial correlation between protein and single-nucleus 
RNAseq data (Figure 2.3A). 
 
Figure 2.3: Regulatory genes in distinct adult ENS subsets.  
(A) Transcription and splicing factors with known roles in ENS development (top). Differentially 
expressed factors newly identified in this study (bottom). n.s. = not significantly differentially 
expressed between neuron clusters. Color key shows loge(normalized mean gene expression 
within each cluster). (B) Feature plots of select regulatory genes. Color key shows loge(normalized 
gene expression). (C-G) Myenteric plexus wholemount immunohistochemistry in young adult 
ChAT-EGFP-L10A distal colon shows expression in neuron subsets. (H) Wholemount myenteric 
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plexus immunohistochemistry in distal colon from tamoxifen-treated Etv1-CreErt2;R26R-TdTomato 
mice. TDTOMATO is in many NOS1+ neurons and  some non-neuronal cells with ICC morphology. 
(I-M) Quantification of immunohistochemistry. TBX3 is mostly in nitrergic (NOS1+) neurons (I, 
p<0.0001, n=3). SATB1 (J, p=0.013, n=3), PBX3 (K, p<0.0001, n=3), and RBFOX1 (L, p=0.0006, 
n=3) are mostly in cholinergic (EGFP+) neurons, consistent with single-cell data. PHOX2B is 
equally abundant in Chat-EGFP+ and Chat-EGFP- cells (M, p=0.2193, n=4). (N) Quantification of 
(H) shows 56.4±3.6% of NOS1+ neurons are TDTOMATO+. Only 5.6±0.9% of NOS1- neurons are 
TDTOMATO+ (p=0.0002, n=3). (O-P) Cholinergic (Chat-EGFP+, O) and nitrergic (NOS1+, P) 
identity for cells expressing select factors. SATB1 (p=0.0022), PBX3 (p=0.0026), and RBFOX1 
(p=0.019) are largely restricted to cholinergic (Chat-GFP+) neurons. PHOX2B is in both cholinergic 
and non-cholinergic neurons (p=0.370) (P values compare Transcription 
factor+EGFP+/Transcription factor+ versus EGFP+/Total neuron ratios). TBX3 (p<0.0001) and 
ETV1 (p<0.0001) are primarily in nitrergic (NOS1+) neurons (P values compare Transcription 
factor+NOS1+/Transcription factor+ versus NOS1+/Total neuron ratios). (J-P) Student’s t-test. (I) 
ANOVA with Tukey’s post-hoc test. Scale bar = 100 microns. ChAT-EGFP-L10A = Chat-EGFP. 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
 
Adult neuron subtype transcription factor patterns are largely established by E17.5 
In mice, CHAT+ and NOS1+ enteric neurons are identifiable by late gestation and appear 
lineage committed (35,36). To identify lineage specific transcription factors at E17.5, we performed 
RNAseq using whole bowel from ChAT-L10a-EGFP wt/wt; Nos1-CreERT2Cre/wt;TdTomato+ and 
ChAT-L10a-EGFP+; Nos1-CreERT2wt/wt;TdTomato+ littermates after E15.5 tamoxifen treatment. In 
these mice, EGFP marks CHAT-lineage and TDTOMATO identifies NOS1-lineage neurons (Figure 
2.4A). 1005 cells were sequenced at 83% saturation. We normalized after removing outliers, 
leaving 707 neurons (Elavl4+), 179 epithelial (Epcam+), and 67 smooth muscle cells (Actg2+) 
(Supplementary Figure 2.4A-B). Reclustering without epithelia and muscle yielded 8 neuron 
clusters (Figure 2.4B), which all had high Ret expression, but were still Dcx+, a marker of immature 





Figure 2.4: Single-cell RNAseq of E17.5 ChAT-EGFP-L10A+ and Nos1-CreERT2Cre/wt;R26R-
TdTomato+ neurons show distinct nitrergic and cholinergic clusters. 
(A) Workflow for RNAseq. (B) T-SNE plot shows neuron subpopulations. (C) Violin plots show 
subgroups had 25,319.7±5562.2 unique RNA transcripts (UMI) and 5291.6±558.8 detected genes 
(nGene) per cell. (D-F) Heatmaps show commonly used enteric neuron markers with > 0 detected 
reads (E), neurotransmitter receptors (F), and ion channels. Color shows loge(normalized mean 
gene expression). (D) *Indicates differential expression across neuron subtypes. (E-F) Genes listed 




Chat transcripts were rare as others reported (8,9), but vesicular acetylcholine transporter Slc18a3 
was highly expressed in neuron clusters with low Nos1 (Supplementary Figure 2.4C-D). Three 
clusters appeared less mature, prominently expressing neurite projection and cytoskeleton 
reorganization genes, based on Gene Ontology (GO) term analysis. Other clusters expressed 
synaptogenesis and maintenance genes suggesting more mature neurons (Supplementary 
Figure 2.4F-G). As in adults, many neurotransmitters, receptors, ion channel subunits, and 
signaling molecules were differentially expressed between subgroups (Figure 2.4D-F and 
Supplementary Figure 2.5A-E), including Gfra1 and Gfra2 (Supplementary Figure 2.5D-E). 
Many differentially expressed regulatory genes identified in adult mouse ENS were also 
differentially expressed in neuron subsets at E17.5, including Casz1, Bnc2, Etv1, Pbx3, Tbx2, Tbx3, 





Figure 2.5: Many differentially expressed regulatory genes at E17.5 are also differentially 
expressed in adult distal colon. 
(A) Transcription and splicing factors with known roles in ENS development (top), and newly-
identified in this study (bottom). n.s. = not significantly differentially expressed between clusters. 
(B) Feature plots. (A,B) Colors show loge (normalized mean gene expression). (C-G) Whole-mount 
immunohistochemistry of E17.5 ChAT-EGFP-L10A mid-small intestine. (H-L) Quantification of 
immunohistochemistry. BNC2 (H, p=0.0005, n=3), PBX3 (I, p=0.0119, n=3), RBFOX1 (J, p=0.0012, 
n=3), and TBX2 (K, p<0.001, n=3) are primarily in cholinergic (Chat-GFP+) neurons. TBX3 (L, 
p<0.0001, n=3, ANOVA with Tukey’s post-hoc test) is primarily in NOS1+ neurons. (M-N) 
Quantification of cholinergic (Chat-EGFP+, M) and nitrergic (NOS1+, N) identity. Neurons 
expressing BNC2 (p=0.0018), PBX3 (p=0.0165), RBFOX1 (p<0.0001), and TBX2 (p=0.0016) are 
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primarily cholinergic (Chat-GFP+) neurons (P values compare Transcription 
factor+EGFP+/Transcription factor+ versus EGFP+/Total neuron ratios). TBX3+ neurons (p=0.003) 
are primarily nitrergic neurons (P values compare Transcription factor+NOS1+/Transcription 
factor+ versus NOS1+/Total neuron ratios). (H-L) Mean +/- SEM. (C-P) ChAT-EGFP-L10A reporter 
= Chat-EGFP. (H-K,M-N) Student’s t-test. (L) ANOVA with Tukey’s post-hoc test. Scale bar = 50 
µm. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.  
 
Conditional Tbx3 loss reduced NOS1+ myenteric neuron density, but Etv1 and Rbfox1 loss 
did not alter CHAT/NOS1 subtype ratios 
For several differentially expressed regulatory genes we determined if mutations altered 
nitrergic or cholinergic enteric neuron abundance. We found that P0 Wnt1-Cre;Tbx3fl/fl;R26R-
Tdtomato mice lacking TBX3 in ENS had a ~30% lower NOS1+ neuron density in small bowel, 
despite normal total neuron density (Figure 2.6A-D). In contrast, P0 mice lacking Etv1 (Etv1-Cre-
ERT2cre/cre;ChAT-L10A-EGFP), which is enriched in nitrergic neurons, had normal NOS1+ to Chat-
EGFP+ enteric neuron ratios (Figure 2.6E-H). Chat-EGFP+ neuron density was also normal in 
Rbfox1 mutants (Wnt1-Cre;Rbfox1fl/fl;Chat-EGFP-L10A) despite Rbfox1 enrichment in cholinergic 
neurons (Figure 2.6J-M). Colonic bead expulsion latency tests were also normal in adult Etv1 
(Figure 2.6I) and Rbfox1 (Figure 2.6N) mutant mice, suggesting intact ENS-mediated distal colon 
motility. Collectively, these findings suggest TBX3 impacts NOS1+ neurons, but ETV1 and 




Figure 2.6: Tbx3 loss in ENS reduces NOS1+ myenteric neurons, but NOS1+ or Chat-EGFP+ 
neuron abundance and colon bead expulsion was normal in Etv1 and Rbfox1 mutants. 
POU3F3 is restricted to colon ENS. 
(A-B) Confocal maximum-intensity projections of NOS1+ (green) and total HuC/D (magenta) 
neurons  in Tbx3 mutant and control P0 small bowel. (C-D) Quantification shows 30% reduction in 
NOS1+/Total neuron ratio in Wnt1-CreCre/wt;Tbx3fl/fl P0 small bowel (C; p=0.041, n=3 per group) 
despite normal total neuron density (D; p=0.601, n=3 per group). (E-F) Confocal maximum-intensity 
projections of P0 small bowel. (E) Control and (F) Etv1-CreERT2Cre/Cre bred to Chat-EGFP-L10A 
and stained for EGFP (green), NOS1 (red), and HuC/D (blue). (G) Quantification shows normal 
NOS1+ and Chat-EGFP+ neuron ratios (p=0.797, two-way ANOVA, n=4 in each group) and normal 
neuron density (H; p=0.117, n=4 in each group) in Etv1 mutant P0 small bowel. (I) Colonic bead 
expulsion latency is normal in Etv1-CreERT2Cre/Cre mice (p=0.429, n=6 control, M=3/F=3, P45-50 
at start of assay), n=5(Etv1-CreERT2Cre/Cre, M=3/F=2, P49-58 at start of assay)). (J-K) Single 
confocal planes in P0 small bowel of control (J) and Wnt1-CreCre/wt;Rbfox1fl/fl (K) bred to Chat-
EGFP-L10A and stained for EGFP (green) and HuC/D (magenta). (L,M) Quantification shows that 
proportion of EGFP+ neurons (p=0.162, n=4 per group) and total neuron density (p=0.470, n=4 per 
group) are normal in Rbfox1 mutants. (N) Colon bead expulsion latency is normal in Wnt1-
CreCre/wt;Rbfox1fl/fl mice (N; p=0.2677, n=5(control, M=2/F=3, P44-46 at start of assay), n=6(Wnt1-
CreCre/wt;Rbfox1fl/fl, M=2/F=4, P46-58 at start of assay)). (O-P) Whole mount shows POU3F3 in 
colon and cecum but not ileum at E14.5 (O) and E17.5 (P). (O) Epifluorescence, unstitched. (P) 
Flattened, stitched confocal Z-stack. (Q) Representative RT-PCR for flow sorted TDTOMATO+ 
ENS cells from Wnt1-Cre;R26R-TdTomato mice confirms Pou3f3 in fetal colon but not small 
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intestine (SI). (C-D, G-I, L-N) Mean +/- SEM. (C-D,H,K-L) Student’s t-test. (I,N) Mann-Whitney. (A-
B,E-F,J-K) Scale bar=100 µm. (O) Scale bar = 500  µm. (P) Scale bar = 1 mm. ChAT-EGFP-L10A 
= Chat-EGFP. *p<0.05. 
 
Pou3f3 is expressed in colon, but not small intestine ENS 
In addition to subtype identity, regional differences in neurons could promote different 
motility patterns. We were intrigued by the observation that Pou3f3 (a.k.a. Brn1), a transcription 
factor important for CNS development (38), was mostly restricted to E17.5 immature Chat2 and 
immature Nos1 clusters (Supplementary Figure 2.6A-B). Since colon ENS matures after small 
bowel, this could be explained by Pou3f3 enrichment in colon ENS, a hypothesis confirmed by RT-
PCR (Figure 2.6Q). Immunohistochemistry using two antibodies showed POU3F3 marks all 
immature and mature colon neurons, but no small bowel neurons (Figure 2.6O-P, Supplementary 
Figure 2.6C-X), as recently reported by others (7). Human colon also showed POU3F3 in the 
nucleus of all submucosal and myenteric neurons. Human small bowel submucosal neurons lacked 
POU3F3, but some small bowel myenteric neurons had cytoplasmic POU3F3 immunoreactivity of 
uncertain significance (Supplementary Figure 2.6Y-V’). These data significantly extend recent 
reports that colon, but not small bowel, enteric neurons express POU3F3. 
Using Pou3f3 to mark E17.5 colon neurons (Supplementary Figure 2.6W’) and restricting 
comparisons to only mature or immature clusters based on GO terms, we identified 5 genes 
differentially expressed  in Pou3f3+ versus Pou3f3- enteric neurons of immature clusters (Slc18a3, 
Klhl1, Dpysl3, Gna14, and Itm2a, Supplementary Figure 2.6X’) and 3 genes differentially 
expressed in Pou3f3+ versus Pou3f3- enteric neurons of mature clusters (Ahr, Pantr1, Zfhx3, 
Supplementary Figure 2.66Y’). Ahr, Pantr1, and Zfhx3 patterns resemble Pou3f3 (Pearson 
Correlation, compare Supplementary Figure 2.6B to Supplementary Figure 2.6A’’) and others 
recently reported Ahr enrichment in colon ENS (7). Differentially expressed genes in immature 
clusters seem less likely to be colon restricted since patterns (Supplementary Figure 2.6Z’) are 
distinct from Pou3f3 (Supplementary Figure 2.6B). Instead, differential expression of Slc18a3 
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(vesicular acetylcholine transporter) and Klhl1 (P/Q-type calcium current density modulator) may 
reflect neuron maturation (39). Dpysl3, a cytoskeletal regulator, was in all groups, but 32% more 
abundant in Pou3f3+ cells (Supplementary Figure 2.6Z’). Gna14, and Itm2a are under-
investigated, but at the highest levels in immature Chat clusters.  
 
Adult human myenteric plexus 
From human colon we sequenced single nuclei of the myenteric plexus region. Human 
enteric neurons comprise <1/10,000 cells and separating ENS from surrounding muscle was 
difficult. To identify ENS and aid microdissection of the myenteric plexus layer, we stained live 
colon with 4-Di-2-Asp (Supplementary Figure 2.7A), a dye taken up by mitochondria in 
presynaptic nerve terminals. We unsuccessfully attempted single cell RNAseq after ENS 
microdissection. Isolating neuronal nuclei using NeuN (40) or PHOX2B antibody staining was 
likewise unsuccessful. Ultimately, we obtained data from a limited number of human colon 
myenteric neuron nuclei by microdissecting using 4-Di-2-Asp, freezing in O.C.T., sectioning, 
Dounce homogenizing, and flow sorting Hoechst+ single nuclei from cell debris. 10x Genomics 
(Figure 2.7A) yielded RNAseq data from 20,167 nuclei of 16 adult colons (Supplementary Table 
2.4) with a mean of 1,455 UMI and 894 genes per nucleus (Supplementary Table 2.5). Our data 
included many smooth muscle, ICC, PDGFRα+ cells, enteric glia, muscularis macrophage, 
vascular endothelial and hematopoietic cells (Figure 2.7B; Supplementary Figure 2.7B-J; i.e., 
most cells that impact bowel motility). One cluster of 48 cells was strongly positive for neuronal 
genes like ELAVL4, SNAP25, and UCHL1 (Supplementary Figure 2.7N-R). Because of small cell 
numbers, we used hierarchical Euclidean clustering based on the top 50 markers distinguishing 
neurons from other cells. This gave two distinct clusters (Figure 2.7C) that differ in 
NOS1/VIP/GAL+ expression. CHAT and SLC18A3 (VAChT) transcripts were not detected in either 
neuron subgroup, probably due to low read depth, as low CHAT was also noted by other groups 
(8,9). We next asked if any of the 41 transcription or splicing factors differentially expressed in 
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mouse Nos1+ versus Chat+ myenteric neurons were also differentially expressed in human enteric 
neuron subtypes. Consistent with mouse data, ETV1 was most abundant in NOS1+ neurons, while 
RBFOX1 and BNC2 were enriched in NOS1- neurons (Figure 2.7D) after multiple comparison 
testing. Immunohistochemistry confirmed BNC2 (Figure 2.7E-H,Y), PBX3 (Figure 2.7I-L,Z), 
RBFOX1 (Figure 2.7M-P,A’), TBX2 (Figure 2.7Q-T,B’), and TBX3 (Figure 2.7U-X,C’) were 
differentially expressed in human enteric neuron subtypes, with patterns similar to mouse (i.e. most 







Figure 2.7: Human myenteric plexus NOS1/VIP/GAL+ and NOS1/VIP/GAL- neurons 
differentially express many regulatory genes also differentially expressed in mouse ENS. 
(A) Workflow for single-nucleus RNAseq of adult human colon myenteric plexus. (B) T-SNE plot of 
20,167 nuclei shows glia, ICC, muscularis macrophages, Pdgfrα+ cells, smooth muscle, T cells, 
endothelium, and unknown groups. Neurons comprise one small cluster (~48 cells). (C) Heatmap 
shows 50 genes with the highest fold difference between neurons and other cells. Hierarchical 
clustering suggests 2 subgroups: NOS1+/VIP+/GAL+ (17 neurons) and NOS1-/VIP-/GAL- (31 
neurons). (D) Heatmap shows transcription and splicing factors differentially expressed in mouse 
colon that were in >10% of human myenteric neurons. RBFOX1, ETV1, and BNC2 were 
differentially expressed between NOS1/VIP/GAL+ and NOS1/VIP/GAL- human neurons (Wilcoxon 
rank-sum test with Bonferroni correction). (E-X) Maximum intensity projections of confocal Z-stacks 
show adult human colonic ENS. BNC2 (E-H). PBX3 (I-L, white arrowheads indicate nuclear PBX3 
in neurons.), RBFOX1 (M-P), TBX2 (Q-T) and TBX3 (U-X) are present in subsets of human 
myenteric neurons. (Y-C’) Quantification of immunohistochemistry shows BNC2 (Y, p=0.0001, 
n=3), PBX3 (Z, p=0.0021, n=3), RBFOX1 (A’, p=0.0007, n=3), and TBX2 (B’, p=0.0089, n=3) are 
primarily in CHAT+ neurons. TBX3 (C’, p=0.0004, n=3) is primarily expressed in NOS1+ neurons. 
(Z-A’) Quantification of CHAT+ (D’) and NOS1+ (E’ cells reveals BNC2 (p=0.0102), PBX3 
(p=0.0021), RBFOX1 (p=0.0016), and TBX2 (p=0.0162) are largely restricted to CHAT+ neurons 
in adult human ENS (P values compare Transcription factor+EGFP+/Transcription factor+ versus 
EGFP+/Total neuron ratios). TBX3 (p=0.0073) is primarily in NOS1+ neurons (P values compare 
Transcription factor+NOS1+/Transcription factor+ versus NOS1+/Total neuron ratios). (Y-E’) Mean 
+/- SEM and Student’s t-test. *p<0.05, **p<0.01, ***p<0.001.  
 
2.4 Discussion 
Life-threatening bowel motility disorders like HSCR and chronic intestinal pseudo-
obstruction (41) are challenging to treat and difficult to diagnose. To facilitate molecular diagnostics, 
enhance understanding of ENS function, and advance new strategies like stem cell therapy (42,43), 
we used single-cell transcriptomics to identify a vast array of neurotransmitters, receptors, ion 
channels, signaling molecules, and mRNA regulatory genes. These data identified 7 mouse 
myenteric neuron subclasses in adult distal colon and 8 neuron groups at E17.5. 
Immunohistochemistry in mouse and human validated RNAseq, and functional studies identified 
new ENS roles for TBX3, GDNF and NRTN. Our analyses complement recent data from others 
examining different ages and bowel regions (6–9), providing a foundation for novel diagnostics and 
disease management.  
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Several transcription factors were differentially expressed in nitrergic versus cholinergic 
neurons. We therefore tested if gene loss altered Chat or Nos1 subtype abundance. We found that 
Tbx3 loss in Wnt1-lineage cells reduced NOS1+ myenteric neuron density, but not total neuron 
density. Interestingly, Tbx3 expression in limb bud is induced by the transcription factor HAND2 
(44), and Hand2 mutations cause complete loss of NOS1+/VIP+ enteric neurons (45), suggesting 
TBX3 also acts downstream of HAND2 in the ENS. In contrast, NOS1+ and Chat-EGFP+ neuron 
density was normal in Etv1 mutant mice although most adult NOS1+ myenteric neurons express 
Etv1 and ETV1 regulates CNS neuron subtype differentiation (46). Similarly, while the splicing and 
mRNA binding protein RBFOX1 (47,48) is present in most ENS cholinergic neurons and RBFOX1 
regulates CNS neuron subtype differentiation (49), the percentage of Chat-EGFP+ myenteric 
neurons was normal in Wnt1-CreCre/wt; Rbfox1fl/fl mice. Normal colonic bead expulsion latency in 
Etv1 and Rbfox1 mutant mice suggests redundant mechanisms in the ENS prevent obvious 
anatomic or functional defects.  
Another striking observation is that the transcription factor POU3F3 is found in the nucleus 
of all mouse and human colon enteric neurons, but not in small bowel neurons as another group 
recently confirmed (7). POU3F3 function in colon ENS is not known, but POU3F3 regulates cortical 
neuron migration and neurogenesis (50,51). Human mutations cause intellectual disability, speech 
delay, autism, epilepsy, craniofacial anomalies and cryptorchidism (52), but effects of POU3F3 
mutation on bowel function were not reported. Restricted colon expression is interesting because 
colon motility and ENS structure differ between colon and small bowel (13,19,23,24,53), but we 
know little about underlying developmental mechanisms. The observation that there are colon-
restricted ENS transcription factors suggests more intense investigation of regional gene 
expression in the ENS may be valuable. 
Human RNAseq yielded data from 17 NOS1+ and 31 NOS1- myenteric neurons as well as 
from many other cells that impact bowel motility. Guided by RNAseq, we found ETV1 was more 
abundant  in human nitrergic neurons, while RBFOX1 and BNC2 were enriched in non-nitrergic 
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neurons, suggesting subtype-specific genes may be conserved between humans and mice. 
Immunohistochemistry confirmed TBX3, PBX3, and TBX2 are also present in subsets of human 
enteric neurons as predicted by mouse data. 
Many other genes differentially expressed in enteric neuron subclasses may merit investigation. 
For example, ZEB2 mutations cause Mowat-Wilson syndrome, characterized by Hirschsprung 
disease (HSCR), intellectual disability and distinctive facial features. Post-surgical outcomes in 
Mowat-Wilson syndrome are worse than for isolated HSCR and ZEB2 mutations cause chronic 
constipation without HSCR (54,55) suggesting Zeb2 might have roles beyond bowel colonization 
by ENS precursors. Zfhx3, another HSCR-associated gene (56) drives neuronal differentiation in 
other regions, but roles in ENS subtype specification are unexplored. 
 
Integrating new and old data about ENS subtypes  
Using neurotransmitter-associated markers in adults (Supplementary Table 2.2) and at 
E17.5 (Supplementary Table 2.3), we correlated our RNAseq data with known ENS subtype 
markers. Subtype designations at E17.5 include small bowel and colon neurons (distinguished by 
Pou3f3) and immature clusters defined by Gene Ontology (GO) Term modules (Supplementary 
Figure 2.4F, G). The similarities between E17.5 small bowel and adult colon suggest that some 
aspects of neuron differentiation are similar across bowel regions and completed by E17.5. Many 
newly identified differentially expressed genes are highlighted in Supplementary Tables 2.2 and 
2.3. Some genes known to be expressed in enteric neuron subtypes were not detected (see 
Supplementary Table 2.2), but lack of expression is uninterpretable, because of limited read depth 
in adult colon nuclei. In adults, Calcb neurons appear to be AH/Dogiel type II intrinsic sensory 
neurons that express neurofilament M (Nefm), Nav1.9 (Scn11.1a), calretinin (Calb2), NK1 
tachykinin receptor (Tacr1), serotonin receptors Htr3A and Htr3b, and purine receptor P2rx2 
(19,57,58). Chat1 neurons express the mechanosensitive channel Piezo1 suggesting these cells 
are stretch sensitive intrinsic sensory neurons, but other sensory neuron markers are absent. There 
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are reports of mechanosensitive interneurons and motor neurons (59), so Chat1 neurons may 
correspond to these. Tac1 and Penk co-expression make Chat2 and Chat3 clusters excitatory 
motor neurons or interneurons (19), Supplementary Figure 2.1K-S). Unexpectedly, however, 
Chat3 neurons also express hepatocyte growth factor receptor Met and do not express CGRP 
(Calcb), suggesting Met+ colonic neurons may differ from small bowel where MET and CGRP were 
found in the same neurons by immunohistochemistry (60). Finally, Chat4 cells appear to be 
interneurons based on co-expression of Slc18a3, Chat, Nos1, Vip, and Calb1. Thus, many findings 
fit well with known neuron subtypes, and immunohistochemistry correlates well with RNAseq, 
providing high confidence in our results. We point out unexpected findings to suggest there is more 
to learn and that future studies based on our RNAseq are needed to fully define adult enteric neuron 
subtypes. 
Defining neuron subtypes at E17.5 presents an added challenge because differentiation is 
incomplete. Supplementary Table 2.3 highlights some markers differentially expressed in neuron 
subtypes. Since almost all cholinergic and nitrergic neurons at E17.5 remain cholinergic or nitrergic 
respectively in adults (35,36), we extrapolate from adult data. Assessment of maturity is based on 
GO Term analysis. Colon neurons were identified by Pou3f3 expression. Chat cluster 1 and Chat 
cluster 2 markers suggest small bowel excitatory motor neurons and intrinsic sensory neurons, 
respectively. Chat cluster 2 also expresses BMP and TGFβ signaling antagonists (Nog, Bambi, 
Smad7), which may provide new insights into ENS development. Immature Chat cluster 1 appears 
to be developing myenteric interneurons that express Slc17a6, similar to the adult Chat4 cluster. 
Nos1 clusters 1 and 3 are most likely inhibitory motor neurons, but could also be interneurons. 
Nos1 cluster 2 represents possible inhibitory interneurons based on the expression of the 
transcription factor Neurod6 (9). Interestingly, Nos1 cluster 1 differentially expresses Ednrb, but the 
role of Ednrb/EDN3 signaling at this time is not known. We highlight these observations to 




GDNF and NRTN acutely affect calcium signaling in distinct adult enteric neuron 
populations  
Our data also provide new insight into adult gene function. We knew already that 
GDNF/GFRA1/RET signaling is essential during gestation for ENS precursor survival, proliferation, 
and bowel colonization (61). As the ENS matures, GDNF/GFRA1/RET signaling enhances 
neuronal differentiation, increases neurite growth, and alters axon trajectories for NOS1+ enteric 
neurons (62). Then, in adults, GDNF increases the strength of bowel contraction in the ascending 
limb of the peristaltic response (28). We were therefore unsurprised that GDNF altered calcium 
signaling in some enteric neurons and that GDNF acutely enhanced basal and EFS-evoked motor 
patterns. In contrast, although NRTN/GFRA2/RET are known to influence bowel motility and 
support acetylcholinesterase+ and substance P+ neurites (25,26), acute effects of NRTN on the 
ENS or bowel motility had not been demonstrated. Our data confirm and extend prior observations. 
Gfra1 and Gfra2, preferred co-receptors for GDNF and NRTN respectively, are expressed in largely 
non-overlapping populations of Ret+ E17.5 and adult myenteric neurons. GFRA1 is in ~90% of 
NOS1+ myenteric neurons, but in very few NOS1- neurons, so we anticipated GDNF effects 
primarily in NOS1+ neurons. However, 44% (33/75) of GDNF influenced neurons were non-
nitrergic. This might occur because GDNF activates RET via GFRA2 (NRTN’s preferred co-
receptor) at high (pharmacologic) concentrations (63–65), but this seems unlikely since GCaMP6s 
signaling was altered by both GDNF and NRTN in only 8% of myenteric neurons. Instead, the 
observation that some neurons had increased and others decreased GCaMP activity in response 
to each trophic factor suggests both direct and indirect effects were measured and that responses 
may depend on synaptic inputs, as confirmed by TTX/hexamethonium data. The hypothesis that 
GDNF and NRTN sensitize responsive neurons to incoming stimuli is also supported by our prior 
studies of dorsal root ganglion neurons where these factors acutely potentiate TRPV1-induced 
calcium signals and induce hyperalgesia when injected into hindpaw (66). Although we do not know 
the source of calcium (e.g., intra- or extracellular) or whether evoked GCaMP signals were activity-
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dependent, our data collectively show that NRTN and GDNF acutely influence non-overlapping 
sets of myenteric neurons and differentially regulate bowel motility.  
 
Summary 
Bowel motility disorders remain poorly defined in part because the ENS is complicated and 
under-investigated. As we move into an era of advanced genetic testing for people with life-
threatening medical problems like chronic intestinal pseudo-obstruction, we remain hampered by 
inadequate data about enteric neuron subtypes that support normal bowel function. In addition to 
defining many subtype specific molecules, we demonstrated new roles for Tbx3, GDNF and NRTN, 
and showed colon- specific POU3F3 expression in enteric neurons at many ages, combining data 




Studies adhere to ARRIVE (Animals in Research: Reporting In Vivo Experiments) 
guidelines (69). Mouse experiments were performed in accordance with Institutional Animal Care 
and Use Committee (IACUC) approval from Children’s Hospital of Philadelphia (IACUC#19-
001041) and University of Pittsburgh (IACUC#IS00013297) or University of Melbourne Animal 
Experimentation Ethics Committee (project number 1714308.2). Human colon was acquired with 
Institutional Review Board approval from Perelman School of Medicine at University of 
Pennsylvania (IRB#804376) and from Children’s Hospital of Philadelphia (IRB#13-010357). 
 
Animals 
B6.FVB(Cg)-Tg(Chat-EGFP/Rpl10a,Slc18a3)DW167Htz/J mice (referred to as ChAT-
EGFP-L10a (RRID:IMSR_JAX:030250; C57BL/6J) were a kind gift from Dr. Joseph Dougherty at 
Washington University School of Medicine in St. Louis. Tbx3tm3.1Moon mice (referred to as Tbx3;  
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RRID:MGI:5538564; described previously (22); mixed background) were a kind gift from Dr. Anne 
Moon at Geisinger Commonwealth School of Medicine. B6.129S2-Rbfox1tm1.1Dblk/J mice 
(referred to as Rbfox1; RRID:IMSR_JAX:014089; C57BL6/J) were a kind gift from Dr. Douglas 
Black at the University of California Los Angeles. Gfra1tm2.1Jmi mice (referred to as Gfra1-Gfp; 
RRID:MGI:3715157, C57BL/6) were a kind gift of Dr. Sanjay Jain at Washington University School 
of Medicine in St. Louis. C57BL/6J mice (RRID:IMSR_JAX:000664), H2az2(Tg(Wnt1cre)11Rth 
mice (referred to as Wnt1-Cre; RRID:IMSR_JAX:003829), B6;129S6-Gt(ROSA)26Sortm1(CAG-
tdTomato*,-EGFP*)Ees/J mice (referred to as ROSAnT-nG; RRID:IMSR_JAX:023035), B6;129S-
Gt(ROSA)26Sortm1.1Ksvo/J mice (referred to as R26R-H2b-mCherry; RRID:IMSR_JAX:023139), 
B6(Cg)-Etv1tm1.1(cre/ERT2)Zjh/J mice (referred to as Etv1-CreERT2 mice; 
RRID:IMSR_JAX:013048), Slc17a6tm2(cre)Lowl/J mice (referred to as Vglut2-IRES-Cre mice; 
RRID:IMSR_JAX:016963), B6;129S-Nos1tm1.1(cre/ERT2)Zjh/J mice (referred to as Nos1-
CreERT2; RRID:IMSR_JAX:014541), Gt(ROSA)26Sortm9(CAGtdTomato)Hze mice (referred to as 
R26R-TdTomato; RRID:IMSR_JAX:007909), B6.FVB-Tg(EIIa-cre)C5379Lmgd/J (referred to as 
E2a-Cre RRID:IMSR_JAX:003724; C57BL/6), and B6J.Cg-Gt(ROSA)26Sortm96(CAG-
GCaMP6s)Hze/MwarJ (referred to R26R-Gcamp6s; RRID:IMSR_JAX:028866; C57BL/6) were 
obtained from The Jackson Laboratory (Bar Harbor, ME). Wnt1-Cre mice on a mixed C57BL/6J x 
CBA/J)F1 background were bred into R26R-H2b-mCherry mice on a mixed 129S4/SvJaeSor x 
C57BL/6J background and maintained on a mixed C57BL/6J x 129S4/SvJaeSor x CBA/J)F1 
background. Etv1-CreERT2 mice were bred to R26R-TdTomato mice and ChAT-EGFP-L10a mice 
to generate Etv1-CreERT2;R26R-TdTomato;ChAT-EGFP-L10a mice on a C57BL/6J background. 
Vglut2-IRES-Cre mice on a C57BL/6;FVB;129S6 background were bred to R26R-TdTomato on a 
C57BL/6J background and maintained on a mixed C57BL/6;FVB;129S6 background. Nos1-
CreERT2 mice were crossed with R26R-TdTomato mice and ChAT-EGFP-L10a mice to generate 
ChAT-EGFP-L10a; Nos1-CreERT2; R26R-TdTomato mice and maintained on a C57BL/6 
background. Rbfox1;Wnt1-Cre;R26R-TdTomato;ChAT-EGFP-L10a mice were generated by 
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crossing Rbfox1 mice to Wnt1-Cre mice, ChAT-EGFP-L10a mice, and R26R-TdTomato mice and 
were maintained on a mixed background. Wnt1-Cre;Tbx3 mice were generated by crossing Wnt1-
Cre mice to Tbx3 mice and were maintained on a mixed background. E2a-Cre mice were crossed 
with R26R-Gcamp6s mice to generate mice that express GCaMP6s (a genetically encoded calcium 
indicator) in all cells. E2a-Cre;R26R-GCaMP6s mice were maintained on a pure C57BL/6 
background. Genotyping was performed using previously published and novel primers 
(Supplementary Table 2.9) and by Transnetyx (Cordova, TN). Vaginal plug day was considered 
day E0.5. Experimental animals of the correct strain, genotype, and age were randomly selected 
from the total pool of mice available. General animal husbandry information for the mice used in 
this study is provided in Supplementary Table 2.10. 
 
Human colon 
Colon tissue was acquired with Institutional Review Board approval from Perelman School 
of Medicine at University of Pennsylvania (IRB #804376) and the Children’s Hospital of Philadelphia 
Institutional Review Board (IRB#13-010357) using the Abramson Cancer Center Tumor Bank. 
Colon was de-identified, providing limited clinical data. Resected colons were maintained at 
ambient temperature until arrival in pathology, where they were transferred to ice-cold Dulbecco-
modified PBS (DPBS) 1-4 hours after resection. Pathologists selected regions of colon without 
gross abnormalities, and colon specimens were transferred to the laboratory in DPBS on ice. 
 
Tamoxifen treatment  
Tamoxifen (10mg/mL or 20mg/mL; Sigma, Cat#T5648) was prepared by first adding 200 
uL ethanol and then 1800 uL sunflower oil (Sigma, Cat#S5007). Tamoxifen was dissolved by 
alternately vortexing and incubating in a 37ºC water bath. Nos1-creERT2;Chat-EGFP-L10A;R26-
TdTomato E15.5 dams were injected once with 200mg/kg tamoxifen at 10mg/mL concentration. 
Etv1-CreERT2;Chat-EGFP-L10A;R26-TdTomato E15.5 dams were gavaged once with tamoxifen 
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at 200mg/kg concentration at 20mg/mL concentration and pups were dissected at E17.5. Adult 
Etv1-CreERT2;R26-TdTomato adult mice were gavaged twice (two days apart) with 233mg/kg 
tamoxifen at 20mg/mL concentration three weeks prior to dissection. 
 
Preparing young adult mouse colon for nuclei isolation 
Wnt1-CreCre/wt;R26R-H2b-mCherry+ 47-52-day-old mice (8 females, 1 male) were 
euthanized with CO2. Colon was removed, flushed with cold, sterile Dulbecco’s phosphate buffered 
saline (DPBS) using a 20 mL syringe to remove luminal contents, and placed in fresh cold, sterile 
DPBS. Colon was carefully cut along the mesentery, pinned mucosal side down on dishes treated 
with Sylgard Elastomer 184 (Sylgard Elastomer 184 Silicone Encapsulant Clear, Dow Corning, 
Midland, MI). Muscularis was carefully peeled from the mucosa and placed in cold O.C.T. 
compound (Fisher Healthcare Tissue-Plus O.C.T. Compound; Thermo Fisher Scientific, Hampton, 
NH; Cat#23-730-571) in a biopsy specimen cryomold (VWR, Radnor, PA; Cat#4565), frozen in 
methylbutane on dry ice, and stored at -80°C. 
 
Preparing adult human colon for nuclei isolation 
Using insect pins (Fine Science Tools, Cat# 26002-20), colons were maximally stretched 
and pinned serosa side up on 30 mm dishes treated with Sylgard Elastomer 184 (Sylgard 
Elastomer 184 Silicone Encapsulant Clear, Dow Corning, Midland, MI). Tissue was incubated in 9 
parts carboxygenated (95% oxygen, 5% CO2) Krebs-Ringer solution (118 mM NaCl (Sigma, 
Cat#S6191), 4.6 mM KCl (Thermo Fisher Scientific, Cat#BP366-500), 2.5 mM CaCl2 (Cat# C7902), 
1.2 mM MgSO4 (Sigma, Cat#M-7506), 1 mM NaH2PO4 (Sigma, Cat#S0751), 11 mM D-(+)-Glucose 
(Sigma, Cat#G-7021), 25 mM NaHCO3 (Thermo Fisher Scientific, Cat#BP328-500), pH 7.4) and 1 
part 4-(4-(Dimethylamino)styryl) -N-Methylpyridinium Iodide (4-Di-2-Asp; Abcam, Cambridge, U.K, 
Cat# ab145266) at room temperature in sterile DPBS. After 10 minutes, the tissue was transferred 
to ice-cold carboxygenated Krebs-Ringers solution under a SteREO Discovery.V20 fluorescence 
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dissecting scope (ZEISS, Oberkochen, Germany, 488 nm filter). Fluorescent ENS was carefully 
dissected from muscularis by peeling away longitudinal muscle strips with Dumont #5 forceps (Fine 
Science Tools, Cat#11251-30), placed in cold O.C.T. compound (Fisher Healthcare Tissue-Plus 
O.C.T. Compound; Thermo Fisher Scientific, Hampton, NH; Cat#23-730-571) in a biopsy specimen 
cryomold (VWR, Radnor, PA; Cat#4565), frozen in methylbutane (Thermo Fisher Scientific 
Cat#O3551-4) on dry ice, and stored at -80°C. 
 
RNA extraction for RIN assessment prior to sequencing 
One to three days before sequencing, frozen mouse or human tissues were sectioned on 
a Microm HM 505 E Cryostat (GMI, Ramsey, MN; 100 µM sections, -20°C). RNA was extracted 
from several (1-5) 100 µM sections using the Qiagen RNeasy Plus Micro kit (Qiagen, Hilden, 
Germany; Cat# 74034) and using Qiagen's RNase Free DNase Set (Qiagen, Cat# 79254). 
Samples were run on an 2100 Agilent Bioanalyzer using an RNA 6000 Pico Kit (Agilent, Santa 
Clara, CA, Cat#5067-1513), and tissue was used if RNA Integrity Number (RIN) was > 7.0. 
 
Nuclei isolation and sorting 
To isolate nuclei, frozen colon sections (100 µm) in ice-cold lysis buffer (10mM Tris HCl 
pH 7.5 (Cat# 15567-027), 10 mM NaCl (Sigma, Cat#S6191), 3 mM MgCl2 (Cat# BP214-500), 
0.005% Nonidet P40 Substitute (Thermo Fisher Scientific, Cat#AM9010; Sigma, Cat#74385) were 
chopped rapidly with iridectomy scissors (1 minute), transferred to a pre-cooled Dounce 
homogenizer (VWR, Cat#357538) on ice, homogenized 15 strokes with the loose pestle and 40 
strokes with the tight pestle, filtered through MACS SmartStrainer (Miltenyi Biotec, Cat#130-098-
458), centrifuged (590xg, 8 minutes, 4°C), and resuspended in staining buffer (1x phosphate-
buffered saline (PBS), 1% w/v Ultrapure BSA (Life Technologies, Cat#AM2618), 0.2U/mL Protector 
RNase inhibitor, (Sigma, Cat#3335399001)), 2.5µg/mL Hoechst 33342 Trihydrochloride Trihydrate 
(Thermo Fisher Scientific, Cat# H3570) was added to a final concentration of 2.5 µg/mL before 
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filtering (FlowMi strainer, VWR, Cat#H13680-0040) and flow sorting (MoFlo Astrios) into 5µL 
staining buffer using a 70µm nozzle to isolate Hoechst+/mCherry+ nuclei (mouse) or Hoechst+ 
nuclei (human). 
 
Whole cell isolation from E17.5 mice 
 An E17.5 Nos1-CreERT2;ChAT-L10A-EGFP;R26R-TdTomato dams, tamoxifen treated 
(200 mg/kg) at E15.5 was euthanized, and pups were rapidly dissected on ice (2 TdTomato+, 3 
GFP+). For RNA-seq, full-length small intestines and colon dissociated together were used for 
RNA-seq. For RT-PCR, TdTomato+ E14.5 and E17.5 small intestine and colon from Wnt1-
Cre+;R26-TdTomato+ mice were analyzed separately. Tissue in carboxygenated 1x Hanks’ 
Balanced Salt Solution (HBSS, Thermo Fisher Scientific, Cat#14025092) was cut into small pieces 
with insulin needles, and dissociated with Liberase (Sigma, Cat#5401135001) plus DNase I 
(0.02U/µL, Roche, Basel, Switzerland; Cat#04716728001), MgCl2 (6mM, Cat# BP214-500) and 
CaCl2 (1mM, Cat# C7902) in HBSS (37oC, 40 minutes) with repeated trituration (P1000). 
Dissociated cells were, passed 2-3x through 35 µm filters (Falcon, Cat#352235), pelleted (170xg, 
3 minutes, 4°C) in 10% fetal bovine serum (FBS)/Iscove's DMEM (Corning, Cat#10-016-CM), 
resuspended in FACS buffer (0.04% w/v BSA (Thermo Fisher Scientifics, Cat#AM2618) in HBSS 
(Thermo Fisher Scientific, Cat#14025092)), filtered again, and sorted (BD FACSJazz, 100µm 
nozzle) into 300μL FACS buffer for sequencing. For RT-PCR, tdTomato+ cells were collected in 
1mL Iscove's DMEM/10% FBS, centrifuged (600xg, 5 minutes, 4°C) and resuspended in Buffer 
RLT plus (Qiagen, Cat#74034). 
 
Library generation, sequencing, and data processing 
Libraries prepared with Chromium Single Cell 3’ Reagent Kits v2, (Cat#120237, 10X 
Genomics, Pleasanton, CA) were sequenced on an Illumina HiSeq 2500. Cell Ranger pipeline (10x 
Genomics) was used to convert BCL files into FASTQ files, perform STAR alignment (70), filter, 
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count UMI, and generate gene-barcode matrices. Cell Ranger Aggr pipeline (10x genomics, v. 
3.0.0) was used to aggregate multiple samples, normalize outputs, and re-compute gene-barcode 
matrices on combined data. 
 
Analysis of murine single-nucleus and single cell sequencing data  
Using Seurat (17,18), gene-barcode matrices were imported into R, filtered to remove low-
expressors or doublets (nGene=200-5000 for adult distal colon, nGene = 1000-9000 for E17.5 
whole bowel) and mitochondrial contaminants (percent mitochondria <10% for adult distal colon, 
percent mitochondria <5% for E17.5 whole bowel), normalized, scaled to regress out UMI and 
percent mitochondria. Cells were clustered using the most statistically significant principal 
components. To cluster the E17.5 mouse data, we excluded genes located on the X- and Y-
Chromosomes from the principal components and included principal components up to the point 
where either any additional principal component contributed less than 5% of standard deviation 
and the principal components cumulatively contributed to 90% of the standard deviation or when 
the variation changes by less than 0.1% between consecutive principal components (71). This 
turned out to be 15 principal components. For adult mouse distal colon data, we found that taking 
all of the recommended statistically significant principal components resulted in difficult-to-interpret 
clustering, possibly due to batch effects in our dataset, and that the first ~11 components were 
sufficient to cluster our data in a biologically meaningful way. When reclustering was performed on 
subsets of data (i.e., to filter out contaminants), subsetted data was rescaled and reclustered using 
the same method described above, minus the normalization step. To identify genes that were 
differentially- expressed between clusters, clusters were compared one at a time to all other cells 
in the dataset using a Wilcoxon Rank Sum test with Bonferroni multiple testing correction (Seurat's 
FindAllMarkers command). A cutoff of at least 10% of cells in a group expressing a gene of interest 
was required for genes to be tested, and only genes with loge(fold change) > 0.25 were included in 
the analysis. Heatmaps (Figures 2.1, 2.3-2.5, Suppl. Figures 2.2, 2.5) were generated by taking 
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the mean of the log-normalized data scaled by Seurat for cells within each cluster. Except where 
indicated, only genes that were differentially expressed between neuronal clusters are shown. 
Hierarchical clustering (Figure 2.7C) was performed using the complete linkage method. For the 
GO Term analysis, we combined the three putative immature clusters into one and compared gene 
expression for these three clusters with the gene expression of all other clusters using a Wilcoxon 
Rank Sum test with Bonferroni multiple testing correction (Seurat's FindMarkers command). We 
performed GO Enrichment Analysis for GO biological processes (PANTHER Overrepresentation 
Test, GO Ontology database released 2020-02-21) using Fisher's exact test with FDR correction. 
We submitted differentially expressed genes for the immature clusters (immature Chat cluster1, 
immature Chat cluster 2, immature Nos1 cluster) and compared these to the reference gene list for 
mus musculus (22265 genes). We also submitted differentially expressed genes for the more 
mature cluster (Chat cluster 1, Chat cluster 2, Nos1 cluster 1, Nos1 cluster 2, Nos1 cluster 3) and 
compared these to the reference gene list for mus musculus (22265 genes). We reported the 20 
most enriched GO Terms. To identify genes differentially expressed between colon and small 
intestine, we defined colonic neurons as all cells with detectable Pou3f3 expression. We compared 
gene expression using a Wilcoxon Rank Sum test with Bonferroni multiple testing correction 
(Seurat's FindMarkers command) for neurons within the immature clusters (Immature Chat cluster 
1, Immature Chat cluster 2, Immature Nos1 cluster) or within the mature clusters (Chat cluster 1, 
Chat cluster 2, Nos1 cluster 1, Nos1 cluster 2, and Nos1 cluster 3) to normalize for the relatively 
more immature state of development of the majority of Pou3f3-expressing cells  (40 mature Pou3f3-
expressing neurons versus 503 other mature neurons and 94 immature Pou3f3-expressing 
neurons versus 62 other immature neurons). We followed up the identification of potentially colon-
specific genes by correlating the gene expression of the gene in question with Pou3f3 expression 





Analysis of human single-nucleus sequencing data 
Using Seurat (17,18), gene-barcode matrices were imported into R, filtered to remove low-
expressors or doublets (nGene=200-5000) and mitochondrial contaminants (percent mitochondria 
<10%), normalized, and scaled to regress out UMI and percent mitochondria. Nuclei were clustered 
using the most statistically significant principal components identified by elbow plot (11 principle 
components). Since unbiased clustering initially did not detect the small group of neurons as a 
distinct group, we identified 48 neurons by isolating all nuclei expressing any copies of ELAVL4, 
UCHL1, or SNAP25 (Supplementary Figure 2.7N-P). These nuclei were reclustered. We saw 7 
subgroups that we believe are doublets containing neuronal and non-neuronal nuclei based on co-
expression of genes like ACTG2, PLP1, KIT 9 (Supplementary Figure 2.7Q-R). One subgroup 
appeared to be pure single neuron data based on high expression of other neuronal markers like 
SYT1 and DSCAM and the absence of markers for other well-defined cell populations 
(Supplementary Figure 2.7Q-R). The strongly-positive cluster (48 neurons) was mapped back 
onto the t-SNE plot. To identify neuron-specific genes, we compared this cluster of neurons against 
all other cell populations using a Wilcoxon Rank Sum test with Bonferroni multiple testing correction 
(Seurat’s FindMarkers command). A cutoff of at least 25% of cells in a group with expression > 0 
was required for genes to be tested. Neuron gene expression for the top 50 neuron-specific genes 
was graphed and neurons were clustered using the Euclidean distance method (Figure 2.7C). This 
revealed two groups of neurons, one which was NOS1+, and another that was NOS1-. We imported 
a list of 36 transcription and splice factors identified as significantly different in mouse adult colon 
Nos1 and Chat expressing neurons. Using this list and Seurat’s FindMarkers command, we 
compared expression for these genes between NOS1+ and NOS1- neurons and found differential 






Preparing bowel for whole mount immunochemistry 
E17.5 bowel was washed in PBS, straightened with stainless steel insect pins (Fine 
Science Tools, 26002-20) on Sylgard® Elastomer 184 (Silicone Encapsulant Clear, Dow Corning, 
Midland, MI), and fixed (4% paraformaldehyde (PFA), 20 min, room temperature (RT)). P0 small 
intestine in ice-cold PBS was opened along mesenteric border, pinned with insect pins serosal side 
up without stretching onto Sylgard® Elastomer 184 (Sylgard Elastomer 184 Silicone Encapsulant 
Clear, Dow Corning, Midland, MI), before fixing (4% PFA, 20-30 minutes, RT) and peeling 
muscularis from mucosa/submucosa. Adult distal colon flushed with ice-cold PBS, was opened 
along the mesenteric border. Muscle layers were peeled from mucosa/submucosa using Dumont 
#5 forceps (Fine Science Tools, Cat# 11251-30), maximally stretched, pinned (insect pins) to 
Sylgard® Elastomer 184, fixed (4% PFA, 20-30 minutes, RT), briefly washed (1x PBS), equilibrated 
in 50% glycerol/50% PBS (30 minutes, RT or overnight, 4ºC) before storage (-20°C). For high 
magnification anti-enkephalin and anti-substance P staining, colon opened along mesenteric 
border was stretched, pinned, and fixed (4% PFA, overnight, 4°C), rinsed in 1x PBS (3 x 10min), 
and the dissected with fine forceps to remove mucosa, submucosa, and circular muscle from 
myenteric plexus attached to longitudinal muscle.  
Anti-enkephalin and anti-substance P antibodies studies used C57BL6 wild-type mice. 
Proximal, mid and distal-colon tissue was removed, opened along the mesenteric border, cleaned 
of fecal matter, stretched and pinned to Sylgard Elastomer 184 and post-fixed (4% PFA, overnight, 
4°C). After rinsing 3 times (10-minute/rinse) in 1x phosphate-buffered saline, mucosa, submucous 
plexus and circular muscle were removed with fine forceps, leaving preparations of myenteric 
plexus attached to longitudinal muscle.  
 
Whole mount immunohistochemistry 
Bowel stored at -20oC in 50% glycerol/50% PBS was rinsed in PBS, blocked (2 hours, PBS 
+ 0.5% Triton X-100 (Sigma, Cat# T8787) (PBST) with 5% Normal Donkey Serum (NDS; Jackson 
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ImmunoResearch Laboratory, West Grove, PA, RRID: AB_2337258), incubated in primary 
antibody (Supplementary Table 2.7) with gentle rocking (4°C, 2 days) except for ANNA-1 which 
was incubated overnight (4°C). After washing (3 x 5 minutes,  0.5% PBST) and secondary antibody 
(Supplementary Table 2.7) incubation in blocking solution with gentle rocking (1 hour, RT), tissue 
was washed (3 x 5 minutes, PBS), and mounted in 50% glycerol/50% PBS. 
For high magnification imaging, longitudinal muscle with exposed myenteric plexus was placed in 
10% Casblock (Thermo Fisher Scientific, Cat# 008120) with 0.1% Triton X-100 (ProSciTech, 
Thuringowa, QLD) in PBS (30 minutes, RT), then in primary antisera (Supplementary Table 2.7) 
(24-48 hours, 4°C) before rinsing (PBS, 3x 10min), and secondary antisera staining 
(Supplementary Table 2.7) (2 hours, RT). After rinsing (PBS, 3x 10min), preparations were 
mounted using fluorescence mounting medium (DAKO, Carpenteria, CA).  
 
NADPH diaphorase staining 
Bowel was pinned flat and fixed (4% PFA, 20min, RT), briefly washed (1xPBS), incubated 
in 0.1M phosphate buffer, pH7.4 with 1mg/mL beta-nicotinamide adenine dinucleotide phosphate 
(beta-NADPH, Sigma, Cat# N750), 0.1mg/mL nitroblue tetrazolium (Sigma, Cat#11383213001), 
0.3% Triton-X 100 (1 hour, 37oC), washed in PBS, and imaged immediately in a custom-made 
holding chamber.  
 
Preparing human colon for whole mount immunochemistry 
Human colon with fat trimmed was pinned serosa side up on Sylgard® Elastomer 184 
plates in ice-cold PBS using stainless steel insect pins. Tissue was maximally stretched during 
pinning to make the colon as thin as possible. Pinned tissue was fixed overnight (4ºC, 4% PFA), 





Immunofluorescence staining of human colon whole mount 
Following our new protocol (14), 0.7-1cm x 0.7-1cm colon pieces were washed (1x PBS, 
RT), incubated in 100% methanol on ice (1 hour), treated with Dent's bleach (1 mL 30% hydrogen 
peroxide (Thermo Fisher Scientific, Cat #H1009), 1 mL dimethyl sulfoxide (Sigma, Cat#D2650), 4 
mL 100% methanol (72)) at room temperature (2 hours), washed again (1x PBS, 3x5 minutes, room 
temperature), blocked (0.5% Triton X-100, 5% NDS in PBS, 3 days) and then incubated 14 days 
in blocking solution with primary antibodies (Supplementary Table 2.7, 37oC, 40-100 rpm). 
Following PBS washing (1 day, 3 washes, gentle rocker, RT), colon was incubated in secondary 
antibodies 3 days, 37ºC, 40-100 rpm), washed in PBS over 1 day, dehydrated in a methanol series, 
placed in Murray's clear (2:1 benzyl benzoate:benzyl alcohol, gentle rocking, RT) until translucent 
(30-60 min). Transparent colon mounted on glass slides in Murray's clear was imaged within 1 day. 
For details see (dx.doi.org/10.17504/protocols.io.wyeffte). 
  
Microscopy 
Images were acquired with a Zeiss LSM 710 confocal microscope with 20x/0.8 air or 
63x/1.4 oil DIC M27 Plan-Apochromat objectives and Zeiss Zen software version 2.3 14.0.14.201 
(Zeiss, Oberkochen, Germany) or upright fluorescent Olympus BX60 microscope with Axiocam 
CCD camera and Axiovision software. ImageJ (NIH) and Photoshop CS6 (Adobe, San Jose, CA) 
were used to crop and uniformly adjust color. High magnification myenteric plexus images were 
acquired with a Zeiss LSM 880 Airyscan microscope with a Plan-Apochromat 63x1.40 Oil DIC M27 
objective (Carl Zeiss Microscopy, North Ryde, NSW, Cat#420782-990-799) at the Biological Optical 
Microscopy Platform (BOMP), University of Melbourne.  
 
Image analysis 
Counting for adult mouse distal colon and human colon was performed on >5 randomly-
selected x20 fields per animal in each region using ImageJ's CellCounter module (NIH). Because 
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of high cell density at E17.5, only half of each 20X field was counted. Investigators were blinded to 
genotype when comparing knockout to control mice. High magnification myenteric plexus images 
were processed to quantify substance P and enkephalin colocalization using Imaris 9.0.0 (Bitplane) 
(22). 
 
RNA extraction and RT-PCR for Pou3f3 expression analysis 
Wnt1-Cre;R26-TdTomato E14.5 and E17.5 dams were euthanized with 5% CO2, and pups 
were removed from the mother. For each litter, all TdTomato+ small intestines and colons were 
combined to increase cell count. Small intestines and colons were dissected in ice-cold Dulbecco-
modified PBS, transferred to HBSS (Thermo Fisher Scientific, Cat No: 14025092), separated, 
divided into small pieces using insulin needles (Beckton Dickerson, Cat#08290-3284-18), and 
dissociated for 30 minutes at 37°C in Liberase (Sigma, Cat#5401135001) supplemented with 
DNase I (Roche, Basel, Switzerland; Cat#04716728001), MgCl2 (6 mM) and CaCl2 (1 mM) in HBSS 
with P1000 trituration. Cells were filtered, washed with Iscove's DMEM (Corning, Cat#10-016-CM), 
and resuspended in FACS buffer (10mM HEPES, 1mg/mL BSA, 1% penicillin and streptomycin 
(Thermo Fisher Scientific, Cat#15140122) in HBSS). Fluorescent TdTomato+ cells were sorted on 
a BD FACSJazz and collected in Iscove's DMEM with 10% FBS. Cells were spun down at 600xg, 
resuspended in Buffer RLT plus, and RNA was isolated using the Qiagen RNeasy Plus Micro Kit 
(Qiagen, Hilden, Germany; Cat# 74034) with DNase treatment (Qiagen, Cat#79254). 
RNA integrity and concentrations were measured on a 2100 Agilent Bioanalyzer using an 
RNA 6000 Pico Kit (Agilent, Santa Clara, CA, Cat#5067-1513). All samples used had RIN ≥ 7. 
cDNA was generated using Superscript II RNase H (Thermo Fisher Scientific, Cat#18064022). RT-
PCR was performed using KAPA mixture (KAPA biosystems, Cat#KK7352) and previously- 





Colon Bead Expulsion studies 
Young adult mice (P44-58 at begin of assay, P49-64 at end of assay) were anesthetized 
with 2L/min carbogen with 2.5% (v/v) isoflurane (Piramal, Cat#NDC 66794-017-10) for 1.5 minutes 
before the start of the experiment, anesthesia was continued until completed bead insertion. A 
glass bead (3 mm, Sigma, Cat#Z143928) lubricated with sunflower seed oil (Sigma, Cat#S5007) 
was inserted 2 cm into the colon using a custom-made 3-mm rounded glass rod. Glass rod was 
removed, isoflurane stopped, mice were placed in empty cages, and time to bead expulsion was 
recorded. If a mouse regained consciousness before bead insertion, mice were anesthetized for 
an additional 2-4min. Assay was repeated 3 times per mouse (48-96 hours between procedures). 
Mice had free access to food and water prior to the experiment. 
 
Calcium imaging full thickness colon 
Colons from E2a-Cre;R26R-Gcamp6s mice aged 12-16 weeks were cut longitudinally and 
pinned (mucosa facing down) in a Sylgard-lined dish superfused with carbogenated (95% O2, 5% 
CO2) artificial cerebrospinal fluid (ACSF) (29), freshly prepared, maintained at 35ºC.  Nifedipine 
(1µM, Sigma, Cat# N7634) in ACSF improved stability for calcium imaging analyses. GCaMP6s in 
myenteric neurons was imaged with an upright DM6000FS Leica fluorescence microscope (Leica, 
Buffalo Grove, IL) and EMCCD camera (Photometrics; Roper Scientific, Tucson, AZ) using a x20 
objective. Images were collected with Metamorph software (Molecular Devices, San Jose, CA) at 
10 Hz sampling rate. For each field, spontaneous activity was imaged 2 min, before two 30s movies 
were collected in response to electrical field stimulation (EFS; 100 µs pulse, 20 Hz, 1 s) using 
concentric electrodes 5 mm oral or aboral to imaging fields (order randomized). Recombinant rat 
GDNF (Cat. #512-GF, R&D Systems) or NRTN (Cat. #450-11, PeproTech) were added at 10nM 
final concentration (order of presentation randomized). We recorded spontaneous activity in 2-min 
movies collected intermittently while ligands continuously superfused circulating ACSF for 10 min. 
Responses to oral and aboral stimulation were then re-imaged. Colon was washed for 30 min and 
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baseline activity and responses were re-imaged before the next receptor ligand was applied. In a 
subset of experiments, the addition of tetrodotoxin (TTX, 0.5µM, Cat. #T8024, Sigma) or 
hexamethonium (HEX, 300µM, Cat. #H0879, Sigma) blocked all neural transmission or excitatory 
synaptic transmission, respectively, allowing for  identification of myenteric neurons directly 
activated by GDNF or NRTN. Spontaneous activity was recorded (three 2-min movies) at baseline, 
10 min following TTX or HEX, and during application of GDNF or NRTN (in the presence of either 
TTX or HEX; order of presentation of GDNF/NRTN was randomized). Colon tissue was then 
“washed” with the particular blocker, activity was re-imaged, and the next receptor ligand was 
applied while imaging responses. 
 
Analysis of live GCaMP6s imaging 
Metamorph (Molecular Devices, Downington, PA) image files exported to ImageJ (NIH) 
were coded for blind analysis. Circular ROIs were drawn on all myenteric neurons in each field.  
Amplitude of GCaMP6s signals were analyzed and quantified as described (Smith-Edwards et al. 
2016). We calculated ΔF/F0 [% = ((F − F0)/F0) x 100], where F is peak fluorescence and F0 is 
baseline mean fluorescence; ΔF/F0 of 4SD > baseline was considered a response. Time control 
studies, in which GCaMP6s activity from individual neurons was measured over time, were used 
to determine whether changes in activity were significantly altered due to GDNF or NRTN 
application. Tissue movement along x- and y-axes was measured using ImageJ Template-
Matching plugin. Time-lapse color-coded images created in ImageJ use pixel color to indicate when 
pixels reached maximum F, providing spatial and temporal information about activity.  
 
Statistics 
We used Prism 7.03 (GraphPad Software, San Diego, CA) software.  A cutoff of p < 0.05 
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Supplementary Figure 2.1: Initial processing of single nucleus RNA-seq data from young 
adult Wnt1-crecre/wt; R26R-H2B-mCherrych/wt mouse colon with validation of enkephalin and 
substance P co-expression. 
(A-D) H2B-mCherry fluorescence (red) in 50 day old Wnt1-crecre/wt; R26R-H2B-mCherrych/wt mice 
colocalizes with HuC/D+ neurons (green) and S100β+ glia (blue) in the ENS. ~73% of HuC/D+ 
neurons were H2B-mCherry+. (E) T-SNE plot of all cell groups from distal colon of Wnt1-crecre/wt; 
R26R-H2B-mCherrych/wt mice. (F-J) Feature plots for Actg2 (F), Pdgfrα (G), Kit (H), Elavl4 (I), and 
Plp1 (J) indicate the locations of SMC, Pdgfrα+ cells, ICC, neurons, and glia respectively. Color 
key represents loge(normalized gene expression). Scale bar 100μm. (K-M) Enkephalin (green) 
colocalizes with substance P (red) in myenteric neuron cell bodies in proximal (K), mid (L), and 
distal colon (M). (N-P) Most myenteric intraganglionic neuron varicosities in proximal (N), mid (O), 
and distal colon (P) express both enkephalin (green) and substance P (red). (Q-R) Most 
enkephalin+ (green) neuron varicosities in circular smooth muscle in mid-colon (Q) and distal colon 
(R) also express substance P (red), but only a subset of substance P-expressing neuron 
varicosities in circular smooth muscle express enkephalin. (K-R) Images representative of n=3 
preparations per colon region and n=3 images per preparation.  (S) Quantification of colocalization 
of enkephalin and substance P in varicosities within mid-colon myenteric ganglia and  within circular 
smooth muscle. (T) EGFP (green) fluorescence signal colocalizes with TDTOMATO+ (red) neurons 
(blue) in Vglut2-IRES-Cre; R26R-TdTomato; ChAT-EGFP-L10A mice. (U) In a small subset of 
HuC/D+ neurons (blue), TDTOMATO+ (red) does not colocalize with EGFP fluorescence signal in 
Vglut2-IRES-Cre; R26R-TdTomato; ChAT-EGFP-L10A mice. (V) Quantification of the 
colocalization of EGFP fluorescence with TDTOMATO fluorescence in Vglut2-IRES-Cre; R26R-
TdTomato mice. (K-M) Scale bar = 10μm. (N-R) Scale bar 5μm. (K-R) White arrows point towards 
cells and varicosities that express both enkephalin and substance P. (N-R) White arrowheads point 
towards varicosities that express enkephalin only. Empty arrowheads point towards varicosities 






Supplementary Figure 2.2: Percent of cells per cluster with detectable levels of differentially 
expressed neurotransmitters, commonly used enteric neuron immunohistochemical 
markers, neurotransmitter receptors, and regulatory factors in adult distal mouse colon. 
Average expression per cluster and percent of cells per cluster with detectable levels of 
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differentially expressed ion channels and signaling pathway molecules in adult distal mouse 
colon.  
(A-B) Proportion of cells per cluster with expression values >0 for differentially expressed 
neurotransmitters, immunohistochemical markers (A) and neurotransmitter receptors (B). Color bar 
applies to both panels. (C) Average expression of differentially expressed ion channel (subunit) 
genes for different neuron and glial groups. (D) Proportion of cells per cluster with expression 
values >0 for differentially expressed ion channels. (E) Average expression for selected ligands 
(left) and receptors (right) that were differentially expressed between different neuron and glial 
subclasses. (F) Proportion of cells per cluster with expression values >0 for differential expressed 
ligands (left) and receptors (right). (G) Proportion of cells per cluster with expression values >0 for 
transcription and splicing factors with known roles in ENS development(top), and regulatory genes 
(transcription factors and splicing factors) newly-identified in the ENS in this study (bottom). n.s. = 
not significantly differentially expressed between neuron clusters. (C-E) Color key represents 








Supplementary Figure 2.3: Gfra1 is expressed in adult enteric neurons and glia. GDNF 
modulates activity in some myenteric neurons and enhances colon muscularis movement. 
(A) Whole mount immunohistochemistry using Gfra1Gfp/wt distal colon shows colocalization of GFP 
(green) with S100B+ (red) glia and HuC/C (blue) neurons. Scale bar = 100 microns. (B) NADPH 
diaphorase stained colon identifies nitric oxide producing neurons. (C) Corresponding GCaMP6s 
imaging field. (D) GCaMP6s imaging field in (C) where yellow arrowheads identify putative nitrergic 
myenteric neurons and asterisks indicate putative NADPH diaphorase positive neurons with low 
GCaMP6s signal. (E) Quantification of GDNF- and NRTN-responsive nitrergic neurons (n=3 fields 
from separate experiments, p=0.0298, Fisher Exact test, 2x2 contingency table (NOS+/NOS- and 
GDNF response/NRTN response)). (F, G) Quantitative data for GCaMP6s imaging fields stained 
post-hoc for NADPH diaphorase, indicating response to GDNF and NRTN. (F) Responsive nitrergic 
neurons. (G) Responsive non-nitrergic neurons. (H) Heatmap illustrating GCaMP6s activity before 
and after addition of the nicotinic acetylcholine receptor antagonist hexamethonium (HEX) and 
during the sequential application of GDNF and NRTN. Each row represents a single neuron and 
colors represent the magnitude of the change in GCaMP6s activity (red = no activity change). 
Dotted line shows GDNF and NRTN responsive neurons. Activity was assessed for 352 total 
neurons in 4 independent colon sections from 1 mouse. (I) Heatmap focusing only on GDNF- and 
NRTN-responsive neurons illustrating GCaMP6s activity before and after hexamethonium (HEX) 
addition and during the sequential application of GDNF and NRTN. 28 neurons were only GDNF-
responsive, 24 neurons only NRTN-responsive, and 9 neurons responded to both GDNF and 
NRTN. Each row represents a single neuron and colors represent the magnitude of the change in 
GCaMP6s activity (red = no activity change). (J-M) Percent of total observed neurons per 
GCaMP6s imaging field with increased activity after electrical field stimulation (EFS) applied 5 mm 
oral (J, L) or aboral (K,M) relative to the imaging field at baseline (vehicle) and in the presence of 
GDNF (J, K) and NRTN (L, M). GDNF increases the percent of activated neurons after orally 
applied EFS (J, p=0.0068, ratio paired t-test). (N-Q) Tissue displacement (micrometers) after EFS 
applied 5 mm oral (N, P) or aboral (O,Q) relative to the imaging field at baseline (vehicle) and in 
the presence of GDNF (N, O) and NRTN (P-Q). Tissue displacement is increased in the presence 
of GDNF after orally applied EFS (N, p=0.0230, ratio paired t-test). (B-G) n=3 fields of view from 







Supplementary Figure 2.4: Single-cell sequencing of E17.5 ChAT-EGFP-L10A+ and Nos1-
CreERT2Cre/wt;R26R-TdTomato+ cells reveals several neuron clusters at different stages of 
maturity. 
(A) T-SNE plot of all cell groups isolated from E17.5 bowel. (B) Feature plots of Acta2 as smooth 
muscle marker, Epcam as an intestinal epithelial marker, and Elavl4 as a pan-neuronal marker. 
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Color key represents loge(normalized gene expression). (C) After removing the epithelial and 
smooth muscle cells from the dataset and reclustering, T-SNE plot reveals multiple neuron 
subpopulations. (D) Expression of Nos1 and the cholinergic marker Slc18a3/VachT verifies the 
presence of the expected cholinergic and nitergic neuronal subpopulations. Chat expression was 
low throughout, but overlapped with Slc18a3 expression. Color key represents loge(normalized 
gene expression). (E) All neurons have high expression of pan-neuronal markers Tubb3 and Elavl4. 
There is minimal contamination with glial cells based on the expression of enteric glial marker Plp1. 
Sox10, which marks enteric glia and enteric neural crest precursors was also low, but Ret, which 
is expressed in ENS precursors and many neurons, was present in all clusters. This suggests that 
these cells are lineage-restricted neurons, however, all neurons still express the immature pan-
neuronal marker Dcx. (F) GO Term analysis of differentially expressed genes in the three more 
immature neuron clusters (immature chat cluster 1, immature chat cluster 2, immature Nos1 
cluster) compared to all other clusters indicates that these neurons are actively involved in 
cytoskeletal reorganization and neurite extension. (G) GO Term analysis of differentially expressed 
genes in the five more mature neuron clusters (Chat cluster 1, Chat cluster 2, Nos1 cluster 1, Nos1 
cluster 2, and Nos1 cluster 3) compared to the immature clusters (Immature Chat cluster 1, 
Immature Chat cluster 2, and Immature Nos1 cluster) indicates that these neurons are actively 




Supplementary Figure 2.5: Cholinergic and nitrergic neuron subsets at E17.5 differentially 
express ion channels and signaling pathway molecules as well as many regulatory genes 
found in adult distal colon ENS.  
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(A) Neurotransmitter and commonly used enteric neuron immunohistochemical markers with > 0 
detected reads. Asterisks mark genes differentially expressed across the distinct neuron 
subclasses. Color key represents proportion of cells per cluster with expression values >0. (B-C) 
Neurotransmitter receptor (B) and ion channel (C) genes differentially expressed across distinct 
neuron subclasses. Color key represents proportion of cells per cluster with expression values >0. 
(D-E) Genes involved in extracellular signaling pathways differentially expressed across neuron 
subclasses. (D) Color key represents loge(normalized average gene expression within each 
cluster). (E) Color key represents proportion of cells per cluster with expression values >0. (F) 
Transcription and splicing factors with known roles in ENS development (top), and newly-identified 
in the ENS in this study (bottom). n.s. = not significantly differentially expressed between neuron 
clusters. Color key represents proportion of cells per cluster with expression values >0. (G-K) 
Whole-mount immunohistochemistry of select regulatory genes in E17.5 ChAT-EGFP-L10A 
reporter mouse mid-colon shows gene localization in neuron subsets. BNC2 (G), PBX3 (H), and 
RBFOX1 (I) are predominantly expressed in cholinergic (EGFP+) neurons. (B-D) White arrowheads 
indicate neurons that express the regulatory gene in question, but are not cholinergic. (J) TBX2 
does not have nuclear or diffuse cytoplasmic staining in the E17.5 colon. Instead, TBX2 
immunoreactive cytoplasmic aggregates were detected in a subset of cholinergic (EGFP+) neurons 
(notched white arrowheads). (K) TBX3 is expressed in some cholinergic (EGFP+, white arrows) 
and most nitrergic (NOS1+, empty arrowheads) neurons. (G-K) ChAT-EGFP-L10A reporter = Chat-







Supplemental Figure 2.6: Pou3f3 is expressed in mouse colon but not small intestine ENS.  
(A) Feature plot shows scattered E17.5 enteric neurons expressing Pou3f3 throughout the neuron 
clusters. Color key represents loge(normalized gene expression). (B) Violin plot of Pou3f3 
expression in E17.5 enteric neurons indicates that Pou3f3 is predominantly expressed in Immature 
Chat cluster 2 and Immature Nos1 cluster. (C-X) Whole mount immunohistochemistry confirms that 
POU3F3 immunoreactivity (green) is not detected in most of the small bowel at E12.5 (C), E14.5 
(E), E17.5 (H), or in adulthood (N,T). POU3F3 immunoreactivity is easily detected in proximal colon 
(D) at E12.5 (arrows) and throughout the colon at E14.5 (F), E17.5 (K), and in adulthood (Q,W). 
(L,R,X) At E17.5 and in adulthood, colonic POU3F3 co-localizes with the enteric neuron marker 
HuC/D. (Y-V’) Confocal z-stack maximum intensity projections at lower magnification (Y-J’) and 
high magnification (K’-V’) of whole mount immunohistochemistry for POU3F3 in adult human small 
intestine (Y-A’, E’-G’, K’-M’, Q’-S’) and adult human colon (B’-D’, H’-J’, N’-P’, T’-V’) shows nuclear 
POU3F3 localization only in colonic neurons. No POU3F3 staining was detectable in human small 
intestine submucosal plexus (Y-A’, K’-M’), whereas clear nuclear POU3F3 staining could be seen 
in human colon submucosal neurons (B’-D’, N’-P’). Cytoplasmic POU3F3 antibody staining was 
present in a subpopulation of human small intestine myenteric neurons (E’-G’, Q’-S’). In the human 
colon myenteric plexus all neurons showed clear nuclear POU3F3 localization (H’-J’, T’-V’). (W’) 
Feature plot showing scattered E17.5 enteric colonic neurons. Cells expressing Pou3f3 were 
assigned colonic identity. Red circle marks immature clusters: immature Chat cluster 1, immature 
Chat cluster 2, and immature Nos1 cluster. (X’) Genes differentially expressed by cells assigned 
colon identity compared to cells assigned small intestine identity within the three immature clusters 
(immature Chat cluster 1, immature Chat cluster 2, immature Nos1 cluster). (Y’) Genes differentially 
expressed by cells assigned colon identity compared to cells assigned small intestine identity within 
the three mature clusters (Chat cluster 1 and 2 and Nos1 cluster 1, 2, and 3). (Z’) Violin plots 
showing expression of the differentially expressed genes across all E17.5 neuron clusters indicate 
that the genes identified in (X’) are specific to immature Chat cluster 1 and not colon or small 
intestine (Pearson Correlation between the expression of the identified gene and Pou3f3 supports 
this conclusion: p>0.1 for all, except Dpysl3, corr. coeff.=0.0819, p=0.0294) (A’’) Violin plots 
showing expression of the differentially expressed genes across all E17.5 neuron clusters suggest 
that the expression of genes Ahr and Pantr1 and possibly Zfhx3 are specific to colon myenteric 
neurons (Pearson Correlation between the expression of the identified gene and Pou3f3 supports 
this conclusion: Ahr, corr. coeff.= 0.3581, p<2.2x10-6; Pantr1, corr.coeff.=0.5640,  p<2.2x10-6; 
Zfhx3, 0.4034, p<2.2x10-6). SP = submucosal plexus, MP = myenteric plexus. Images are 






Supplementary Figure 2.7: Human single nucleus RNA-seq analysis from 20,167 cells 
yielded data from 48 definitive neurons and many other cells that impact bowel motility 
including SMC, ICC, PDGFRA+ cells, muscularis macrophage, and glia. 
(A) Human myenteric plexus after incubation with 4-Di-2-Asp, with muscle layers partially peeled 
away. (B-J) Feature plots showing genes expressed highly in adult human smooth muscle (B, C; 
ACTG2, MYH11), glial cells (D, E; PLP1, SOX10), ICC (F; ANO1), PDGFRA+ cells (G; PDGFRA), 
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vessel endothelial cells (H; VWF), muscularis macrophages (I; CD14), and T cells (J; CD2). Color 
key represents loge(normalized gene expression). Scale bar = 50µm. (K-M) T-SNE plots of human 
nuclei colored by sample number (K), colon location (right versus sigmoid; L), and sex (M). Cells 
from different colon regions and different sexes largely form the same t-SNE clusters. (N-P) Feature 
plots show location of ELAVL4 (N), UCHL1 (O), and SNAP25 (P) expression suggest that a small 
population of neurons expressing all three is present in this dataset, but most of the 20,000 nuclei 
are not ELAVL4, SNAP25, or UCHL1-positive. Color key represents loge(normalized gene 
expression). (Q) T-SNE plot of all human nuclei expressing ELAVL4, UCHL1, or SNAP25 (inclusive 
or) reveals many populations that may be doublets because they cluster with nuclei expressing 
non-neuronal cell markers. For this manuscript, we only describe in detail expression data for the 
tight cluster of cells we believe are single neurons based on high expression of ELAVL4, SNAP25, 
UCHL1, SYT1, and DSCAM (highlighted with red circle) (R) Feature plots of neuronal markers 
(ELAVL4, SNAP25, UCHL1, SYT1, and DSCAM), SMC markers (ACTG2), glial cell markers 
(PLP1), ICC markers (KIT), and PDGFRA+ cell markers (PDGFRA) suggest that other populations 





Supplementary Table 2.1: Methods used to isolate cells or nuclei for RNA-seq. 
Genotype Whole cells, 
or nuclei? 
Description 
Wnt1-Cre;R26R-EGFP Cells The EGFP signal in Wnt1-Cre;R26R-EGFP animals 
was too weak to flow sort effectively given the high 
degree of background in the 488 channel. 
Wnt1-Cre;R26R-
tdTomato 
Cells The localization of tdTomato to neurites in our Wnt1-
Cre;R26R-Tdtomato line was problematic, since we 
desired clean separation of single cells. Sorting 
myenteric plexus from this mouse line often resulted in 
preps with neurites attached to tdTomato- cells. We 
tried dissociating with different proteases (cold active 
protease, dispase and collagenase), different 
incubation times (15 minutes, 30 minutes), multiple 
methods of trituration (pipette-based, needle-based), 
and different bowel layers, with little improvement in 
outcome 
Wnt1-Cre;ROSANT-NG Nuclei Wnt1-Cre;RosaNT-NG mice had tdTomato in their nuclei 
at baseline; with CRE-induced recombination, they 
accumulated EGFP in their nuclei instead of tdTomato. 
Unfortunately, these mice lost fluorescent signal 
during the Dounce homogenization procedure. We 
hypothesize that membrane damage associated with 





Nuclei Successful and used to generate data in Figures 1 
through 4. 
Wild type Nuclei We attempted to use directly-conjugated NeuN and 
PHOX2B antibodies to isolate mouse ENS nuclei with 
flow sorting, since some neuronal nuclei in mouse 
stain with this NeuN antibody by 
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Supplementary Table 2.4: Characteristics of colon resection samples  






RNA Integrity #: 
Surrounding 
muscle 
4579 54 M Cecal polyp Right colon 7.6 7.9 
4602 75 M Hx of cecal lesion Right colon 7.5 6.9 
4683 38 M 
Goblet cell 
carcinoma Right colon 7.9 8 
4695 77 F Colonic mass Right colon 7.4 7.4 
4701 78 M Rectal cancer 
Sigmoid 
colon 8.2 6.3 




and 7.10 (3 
pieces) 7.6 
4969 83 M Adenocarcinoma Right colon 6.5 
7.90, 5.80 (2 
pieces) 
4966 71 F Bowel obstruction Right colon 7.2 8.1, 7.9 (2 pieces) 
4988 65 F Colon polyp Right colon 
5.20 and 
2.90 (RNA 
conc. v low)* 
7.5 and 7.4 (2 
pieces) 




conc v. low)*  7.1 
5031 70 M Colon polyp Right colon 7.8 7.4 and 7.2 
5035 24 M Volvulus 
Sigmoid 
colon 8 6.6 and 7.2  
5040 44 M Colonic mass Right colon 7.7 7.5 and 7.8 




colon 6.6 7.4 
5054 36 F Bowel adhesions Right colon 7.6 7.20 and 7.70 





Supplementary Table 2.5: UMI and gene counts from colon resection samples 
Sample ID 
Cells or nuclei 
loaded 
(predicted 
from FACS)  

















4579 4000 680 0.17 2,474 1,559 
4602 6900 2,316 0.3356522 2,004 1,268 
4683 6300 2,081 0.3303175 1,397 876 
4695 4000 833 0.20825 1,487 974 
4701 12300 4,414 0.3588618 1,296 780 
4950 5200 1,237 0.2378846 1,415 910 
4969 5300 653 0.1232075 1,262 1,262 
4966 2100 432 0.2057143 1,856 1,193 
4988 1200 237 0.1975 2,354 1554 
4992 673 60 0.089153 3,939 2336 
5031 5200 1728 0.3323077 1,538 967 
5035 7100 2524 0.355493 1,886 1119 
5040 2300 755 0.3282609 1,941 1212 
5047 5000 957 0.1914 1,701 1013 
5054 3100 1219 0.3932258 2,071 1216 

















Descriptive Statistics:  
Mean ± standard deviation // Median 
(range if n=3, interquartile range if 
n>3) 















Varicosities within myenteric ganglia: 
% of Enk+ varicosities that were SP+: 
74.5 ± 23.6 // 86.9 (41.9) 
% of SP+ varicosities that were Enk+: 
81.2 ±  8.7 // 78.0 (16.5) 
 
Varicosities in circular muscle: 
% of Enk+ varicosities that were SP+: 
76.5 ± 5.0 // 78.7 (9.3) 
% of SP+ varicosities that were Enk+: 
44.7 ±  8.4 // 41.9 (16.0) 
Figure 2 - Gfra1-
GFP quantification 
(mouse adult distal 
colon) 
3 614 Student’s t-
test 
% of NOS1+ that were GFP+: 88.9 ± 
1.8 //89.1 (3.7) 
% of NOS- neurons that were GFP+: 
8.8 ± 5.7 //7.7 (11.2) 
Figure 2 - NADPH 
diaphorase 
staining 





Figure 3 - Etv1-
CreERT2;TdTomat
o x NOS1 
quantification 
(mouse adult distal 
colon) 
3 1101 Student’s t-
test 
% of NOS+ neurons that were TDT+: 
56.4 ± 6.3 //  59.7 (11.3) 
% of NOS- neurons that were TDT+: 
5.6 ± 1.5 // 5.6 (3.0) 
 
% of TDTOMATO+ neurons that were 
NOS+: 85.0  ± 5.8 // 85.7 (11.6) 
% of TDTOMATO neurons that were 
NOS-: 15.0 ± 5.8 // 14.3 (11.6) 
Figure 3 - PBX3 x 
Chat-EGFP 
quantification 
(mouse adult distal 
colon) 
4 2684 Student’s t-
test 
% of EGFP- neurons that were 
RBFOX1+: 31.4 ± 6.0 // 29.5 (10.9) 
% of EGFP+ neurons that were 














Descriptive Statistics:  
Mean ± standard deviation // Median 
(range if n=3, interquartile range if 
n>3) 
% of PBX3+ neurons that were EGFP+: 
79.2 ± 5.3 // 79.4 (12.3)  
% of PBX3+ neurons that were EGFP-: 
20.8 ± 5.3 // 20.6 (10.2) 




(mouse adult distal 
colon) 
4 2136 Student’s t-
test 
% of EGFP- neurons that were 
PHOX2B+:  69.9 ± 7.3 // 72.0 (13.5) 
% of EGFP+ neurons that were 
PHOX2B+: 76.1 ± 5.1 // 76.3 (9.5) 
 
% of PHOX2B+ neurons that were 
EGFP+: 60.8 ± 2.9 // 62.1 (4.9) 
% of PHOX2B+ neurons that were 
EGFP-: 39.2 ± 2.9 // 37.9 (4.9) 




(mouse adult distal 
colon) 
3 993 Student’s t-
test 
% of EGFP- neurons that were 
RBFOX1+: 39.4 ± 3.8 // 38.7 (7.6) 
% of EGFP+ neurons that were 
RBFOX1+: 82.5 ± 6.7 // 78.8 (11.8) 
 
% of RBFOX1+ neurons that were 
EGFP+: 74.2 ± 5.8 // 76.9 (10.7) 
% of RBFOX1+ neurons that were 
EGFP-: 25.8 ± 5.8 // 23.1 (10.7) 
Figure 3 - SATB1 
x Chat-EGFP 
quantification 
(mouse adult distal 
colon) 
3 1028 Student’s t-
test 
% of EGFP- neurons that were 
SATB1+: 7.9 ± 12.3 // 1.6 (22.1) 
% of EGFP+ neurons that were 
SATB1+: 50.0 ± 12.0 // 45.3 (22.5) 
 
% of SATB1+ neurons that were 
EGFP+: 94.8 ± 7.9 // 98.8 (14.3) 
% of SATB1+ neurons that were EGFP-
: 5.2 ± 7.9 // 1.2 (14.3) 
Figure 3 - TBX3 x 
NOS1 
quantification 
(mouse adult distal 
4 1033 Student’s t-
test 
% of NOS+/EGFP- neurons that were 
TBX3+: 90.9 ± 8.2 // 92.0 (15.7)  
% of NOS+/EGFP+ neurons that were 













Descriptive Statistics:  
Mean ± standard deviation // Median 
(range if n=3, interquartile range if 
n>3) 
colon) % of NOS-/EGFP+ neurons that were 
TBX3+: 23.4 ± 7.7 // 26.3 (13.1) 
 
% of TBX3+ neurons that were EGFP+: 
31.0 ± 7.0 // 34.5 (10.6)  
% of TBX3+ neurons that were EGFP-: 
69.0 ± 7.0 // 65.5 (10.6) 
 
% of TBX3+ neurons that were NOS+: 
66.0 ± 5.6 // 64.5 (10.0) 
% of TBX3+ neurons that were NOS-: 
34.0 ± 5.6 // 35.5 (10.0) 
Figure 3 - All 
neurons (mouse 




 N/A % of total neurons that were 
EGFP+:58.1 ± 4.4 // 58.8 (8.8) 
% of total neurons that were EGFP-: 
41.9 ± 4.4 // 41.2 (8.8) 
 
% of total neurons that were NOS+: 
38.1 ± 4.5 // 39.2 (7.9) 
% of total neurons that were NOS-: 
61.9 ± 4.5 // 60.8 (7.9) 
Supplementary 




(mouse adult distal 
colon) 
3 114 N/A % TDTOMATO+/EGFP+/HUC+: 
4.1 ± 1.5 //  3.5 (2.7) 
 
% TDTOMATO+/EGFP-/HUC+:  
95.9 ± 1.5 // 96.5 (2.7) 





3 6186 Student’s t-
test 
BNC2+EGFP+/EGFP+: 
54.8 ± 5.2 // 52.3 (9.5) 
BNC2+EGFP-/EGFP-: 
21.6 ± 1.5 // 21.3 (2.94) 
BNC2+EGFP+/BNC2+: 
78.7 ± 1.1 // 78.7 (2.1) 
EGFP+HUC+/HUC+: 













Descriptive Statistics:  
Mean ± standard deviation // Median 
(range if n=3, interquartile range if 
n>3) 





3 10259 Student’s t-
test 
PBX3+EGFP+/EGFP+: 
53.4 ± 13.3 // 60.6 (23.4) 
PBX3+EGFP-/EGFP-: 
12.1 ± 9.5 // 9.7 (18.6) 
PBX3+EGFP+/PBX3+: 
85.7 ± 8.6 // 84.5 (17.1) 
 EGFP+HUC+/HUC+: 
56.2 ± 9.6 // 55.8 (19.1) 






3 11522 Student’s t-
test 
RBFOX1+EGFP+/EGFP+: 
49.7 ± 9.4 // 48.3 (18.7) 
RBFOX1+EGFP-/EGFP-: 
3.7 ± 2.1 // 4.0 (4.2) 
RBFOX1+EGFP+/RBFOX1+: 
95.3 ± 2.1 // 95.7 (4.1) 
 EGFP+HUC+/HUC+: 
59.7 ± 2.8 // 60.6 (5.3) 





3 8369 Student’s t-
test 
TBX2+EGFP+/EGFP+: 
51.5 ± 4.3 // 51.4 (8.5) 
TBX2+EGFP-/EGFP-: 
7.8 ± 7.3 // 3.7 (12.7) 
TBX2+EGFP+/TBX2+: 
92.3 ± 5.1 // 94.7 (9.3) 
EGFP+HUC+/HUC+: 
60.9 ± 5.1 // 63.3 (9.4) 











49.1 ± 6.3 // 48.1 (12.5) 
TBX3+NOS1+/NOS1+: 
95.2 ± 1.7 // 94.6 (3.4) 
TBX3+NOS1+EGFP+/NOS1+EGFP+: 
91.2 ± 3.9 // 91.4 (7.8) 
TBX3+EGFP+/TBX3+: 
60.9 ± 5.1 // 0.5 (0.1) 
TBX3+NOS1+/TBX3+: 
44.6 ± 3.2 // 43.9 (6.3) 
TBX3+EGFP+NOS1+/TBX3+: 













Descriptive Statistics:  
Mean ± standard deviation // Median 




68.3 ± 1.6 // 67.5 (3.0) 
NOS1+/(sum of 
EGFP+,NOS1+,NOS1+EGFP+): 
31.1 ± 1.7 // 32.0 (3.0) 
EGFP+NOS1+/(sum of 
EGFP+,NOS1+,NOS1+EGFP+): 
0.8 ± 0.0 // 0.8 (0.1) 















% Chat-EGFP+ neurons:  
KO: 39.5 ± 6.6 // 41.03 (12.4) 
Control:  40.0 ± 2.9 // 39.6 (5.5) 
 
% NOS1+ neurons:  
KO: 14.5 ± 3.2 // 15.8 (5.4) 
Control:  12.9 ± 2.7 // 12.6 (5.2) 
 
% Chat-EGFP+/NOS1+ neurons:  
KO: 2.4 ± 0.5 // 2.5 (0.9) 
Control: 1.6 ± 0.6 // 1.5 (1.1)   
 
% Chat-EGFP-/NOS1- neurons:  
KO: 43.6 ± 5.7 // 43.1 (10.5) 
Control: 45.5 ± 2.6 // 45.4 (4.9) 
 
Total Neuron Density:  
KO: 3530 ± 563.3 // 3334 (980) 
Control: 4241 ± 535.6 // 4144 (1009) 












% NOS1+ neurons:  
KO: 18.2 ± 3.3 // 17.4 (6.6) 
Control: 26.0 ± 3.0 // 26.4 (6.0)   
 
Total Neuron Density: 
KO: 2180 ± 403.2 // 2075 (786)  
Control: 2337 ± 260.6 // 2302 (517) 













Descriptive Statistics:  
Mean ± standard deviation // Median 






4 (KO) (control), 
5348 (KO) 
test KO: 47.4 ± 2.9 // 47.3 (5.1) 
Control:  53.6 ± 7.3 // 53.6 (14.1) 
Total Neuron Density: 
KO: 1603 ± 352.2 //1589 (674)  
Control: 1789 ± 364.6 // 1903 (665) 




3 2675 Student’s t-
test 
BNC2+CHAT+/CHAT+: 
36.6 ± 4.1 // 34.3 (7.1) 
BNC2+CHAT-/CHAT-: 
1.6 ± 1.3 // 0.8 (2.3) 
BNC2+CHAT+/BNC2+: 
97.9 ± 1.3 // 97.9 (2.7) 
CHAT+HUC+/HUC+: 
66.6 ± 11.8 // 60.0 (20.6) 




3 2439 Student’s t-
test 
PBX3+CHAT+/CHAT+: 
19.0 ± 4.3 // 19.9 (8.6) 
PBX3+CHAT-/CHAT-: 
1.1 ± 0.3 // 1.1 (0.6) 
PBX3+CHAT+/PBX3+: 
97.5 ± 1.1 // 97.2 (2.2) 
CHAT+HUC+/HUC+: 
68.7 ± 6.9 // 67.7 (13.8) 
Figure 7 - 
RBFOX1 x CHAT 
quantification 
(human colon) 
3 2825 Student’s t-
test 
RBFOX1+CHAT+/CHAT+: 
44.4 ± 7.7 // 41.4 (14.4) 
RBFOX1+CHAT-/CHAT-: 
1.5 ± 1.4 // 1.6 (2.8) 
RBFOX1+CHAT+/RBFOX+: 
99.4 ± 0.5 // 99.3 (1.0) 
CHAT+HUC+/HUC+: 
87.4 ± 2.7 // 86.9 (5.3) 




3 3427 Student’s t-
test 
TBX2+CHAT+/CHAT+: 
7.8 ± 2.8 // 6.2 (4.8) 
TBX2+CHAT-/CHAT-: 
0.1 ± 0.1 // 0.1 (0.2) 
TBX2+CHAT+/TBX2+: 













Descriptive Statistics:  
Mean ± standard deviation // Median 
(range if n=3, interquartile range if 
n>3) 
CHAT+HUC+/HUC+: 
69.6 ± 12.9 // 72.5 (25.3) 




3 972 Student’s t-
test 
TBX2+NOS1+/NOS1+: 
90.0 ± 9.7 // 92.4 (19.0) 
TBX2+NOS1-/NOS1-: 
16.4 ± 6.5 // 14.9 (12.8) 
TBX3+NOS1+/TBX3+: 
83.5 ± 8.9 // 83.3 (17.7) 
NOS1+HUC+/HUC+: 





Supplementary Table 2.7: List of Antibodies 
Antibody Concentration Catalog 
number 
Source 
Rabbit anti-NOS1 1:200 (mouse), 
1:100 (human) 
AB5380 Sigma, RRID:AB_91824 
Goat anti-CHAT 1:100 (human) AB144P Sigma, RRID:AB_2079751 
ANNA-1 (HuC/D) N/A (mouse) N/A Kind gift from Dr. V. Lennon, 
Mayo Clinic 
Mouse anti-HuC/D 1:200 (human) A21271 Thermo Fisher Scientific, 
RRID:AB_221448 
Goat anti-TBX3 1:100 (human and 
mouse) 
AF4509-SP R&D Systems, 
RRID:AB_2240328 
Goat anti-PHOX2B 1:100 (mouse) AF4940-SP R&D Systems, 
RRID:AB_10889846 
Rabbit anti-SATB1 1:100 (mouse) ab109122 Abcam, 
RRID:AB_10862207 
Chicken anti-GFP 1:500 (mouse) #GFP-1020 Aves Labs, 
RRID:AB_10000240 
Rabbit anti-S100B 1:200 (mouse) Ab52642 Abcam; RRID:AB_882426 
Rabbit anti-PBX3 1:100  (human and 
mouse) 
12571-1-AP Proteintech Group; 
RRID:AB_2160469 
Rabbit anti-TBX2 1:100 (human and 
mouse) 
22346-1-AP Proteintech Group 
Rabbit anti-POU3F3 1:100  (human and 
mouse) 
HPA067151 Sigma; RRID:AB_2685790 
Rabbit anti-RBFOX1 1:100 (human and 
mouse) 
HPA040809 Sigma; RRID:AB_10796228 





Santa Cruz; no longer sold 






1:500 (mouse) AB5026 Sigma; RRID:AB_91644 
Rat anti-Substance P 
(NC1/34) 
1:800 (mouse) AB150349 Abcam 
Alexa Fluor goat anti-
human 647 
1:400 (mouse and 
human) 




1:400 (mouse and 
human) 




1:400 (mouse and 
human) 









1:400 (mouse and 
human) 








1:400 (mouse and 
human) 




1:400 (mouse and 
human) 




1:400 (mouse and 
human) 




1:400 (mouse and 
human) 




1:400 (mouse and 
human) 








Supplementary Table 2.8: List of RT-PCR primers 
























Supplementary Table 2.9: List of PCR primers for mouse genotyping 
Gene 
(Strain) 
Primer Sequence Band size Genotyping 
solution 
Reference 
Tbx3  F: 5'-GTG TGA GAC AGA 
GAA ATC AGT GG-'3 
R: 5’-5' CCA ACT GGT 











F: 5'-TCA TAG AGG CGC 
AGA GTT CC-3' 
R: 5'-CTG AAC TTG TGG 
CCG TTT AC-3' 


































(27) and personal 
correspondence 
with Dr. Sanjay 
Jain’s laboratory  
Cre (Wnt1-
Cre) 
F: 5’- GCA TTA CCG GTC 
GAT GCA ACG AGT GAT 
GAG-3’ 
R: 5’-GAG TGA ACG AAC 
CTG GTC GAA ATC AGT 
GCG-3’ 












Common F: 5’-AAA GTC 
GCT CTG AGT TGT TAT-3’ 
Mutant R: 5’-TTA TGT AAC 
GCG GAA CTC CA-3’ 
WT R:  5’GGA GCG GGA 
GAA ATG GAT ATG-3’ 
Mut: 309bp 
















F: 5’-GCA TTA CCG GTC 
GAT GCA ACG AGT GAT 
GAG-3’ 
R: 5’-GAG TGA ACG AAC 
CTG GTC GAA ATC AGT 
GCG-3’ 











F: 5’-GCA TTA CCG GTC 
GAT GCA ACG AGT GAT 
GAG-3’ 
R: 5’-GAG TGA ACG AAC 
CTG GTC GAA ATC AGT 
GCG-3’ 


































WT F: 5’-CCC TCC CCT 
CTC ATT TTC TC-3’ 
Mut F: 5’-TGG TTT GTC 
CAA ACT CAT CAA-3’ 
Common R: 5’-ACA GTT 












F: 5’-GCG GTC TGG CAG 
TAA AAA CTA TC-3’ 
R: 5’-GTG AAA CAG CAT 
TGC TGT CAC TT-3’  








Mut F: 5’-ACG AGT CGG 
ATC TCC CTT TG-3’ 
Mut R: 5’-AGA CTG CCT 
TGG GAA AAG CG-3’ 
WT F: 5’-AAG GGA GCT 













Primer Sequence Band size Genotyping 
solution 
Reference 
WT R: 5’-CCG AAA ATC 





Supplementary Table 2.10: ARRIVE Guidelines - General animal husbandry information 
Location of Animal 
facility (types of 
experiments) 










of myenteric plexus 
stained with 
substance P and 
enkephalin) 
Facility Type Conventional: cages are 
opened at room air, face 
masks are not required 
when handling mice 
Barrier housing and 
maintained with caging 







opened under Animal 
Transfer Station 
Facility Type Specific pathogen free, 
Pathogens detected in 
room within the past 2 
years: MNV (mouse 
norovirus), Helicobacter 
not tested but likely 
present 
Specific pathogen free; 
sentinel testing for 
excluded pathogens 
and MNV 
Specific pathogen free; 





Daily Daily Daily (food and water) 
Weekly (health check) 
Bedding ¼ inch corn cob (The 
Andersons, Product 4B) 





Cage type Lab Products (Seaford, 
DE) 75 sq. in. Ventilated. 
Allentown mouse IVC 
caging 




Location of Animal 
facility (types of 
experiments) 










of myenteric plexus 
stained with 




Standard tunnel washer Standard tunnel 
washer, boxes 




Mouse diet Mouse Diet 5015 (Lab 




Prolab Isopro RMH 
3000 (5P75) irradiated 
Jackson labs: LabDiet® 
5K52 formulation (6% 
fat). 
Animal Facility: 
Barastoc WEHI Mice 
Cubes, irradiated 
Light-dark cycle 12/12 
  
12/12 12/12 
Temperature 72°F +/- 2°F 72°F +/- 4°F 18-24°C +/- 1°C  
Humidity 30-70% depending on 
the day/season 
30-70% depending on 
the day/season 
30-70% depending on 
the day/season 








Filtered water bottles 




Location of Animal 
facility (types of 
experiments) 










of myenteric plexus 
stained with 
substance P and 
enkephalin) 
Access to food and 
water 
Continuous Continuous Continuous 
Number of mice per 
cage 
1-5 (20-30g) 1- 4 males, 1-5 females 1-5 
Cage Enrichment house/dome (Bioserve, 
S3174) and nestlet 
(Ancare) 
house/dome (Bioserve, 
S3174) and nestlet 
(Ancare) 
house/dome, tissues, 
chewing wooden block 
for single-housed mice 
Mating strategy Continuous Continuous not applicable in this 
study 
Age at weaning 19-20 days 19-28 days 19-21 days (not 
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CHAPTER 3: Development of a screening platform to identify transcription factors 
directing enteric neuron subtype specification and differentiation 
 
This manuscript is being prepared for publication. This chapter details progress towards 
establishing a high-throughput screening system to test the effect of transcription factor 
overexpression on enteric neuron subtype differentiation. Authors: Sabine Schneider, Sohaib K 
Hashmi, Chinmay Kalluraya, Paul Gadue, Deborah L. French, Robert O. Heuckeroth. (2020) 
 
3.1 Abstract 
Enteric neuropathies, dysfunction of the enteric nervous system (ENS), can cause 
devastating disease in affected individuals. The symptoms include abdominal pain, diarrhea, 
vomiting, distention and in severe cases sepsis and death. Our current treatment options remain 
limited to supportive treatment and surgical resection of the most severely affected bowel regions. 
The underlying cause of enteric neuropathy is loss or dysfunction of one or more enteric neuron 
subtypes. One enticing way to study these disorders and develop new therapy takes advantage of 
recently developed in vitro differentiation protocols for human pluripotent stem cells (hPSCs). Stem 
cell therapies aim to replace or supplement missing or defective ENS cell types to re-establish 
functioning neural circuits. However, in vitro differentiation protocols are not yet sophisticated 
enough to direct differentiation into specific neuronal subtype fates. My hypothesis was that a better 
understanding of the extracellular signals and transcriptional regulation that controls subtype 
specification and differentiation would facilitate protocol development for directed  differentiation of 
stem cells to specific ENS subtype fates. Here, we present progress towards the goal of testing the 
effects of select transcriptional regulators on stem cell differentiation into cholinergic versus 
nitrergic enteric neuron fates. To pursue this work we established an in vitro ENS differentiation 
protocol in our lab and created a small library of doxycycline-inducible lentiviral vectors that express 
transcriptional regulators differentially expressed in developing enteric neuron subtypes. We are 
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currently validating CHAT and NOS1 fluorescent reporter hPSC lines to facilitate future screening 
of the transcriptional regulator library.  
  
3.2 Introduction 
The enteric nervous system (ENS) is a complex network of 500 million neurons and glia 
that spans the entire length of the bowel. More than 20 specialized enteric neuron subtypes form 
repeating neural circuits that coordinate vital functions like muscle contraction and epithelial ion 
transport (1–4). For this reason, congenital and acquired imbalances in enteric neuron subtypes 
may cause debilitating and potentially life-threatening gastrointestinal motility disorders (5–7). 
Symptoms include constipation, nausea, vomiting, abdominal pain and distention, and in some 
cases sepsis and early death (5, 7). For all of these ENS disorders, quality of life can be poor and 
few effective treatments exist (7–9). If an obvious ENS abnormality is regionally restricted, surgical 
removal of the affected bowel region is routine. An example is Hirschsprung disease where the 
ENS is completely missing in the distal bowel and surgical resection of the abnormal region can be 
curative. However, in many children, debilitating symptoms persist after Hirschsprung disease 
surgery (10–12). One explanation for post-surgical problems appears to be dysfunctional ENS 
circuitry in areas of the bowel where the ENS looks grossly normal (13–17). When bowel motility is 
abnormal in many regions, the problem is called chronic intestinal pseudo-obstruction (CIPO). For 
CIPO, treatment options are particularly limited (8, 9). Neuropathic CIPO is presumed to be caused 
by altered enteric neuron subtype ratios and neuron subtype dysfunction, but exact genetic 
mutations and the mechanisms of disease are still only rarely identified (see our work in chapter 2 
to address this problem).  
For both Hirschsprung disease and CIPO, an ideal therapy would replace the missing or 
defective ENS cell types (18). Recent advances in stem cell biology have made stem cell therapy 
an enticing possibility. Patient-derived human pluripotent stem cells (hPSCs) can now be robustly 
generated. hPSCs can be cultured long-term in serum-free, chemically-defined, and xeno-free 
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culture media without loss of pluripotency (19) and innovations in genome-editing technology (20) 
have dramatically simplified the process of correcting gene defects. Even more excitingly, several 
differentiation protocols have been developed to convert human pluripotent stem cells into enteric 
nervous system cells (21–26). However, no differentiation protocol is optimized to generate specific 
ENS subtypes. This is not surprising since only limited mouse (27, 28) and human (28) gene 
expression data sets were available to guide hypothesis-driven protocol development. Most 
importantly, only a few extracellular signaling molecules (BMP2/4 and Noggin (29–31), NRTN (32, 
33), 5-HT (34), and GDNF (35)), extracellular matrix components (laminin-I, heparan sulfate, 
collagen-I, and collagen-IV (36)), and transcription factors (Ascl1/Mash1 (37), Sox6 (28), Hand2 
(38, 39), Dlx1/Dlx2 (40), and Smad1 (31)) have been shown to affect specification or differentiation 
of enteric neuron subtypes in experimental models. Our work (Chapter 2) and that of others (41–
44) now provide exciting new gene expression data defining extracellular factors and transcriptional 
regulatory networks that could facilitate directed enteric neuron subtype differentiation. Using our 
own data, I decided to explore a fundamental question of enteric nervous system development: Is 
the expression of a defined number of transcription factors sufficient to direct differentiation of a 
multipotent enteric neural precursor into a cholinergic versus a nitrergic enteric neuron fate?  
Cholinergic and nitrergic cell types make up the vast majority of enteric myenteric neurons 
and include excitatory and inhibitory motor neurons respectively. In mouse small intestine 
myenteric plexus, ~30% of all neurons are nitrergic, ~60% cholinergic, and ~3% both cholinergic 
and nitrergic (45, 46). In human colon myenteric plexus, 43-51% of all neurons are nitrergic only, 
28-52% cholinergic only, and 4-10% both nitrergic and cholinergic (see Chapter 6 Supplemental 
Table 6.4 and 6.5 for a more in depth discussion of human myenteric plexus staining). These 
cholinergic and nitrergic neurons are derived from a common enteric neuron precursor and the 
subtype fate decision is made at or after the penultimate cell division (27). The observation that 
enteric neuron subtypes diverge from a common precursor late in differentiation supports the 
hypothesis that a few transcriptional regulators could control enteric neuron subtype differentiation. 
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Even more compellingly, one myenteric interneuron subtype appears to differentiate post-
mitotically from a common precursor that also produces inhibitory motor neurons in a Pbx3-
dependent manner (42). To more broadly investigate the transcriptional regulation of cholinergic 
versus nitrergic enteric neuron subtype fate, we established an hPSC differentiation protocol that 
generates  enteric neuron and glial subtypes. We are currently developing fluorescent reporter 
hPSC lines to facilitate identification of nitrergic and cholinergic enteric neurons and we have 
generated doxycycline-inducible lentiviruses that express selected transcriptional regulators. We 
are now poised to use this system to test the hypothesis that specific transcription factors can direct 
enteric neuron subtype differentiation into either cholinergic or nitrergic fate. This system can also 
be easily adapted to systematically study extracellular signaling pathways regulating cholinergic 
and nitrergic neuron subtype differentiation. 
 
3.3 Results 
Reproducible differentiation of human pluripotent stem cell-derived into enteric neuron and 
glial subtypes  
We used the differentiation protocol developed by Fattahi et al. (22), as well as the feeder-
free version of the protocol by Barber et al. (25) to reproducibly differentiate human pluripotent stem 
cells (hPSCs) into enteric neurons and glia (called Enteric Neural Crest-derived Cells or ENC). On 
day 11/12 of ENC differentiation, we were able to verify the presence of CD49D+/p75+ enteric 
neuron precursors (Figure 3.1A-B) (22, 47). Cells expressing high levels of CD49D were isolated 
via FACS and ENC differentiation was continued with purified enteric neuron precursors. By day 
17 of differentiation, enteric neuron precursors had a mesenchymal appearance (flat, low 
nucleus:cytoplasm ratio), were highly migratory (data not shown) and individual cells were often 
connected to neighboring cells by thin neurites (Figure 3.1C), similar to migrating enteric neuron 
precursors in mouse (48, 49). Around day 25 of differentiation, cells adopted a more rounded 
appearance with longer, more robust neurites (Figure 3.1D). Immature enteric neurons and glia 
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then started aggregating after day 30 (Figure 3.1E). These cell body aggregates connected by 
fasciculated neurites closely resemble enteric ganglia, the clusters of neurons and glia that are 
characteristic of a normal mature ENS (50). By day 36, tubulin 3 beta (TuJ1+)- expressing neuron 
cell bodies and a dense network of long TuJ1+ axons were interspersed with S100B+ glial cells 
(Figure 3.1F). After day 60 of differentiation, the cultures were dominated by small, tight “ganglion”-
like cell aggregates (Figure 3.1G)  and larger, dense cell accumulations (Figure 3.1H) connected 
to each other by thick strands of fasciculated neurites (Figure 3.1G-H).  
The “mature” ENC differentiation cultures after day 60 contained enteric neurons that 
expressed a wide variety of important enteric neuron subtype markers: CALB2 (calretinin), GABA 
(gamma butyric acid), NPY (neuropeptide Y), NOS1 (nitric oxide synthase I), RET(REarranged 
during Transformation proto-oncogene), SST (somatostatin), TAC1 (substance P), TH (tyrosine 
hydroxylase), TPH2 (tryptophan hydroxylase 2), and VIP (vasoactive intestinal peptide) (Figure 
3.1I). “Mature” ENC cultures included large numbers of p75+ enteric glia (Figure 3.1I) co-
expressing combinations of the glial markers S100B, GFAP, and SOX10 (Figure 3.1J-K) (51). We 
detected the pan-enteric neuron marker PHOX2B (52) in most of the enteric neurons within our 
culture, including TH+ neurons (Figure 3.1L). We also assessed co-expression of some neuron 
subtype marker combinations in our cultures. As expected based on immunohistochemical 
characterization of mouse enteric neuron subtypes (45, 53), NOS1 and CALB2 were generally not 
expressed by the same neurons (Figure 3.1M) while many neurons co-expressed calretinin 
(CALB2) and vesicular acetylcholine transporter (SLC18A3), a combination present in most 
cholinergic neurons (Figure 3.1N) (46, 53). A small subset of neurons co-expressed vasoactive 
intestinal peptide (VIP) and somatostatin (SST, Figure 3.1O), a neuropeptide combination that 
marks interneurons and submucosal secretomotor neurons in guinea pig (54). These observations 
extend previous immunohistochemical characterizations of the enteric neuron and glial subtypes 
found in “mature” ENC cultures (22, 24–26). The presence of all expected enteric neuron subtype 
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markers indicates that these two ENC differentiation protocols allow for the differentiation of many 
important categories of enteric neuron subtypes.  
 
Figure 3.1: Reproducible differentiation of hPSC-derived enteric neuron and glia 
A) Fluorescence activated cell sorting at day 11 of differentiation shows robust generation of 
CD49D (α4 integrin)-expressing enteric nervous system precursor cells. Compare unstained cells 
(left) to CD49D-stained cells (right). (B) CD49D-expressing cells also express the enteric nervous 
system precursor marker p75 (LNFR, low-affinity nerve growth factor receptor) by fluorescence 
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activated cell sorting at day 11 of differentiation. Compare unstained cells (left) with p75/CD49D-
stained cells (right). (C) At day 17 of differentiation, the enteric neural precursor cells have a 
mesenchymal appearance and extend thin neurites. (D-E) The cells gain a more rounded 
appearance up by day 28 of differentiation (D) and start aggregating into “ganglia”-like structures 
by day 33 (E). (F) By day 36 of differentiation, expression of the pan-neuronal marker TuJ1 (tubulin 
3 beta) and the glial marker S100B can be appreciated in distinct cell populations. (G-H) Extensive 
networks of fasciculated neurites connect tight “ganglia”-like cell clusters and looser cell aggregates 
after day 60 of differentiation. (I) The expected wide variety of enteric glial markers and enteric 
neuron subtype markers can be detected in mature cultures after day 60 of differentiation. TPH2 
(tryptophan hydroxylase 2), NOS1 (nitric oxide synthase 1), CALB2 (calretinin), p75 (LNFR, low-
affinity nerve growth factor receptor), TH (tyrosine hydroxylase), GABA (gamma aminobutyric acid), 
CGRP (calcitonin gene-related peptide), NPY (neuropeptide Y), RET (rearranged during 
transfection proto-oncogene), SST (somatostatin), TAC1 (substance P), and VIP (vasoactive 
intestinal peptide). Pan-neuronal marker TUJ1 (tubulin 3 beta) is shown for context in a subset of 
panels. (J-O) Coexpression was assessed from a limited number of glial and neuron subtype 
markers: (J) S100B and GFAP as well as (K) S100B and SOX10 are coexpressed by subsets of 
enteric glia. (L) Pan-enteric neuron marker PHOX2B is expressed in differentiated neurons 
(including TH-expressing neurons). (M) NOS1 and CALB2 are not expressed in the same neurons. 
(N) CALB2+ neurons co-express the pan-cholinergic neuron marker SLC18A3 (vesicular 
acetylcholine transporter and lastly, (O) VIP and SST are coexpressed in a subset of neurons. 
(F,I,J) Blue pan-nuclear marker is Hoechst. (C-E, G-H) Scale bar = 100 μm. (F)  Scale bar = 50 
μm. (I-O)  Scale bar = 20 μm. 
 
Generating a NOS1 and CHAT fluorescent reporter H9-hESC cell line to facilitate 
identification of nitrergic and cholinergic enteric neurons 
Quantification of cholinergic and nitrergic neurons in mature ENC cultures is necessary to 
determine if transcription factor overexpression enhances enteric neuron differentiation into 
cholinergic or nitrergic neurons. However, commonly used immunohistochemical markers choline 
acetyltransferase (CHAT), vesicular acteylchine transporter (SLC18A3), and neuronal nitric oxide 
synthase (NOS1) are in neuron cell bodies and their extensive neurites (45) making it difficult to 
count individual cell bodies in dense neuron aggregates. To address this problem, I decided to 
generate fluorescent reporter H9-hESC lines that label cholinergic and nitrergic neurons. Using 
CRISPR/CAS9, we generated two independent reporter lines with a nuclear localized tandem dimer 
red fluorescent protein (tdRFP) knocked  into the 3’ untranslated region (3’ UTR) of either the 
endogenous NOS1 locus or the endogenous CHAT locus. An internal ribosome entry site (IRES) 
sequence after the NOS1 and CHAT stop codons permits expression of nuclear tdRFP from the 
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same mRNA as the endogenous NOS1 and CHAT transcripts, respectively. Thus, tdRFP 
expression can serve as a proxy for NOS1 or CHAT expression. We included a floxed puromycin 
selection cassette at the 3’ end of the CRISPR insertion template (Figure 3.2A) and screened ~300 
clones by PCR for correct genomic insertion of the IRES-NLS-tdRFP-puromycin selection cassette 
(Figure 3.2B-E). We expanded one morphologically healthy hPSC clone for each of NOS1 or 
CHAT fluorescent reporter genomic insertion. Chromosomal G band analysis for the CHAT reporter 
line confirmed the absence of chromosomal aberrations (Supplementary Figure 3.1). The NOS1 
reporter line has not yet been karyotyped.  
Both reporter clones were subsequently transfected with pCAG-Cre-GFP to excise the 
floxed puromycin selection cassette, which was verified by PCR (Figure 3.2G-J). We attempted 
differentiations with NOS1 and CHAT fluorescent reporter lines, but  unfortunately saw only faint 
cytoplasmic tdRFP with no nuclear-localized tdRFP (data not shown). Upon re-examination of the 
repair template, we found a 10 bp spacer between the NLS and tdRFP sequences that introduced 
a frameshift preventing production of normal protein. However, the tdRFP sequence itself has an 






Figure 3.2: Development of CHAT and NOS1 3’UTR fluorescent reporter knock-in h9-hESC 
cell lines 
A) Schematic of the CRISPR repair template integrated into the genomic CHAT and NOS1 loci. An 
internal ribosomal entry site (IRES), the coding sequence for tandem-dimer RFP (TdRFP) with a 
nuclear localization sequence (NLS), and a purmycin selection cassette were introduced into the 
3’UTR of the CHAT and NOS1 loci. The dsDNA repair template homology arms extend 1kb both 
upstream (5’) and downstream (3’) from the Cas9 cut site within the CHAT and NOS1 3’UTRs. (B-
E) Four sets of primers were used to verify a complete insertion of the repair template into the 
correct genomic location (see Supplementary Table 3.3). (F) Schematic of the genomic locus with 
inserted repair template. The approximate location of the primer pairs (B-D) are marked by colored 
arrows. (G) Transient expression of CRE removed the puromycin selection cassette from the NOS1 
clone with correct insertion of the repair template (see B-D) and allowed us to select 3 clones (1,3 
and 8) with retained correct genomic insertion (see Supplementary Table 3.3). (H) Schematic of 
the NOS1 genomic locus with inserted repair template. The approximate location of the primer pair 
(G) is marked by arrows. (I) Transient expression of CRE removed the puromycin selection 
cassette from the CHAT clone with correct insertion of the repair template (see B-D) and allowed 
us to select 2 clones (3 and 7) with retained correct genomic insertion (see Supplementary Table 
3.3). (J) Schematic of the CHAT genomic locus with inserted repair template. The approximate 
location of the primer pair (G) is marked by arrows.  
 
Lentiviral overexpression of transcription factors specific to enteric neuron subtypes 
 I chose nine transcription factors to overexpress in differentiating ENC cultures. These 
transcription factors were selected based on differential expression in myenteric cholinergic or 
nitrergic enteric neuron subtypes as defined by single cell RNA-sequencing data at embryonic day 
17.5 (E17.5) and single nucleus sequencing in adult mouse colon (see Chapter 2 and Figure 3.3A-
B). Some selected transcription factors are expressed in all cholinergic neuron clusters, but few 
nitrergic neuron clusters in E17.5 mouse ENS (Casz1 and Meis1), some are only detected in 
specific cholinergic clusters (Bnc2, Tbx2, and Pbx3), and some are primarily restricted to nitrergic 
neuron clusters (Creb5, Etv1, Ebf1) (Figure 3.3B and Chapter 2). 
I decided to introduce the transcription factors into enteric neural precursors via lentiviral 
infection. Transcription factor expression was controlled by a doxycycline-inducible cis regulatory 
element for tight temporal control (see Supplementary Figure 3.2A). As proof-of-principle, I 
infected enteric neural precursors at day 22 of differentiation with high titer lentiviral particles 
carrying the cDNA sequence for doxycycline-responsive transcriptional activator, reverse 
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tetracycline-controlled transactivator (rtTA), and EBF1 cDNA with added V5 and His tag 
sequences. Differentiating ENC cultures were treated with doxycycline from day 24 to day 27 and 
analyzed for EBF1 expression at day 27 of differentiation. Enteric neuron precursors were identified 
by SOX10 expression and nuclear expression of both V5 and His protein tags verified efficient 
EBF1 expression in the vast majority of cells (Figure 3.3C). 
 
Figure 3.3: Successful generation of lentiviral overexpression vectors for select 
transcription factors to be used in overexpression screen  
(A) TSNE plot of embryonic day 17.5 (E17.5) mouse enteric neuron single cell sequencing data 
shows 4 clusters of nitrergic neurons (1 immature  and 3 mature clusters) and 4 clusters of 
cholinergic neurons (2 immature and 2 mature clusters) (see chapter 2). (B) Dot plot with nine 
transcription factors differentially expressed in cholinergic or nitrergic E17.5 enteric neuron 
cluster(s). The transcription factors were selected for the overexpression screen and cloned into 
the FU-tetO-Gateway lentiviral expression vector under control of a tetracycline response element 
(see Supplementary Table 3.4 and Supplementary Figure 3.2). Dot plot illustrates both the fold 
change in transcription factor differential expression per cluster (denoted by color shades ranging 
from blue to red) and percent of cells per cluster expressing the transcription factor (denoted by 
circle diameter). (C) Transcription factor EBF1 is successfully expressed in enteric neuron 
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precursors (SOX10+) at day 27 of differentiation. Enteric neuron precursors at day 22 of 
differentiation were infected with lentiviral expression vector carrying the EBF1 coding sequence 
and expression of the HIS and V5 tag can be verified. Hoechst is used to mark all nuclei in the field 
of view. (A-B) Imm.= immature. (B) Color legend denotes fold change (average normalized gene 
expression level in cluster of interest/ average normalized gene expression level in all other 
clusters). (C) Scale bar = 50 μm. 
 
3.4 Discussion and Future Directions 
The future of targeted stem cell therapies for enteric neuropathies like CIPO depends on 
understanding the transcriptional regulation of enteric neuron subtype specification and 
differentiation. Some studies using conditional knockout mouse models studies have already 
implicated transcription factors in enteric neuron subtype differentiation (28, 31, 37–40, 42, 55). 
However, conditional knockout mouse models  are  a low-throughput tool to identify transcription 
factors that critically influence differentiation. In contrast, high-throughput screening in pluripotent 
cells could rapidly identify transcriptional regulators that alter enteric neuron subtype 
differentiation.  
An important consideration is that redundancy in transcription factor regulatory networks 
frequently obscures regulatory functions of single transcription factors in loss-of-function studies 
(56, 57). Gain-of-function studies thus may have a higher chance of revealing a regulatory role for 
a given transcription factor. However, only rare transcription factors can induce the expression of 
genes in transcriptionally silent chromatin regions (58, 59) which may encompass gene loci with 
cell type or cell subtype-specific expression. Limited combinations of pioneer factors are able to 
initiate gene regulatory networks that can convert one distantly related mature cell type to another 
(60–62) or, rarely, single-handedly establish a specific cell fate (63). Therefore, the overexpression 
system I established may increase the likelihood of elucidating regulatory functions of specific 
transcription factors in differentiating enteric neurons. Candidate transcription factors can be 
expressed in immature enteric neurons. These cells have already established enteric neuron-
specific transcriptional regulatory networks, and may express required transcriptional coregulators 
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for subtype specific gene modules. Most importantly, subtype-specific gene loci may already be 
accessible to transcription factor binding due to permissive chromatin modifications  (64). 
 My selection of transcription factors was based on my newly generated mouse single cell 
and single nucleus data. Mouse models well-recapitulate a number of human enteric neuropathies 
(65–67) and regulatory relationships between specific genes and transcription factors appear to be 
largely conserved between mammals (68). However, there are interspecies differences in enteric 
neuron subtype neurotransmitter expression (45) and enteric neuron subtype ratios (52). It is 
possible that transcriptional regulation of enteric neuron subtype differentiation is altered in subtle 
but important ways when comparing mouse and human. This makes it even more important that 
the role of candidate transcriptional regulators is assessed in human cells. 
 We chose transcription factors based on their differential expression in fetal and adult 
cholinergic versus nitrergic myenteric neuron subsets. Most selected transcription factors also have 
roles in CNS neuron subtype differentiation (Supplementary Table 3.4). Our novel data shows 
that Tbx3 is required for normal perinatal numbers of myenteric nitrergic neurons (Chapter 2) and 
others reported Pbx3 is required for differentiation of a subset of myenteric interneurons (Pbx3, 
(42)). This makes these transcription factors perfect candidates to test and validate the transcription 
factor overexpression screen as we differentiate hESC into enteric neurons. 
 To facilitate the identification of cholinergic and nitrergic neurons in dense enteric nervous 
system cultures (after day 60 of ENC differentiation), I decided to generate fluorescent reporter 
lines that will label any nitrergic (NOS1-expressing) or cholinergic (CHAT-expressing) cells. 
Addition of a nuclear localization sequence to the tdRFP protein should further simplify 
quantification of these neurons since dense networks of neurites will not contain tdRFP. I decided 
to introduce the tdRFP sequence into the 3’UTR to avoid having to select for heterozygous insertion 
of the construct into hPSC. Homozygous loss of Chat (69) and Nos1 leads to structural ENS defects 
(70) and beyond that, we wanted to minimize changes in endogenous gene expression as much 
as possible. One drawback of this design decision is the dependence of tdRFP translation efficiency 
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on the transcription rate of the endogenous CHAT and NOS1 transcripts. Recent data we and 
others generated shows that in both mouse and human, NOS1 transcripts are abundant in nitrergic 
neurons, however, CHAT transcripts are rare (Chapter 2 and (42, 43)). This may reflect low CHAT 
RNA transcript stability or possibly predominantly local CHAT protein translation at pre-synaptic 
terminals (71, 72). Since the tdRFP has been introduced into the 3’UTR after an IRES sequence, 
translation of tdRFP will likely be less efficient than that of the endogenous CHAT and NOS1 
transcripts (73) and thus tdRFP signal could be very low even in unambiguously cholinergic 
neurons. However, the half-life of RFP proteins is around 20-26 hours (74–76), so even a low 
translation rate may be sufficient to detect tdRFP fluorescence.  
 Unfortunately, we detected a frameshift in both the CHAT and NOS1 fluorescent lines, 
which likely explains the lack of nuclear tdRFP signal and low tdRFP signal overall. We will continue 
the characterization of the lines we generated to see if the reporters can be used despite the design 
error. However, it is likely that we will have to repeat the reporter line CRISPR screen with a correct 
CRISPR repair template without the frame-shift. At this point, we do not predict this to take very 
long since all tools have already been generated and validated in our hands.  
 Our screen currently only focuses on cholinergic versus nitrergic fate decisions, but could 
be extended to look at other functionally relevant neuron subtypes like intrinsic sensory neurons or 
motor neurons (1). We have already extended the previously published characterization of enteric 
neuron subtypes that spontaneously arise in ENC differentiation cultures (22, 25) by staining for 
known mouse and human enteric neuron subtype markers. We were able to verify the presence of 
many important markers and the expected co-expression patterns for a much smaller subset. To 
better understand the possibilities and limitations of the current ENC differentiation protocols, we 
plan on quantifying the proportions of total neurons co-expressing unique combinations subtype 
markers using single cell/nucleus RNA sequencing data that has only recently been generated 
(Chapter 2 and (42–44)).  
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Since at least some subtype fate decisions are made late in the enteric neuron 
differentiation timeline (27, 42) and may require tight temporal control of transcriptional regulator 
expression, we chose a lentiviral vector with a doxycycline-responsive cis regulatory element (TRE) 
5’ to the transcription factor sequences (Supplementary Figure 3.2A) (77, 78). Introduction of 
doxycycline in the cell culture medium for differentiating enteric neuron precursors would then 
permit us to control the timing of transcription factor gene expression. Stable genomic insertion of 
the construct allows us to infect differentiating enteric neural precursors before they form tight 
aggregates (compare Figure 3.1C to Figure 3.1F), thereby maximizing infection efficiency. 
Differentiating cells are thus infected days to weeks before “mature” enteric neuron subtypes are 
observed in culture. We currently plan to infect enteric neural precursors at day 20-22 of 
differentiation and to start transcription factor overexpression by day 25 (concurrent with the change 
in enteric neural precursor morphology to a rounded cell shape and shortly before first detection of 
pan-neuronal marker tubulin III beta (Figure 3.1D-F). Cultures will be monitored closely for the 
appearance of cholinergic/nitrergic neurons (nuclear RFP+ neurons) and mature ENC cultures will 
be quantified for the absolute numbers and cholinergic/nitrergic to total neuron ratio 
(Supplementary Figure 3.2B).  
We are now poised to use this system to study the effects of select transcription factors on 
enteric neuron subtype differentiation into either cholinergic or nitrergic fate. Furthermore, this 
system can easily be expanded to study fate decisions for functionally important sub-categories of 
cholinergic and nitrergic neurons (e.g. intrinsic sensory neurons or inhibitory motor neurons) as 
well as the effects of extracellular signaling pathway modulation (e.g. addition of trophic factors and 
small molecule inhibitors) on neuron subtype differentiation.   








Maintenance of pluripotent stem cells on a feeder layer 
 Human pluripotent stem cells (hPSCs, H9-hESCs; WA09, WiCell, Madison, WI; NIH 
Registration Number 0062) were maintained in HES medium (see Reagents and Solutions in 
Supplementary Data) on a layer of irradiated mouse embryonic fibroblasts (MEFs) plated on 
gelatin-coated tissue culture dishes. HPSCs were examined daily by brightfield microscopy to verify 
normal morphology and passaged once colonies were compact, rounded, and almost touching 
(every 3-4 days) without being raised. 1-4 days before passaging hPSCs, irradiated MEFs were 
plated on 6-well plates coated with 0.1% gelatin (Sigma-Aldrich; Cat# G1890) in MEF medium (see 
Reagents and Solutions in Supplementary Data). Before plating PSCs on the MEF feeder-layer, 
the wells were washed 1x with Iscove’s Modified Dulbecco’s Eagle Medium (IMDM, ThermoFisher, 
Cat#12440053). To  passage one well of a 6-well plate of hPSCs, 1 mL of TrypLE Express 
(Invitrogen, Cat#12605010) was added to the hPSC plate and incubated at room temperature (RT) 
for 3 minutes. The well was then gently agitated and inspected by brightfield microscopy. Once 
most of the MEFs had detached and the edges of the hPSC colonies had lifted off while the center 
remained firmly attached, TrypLE was aspirated and the well was washed once with IMDM. IMDM 
was then aspirated and 1 mL of HES medium was added to the well. The hPSC colonies were 
gently removed from the bottom of the well using a rubber cell scraper (Fisher Scientific, Cat#50-
809-208). Cells were triturated three times with a P1000 pipet tip and a subset of cells (1:10 
passaging ratio for maintenance culture) was transferred to a 14 mL Falcon tube (Corning, 
Cat#352059) containing HES medium supplemented with 10 μM Rho-associated kinase inhibitor 
(ROCKi) (Y-27632 dihydrochloride, R&D Systems, Cat#1254/1). 2 mL of cell suspension was 
plated per well and cultured at 37°C in 5% carbon dioxide, 5% oxygen, and 90% nitrogen. HES 
medium with ROCKi was replaced with normal HES medium after allowing cells to attach overnight 
and replaced daily until cells were ready for their next passage. To freeze cells, the normal 
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passaging protocol was followed (as above), but cells were scraped into IMDM after dissociation 
with TrypLE. PSCs were triturated, and the cell suspension was transferred to a 15 mL Falcon tube, 
and centrifuged at 270 xg for 3 minutes. The media was aspirated and the cell pellet was 
resuspended in 50% FBS, 40% HES media, and 10% dimethyl sulfoxide (DMSO) (Sigma, 
Cat#2650-100ml). Resuspended cells were transferred into labeled cryovials and placed into 
freezing containers containing isopropanol at -80°C for 24 hours before being transferred to liquid 
nitrogen for long-term storage. 
 
Maintenance of pluripotent stem cells in feeder-free conditions 
 To transition hPSCs from MEF feeders to feeder-free conditions, tissue culture plates were 
coated with Corning® Matrigel® hESC-Qualified Matrix, LDEV-free (Corning, Cat#354277). The 
Matrigel was diluted 1:100 in DMEM/F12 (Dulbecco's Modified Eagle Medium: Nutrient Mixture F-
12, ThermoFisher, Cat#11320033) and incubated at room temperature for 45 min  to 1 hour. 
Matrigel was then aspirated and replaced with IMDM and used right away or stored at 37°C in 5% 
carbon dioxide for up to 1 week. HPSCs on a MEF feeder layer were dissociated with TrypLE as 
previously described and plated on the Matrigel-coated plates at a ratio of 1:6 in Essential 8 (E8) 
Flex medium (Gibco, Cat#A2858501). Cells were cultured at 37oC in 5% carbon dioxide. Cells were 
fed every day with 2 mL/well (6-well plate) of fresh E8 medium. HPSCs were adapted to feeder-
free conditions after 2-3 passages. To passage feeder-free hPSCs, colonies were observed by 
brightfield microscopy daily. Once colonies were large but still tightly formed and covered close to 
75% of the well, the well was washed once with 1x Dulbecco’s Phosphate Buffered Saline (DPBS) 
without calcium and magnesium (Cat#21-031-CV), and 0.5 mM EDTA (EDTA Buffer, pH 8, 0.5 M, 
Invitrogen, Cat#15575020) diluted in 1x DPBS (EDTA-PBS) (pre-warmed to 37°C) was added. 
Cells were incubated with EDTA-PBS for 4 minutes while closely observing the well under a 
brightfield microscope. When the cells in the colonies appeared rounded and cells at the center 
began to separate from each other, EDTA-PBS was gently removed and 1 mL E8 Flex medium 
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was added to the well followed by gentle agitation to lift off cell aggregates. A P10 pipet tip was 
used to gently draw up the cell aggregates into a 14 mL Falcon tube with E8 media and cells were 
plated at a passaging ratio of 1:3-1:5 on a new plate coated with 1:100 Matrigel. For cryopreserving 
feeder-free PSCs, cells were passaged with 0.5 mM EDTA-PBS as previously described. After 
removing EDTA-PBS, 1 mL/well of STEM-CellBanker-GMP Grade (Amsbio LLC, Cat#NC0400932) 
was added and cell aggregates were lifted off by gentle agitation. After triturating once, 
resuspended cells were transferred into labeled cryovials and placed into freezing containers with 
isopropanol at -80°C for 24 hours before being transferred to liquid nitrogen for long-term storage.   
 
Differentiation of pluripotent stem cells into enteric neural crest precursor cells 
Differentiation of hPSCs into enteric neurons and glia starting from hPSCs maintained on a 
MEF feeder-cell layer (22) 
Up to a week before starting a differentiation, 6-well plates were prepared for differentiation 
by coating with Matrigel (Corning Matrigel Basement Membrane Matrix, Corning, Cat#354234). The 
Matrigel was thawed on ice and diluted 1:20 with DMEM/F12 medium (Dulbecco's Modified Eagle 
Medium: Nutrient Mixture F-12, ThermoFisher, Cat#11320033). The diluted Matrigel was added to 
the wells and allowed to incubate at 37°C for 1-2 hours. The plates were monitored carefully under 
a brightfield microscope to identify the ideal Matrigel layer thickness at which regular, elongated, 
feathery aggregates were visible on the well bottom (79).  
One to three days before the start of differentiation, hPSCs were passaged onto 1:20 
Matrigel. Differentiations were carried out in tissue culture-treated 6-well plates. For passaging, the 
wells were washed briefly with Iscove’s Modified DMEM (IMDM). 0.05% Trypsin-EDTA (Mediatech, 
Cat#MT25-052-CI) was added to each well (1 mL/well). During the incubation with Trypsin at room 
temperature for 1-2 minutes, the plate was continuously agitated with vigorous side-to-side motions 
across the cell culture hood surface. This allowed the MEF feeder layer cells to detach very quickly 
while the hPSC stayed firmly attached to the bottom of the well. Once most of the MEF had 
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detached, the trypsin was carefully aspirated from the side of the well and the dish was left without 
any medium for another 1-2 minutes at room temperature. At this point, HES medium was added 
to the wells (1mL/well) and the cells were triturated 2-3 times with a P100 pipet before they were 
counted and replated on 1:20 Matrigel at a cell density of 100,000 cells/cm2. Differentiation was 
started 1 to 3 days after plating on 1:20 Matrigel once hPSCs reached a 70-80% confluent 
monolayer (see Fattahi et al. 2015 for images denoting the optimal cell density at the start of 
differentiation (79)).  
On day 0 of differentiation, HES medium was replaced with 2 mL/well KSR medium for 
differentiation day 0-1 (see Supplementary Materials - Reagents and Solutions). Differentiating 
cultures were maintained in 37°C in 5% carbon dioxide. On day 2 of differentiation, KSR medium 
for differentiation day 0-1 was replaced with 2 mL/well KSR medium for differentiation day 2-11 
(see Reagents and Solutions in Supplementary Data). On day 4 of differentiation, the medium was 
replaced with 2 mL/well 75% (v/v) KSR medium for differentiation day 2-11 and 25% (v/v) N2 
medium (see Reagents and Solutions in Supplementary Data). On day 6 of differentiation, the 
medium was replaced with 4 mL/well 50% (v/v) KSR medium for differentiation day 2-11 and 50% 
(v/v) N2 medium plus the addition of 1 µM retinoic acid (100mM, Sigma, Cat#R2625). On day 8 of 
differentiation, the medium was replaced with 4 mL/well 25% (v/v) KSR medium for differentiation 
day 2-11, 75% (v/v) N2 medium, and 1 µM retinoic acid (100mM, Sigma, Cat#R2625). On day 10 
of differentiation, the medium was replaced with 4 mL/well N2 medium with 1 µM retinoic acid. 
CD49D-expressing enteric neural precursors were purified via fluorescence activated cell sorting 
on day 11 of differentiation.  
Differentiation of hPSCs into enteric neurons and glia starting from hPSCs maintained in 
feeder-free conditions (25) 
Two days before start of differentiation, hPSCs in feeder-free conditions were passaged 
according to the methods specified above, but with a passaging ratio of 5:6 (cell aggregates from 
5x wells of a 6-well plate are seeded in 6x wells of a 6-well plate) on a plate coated with 1:100 
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Matrigel (Corning, Cat#354234). Culture medium is replaced with fresh Essential 8 Flex medium 
(Gibco, Cat#A2858501) the next day. Two days after plating, differentiation was started if the hPSC 
cultures had proliferated to a confluent monolayer. This was considered day 0 of differentiation and 
the maintenance medium (Essential 8 Flex medium) was switched to 2mL/well differentiation 
medium A (see Reagents and Solutions in Supplementary Data). Whenever medium was 
aspirated, care was taken to slowly aspirate from the edge of the wells in order to not disrupt the 
cell layer in the wells. On day 4 of differentiation, differentiation medium A was replaced with 
differentiation medium B (see Reagents and Solutions in Supplementary Data) at 2mL/well. On day 
6, the medium in the wells was replaced with fresh differentiation medium B at 4mL/well. On day 8, 
differentiation medium B was replaced with differentiation medium C (see Reagents and Solutions 
in Supplementary Data) at 4mL/well. On day 10 of differentiation, the medium in the wells was 
replaced with 6mL/well fresh differentiation medium C. CD49D-expressing enteric neural 
precursors were purified via fluorescence activated cell sorting on day 12 of differentiation.  
 
Differentiation of enteric neural crest precursor cells into enteric neurons and glia 
ENC spheroid phase (differentiation days 11/ 12 to 15) 
After FACS-mediated purification of CD49D+ enteric neural crest precursor cells on day 
11/12 of differentiation, the sorted cells were resuspended in NC medium (see Reagents and 
Solutions in Supplementary Data) at a concentration of 2.5 million cells/mL NC medium and plated 
at 2mL/well in a 6-well plate (Costar® 6-well Clear Flat Bottom Ultra-Low Attachment 6-Well Plate; 
Corning, Cat#3471). During these 3-4 days, the cells aggregated into and proliferated as floating 
spheroids. Two days after plating (differentiation day 13/14), the old NC medium was removed by 
gently swirling the plate with the ENC spheroids so that they group at the center of the well. This 
allowed careful aspiration of the old NC medium with a P1000 pipet from the edge of the well while 
actively avoiding the removal of any ENC spheroids. 2 mL/well fresh NC medium was added.  
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Enteric Neuron Induction (differentiation days 15 to >60) 
On day 15 of differentiation, the ENC spheroids are grouped at the center of their wells by 
gently swirling the plate and the NC medium was carefully aspirated from the edge of the well with 
a P1000 pipet. 1 mL/well accutase was added to the wells and the plate was incubated at 37°C for 
30 minutes to dissociate the ENC spheroids. The spheroids were then mechanically dissociated 
with a P1000 pipet and cells were pelleted (270xg, 3 min). The cells were resuspended in EN 
medium (see Reagents and Solutions in Supplementary Data) and plated on poly-L-
ornithine/laminin/fibronectin-coated glass coverslips in 12-well plates at a cell density of 100,000 
cells/cm2. EN medium was replaced every 2 days until day 50 of differentiation. After that EN 
medium was supplemented with 2 μg/mL laminin-I (L, R&D Systems, Cat#3400-010-01) and 2 
μg/mL fibronectin (FN, BD Biosciences, Cat#356008) and replaced weekly.  
Preparation of poly-L-ornithine/laminin/fibronectin-treated long-term ENC culture plates 
Two to seven days before ENC spheroids were plated for enteric neuron induction 
(between day 6 and 13 of differentiation), the plates used for long-term ENC culture were prepared 
for seeding. Glass coverslips were placed into each well (18mm glass coverslips (Fisherbrand, 
Cat#12-546) were used for 12-well plates) and 15 μg/mL poly-L-ornithine hydrobromide (Sigma, 
Cat#P3655) in 1xPBS was added. The plate was then incubated overnight at 37°C. The next day, 
the poly-L-ornithine hydrobromide solution was replaced with 2 μg/mL laminin-I (R&D Systems, 
Cat#3400-010-01) and 2 μg/mL fibronectin (BD Biosciences, Cat#356008) in 1x PBS and the plate 
was incubated overnight at 37°C and used the next day or left at 37°C until needed (up to 6 days). 
Before cell seeding, the laminin/fibronectin solution was aspirated and replaced with EN medium. 
 
Flow cytometry to confirm maintenance of pluripotency 
To confirm pluripotency, hPSCs were assessed by flow cytometry for expression of cell 
surface markers associated with the pluripotent state. One well of PSCs was washed once with 1x 
Dulbecco’s Phosphate Buffered Saline (DPPBS) (Invitrogen, Cat#14190136), treated with 1 mL 
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0.25% Trypsin-EDTA (Invitrogen, Cat#25200056) for 5 minutes at 37°C to dissociate colonies into 
single cells, neutralized with 0.5 mL Fetal Bovine Serum (FBS) (Tissue Culture Biologicals, 
Cat#101), and centrifuged at 270 xg for three minutes. The pellet was resuspended in 500 μL FACS 
Buffer (see Reagents and Solutions in Supplementary Data) and 100 μl each was pipetted into 4x 
wells of a 96-well plate. The plate was spun down for two minutes at 750xg. The pellets were 
resuspended once more in 100 μL of FACS buffer and spun down for two minutes at 750 xg. Each 
well was resuspended in fluorophore-conjugated antibody mixtures as follows: 1 - Unstained control 
(100 μl FACS buffer), 2 - SSEA3 (1:50)/SSEA4 (1:400) in 100 μl FACS buffer, 3 - Tra 1-60 
(1:50)/Tra 1-81 (1:50) in 100 μL FACS buffer, and 4 - SSEA1 (1:50)/SSEA5 (1:200) in 100 μL FACS 
buffer. Antibody catalog numbers are in Supplementary Table 3.1. Cells were incubated with the 
antibodies for 15 minutes in the dark at room temperature. 80 μL of FACS buffer was added to 
each well and the plate is spun down at 750 xg for 2 minutes. The pellet was resuspended in 200 
μL FACS buffer and spun down once more at 750 xg for 2 minutes. Finally, the cells were 
resuspended in 100 μL of FACS buffer and analyzed for cell surface marker expression using the 
Cytoflex LX (Beckman Coulter).   
 
Purification of enteric neural precursors via FACS at day 11/ 12 of differentiation 
On day 11 of differentiation (if hPSCs were maintained on a feeder layer) or day 12 of 
differentiation (if PSC were maintained in feeder-free conditions), all wells were washed once with 
2 mL/well sterile 1x DPBS before dissociation with 1mL/well Accutase (Innovative Cell 
Technologies, Cat#AT104) at 37°C for 20-30 min. After gentle agitation of the plate, all cells were 
collected with a P1000 pipet, titrated 2-3 times, and transferred into one 14 mL Falcon tube per 6-
well plate. The cells were pelleted (270 xg, 3 min) after addition of 4 mL 10% FBS in IMDM. The 
cell pellet was then resuspended in 600µL IMDM supplemented with 10% FBS, 10 uL/mL DNaseI 
(EMD Millipore; Cat#260913), and 3 μL/mL monothioglycerol (MTG, Sigma Aldrich; Cat#M6145) 
plus anti-CD49D antibody (see Supplementary Table 3.1). The cells were incubated on ice for 15 
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min protected from light exposure with periodic agitation. The cells were subsequently washed 
twice by the addition of 5 mL IMDM supplemented with 10% FBS and subsequent pelleting (270 
xg, 3 min). After the second wash, the cells were resuspended in IMDM supplemented with 10% 
FBS, 10 uL/mL DNaseI (EMD Millipore; Cat#260913), and 3 μL/mL monothioglycerol (MTG, Sigma 
Aldrich; Cat#M6145), passed through a mesh strainer (Falcon, Cat#352235), and sorted on a BD 
FACSJazz (BD Biosciences), MoFlo Astrios (Beckman-Coulter), or BD FACSAria Fusion (BD 
Biosciences) to isolate CD49D-expressing cells. Cells were sorted into IMDM supplemented with 
10% FBS, 10 μL/mL DNaseI, and 3 μL/mL MTG (Sigma Aldrich; Cat#M6145), centrifuged (270 xg, 




Cells on glass coverslips were washed with phosphate-buffered saline (PBS), fixed (4% 
paraformaldehyde, 20 minutes, RT), washed twice with PBS, blocked (5% normal donkey serum 
(NDS), 0.5% Triton X-100 in PBS (0.5% PBST)) (1 hour, RT), incubated in primary antibodies (5% 
NDS, 0.5% PBST 1 hour, RT) (see Supplementary Table 3.1, washed 3 x 5 minutes (0.5% PBST), 
and then incubated in secondary antibodies (see Supplementary Table 3.1) (0.5% PBST, 30 
minutes, dark, RT). Cells washed three times in PBS, incubated in Hoechst 3342 nuclear dye 
(1:1000, Invitrogen, Cat#H3570) (30 minutes, RT) were washed two times in PBS, mounted in 
Prolong Gold AntiFade Mountant (Life Technologies; Cat#P36934) and allowed to set (overnight, 
dark, RT) before long-term storage at 4°C.  
 
Microscopy 
Immunofluorescence images were acquired on a Zeiss LSM 710 laser scanning confocal 
microscope and Zeiss ZEN 2.3 SP1 FP3 (black) (Version 14.0.18.201; Zeiss, Oberkochen, 
Germany) software with a 20x/0.8 air or 63x/1.4 oil DIC M27 Plan-Apochromat objective. The Zeiss 
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LSM 710 condenser numerical aperture is 0.55. Confocal images were processed in ImageJ to 
crop, scale, and uniformly color adjust. Brightfield images were acquired on a Leica DFC340 FX 
camera attached to a Leica DMI4000B microscope with Leica Application Suite X version 
1.5.1.13187 (Leica Microsystems, Wetzlar, Germany).  
 
Generating NOS1 3’UTR and CHAT 3’UTR fluorescent reporter human embryonic stem cells 
(hESCs) 
Guide RNA design 
The genomic sequence for human NOS1 (Transcript ID ENST00000618760.4, NOS1-202, 
Location Chromosome 12: 117,208,142-117,452,170) and CHAT ITranscript ID 
ENST00000395562.2, CHAT-205, Chromosome 10:49,609,095-49,665,104) were obtained from 
the Ensembl Genome Browser (NOS1: Ensembl 87 December 2016 release, CHAT: Ensembl 89 
May 2017) (80). A region of 150 bp within the 3’UTR of NOS1 starting from 30bp 3’ of the STOP 
codon was analyzed for suitable CRISPR/Cas9 guide RNAs (gRNAs) using the Broad Institute 
software crispr.mit.edu (Feb. 2017) (81).  A 150bp region encompassing the entire CHAT 3’UTR 
and a short region upstream from the STOP codon was analyzed for suitable gRNAs using the 
software http://crispor.tefor.net/ (July 2017) (82) and genome version “UCSC Feb. 2009 
(GRCh37/hg19) + SNPs: 1000 Genomes, ExaC”. Four gRNAs were chosen for testing based on 
the best combinations of specificity/quality scores (see Supplementary Table 3.2). Each gRNA 
has a 20 bp sequence with a NGG protospacer adjacent motif (PAM) sequence at the 3’ end. The 
sequences were edited in the following way for cloning into the empty gRNA cloning vector 
(Addgene Plasmid #41824; RRID:Addgene_41824; gRNA_Cloning Vector was a gift from George 
Church) (83): 1) The PAM sequence was removed. 2) The nucleotide at the 5’ end was changed 
to a G if it was not already a G. 3) Homology arms were added as follows:  
5’- TTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACC- add gRNA sequence here -3’ 
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5’- GACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAAC- add reverse complement of 
gRNA sequence here -3’ 
The 60 bp oligos (sequence and reverse complement of sequence) were ordered as 25 nmole 
oligos (Purification: Standard desalting) (Integrated DNA Technologies, IDT) and annealed in a 1:1 
ratio (95°C for 5 minutes, cool at RT for 10 minutes). The annealed product was amplified using 
Phusion High-Fidelity DNA Polymerase (New England Biolabs Catalog#M0530S) (98oC for 30s, 30 
cycles (98°C for 10s, 55°C for 20s, 72°C for 30s), 72°C for 5 min, 4°C hold). The PCR product was 
visualized by agarose gel electrophoresis using a 1.5% agarose gel. The product band was excised 
under ultraviolet light and purified using the NucleoSpin Gel and PCR Clean-Up kit (Machery-
Nagel,PA, USA; Cat#740609). 
 The gRNA empty cloning vector was digested using the AflII restriction enzyme and Gibson 
Assembly (Gibson Assembly Master Mix; New England Biolabs, Catalog#E2611) was used to clone 
the PCR-amplified gRNA sequences into the vector. The assembled gRNA vectors were 
transformed into NEB 5-alpha Competent E. coli (High Efficiency) (New England Biolabs, 
Catalog#C2987H), colonies were picked and amplified by miniprep, and plasmids were purified 
using the QIAprep Spin Miniprep Kit (QIAGEN, Catalog#27106). Sequences were verified by 
Sanger sequencing. 
Guide RNA testing 
 H9-hESCs (H9-hESCs; WA09, WiCell, Madison, WI; NIH Registration Number 0062) were 
plated in a 6-well dish on a feeder layer of irradiated MEFs to reach 30-60% confluency after 24 
hours. Media was changed 4 hours before transfection. H9-hESCS were transfected with the 
identified gRNAs and pCas9_GFP (pCas9_GFP was a gift from Kiran Musunuru (Addgene 
plasmid#44719; http://n2t.net/addgene:44719; RRID:Addgene_44719)) (84) using 0.104 μg of 
plasmid/cm2 of plate surface area and Lipofectamine Stem Transfection Reagent (ThermoFisher 
Scientific, Cat#STEM00003) following manufacturer instructions. Transfected cells were incubated 
for 48 hours in 5% oxygen, 5% carbon dioxide, and 90% nitrogen at 37°C and sorted for GFP 
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positive cells. Sorted hESCs were plated in conditioned HES medium (see Reagents and Solutions 
in Supplementary Data) at 5000 cells/plate on 100 mm dishes coated with Corning® Matrigel® 
hESC-Qualified Matrix, LDEV-free (Corning, Cat#354277) (diluted 1:3 in DMEM/F12). Up to 20 
colonies were manually picked using a 200 μL pipet tip after 10-15 days when they reached ~1 mm 
in diameter and transferred into PCR strip tubes. After triturating 3-4 times, the colonies in PCR 
strip tubes were pelleted at 10,000 x g for 5 minutes and the supernatant was removed. 20 μL 
Proteinase K buffer (see Reagents and Solutions in Supplementary Data) was added to each tube 
followed by incubation at 55°C for 1 hour and inactivation at 94°C for 10 minutes. The digest was 
vortexed and centrifuged at 10,000 x g for 5 minutes and 5 μL of digest was used in a PCR reaction 
using primers specified in Supplementary Table 3. The PCR products were analyzed by agarose 
gel electrophoresis using a 2.5% agarose gel. Size changes and presence of doublets was used 
to determine cutting efficiency and gRNAs CHAT-1 and NOS1-2 were chosen.  
NOS1 3’UTR and CHAT 3’UTR fluorescent reporter cell line creation 
 NOS1 3’UTR and CHAT 3’UTR fluorescent reporter cell lines were created using H9 
human embryonic stem cells (H9-hESCs; WA09) (WiCell, Madison, WI; NIH Registration Number 
0062). A tandem dimer red fluorescent protein (tdRFP) reporter was introduced in separate screens 
into the 3’ untranslated regions (3’UTRs) of NOS1 and CHAT in H9-hESCs. gRNA binding 
sequences in the CHAT and NOS1 3’UTR were identified. A gRNA screen was performed (see 
methods above and gRNA sequences in Supplementary Table 3.2) and gRNAs CHAT-1 and 
NOS1-2 were chosen for subsequent gene editing. A plasmid was created to serve as the 
homology-directed repair template after the Cas9-induced double-stranded DNA break. The repair 
template consisted of an internal ribosome entry site (IRES) followed by tdRFP with a 5’ nuclear 
localization signal (NLS) (repair constructs are referred to as NOS1 3’UTR IRES-NLS-tdRFP and 
CHAT 3’UTR IRES-NLS-tdRFP). 1 kb homology arms were added at the 5’ and 3’ ends of the 
repair template. The repair template also included a loxP-flanked puromycin selection cassette. 
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However, this was not utilized due to the unavailability of puromycin-resistant MEFs at the time of 
the experiment. 
H9-hESCS were transfected with the identified gRNAs and pCas9_GFP (pCas9_GFP was 
a gift from Kiran Musunuru (Addgene plasmid#44719; http://n2t.net/addgene:44719; 
RRID:Addgene_44719)) (84) using 0.104 μg of plasmid/cm2 of plate surface area and 
Lipofectamine Stem Transfection Reagent (ThermoFisher Scientific, Cat#STEM00003) following 
manufacturer instructions. Transfected cells were incubated for 48 hours in 5% oxygen, 5% carbon 
dioxide, and 90% nitrogen at 37°C and sorted for GFP positive cells. Sorted hESCs were plated in 
conditioned HES medium (see Reagents and Solutions in Supplementary Data) at 5000 cells/plate 
on 100 mm dishes coated with Corning® Matrigel® hESC-Qualified Matrix, LDEV-free (Corning, 
Cat#354277) (diluted 1:3 in DMEM/F12). All healthy-looking colonies were manually picked using 
a 200 μL pipet tip after 10-15 days when they reached ~1 mm in diameter and transferred into PCR 
strip tubes. After triturating 3-4 times, half of the volume was plated in HES medium on 48-well 
plates coated with Corning® Matrigel® hESC-Qualified Matrix, LDEV-free (Corning, Cat#354277) 
(diluted 1:3 in DMEM/F12) and seeded with irradiated MEFs 24 hours prior to seeding of the picked 
colonies.The other half of the cell suspension was pelleted at 10,000 x g for 5 minutes and the 
supernatant was removed. 20 μL Proteinase K buffer (see Reagents and Solutions in 
Supplementary Data) was added to each tube followed by incubation at 55°C for 1 hour and 
inactivation at 94°C for 10 minutes. The digest was vortexed and centrifuged at 10,000 x g for 5 
minutes and 5 μL of digest was used in a PCR reaction. Primers for PCR screening of CRISPR 
clones are listed in Supplementary Table 3.3. The PCR products were analyzed by agarose gel 
electrophoresis. Any colonies that showed a correct insertion of the repair template were expanded 
into progressively larger wells with MEF feeder cells plated on 0.1% gelatin (Sigma-Aldrich; Cat# 
G1890) until they could be maintained as normal (see above) and stocks of the cell line clone could 
be frozen for long-term storage. 
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To excise the puromycin selection cassette, clones with the correct insertion were 
expanded and transfected with pCAG-Cre-GFP (pCAG-Cre:GFP was a gift from Connie Cepko 
(Addgene plasmid # 13776; http://n2t.net/addgene:13776 ; RRID:Addgene_13776)) (85) using 
Lipofectamine Stem. GFP positive cells were FAC-sorted after 48 hours and plated at 5000 cells 
per 100 mm dish, and individual colonies were manually picked, as previously described. Colonies 
were screened for excision of the puromycin selection cassette using the primers outside of the 
inserted sequence including the 1kb homology arms (sequences in Supplementary Table 3.3).  
 
Transcription factor cloning into lentiviral expression vector 
Transcription factor cDNA sequences (see Supplemental Table 3.4) were amplified using primers 
that added the Gateway recombination sequence attB1 flanking the ORF: attB1 Fwd: 5’-
GGGGACAAGTTTGTACAAAAAAGCAGGCT-3’ and attB1 Rev: 5’-
GGGGACCACTTTGTACAAGAAAGCTGGGTA-3’. The PCR reaction was run on a 0.7% agarose 
gel and the product band was excised under ultraviolet light and purified using the NucleoSpin Gel 
and PCR Clean-Up kit (Machery-Nagel,PA, USA; Cat#740609). The amplified transcription factor 
sequences were then inserted into the FU-tetO-Gateway lentiviral expression vector (kind gift from 
John Gearhart, Addgene plasmid # 43914 ; http://n2t.net/addgene:43914 ; RRID:Addgene_43914) 
(77) using a One Tube Gateway cloning reaction (86). 100 fM (315 ng) of Gateway pDONR221 
Vector (ThermoFisher, Cat#12536017) and 300 fM of the amplified transcription factor sequences 
were combined with 3 μL BP Clonase II enzyme mix (ThermoFisher, Cat#11789100) and TE buffer 
pH 8.0 was added up to a final volume of 15 μL. The reaction mixture was incubated at room 
temperature overnight. To assess the efficiency of the first step of the reaction (BP reaction), 0.5 
µl of proteinase K solution (ThermoFisher, Cat#11789100) was added to 5 μL of the BP reaction 
mixture and incubated at 37°C for 10min and then transformed into OneShot TOP10 Competent 
Cells (ThermoFisher, Cat#C404003). 100 fM (678 ng) of FU-tetO-Gateway lentiviral expression 
vector and 3 μL LR Clonase II enzyme mix (ThermoFisher, Cat#11791100) were added to the 
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remaining 10 μL of BP reaction and TE buffer pH 8.0 was added up to a final volume of 15 μL. The 
reaction mixture was incubated at room temperature overnight and to stop the reaction, the reaction 
was incubated at 37°C for 10 minutes in the presence of 2 µl of proteinase K solution 
(ThermoFisher, Cat#11791100). 2 µl of LR clonase reaction was subsequently transformed into 
OneShot TOP10 Competent Cells (ThermoFisher, Cat#C404003), colonies were picked, amplified 
by miniprep, and plasmids were purified using the QIAprep Spin Miniprep Kit (QIAGEN, 
Catalog#27106). Sequences were verified by Sanger sequencing. 
 
Lentivirus production 
 This protocol closely follows the recommendations made by Wang et al. (87). HEK293T 
cells (ATCC, Cat#CRL-3216) were seeded at a cell density of 3.5x106 cells/plate on 2x 10 cm plates 
per transcription factor lentiviral expression vector in HEK293T culture medium (see Reagents and 
Solutions in Supplementary Data). The next day, the culture medium was exchanged and the cells 
were transfected: Per 10 cm plate, 48 µL FuGENE transfection reagent (Promega, Cat#E2311) 
was added to 600 µL IMDM (ThermoFisher, Cat#12440053) without touching the side of the well 
or microcentrifuge tube. The FuGENE/IMDM mixture was left at room temperature for 5 minutes. 4 
µg of each lentiviral packaging vector pVSV-G (88), pMDLg/pRRE (89), and pRSVREV (89) and 4 
µg  of the FU-tetO-Gateway lentiviral expression vector were combined separately before addition 
to the FuGENE/IMDM mixture. The FuGENE/IMDM/DNA mixture was gently mixed (several 
inversions of microcentrifuge tube) and left undisturbed at room temperature for 20 minutes. The 
transfection mix was then slowly added to the culture medium on the HEK293T culture plate and 
the plate was tilted several times to mix the contents. The plates were left undisturbed for 3 days 
at 37°C in 5% carbon dioxide before the media was collected and passed through a Millex-HV 
Syringe Filter Unit, 0.45 µm, PVDF, 33 mm (Sigma, Cat#SLHV033RS) using a 20mL syringe 
(Becton Dickinson, Cat#302830) into ultraclear centrifuge tubes (Beckman Coulter, Cat#344058) 
and the viral particles were pelleted at 24,000 rpm for 90 minutes (no breaking at the end of the 
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spin) in a SW-28 Ti rotor (Beckman Coulter, SW 28 Ti Swinging-Bucket Aluminum Rotor Package, 
Cat#342204).  The ultracentrifuge tubes were then inverted to remove the supernatant and added 
100uL of 1x Dulbecco’s Phosphate Buffered Saline (DPBS, Cat#21-031-CV). After 1 hour at 4°C, 
the virus was aliquoted into 10 µL aliquots and frozen at -80oC for long-term storage. 
To facilitate titering of the FU-tetO-Gateway lentiviral expression vector that only expresses 
the gene product of interest in the presence of doxycycline hyclate (doxycycline, Sigma, 
Cat#D9891-25G) and a reverse tetracycline-controlled transactivator (rtTA), a polyclonal HEK293T 
cell line stably expressing rtTA was created. Briefly, HEK293T cells were infected with FUdeltaGW-
rtTA vector (kind gift from Konrad Hochedlinger, Addgene plasmid # 19780 ; 
http://n2t.net/addgene:19780 ; RRID:Addgene_19780) (90) and maintained in the presence of 0.5 
µg/mL doxycycline for 14 days. 0.5 µg/mL doxycycline, which had been empirically determined to 
be the lowest concentration of doxycycline to kill 100% of HEK293T cells within 48 hours.  
For titering, this polyclonal rtTA-expressing cell line was passaged into a 48-well plate at a 
cell density of 60,000 cells/well.  The next day, a subset of the wells was infected with FUdeltaGW-
rtTA-lentivirus. The virus was serially diluted (1:2 serial dilution from 1:250 to 1:16,000) in the 
presence of  1:2000 protamine sulfate (Fresenius Kai, Cat#C22905, NDC 63323-229-05) and  0.5 
µg/mL doxycycline. The virus-containing culture medium was replaced 24 hours after infection with 
fresh HEK293T culture medium with 0.5 µg/mL doxycycline and the virus was titered 48 hours after 
infection using intracellular flow cytometry. 
 
Intracellular Flow Cytometry for virus titering 
 The wells with infected HEK293T were washed once with 1x Dulbecco’s Phosphate 
Buffered Saline (DPBS) (Invitrogen, Cat#14190136), treated with 1 mL 0.25% Trypsin-EDTA 
(Invitrogen, Cat#25200056) for 5 minutes at 37oC to dissociate colonies into single cells, 
neutralized with 0.5 mL Fetal Bovine Serum (FBS) (Tissue Culture Biologicals, Cat#101), and 
centrifuged at 270 xg for three minutes. The cells were resuspended in IMDM and centrifuged at 
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270 xg for three minutes. The cells were then fixed for 30 minutes at 37°C in 1.6% (v/v) PFA in 
Dulbecco’s Phosphate Buffered Saline (DPBS, Cat#21-031-CV) and then centrifuged (700 xg two 
minutes). The cells were then resuspended in DPBS and centrifuged at 700 xg for two minutes. 
For permeabilization, the cells were washed twice in 1x Intracellular Staining Permeabilization 
Wash Buffer (10x stock, BioLegend, Cat#421002) in DPBS and centrifuged at 700 xg for two 
minutes. The cells were then resuspended in anti-His or anti-V5 primary antibody (details in 
Supplementary Table 3.3) in 1x Intracellular Staining Permeabilization Wash Buffer in DPBS with 
and incubated for 30 minutes at room temperature. The cells were washed twice with 1x 
Intracellular Staining Permeabilization Wash Buffer in DPBS, centrifuged (700 xg, 2 min), and 
supernatant was aspirated. The cells were then resuspended in Alexa Fluor 488-conjugated 
secondary antibody (details in Supplementary Table 3) in 1x Intracellular Staining Permeabilization 
Wash Buffer in DPBS with and incubated for 30 minutes at room temperature. The cells were 
subsequently washed twice with 1x Intracellular Staining Permeabilization Wash Buffer in DPBS, 
centrifuged (700 xg, 2 min), the supernatant was aspirated, and cells were resuspended in FACS 
Buffer (see Reagents and Solutions in Supplementary Data) for analysis on a Cytoflex LX 
(Beckman Coulter).  
 
Lentiviral infection of ENC differentiations 
Differentiating enteric neuron precursors were infected with EBF1-FU-tetO-Gateway-lentivirus and 
FUdeltaGW-rtTA-lentivirus on day 22 of differentiation: EN medium was aspirated from the wells 
and replaced with EN medium supplemented with EBF1-FU-tetO-Gateway-lentivirus (1:1000 
dilution of concentrated virus stock, ~2x108 viral particles/mL), FUdeltaGW-rtTA-lentivirus (1:1000 
dilution of concentrated virus stock, viral titer unknown), and 1:2000 protamine sulfate (Fresenius 
Kai, Cat#C22905, NDC 63323-229-05). The EN medium was replaced the next morning and on 
day 24 of differentiation, EN medium was supplemented with 0.5 μg/mL doxycycline hyclate 
(Sigma, Cat#D9891-25G) to start expression of the EBF1 coding sequence. On day 27 of 
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differentiation, the wells were briefly washed with phosphate-buffered saline (PBS), fixed with 4% 
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3.7 Supplementary Data 
 






Supplementary Figure 3.1: Chromosomal G-band analysis (karyotyping) of CHAT 3’ UTR 
IRES-NLS-tdRFP fluorescent reporter iPSC line 
Cre recombinase overexpression was used to excise the puromycin selection cassette from one 
clone with the correctly inserted full-length CRISPR repair template, CHAT#59. Chromosomal G-





Supplementary Figure 3.2: Looking ahead - the candidate transcription factor 
overexpression screen 
A) Plasmid map of the FU-tetO-Gateway lentiviral expression vector used for this screen (77). The 
Gateway recombination sites (attR1 and attR2) allow for efficient insertion of coding sequences 
into the expression vector “Gateway cassette” under control of a tetracycline response element and 
a T7 promoter. The coding sequence is tagged with a V5 and HIS tag, simplifying verification of 
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infection and expression. (B) Schematic of the planned transcription factor overexpression screen. 
Differentiating enteric neural precursors will be transfected at day 20-22 when the cells are 
transitioning from a mesenchymal phenotype (image on the bottom left, Day 17) to a more rounded 
cell type (image on the bottom middle, Day 25). Doxycycline treatment to turn on transcription factor 
expression is started on day 25, before the cells start aggregating into “ganglia”-like structures 
(image on the bottom right, Day 33). The cells will then be monitored for the appearance of RFP+ 
nuclei, indicating the emergence of NOS1+ or CHAT+ neurons, and the proportion of RFP+ 

















SOX10 (goat) Immunofluorescence 
(1:200) 
Santa Cruz Cat#:sc-17342, 
RRID:AB_2195374 
SOX10 (goat) Immunofluorescence 
(1:200) 
R&D Systems Cat#:AF2864, 
RRID:AB_442208 








TUJ1 (chicken) Immunofluorescence 
(1:400) 
































TAC1 (N-18, goat) Immunofluorescence 
(1:500) 
Santa Cruz Cat#:Sc-9758, 
RRID:AB_661439 






































































V5 tag (rabbit) Immunofluorescence 
(1:200) and Intracellular 










R&D Systems Cat#:MAB050, 
RRID:AB_357353 
Goat anti-Chicken 






























































































































































































Alexa Fluor® 488 
anti-human SSEA-
3 Antibody 
Flow cytometry (1:50) BioLegend Cat#:330305 
RRID:AB_1279441 
Alexa Fluor® 647 
anti-human SSEA-
4 Antibody 
Flow cytometry (1:400) BioLegend Cat#:330407 
RRID:AB_1089201 
Alexa Fluor® 488 
anti-human TRA-1-
60-R Antibody 
Flow cytometry (1:50) BioLegend Cat#:330613 
RRID:AB_2295395 
Alexa Fluor® 647 
anti-human TRA-1-
81 Antibody 
Flow cytometry (1:50) BioLegend Cat#:330705 
RRID:AB_1089245 
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Supplementary Table 3.2: Candidate gRNAs identified using CRISPR Guide RNA Design 
tools for  NOS1 3’UTR IRES-NLS-tdRFP (http://crispr.mit.edu) and CHAT 3’UTR IRES-NLS-
tdRFP (http://crispor.tefor.net/). Selected gRNAs are highlighted in grey. 
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(5’ → 3’) 
Sequence with 
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Specificity score: 82, 
Predicted efficiency: 53 
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Specificity score: 71, 
Predicted efficiency: 54 
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26 (Mor.-Mateos) 
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Specificity score: 60, 
Predicted efficiency: 
67 (Doench ‘16)/ 
48 (Mor.-Mateos) 













Supplementary Table 3.3: PCR primers for screening CHAT and NOS1 3’UTR NLS-tdRFP 
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Primer 
Sequence 
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Supplementary Table 3.4: Transcription factor coding sequences cloned into FUdeltaGW-
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Reagents and Solutions 
Proteinase K Buffer 
10x buffer stock of 50 mM Tris·HCl (pH 7.4), 15 mM ammonium sulfate (pH 9.3), 2.5 mM MgCl2, 
0.1% (v/v) Tween 20, 100 μg/ml Proteinase K (QIAGEN, Catalog#19133). 
 
HES Medium 
Combine DMEM/F12 medium (Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12, 
ThermoFisher, Cat#11320033), 15% (v/v) knockout serum replacement (ThermoFisher, 
Cat#A3181502), 100 μM nonessential amino acids  (NEAA, 100x stock, Thermofisher, Cat#11140-
050), 2 mM GlutaMAX (100x stock, ThermoFisher, Cat#35050061), 1x Penicillin-Streptomycin 
(100x stock, ThermoFisher, Cat#15140122), 0.1 mM β-mercaptoethanol (ThermoFisher, 
Cat#21985-023), and 10 ng/ml human bFGF (can vary from 5-10 ng/μL depending on the cell line, 
R&D Systems, Cat# 233-FB). Store at 4°C for no longer than 1 month. 
 
Conditioned HES medium 
Wash 0.1% gelatin-coated wells with MEF at least 24 hours after plating (see methods above) with 
IMDM to remove traces of FBS. Add HES medium with 15 ng/mL bFGF (R&D Systems, Cat# 233-
FB)) at 200 µL/cm2 to the wells and incubate the medium with the MEF feeder layer at 37°C in 5% 
carbon dioxide. Collect the medium after 48 hours and remove any cellular debris by passing the 
medium through a vacuum filter. 
 
MEF medium 
Iscove’s Modified Dulbecco’s Medium (IMDM, ThermoFisher, Cat#12440053), 15% Fetal bovine 
serum (Tissue Culture Biologicals, Cat#101), 100 μL monothioglycerol (MTG, Sigma Aldrich; 
Cat#M6145) per 100 mL total media volume (from stock diluted 13 µL/mL in IMDM; make fresh 
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daily), 1x Penicillin-Streptomycin (100x stock, ThermoFisher, Cat#15140122).  Store at 4°C for no 
longer than 1 month. 
 
KSR medium for differentiation day 0-1 
Add 10 µM SB431542 (10 mM stock; R&D Systems, Cat#1614), 100nM LDN1931189 (500 µM 
stock, Stemgent, Cat#04-0074-02), 15% (v/v) knockout serum replacement (ThermoFisher, 
Cat#A3181502), 2 mM L-Glutamine (100x stock, ThermoFisher, Cat#25030081), 100 μM 
nonessential amino acids  (NEAA, 100x stock, Thermofisher, Cat#11140-050), 1x Penicillin-
Streptomycin (100x stock, ThermoFisher, Cat#15140122), 0.1 mM β-mercaptoethanol 
(ThermoFisher, Cat#21985-023) to KnockOut DMEM (ThermoFisher, Cat#10829018). Store at 4°C 
for no longer than 2 weeks.  
 
KSR medium for differentiation day 2-11 
Add 10 µM SB431542 (10 mM stock; R&D Systems, Cat#1614), 100nM LDN1931189 (500 µM 
stock, Stemgent, Cat#04-0074-02), 3 µM CHIR99021 (6 mM stock; R&D Systems, Cat#4423), 15% 
(v/v) knockout serum replacement (ThermoFisher, Cat#A3181502), 2 mM L-Glutamine (100x 
stock, ThermoFisher, Cat#25030081), 100 μM nonessential amino acids  (NEAA, 100x stock, 
Thermofisher, Cat#11140-050), 1x Penicillin-Streptomycin (100x stock, ThermoFisher, 
Cat#15140122), 0.1 mM β-mercaptoethanol (ThermoFisher, Cat#21985-023) to KnockOut DMEM 
(ThermoFisher, Cat#10829018). Store at 4°C for no longer than 2 weeks. Starting with day 6 of 
differentiation, add 1 µM retinoic acid (100mM, Sigma, Cat#R2625) to the culture medium the day 
of use.  
 
N2 medium 
Add 3 µM CHIR99021 (6 mM stock; R&D Systems, Cat#4423), 10 µM SB431542 (10 mM stock; 
R&D Systems, Cat#1614), 100nM LDN1931189 (500 µM stock, Stemgent, Cat#04-0074-02), 1% 
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(v/v) N2 supplement (Stemcell Technologies, Cat#07156), 2 mM L-Glutamine (100x stock, 
ThermoFisher, Cat#25030081), 1x Penicillin-Streptomycin (100x stock, ThermoFisher, 
Cat#15140122), to Neurobasal medium (ThermoFisher, Cat#21103049). Store at 4°C for no longer 
than 2 weeks. Starting with day 6 of differentiation, add 1 µM retinoic acid (100mM, Sigma, 
Cat#R2625) to the culture medium the day of use. 
 
Differentiation medium A 
Add 1 ng/mL BMP4 (100 μg/mL stock; R&D Systems, Cat#314-BP), 600 nM CHIR99021 (6 mM 
stock; R&D Systems, Cat#4423), and 10 µM SB431542 (10 mM stock; R&D Systems, Cat#1614) 
to Essential 6 medium (ThermoFisher, Cat#A1516401). Store at 4°C for no longer than 2 weeks. 
 
Differentiation medium B 
Add 1.5 µM CHIR99021 (6 mM stock; R&D Systems, Cat#4423) and 10 µM SB431542 (10 mM 
stock; R&D Systems, Cat#1614) to Essential 6 medium (ThermoFisher, Cat#A1516401). Store at 
4°C for no longer than 2 weeks. 
 
Differentiation medium C 
Add 1.5 µM CHIR99021 (6 mM stock; R&D Systems, Cat#4423), 10 µM SB431542 (10 mM stock; 
R&D Systems, Cat#1614), and 1 µM retinoic acid (100mM, Sigma, Cat#R2625)  to Essential 6 
medium (ThermoFisher, Cat#A1516401). Store at 4°C for no longer than 2 weeks. 
 
NC medium 
Combine Neurobasal medium (ThermoFisher, Cat#21103049) with 2% (v/v) B27 supplement 
(ThermoFisher, Cat#17504044), 1% (v/v) N2 supplement (Stemcell Technologies, Cat#07156), 2 
mM GlutaMAX (100x stock, ThermoFisher, Cat#35050061), 1x Penicillin-Streptomycin (100x stock, 
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ThermoFisher, Cat#15140122), 10 ng/mL FGF2 (R&D Systems, Cat# 233-FB), and 3 µM 
CHIR99021 (6 mM stock; R&D Systems, Cat#4423). Store at 4°C for no longer than 2 weeks. 
 
EN medium 
Combine Neurobasal medium (ThermoFisher, Cat#21103049) with 2% (v/v) B27 supplement 
(ThermoFisher, Cat#17504044), 1% (v/v) N2 supplement (Stemcell Technologies, Cat#07156), 2 
mM GlutaMAX (100x stock, ThermoFisher, Cat#35050061), 1x Penicillin-Streptomycin (100x stock, 
ThermoFisher, Cat#15140122), and 10 ng/mL GDNF (Peprotech, Cat#450-10). Store at 4°C for no 
longer than 2 weeks. The day of use, add 100 µM ascorbic acid (Sigma, Cat#A8960).  
 
HEK293T culture medium 
Add 10% FBS (Tissue Culture Biologicals, Cat#101) and 1x Penicillin-Streptomycin (100x stock, 
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CHAPTER 4: A MOLECULAR-BASED REGENERATIVE MEDICINE APPROACH FOR 
THE TREATMENT OF HIRSCHSPRUNG DISEAS 
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permission. Authors: Rodolphe Soret, Sabine Schneider, Guillaume Bernas, Briana Christophers, 
Ouliana Souchkova, Baptiste Charrier, Franziska Righini-Grunder, Ann Aspirot, Mathieu Landry, 




BACKGROUND & AIMS: Hirschsprung disease (HSCR) is a life-threatening birth defect where 
distal colon is devoid of enteric neural ganglia. Current HSCR treatment is surgical removal of 
aganglionic bowel, but many children continue to have severe problems after surgery. Here, we 
tested a non-surgical therapy based on the hypothesis that post-natal administration of Glial cell 
line-Derived Neurotrophic Factor (GDNF) might induce enteric nervous system regeneration. 
METHODS: GDNF was administered via rectal enema to several HSCR mouse models from 
postnatal day (P) 4 to P8. We assessed survival, ENS structure and regeneration, colon bead 
expulsion, colon epithelial permeability, muscle thickness, neutrophil infiltration, and stool 
microbiome in GDNF-treated and untreated mice. Time-lapse imaging and genetic cell lineage 
tracing were used to identify a source of GDNF-targeted enteric neural progenitors. Human 
aganglionic colon explants from children with HSCR were also cultured with GDNF and evaluated 
for enteric neurogenesis. 
RESULTS: Three different HSCR-model mice had prolonged survival after GDNF enema 
treatment. GDNF-treated mice developed enteric neurons and glia in distal bowel that should have 
been aganglionic, had enhanced colon motility, reduced distal colon epithelial permeability, 
reduced muscle thickness, reduced neutrophil infiltration and partial normalization of 
aganglionosis-induced dysbiosis.  
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Exogenous luminal GDNF penetrated aganglionic colon epithelium, triggering production of 
endogenous GDNF. Some new enteric neurons appear to arise from Dhh-Cre+ lineage Schwann 
cells within extrinsic nerves. Ex vivo cultured explants of human aganglionic bowel also respond to 
GDNF.  
CONCLUSIONS: This study provides hope that GDNF-based regenerative therapy might 
supplement or replace current HSCR treatment.     
 
4.2 Introduction 
The enteric nervous system (ENS) extends along the entire gastrointestinal tract to control 
bowel motility and epithelial activity in response to sensory stimuli (1). Interconnected enteric 
ganglia containing neurons and glia develop from neural crest-derived progenitors before birth. 
Incomplete colonization of distal colon by these ENS progenitors causes Hirschsprung disease 
(HSCR), a condition affecting 1 in 5000 newborns (2). In HSCR, distal colon without ganglia (i.e., 
aganglionic colon) remains tonically contracted, causing functional intestinal obstruction. 
Symptoms also include bowel inflammation and a high risk of sepsis and premature death (2).  
HSCR is subdivided into short-segment (S-HSCR) and long-segment forms (L-HSCR) (2). 
In S-HSCR (>80% of cases), the ENS is absent from rectum and sigmoid colon only. L-HSCR 
means longer regions of distal bowel are aganglionic. Many genes influence HSCR risk (2), and 
genetic risk variants may combine with non-genetic factors (3). The major HSCR-associated gene 
is RET, a transmembrane tyrosine kinase activated when GDNF binds the co-receptor GFRα1. 
GDNF-GFRα1-RET signaling is needed for survival, proliferation, and migration of ENS progenitors 
(4-6). Accordingly, >90% of children with S-HSCR bear non-coding variants that reduce RET 
expression (7). Protein altering RET variants are not common in S-HSCR, but occur in ~35% of 
people with L-HSCR (8, 9). Other genes influencing HSCR risk encode EDNRB signaling pathway 
molecules, transcription factors, guidance and extra-cellular matrix molecules, and diverse 
additional factors (7, 9-11). Male sex also increases HSCR risk ~4-fold, while Down syndrome 
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increases HSCR risk ~100-fold (2). Collectively, these observations mean that most children with 
HSCR have reduced, but not absent RET signaling, and that diverse additional factors impact 
HSCR occurrence. 
 Since 1948, surgical removal of aganglionic bowel has been life-saving for most children 
with HSCR (12). However, post-surgical complications are common and can be long-lasting, 
impacting survival and/or quality of life (2). One ideal alternative approach would be to rebuild the 
ENS and reduce the need for surgery. This idea prompted many groups to develop cell 
transplantation-based HSCR therapies (13). However, despite many encouraging results, some 
difficulties remain (14). The optimal source of stem cells, ideal amplification and/or differentiation 
strategies prior to transplantation, methods of cell delivery, and cell fate after transplantation are 
not yet well defined.  
  Here we tested the hypothesis that endogenous ENS progenitors could be activated after 
birth and generate enteric neurons de novo. Our cell-free strategy is based on the idea that HSCR 
is due to incomplete rostrocaudal colonization of distal bowel by the main subpopulation of ENS 
progenitors, namely neural crest cells of vagal origin (15). Since extracellular matrix in colon 
becomes refractory to migration after a certain developmental window (16), reactivating vagal-
derived ENS progenitor migration seemed unlikely after birth. However, it seemed possible that 
ENS progenitors of sacral (17) or Schwann cell lineage (18) origin, which are already present in 
aganglionic colon, could be induced to proliferate and differentiate into functioning neurons. 
Schwann cells in particular are abundant in hypertrophic extrinsic nerve tracts that populate both 
muscular and submucosal layers of distal aganglionic bowel (19).  GDNF appeared as a primary 
candidate for postnatal reactivation of ENS progenitors in the aganglionic zone notably because of 
its ability to stimulate migration and proliferation of Schwann cells in a RET-independent but 





4.3 Materials and Methods 
Mice  
Details about all mouse lines used are in Supp. Methods.  Enema treatments of most 
mouse lines were performed at Université du Québec à Montréal, except for Ret9/- that were 
treated with mycophenolate (22) and GDNF at the Children’s Hospital of Philadelphia Research 
Institute (as detailed in Supplementary Methods). Where indicated, some HolTg/Tg and Ednrbs-l/s-l 
were also GDNF-treated at the Children’s Hospital of Philadelphia Research Institute after 
reciprocal exchange of mice between Philadelphia and Montreal. Unless specified otherwise (see 
Supplementary Figure 4.1), 10 µl enemas consisting of a 1 µg/µl solution of human recombinant 
GDNF (Peprotech, Cat# 450-10) diluted in PBS were administered daily between P4 to P8 (see 
Supp. Methods for more detail). Clinical grade GDNF (Medgenesis Therapeutix Inc., Canada) and 
a previously described 6XHis-tagged version (23) used for some experiments had similar efficiency 
(see Supp. Methods for other tested molecules). For EdU incorporation assays, mouse pups 
received 10 µl intraperitoneal injections of a 10 mM EdU solution (ThermoFisher Scientific, Cat# 
C10337) once a day during the 5-day (P4 to P8) GDNF enema treatment.   
 
Tissue processing, immunohistochemistry, and imaging 
Bowel was cut longitudinally along the mesentery, washed in PBS, pinned onto Sylgard-
coated petri dishes, fixed with 4% PFA at 4°C overnight, and finally microdissected to separate 
longitudinal/circular muscles from the submucosa/mucosa layer. For ex vivo analyses of living 
tissues, unfixed tissues were microdissected in ice-cold oxygenated Krebs solution. For histological 
analyses, fixed full-thickness bowel segments were embedded in paraffin and transversally 
sectioned at 10 µm. For Western blotting, unfixed organs were weighed and dissolved in RIPA 
buffer, using 1 mL for every 100 mg of tissue (further details are provided in Supplementary 




Analysis of colonic motility and permeability. In vivo analysis of distal colonic motility in P20 mice 
was performed using the bead latency test, as detailed in Supplementary Methods. For ex vivo 
analysis of colonic motility, strips of living muscles from most distal colon (1 cm from the anus) of 
P20 mice were prepared as described above, and attached in the longitudinal direction in a Schuler 
organ bath (Harvard apparatus) filled with oxygenated Krebs solution. Contraction/relaxation of 
longitudinal muscles was then recorded as detailed in Supplementary Methods. For ex vivo 
analysis of mucosal barrier function, segments of living mucosa from most distal colon of P20 mice 
were prepared as described above, mounted in Ussing chambers with 0.5 cm² exposed surface 
area (Warner Instruments, Model U-9926), and evaluated for paracellular permeability as described 
in Supplementary Methods.  
 
Microbiome analysis 
Stool isolation, microbiome sequencing and data analysis were performed as previously 
described (details are provided in Supplementary Methods) (24). 
 
Ex vivo time-lapse imaging and culture of murine aganglionic colon 
For time-lapse imaging, strips of living muscles from the last cm of distal colon from P4 
HolTg/Tg;G4-RFP double transgenic pups were prepared as described above, and pinned onto 
Sylgard-coated 35mm ibidi µ-dishes (ibidi, Cat# 81156). Muscle strips were then cultured in 
suspension as detailed in Supplementary Methods. For ex vivo induction of neurogenesis, strips of 
living muscles from the last cm of distal colon from P4 HolTg/Tg pups were cultured as for time-lapse 
imaging in presence of 0.5 µM EdU. After 96h of culture, tissues were fixed with PFA and processed 






Culture of human aganglionic colon tissues 
Human sigmoid colon tissue was obtained from 12 HSCR patients undergoing Swenson-type 
surgical resection of the aganglionic zone. Nine patients (7 boys and 2 girls; aged between 28 and 
1638 days at the time of surgery) were recruited at the Centre hospitalier universitaire Sainte-
Justine (Montreal, Canada) while 3 patients were recruited at the Children’s Hospital of Philadelphia 
(2 boys and 1 girl; aged between 300 and 1177 days at the time of surgery). After the surgery, full-
thickness colon tissues were placed in ice-cold Krebs solution or Belzer UW Cold Storage Solution 
(Bridge to Life Ltd.) and immediately brought to the relevant research laboratory. Muscle strips 
were then prepared as described above and cut in smaller pieces of 0.5 cm X 0.5 cm. One piece 
was kept aside for validation of aganglionosis via immunofluorescence, while the others were 
cultured for 96h as described above for inducing neurogenesis in mouse tissues. Samples from 
two patients (86 and 1638 days of age at surgery) were in addition cultured for 7 days, under the 
same conditions. At the end of culture period, all tissues were fixed with PFA and processed for 
immunofluorescence and EdU labelling.  
 
Study approval 
All experiments with mice were approved by animal research ethics committees of the 
Université du Québec à Montréal (CIPA reference # 878) and the Children's Hospital of 
Philadelphia Research Institute (IAC reference # 16-001041). Likewise, experiments with human 
samples were approved by human research ethics committees of the Université du Québec à 
Montréal (CIEREH protocol # 491), the Centre hospitalier universitaire Sainte-Justine (CER 
protocol # 4172) and the Children’s Hospital of Philadelphia (IRB protocol # 13-010357). Informed 
consent for the collection and use of human tissues was obtained from all donors, and parents or 






All experiments employed a minimum of three biological replicates. Where relevant, the 
exact number of independent replicates (n) and statistical tests used to calculate P values are 
included in figures and/or legends. P values were determined using GraphPad Prism 6, with the 
exception of microbiome data that were analyzed with R. 
 
4.4 Results 
GDNF enemas rescue aganglionosis in three mouse models of S-HSCR 
Using rectal enemas, we tested if early postnatal administration of GDNF could enhance 
survival of four mouse models of S-HSCR: Holstein (HolTg/Tg; a fully-penetrant model for trisomy 21 
[Collagen VI over-expression]-associated HSCR) (25), TashT (TashTTg/Tg; a partially-penetrant 
model for male-biased HSCR) (26), Piebald-lethal (Ednrbs-l//s-l; a fully-penetrant model for EDNRB 
mutation-associated HSCR) (27) and Ret9/- mutant mice (a hypomorphic model where 
aganglionosis is induced by mycophenolic acid) (22). The enema volume necessary to fill whole 
colon, GDNF concentration, treatment time window, as well as duration and frequency of therapy 
were first empirically determined with HolTg/Tg pups (Supplementary Figure 4.1A-E). Remarkably, 
our selected treatment (i.e., daily administration of 10 µg GDNF in PBS as 10 µl enemas for 5 
consecutive days between postnatal day [P] 4 to P8) prevented death in about half of HolTg/Tg mice 
at P28, the maximum age of survival for control HolTg/Tg mice (Figure 4.1A). Most animals surviving 
to P28 reached adult age after GDNF treatment and mice evaluated could reproduce (two tested  
breeding pairs were fertile). The few animals that were allowed to survive beyond P56 (our adult 
reference age) eventually died from megacolon or dystocia between P68 and P250 
(Supplementary Figure 4.1C). Importantly, the same GDNF enema treatment also prevented 
premature death for more than 60% of Ednrbs-l//s-l mice (Figure 4.1B) and for all male TashTTg/Tg 
pups (Figure 4.1C). Nine GDNF-treated male TashTTg/Tg mice kept for over a year looked healthy 
without any sign of adverse effects. Enema treatment of HolTg/Tg mice using Noggin, endothelin-3, 
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or the serotonin receptor (5-HT4R) agonist RS67506 (rationale provided in Supplementary Table 
4.1) failed to increase life expectancy, suggesting specific benefit to GDNF (Supplementary 
Figure 4.1F). We also failed to further increase the overall survival rate of GDNF-treated HolTg/Tg 
animals either by replacing standard chow with a gel diet (Figure 4.1G) or by combining GDNF 
with vitamin C, serotonin or endothelin-3 (Figure 4.1H).   
 
Figure 4.1: GDNF enemas rescue aganglionic megacolon in HSCR mouse models  
(A-C) Daily administration of GDNF enemas to HolTg/Tg (A), EdnrbS-l/s-l (B) and TashTTg/Tg (C) mice 
between P4-P8 positively impacts both megacolon symptoms and survival rates (Mantel-Cox 
statistical test, GDNF-treated vs PBS-treated groups).  
 
Because modest reductions in RET function are common in people with HSCR, we wanted 
to determine if GDNF enemas could work in RET hypomorphic mice. Unfortunately, there are no 
good mouse models for RET mutation- associated HSCR. Ret-null mice have total intestinal 
aganglionosis (28) whereas Ret heterozygotes are overtly normal (4). We therefore decided to use 
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our established protocol to induce distal bowel aganglionosis in Ret9/- hypomorphic mice using 
mycophenolate mofetil (22). Surprisingly, far less prenatal mycophenolate was needed to cause 
dose-dependent aganglionosis in our novel experimental conditions (with Ret mutants rederived in 
a new animal facility) (Supplementary Figure 4.2A) compared to our prior studies (22), and 
postnatal GDNF enemas did not improve survival compared to PBS alone (Supplementary Figure 
4.2B). Instead, many pups died with distended bowel before the end of GDNF treatment, even at 
the lowest mycophenolate concentration (Supplementary Figure 4.2C). Moreover, many ill pups 
had ganglia throughout the bowel (Supplementary Figure 4.2D), suggesting highly variable 
efficiency of mycophenolate treatment and additional toxicity that complicates data interpretation. 
To determine how GDNF enemas enhanced survival in the other three HSCR mouse 
models, we tested the hypothesis that GDNF induced postnatal neurogenesis in aganglionic distal 
colon. We focused on the Holstein line for practical reasons (fertility is low in Piebald-lethal and 
megacolon incidence is lower in TashT), and analyzed P20 animals because HolTg/Tg mice 
generally reach this stage even without enema treatment (Figure 4.1A). As we reported (25), 
myenteric HuC/D+ neurons and SOX10+ glia were abundant in WT distal colon and absent from the 
last cm of HolTg/Tg colon (Figure 4.2A). In contrast, in HolTg/Tg distal colon, SOX10+ cells were mainly 
within thick extrinsic nerve fibers (Figure 4.2A) where Schwann cells reside (18). Remarkably, 
distal colon from GDNF-treated HolTg/Tg animals had numerous HuC/D+ neurons and SOX10+ glia 
organized into ganglia primarily adjacent to extrinsic nerves (Figure 4.2A). These GDNF-induced 
ganglia formed Tuj1+ interconnected networks in both myenteric and submucosal plexuses (Figure 
4.2B). Quantification of myenteric neuron density in whole colon of HolTg/Tg and male TashTTg/Tg 
mice showed GDNF effects are most prominent in distal colon (i.e., final 3 cm), with minor effects 
in proximal colon (Figure 4.2A and Supplementary Figure 4.3). In the mid-colon of GDNF-treated 
HolTg/Tg mice, the increased neuron density (Figure 4.2A) was mainly due to an enlargement of 
pre-existing myenteric ganglia (Supplementary Figure 4.3A).  In the most distal colon, where 
untreated HolTg/Tg mice are normally devoid of enteric neurons, GDNF-treated HolTg/Tg mice had an 
207 
 
average neuron density that was about 40% that of WT mice (Figure 4.2A). When neuron density 
in the distal colon was too low, GDNF-treated HolTg/Tg mice developed megacolon (Supplementary 
Figure 4.1I). Remarkably, in GDNF-treated TashTTg/Tg males, neuron density in the most distal 
colon was completely restored (Supplementary Figure 4.3B-C).  
EdU incorporation assays confirmed that GDNF induced proliferation of neuron and glia 
progenitors during the 5-day treatment from P4 to P8. Staining of P20 HolTg/Tg colon from mice that 
received daily EdU injections during GDNF treatment revealed many EdU+ HuC/D+ (presumptive 
neurons) and EdU+ SOX10+ (presumptive glia or neuron/glia progenitors) in both myenteric and 
submucosal ganglia (Figure 4.2C-D and Supplementary Figure 4.4). Yet, only a few, very small 
ganglia (i.e., 3 neurons) were fully populated by EdU+ neurons (Supplementary Figure 4.4C). 
Collectively these data suggest that GDNF enemas induce proliferation and differentiation of ENS 






Figure 4.2: GDNF enemas induce a new ENS in the otherwise aganglionic region of P20 
HolTg/Tg mice 
(A) GDNF treatment induces myenteric ganglia containing HuC/D+ neurons and SOX10+ glia. For 
each colon subregion (cylinders), average neuronal density (color-coded) is expressed as the 
percentage of area occupied by HuC/D+ cells in the myenteric plexus (n=6 mice per group; 3 fields 
of view per subregion). (B) Immunofluorescence analysis of TuJ1+ neuronal structures in myenteric 
and submucosal plexus, including GDNF-induced ganglia (arrows). Insets are zoomed-in views of 
dashed boxes. (C-D) EdU incorporated in GDNF-induced myenteric neurons (arrowheads) and glia 
(arrows) during the 5-day treatment. Quantitative results in D are expressed as the number of EdU+ 
cells per mm2 (n=3 WT and 3 GDNF-treated HolTg/Tg mice; 2-7 fields of view per animal; ***P<0.001; 
****P<0.0001; one-way ANOVA with post-hoc Sidak’s test). All images show a z-stack projection 
representative of observations made from 3 mice. Dashed outlines delineate extrinsic nerve fibers 
(A) or a single ganglion (C). Scale bars, 100 µm (A, B) and 50 μm (B insets, C). 
 
 
GDNF-induced ENS is morphologically and functionally similar to WT   
  Again focusing on the HolTg/Tg model, we next asked to what extent GDNF-induced ENS in 
the distal colon resembles WT at P20. Average neuron-to-glia ratio within GDNF-induced myenteric 
ganglia was statistically similar to WT (P=0.16) (Figure 4.3A). Relative proportions of major 
myenteric neuron subtypes, including cholinergic (ChAT+) and nitrergic (nNOS+) neurons, were also 
very similar to WT (Figure 4.3B-C). Moreover, many other neuronal subtypes were detected 
including TH+ dopaminergic neurons, CalR+ excitatory motor neurons, VIP+ inhibitory motor 
neurons, and SubP+ excitatory motor neurons (Figure 4.3C). Interestingly, in proximal and mid 
colon of HolTg/Tg mice (Fig.S5), GDNF treatment also corrected the imbalance of nitrergic 
(increased) and cholinergic (decreased) neuron subtypes that is observed proximal to the 
aganglionic segment in both HSCR mouse models and human patients (29-32).  
To evaluate function of P20 GDNF-induced myenteric ganglia, we analyzed colonic motility 
in vivo, using the bead latency test. In contrast to untreated HolTg/Tg mice that never expelled a 
rectally-inserted glass bead during our 30 minute observation period, a subset of GDNF-treated 
HolTg/Tg expelled the bead in 10-21 min, a bit slower than WT mice (range of 2-8 min) (Figure 4.3D). 
Analysis of neuron density in these GDNF-treated HolTg/Tg mice revealed a robust inverse 
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correlation between time to expel the bead and neuron density in the distal colon (Supplementary 
Figure 4.6A). We also evaluated motility ex vivo using muscle strips from P20 distal colons 
attached to force transducers in organ baths. This system allows electric field stimulation-induced 
contractions of WT colon muscles to be slightly increased by inhibition of nitric oxide synthase with 
L-NAME, which can then be robustly counteracted by inhibition of cholinergic signaling with 
atropine. Reminiscent of in vivo data, colon muscle strips from GDNF-treated HolTg/Tg mice 
displayed one of two distinct response patterns (Figure 4.3E and Supplementary Figure 4.6B), 
either similar to WT or similar to untreated HolTg/Tg. To indirectly test function of P20 GDNF-induced 
submucosal ganglia, we analyzed epithelial permeability to small fluorescently labeled dextran 
molecules (FD4) in Ussing chambers. Once more, distal colonic tissues from GDNF-treated HolTg/Tg 
mice displayed two distinct response types, with mucosa either impermeable to FD4 like WT 
tissues, or permeable to FD4 like control HolTg/Tg tissues from untreated mice (Figure 4.3F). 
To complement ENS analyses, we evaluated other HSCR-associated bowel anomalies. 
HolTg/Tg mouse colon had thicker smooth muscles and more neutrophils than WT mice, but GDNF-
treated HolTg/Tg mouse colon was similar to WT (Figure 4.3G-I and Supplementary Figure 4.7). 
Similarly, stool microbiome profiling demonstrated dysbiosis in P20 HolTg/Tg mouse colon, but 
average abundance of several bacterial genera in HolTg/Tg mouse colon were indistinguishable from 
WT after GDNF treatment (Figure 4.3J). A notable exception was Bacteroides abundance, which 
was low in HolTg/Tg mice and even lower after GDNF treatment. Accordingly, beta diversity analysis 
revealed distinct microbial communities among WT, HolTg/Tg and GDNF-treated HolTg/Tg mice 




Figure 4.3: Phenotypic and functional characterization of the GDNF-induced ENS in P20 
HolTg/Tg mice 
(A-B) WT-like neuron (HuC/D+) to glia (SOX10+) ratio (A), and proportions of nitrergic and 
cholinergic neurons (B) in GDNF-induced myenteric ganglia from distal colon of HolTg/Tg mice (n=6 
mice per group; 3 fields of view per animal). (C) GDNF-induced myenteric ganglia include many 
neuron subtypes (arrows; n=3 mice per marker). Scale bar, 20µm. (D) Bead latency test (n=8-9 
mice per group, *P˂0.05; one-way ANOVA with post-hoc Sidak’s test). (E) Electric field-stimulated 
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and drug-modulated patterns of longitudinal muscle contraction-relaxation (n=6 WT and HolTg/Tg, 
n=7 HolTg/Tg + GDNF; **P˂0.01; ****P˂0.0001; two-way ANOVA with post-hoc Tukey’s test). 
Contractile strength is expressed as the difference from baseline of the area under the curve (AUC) 
values obtained after stimulation (see Fig.S6B). Muscle strips from GDNF-treated HolTg/Tg mice are 
either unresponsive (i.e., like untreated HolTg/Tg mice; 3/7) or responsive (i.e., similar to WT; 3/7).  
(F) Mucosal permeability to FD4 in Ussing chambers (n=6 mice per group; *P˂0.05; **P˂0.01; one-
way ANOVA with post-hoc Sidak’s test). (G-I) H&E staining-based analysis of smooth muscle 
thickness (brackets in G and quantification in H) and neutrophil invasion (asterisks in G and 
quantification in I) in distal colon sections (n=6 mice per group; Scale bar, 150µm; *P˂0.05; 
**P˂0.01; ***P˂0.001; one-way ANOVA with post-hoc Sidak’s test). (J-K) 16S rRNA sequencing-
based microbiome profiling (n=5 mice per group). Bar histograms (J) display the average relative 
abundance at the genera level (*P˂0.05; one-way ANOVA with post-hoc Tukey’s test). Beta-
diversity comparisons (K) with 95% confidence interval ellipses are based on non-metric 
multidimensional scaling (NMDS) of Bray-Curtis dissimilarity of the relative abundance of 
operational taxonomic units among samples (P<0.001; PERMANOVA).  
 
Schwann cells within extrinsic nerves are a target of GDNF in aganglionic colon 
  To elucidate how GDNF induces enteric neurogenesis, we first evaluated GDNF 
distribution in P8 bowel via Western blot, taking advantage of size differences between recombinant 
(15 kDa) and endogenous (20 kDa, glycosylated) GDNF monomers. Recombinant GDNF was 
detected in GDNF-treated HolTg/Tg distal colon but not in proximal colon (Figure 4.4A). Surprisingly, 
while endogenous GDNF is normally only detected in ileum, recombinant GDNF enemas triggered 
robust increases in endogenous GDNF throughout the colon (Figure 4.4A). Recombinant GDNF 
was no longer detected in colon nor in any other tissue at P20, suggesting that administered GDNF 
primarily acts during the treatment period (Supplementary Figure 4.8). To assess precise 
locations of recombinant GDNF during treatment, we treated HolTg/Tg mice using a 6xHis-tagged 
version of GDNF (HisGDNF) (23). Time-course analysis of distal colon 2h after GDNF treatment on 
P4, P6 and P8 revealed HisGDNF accumulated over time in colon submucosa (Figure 4.4B), 
smooth muscles, and subsets of enteric neurons (Figure 4.4C and Supplementary Figure 4.9) of 
HolTg/Tg mice. Interestingly, RET levels also increased (Figure 4.4B and Supplementary Figure 
4.9), supporting the hypothesis that GDNF-RET auto-regulatory loops are activated in GDNF-
treated colon. Remarkably, both HisGDNF and RET were detected in induced neurons close to 
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extrinsic nerves of HisGDNF-treated animals, not only in HolTg/Tg mice (Figure 4.4C) but also in 
Ednrbs-l/s-l mice (Supplementary Figure 4.10A), and in both of our mouse facilities in Montreal and 
Philadelphia (Supplementary Figure 4.10A-B).  
Given that induced neurons and glia were often closely associated with extrinsic nerves, 
we hypothesized that nerve-associated Schwann cells might be GDNF-targeted ENS progenitors. 
We first assessed response of Schwann cells to GDNF using live explants of distal colon muscularis 
externa from P4 HolTg/Tg;G4-RFP double transgenic pups. In these mice, neural crest derivatives 
including Schwann cells are marked by RFP fluorescence (33). Time-lapse imaging of explants 
after 72h of culture suggested GDNF (5 µg/ml) stimulates both migration and proliferation of 
Schwann cells (Figure 4.4D). Impact of GDNF on proliferation of these Schwann cells was 
confirmed via immunofluorescence after 96h of culture, which revealed a 3-fold increase in Ki67+ 
SOX10+ double positive cells upon exposure to GDNF (Figure 4.4E-F).  
To more definitely demonstrate Schwann cells are GDNF targets, we used in vivo genetic 
cell lineage tracing with the Schwann lineage-specific Dhh-Cre driver and the R26[Floxed Stop]YFP Cre 
reporter allele in the Holstein [FVB/N] mutant background. Analysis of proximal and mid colons 
from untreated Dhh-CreTg/+;R26YFP/+ and HolTg/Tg;Dhh-CreTg/+;R26YFP/+ animals at P20 showed that 
the proportion of Schwann cell lineage-derived (YFP+) myenteric neurons increased from 5-7% in 
a pure FVB/N genetic background to 10-11% in presence of homozygous Holstein mutation 
(Supplementary Figure 4.11A-B). Remarkably, the Schwann cell lineage contribution further 
increased to 34% of myenteric neurons in the distal colon of GDNF-treated HolTg/Tg;Dhh-
CreTg/+;R26YFP/+ animals (Figure 4.4G-H). By daily EdU administration during GDNF treatment, we 
identified four subgroups of induced myenteric neurons based on cellular origin (YFP fluorescence) 
and/or EdU incorporation (Figure 4.4G-H and Supplementary Figure 4.11C). While this work 
supports the hypothesis that Schwann cells are a source of GDNF-induced neurons and glia in 
both myenteric (Figure 4.4G-H) and submucosal (Supplementary Figure 4.11C) plexus, it also 
revealed that a majority of induced neurons (66%) were YFP-negative, suggesting a stronger 
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contribution by non-Dhh-expressing cell type(s). Regardless of cellular origin, a majority of induced 
neurons (62%) also did not incorporate EdU, raising the possibility that neurogenesis might result 
from transdifferentiation (i.e., direct differentiation of a post-mitotic cell into another type of 




Figure 4.4: Extrinsic Schwann cells are a source of GDNF-induced neurons and glia in the 
otherwise aganglionic colon 
(A) Distribution of recombinant (r)GDNF (asterisks) and endogenous (e)GDNF (dashed boxes) in 
different subregions of the GI tract from WT, HolTg/Tg and GDNF-treated HolTg/Tg mice at P8. (B-C) 
Accumulation of 6xHis-tagged GDNF (HisGDNF) and RET during enema treatments of HolTg/Tg mice, 
in the submucosa between P4-P8 (B) and in induced myenteric neurons at P8 (C). (D) 10-hour 
long time-lapse recordings of GDNF-cultured aganglionic colon tissues from P4 HolTg/Tg;G4-RFP 
mice showing dividing (arrows) and migrating (arrowheads) Schwann cells on extrinsic nerves (50 
µm-thick z-stacks). (E-F) GDNF exposure for 96h increases Schwann cell proliferation (SOX10+ 
Ki67+) in distal colon explants from P4 HolTg/Tg mice (**P˂0.01; two-tailed Student’s t-test). (G-H) 
Myenteric ganglia from the distal colon of P20 HolTg/Tg;Dhh- CreTg/+;R26YFP/+  mice that were 
administered GDNF and EdU between P4-P8. Four categories of induced neuron are detected: 1) 
EdU-positive Schwann-derived (filled yellow arrowhead); 2) EdU-negative Schwann-derived 
(empty yellow arrowhead); 3) EdU-positive unknown origin (filled white arrowhead); 4) EdU-
negative unknown origin (empty white arrowhead). All blots/images are representative of 
observations made from 3 mice. Quantifications were performed using 3 fields of view per mouse. 
Dashed outlines delineate either an extrinsic nerve fiber (E), or an extrinsic nerve fiber and an 
adjacent single ganglion (C and G). Scale bar, 20µm (B-C), 100µm (D), 50µm (E-F). 
 
GDNF can induce new neurons in human aganglionic colon ex vivo 
  To test if GDNF could induce new enteric neurons in human tissue, we needed an ex vivo 
model. We discovered that 96h of ex vivo GDNF treatment induced neurons in all HolTg/Tg distal 
colon aganglionic tissues, but neurogenesis was much less efficient than in vivo (Figure 4.5A and 
Supplementary Figure 4.12A). Induced neurons rarely clustered into ganglia and such ganglia 
were always very small (Figure 4.5B). In marked contrast to widespread EdU incorporation into 
Schwann cells (Figure 4.5C and Supplementary Figure 4.12B), EdU incorporation in induced 
neurons was also minimal (Figure 4.5B-C). Although not perfect, we used this ex vivo system to 
test if GDNF could induce neurogenesis in aganglionic human colon muscle from children who had 
pull-through surgery to resect aganglionic distal bowel. Our cohort consisted of 12 children with 
epidemiologic characteristics typical of HSCR (i.e., mostly sporadic, male-biased, short-segment) 
(Table 4.1). Culturing small pieces of freshly- isolated muscularis externa with GDNF for 96h 
markedly increased the proportion of EdU+ Schwann cells in 9/9 human tissues where EdU was 
added to media (Figure 4.5D-E). Most importantly, we also detected new neurons expressing 
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HuC/D, βIII-Tubulin (Tuj1), RET, PGP9.5 and PHOX2B in three HSCR explants (Figure 4.5F-G 
and Supplementary Figure 13). These three explants were from the youngest children of our 
cohort (28 to 44 days old) (Figure 4.5G and Table 4.1). Two of these young children had sporadic 
HSCR with unknown genetic causes. The third child had a MEN2A syndrome- associated RET 
mutation (Table 4.1). For older children (n=2; 86 and 1638 days old), we found that extending 
GDNF treatment to 7 days could yield neurons that incorporated EdU (Figure 4.5H). Collectively 




Figure 4.5: Ex vivo preclinical testing of GDNF therapy on explants of aganglionic colon 
from HolTg/Tg mice and human HSCR patients  
(A-C) Distal colon explants from P4 HolTg/Tg mice cultured for 96h with GDNF and EdU (+GDNF) 
or EdU alone (ctl). GDNF-induced HuC/D+ neurons (A) rarely form ganglia (B) and are less likely 
to show EdU incorporation than SOX10+ Schwann cells (arrowhead in B and quantification in C) 
(n=7 explants per condition; *P˂0.05; **P˂0.01; ***P˂0.001; two-tailed Mann-Whitney U test). (D-
G) Aganglionic colon explants from human HSCR patients cultured for 96h with GDNF and EdU 
(+GDNF) or EdU alone (ctl). EdU incorporation was detected in SOX10+ Schwann cells but not in 
HuC/D+ neurons (D-E). GDNF-induced HuC/D+ neurons were detected in a subset of explants (F), 
all originating from patients less than 3 months of age at the time of surgery (G) (n=12 explants per 
condition; *P˂0.05; two-tailed Mann-Whitney U test). (H) Extended culture in presence of GDNF 
for 7 days yielded neurons in explants from older patients, including some that incorporated EdU 
(arrowhead). All displayed images were taken at myenteric plexus level. Dashed outlines delineate 










Here we report that GDNF enemas can regenerate a functional ENS in situ and prevent 
death in three genetically- distinct mouse models of S-HSCR. Detailed mechanistic studies in 
HolTg/Tg mice showed that exogenous GDNF can penetrate the permeable distal aganglionic colon, 
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leading to increased levels of endogenous GDNF and RET in the whole colon. At least some of the 
new neurons and glia appear to arise from extrinsic Dhh-Cre+ lineage Schwann cells, and newly 
organized enteric ganglia appear to be self-sustaining until at least P56 (Supplementary Figure 
4.14).  
One concern for GDNF-based therapy is that RET signaling is often reduced in children 
with HSCR, suggesting GDNF responsiveness would also be reduced. However, most children 
with S-HSCR must have substantial RET activity in ENS precursors because complete RET 
absence causes a much more severe phenotype (i.e., total intestinal aganglionosis) in mice and 
humans (28, 34). Supporting this idea, recent whole genome sequencing studies of people with S-
HSCR found only 4.3% (out of 443 patients) (7) and 6.3% (out of 190 patients) (9) had RET rare 
coding variants predicted to be damaging. Furthermore, rectal GDNF therapy increased levels of 
RET and endogenous GDNF in mouse colon, suggesting positive feedback loops that could 
enhance RET signaling even if initial RET levels were low. This could be particularly valuable since 
RET provides trophic support to some enteric neurons in adults (4) and RET is expressed in a 
subset of GDNF-induced neurons after rectal therapy (Figure 4.4C, Supplementary Figure 4.10A-
B and Supplementary Figure 4.11D). Finally, although some of the GDNF-induced neurons that 
express RET are derived from Schwann cells (Supplementary Figure 4.11D), RET is most likely 
not needed to activate these precursors in aganglionic bowel. GDNF signaling in Schwann cells is 
instead mediated by NCAM (20), and our data show NCAM but not RET expression in Schwann 
cells of extrinsic nerves in aganglionic mouse colon (Supplementary Figure 4.15). Nonetheless, 
we tried to directly determine if reduced RET levels affected GDNF therapy using our previously 
published model of Ret hypomorphic mice exposed to mycophenolate (22). However, several 
problems complicated interpretation in our new experimental conditions, including the occurrence 
of HSCR-like dilated bowel even in absence of aganglionosis (Supplementary Figure 4.2C-D). 
Future studies would need to test GDNF enema effects in other models where reduced RET activity 
is associated with short- segment aganglionosis, but the “ideal” model is not readily apparent. 
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In contrast to Ret mutants, HolTg/Tg, TashTTg/Tg and Ednrbs-l//s-l mice are all reliable models 
of S-HSCR (25-27), recapitulating key hallmarks of the human disease in both aganglionic segment 
and proximal ENS-containing colonic regions (29-32). Although not all GDNF-treated mutant mice 
have prolonged survival, the survival advantage after GDNF treatment in Montreal is dramatic and 
the in situ generation of new enteric neurons in previously aganglionic bowel, which was observed 
in both Montreal and Philadelphia (Supplementary Figure 4.10A-B), is unprecedented. The 
reason why some mice responded better to GDNF than others might be due to the degree of 
aganglionosis-associated inflammation (Figure 4.3G-I). Indeed, although GDNF is known to have 
anti-inflammatory properties (35), the inflammatory microenvironment present in aganglionic bowel 
before GDNF treatment might help trigger a neurogenic response as it does in the context of 
inflammatory bowel disease (36). Unfortunately, the exact inflammatory mediators that enhance 
enteric neurogenesis are not yet known, but once identified we could develop adjunct treatments 
that enhance the effect of GDNF therapy.  
Adjunct treatments might also be developed based on a serendipitous finding we made 
when we tried to replicate our Montreal survival data (Figure 4.1A-C) using HolTg/Tg and Ednrbsl/sl 
mice in Philadelphia. We unexpectedly discovered that these mouse lines live much longer in 
Philadelphia than in Montreal without any specific treatment, even though all our mice originated 
from the same colonies (Supplementary Figure 4.10C-D). The prolonged survival in Philadelphia 
compared to Montreal was especially dramatic for untreated Ednrbs-l/s-l (Supplementary Figure 
4.10C) that lived much longer than previously described in any other mouse facility (27, 30, 37). 
Intriguingly, the survival advantage for untreated HSCR models in Philadelphia occurred despite 
the confirmed presence of distal bowel aganglionosis and/or megacolon (Supplementary Figure 
4.10C-D). In fact, Philadelphia-based untreated mice survived as long as GDNF-treated mice in 
Montreal (Supplementary Figure 4.10E-F) and survival could not be further enhanced in 
Philadelphia by GDNF treatment (Supplementary Figure 4.10E-F) even though GDNF-induced 
neurogenesis was similar in both Montreal and Philadelphia (Supplementary Figure 4.10A-B). 
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One especially attractive hypothesis for all these observations is that GDNF treatment in Montreal 
and non-genetic factors in Philadelphia might both improve a critical pro-survival bowel function 
(e.g., promoting enhanced epithelial barrier function or modulating mucosal immune responses), 
either indirectly (via induced ENS ganglia) in Montreal or directly (bypassing the need for induced 
ENS ganglia) in Philadelphia. Although we suspect that food- and/or microbiota-based mechanisms 
underlie the survival advantage in Philadelphia, there are many variables so defining mechanisms 
is complicated. 
A potentially more straightforward approach to improve GDNF therapy would be to identify 
GDNF-targeted ENS progenitors other than Dhh-lineage Schwann cells that appear to contribute 
only about a third of GDNF-induced neurons. This could lead to an improved GDNF-based cocktail 
that includes additional trophic factor(s) that bind receptors on these other cells. In this regard, 
substantial literature suggests the existence of ENS “stem cells” in postnatal mouse and human 
bowel38, 39, even in aganglionic regions (40, 41). Interestingly, extrinsic nerve fibers of aganglionic 
regions were previously identified as a niche for these ENS stem cells (41). Our data confirm this 
prior observation and further suggest that at least some of these stem cells are in fact Dhh-lineage 
Schwann cells. It is possible that the other ENS progenitors are also Schwann cells that do not 
express CRE in Dhh-Cre mice. In accordance with this possibility, we noted that some SOX10+ 
Schwann cells are not YFP+ in extrinsic nerves from the aganglionic colon of HolTg/Tg;Dhh-
CreTg/+;R26YFP/+ mice at P8 (Supplementary Figure 4.16). The strong contribution of non-Dhh-
expressing cells combined with the location of some GDNF-induced ganglia away from extrinsic 
nerves, however, also suggests the involvement of additional cell type(s), which might include 
sacral neural crest-derived cells. Sacral-derived ENS progenitors can colonize the aganglionic 
colon during prenatal development (42), and our SOX10 immunofluorescence data suggest that 
some of these cells persist in postnatal aganglionic tissues as scattered progenitors and/or enteric 
glia, also expressing the alternative GDNF receptor NCAM (Figure 4.2A and Supplementary 
Figure 4.15). A contribution by differentiated enteric glia of sacral origin might also help explain the 
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observation that many GDNF-induced neurons had not incorporated EdU suggesting they were 
generated via transdifferentiation (Figure 4.4G-H).  
In theory, GDNF-based rectal therapy would be easy to implement since normal saline 
enemas are already commonly used in children with HSCR both before and after pull-through 
surgery. If penetration of GDNF beyond the epithelium was limited, GDNF could be directly injected 
into the colon wall with currently available endoscopes or via a specially designed delivery tool. 
Ideally, GDNF-based rectal therapy would prevent the need for pull-through surgery.  Even if GDNF 
enemas did not work as primary HSCR treatment, GDNF therapy might nevertheless improve post-
surgical outcomes by normalizing ENS structure in the retained distal bowel of the “transition zone” 
(i.e., correcting hypoganglionosis and neuronal subtype imbalance). In addition, since ENS stem 
cell-based therapies are being considered for the treatment of HSCR, GDNF might be a useful 
adjunct to these therapies to promote engraftment. All these considerations make a human clinical 
trial of GDNF-based rectal therapy in children with HSCR appealing. 
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Holstein (Tg[Sox3-GFP,Tyr]HolNpln), TashT (Tg[SRY-YFP,Tyr]TashTNpln), and G4-RFP 
(Gata4p[5kb]-RFP) lines were as previously described (all maintained on a FVB/N genetic 
background) (25, 26, 33),  whereas Piebald-lethal (Ednrbs-l; JAX stock # 000308; C3H/HeJ-
C57BL/6 mixed background) and Dhh-Cre (Tg[Dhh-cre]1Mejr; JAX stock # 012929; FVB/N 
background) were obtained from The Jackson Laboratory. Other mouse lines used were R26[Floxed 
Stop]YFP (Gt[ROSA]26Sortm1(EYFP)Cos; provided by F. Costantini (Columbia University, USA) and 
maintained on a FVB/N background) (43),  RetTGM (here referred to as Ret-null; Rettm1Jmi; 
maintained on a C57BL/6 background) (44), and Ret9 (Rettm2(RET)Jmi; provided by S. Jain 
(Washington University School of Medicine, USA) and maintained on a 129X1/Sv1 background) 
(45). 
For mycophenolate mofetil treatments (22), timed pregnancies were set up by mating Ret+/- 
with Ret9/+ or Ret9/9 mice, considering noon of the day of plug detection as E0.5. At E7.5, the drinking 
water of pregnant dams was replaced with 0.25X PBS adjusted to pH3.6 with added prodrug 
mycophenolate mofetil (Accord Healthcare, NDC Cat# 16729-094) at varying concentrations (250 
µg/mL, 187.5 µg/mL, and 125 µg/mL). Dams remained on mycophenolate mofetil-supplemented 
drinking water from E7.5 to E18.5.   
Enemas were administered using a 24-gauge gavage needle (Fine Science Tools, 
Canada) attached to a micropipette. The head of the gavage needle was introduced in the rectum 
just beyond the anus, and enemas were injected over the course of a few seconds. Pups were then 
placed back with their mother, and either sacrificed for tissue analysis (at age indicated in relevant 




Tissue labelling and imaging 
For immunofluorescence staining, whole microdissected tissues were permeabilized for 2 
hours in blocking solution (10% FBS and 1% Triton X-100, in PBS) before being sequentially 
incubated with specific primary (at 4°C overnight) and relevant secondary (at room temperature for 
2 hours) antibodies, both diluted in blocking solution that was also used to wash tissues between 
all steps. All antibodies and dilution factors, are listed in Supplementary Table 4.2. EdU was 
detected using the Invitrogen Click-iT EdU Imaging Kit (ThermoFisher Scientific, Cat# C10337) in 
accordance with the manufacturer’s instructions. For histological analyses, cross-sections of full-
thickness bowel tissues were stained with hematoxylin and eosin (H&E) as previously described 
(46).   
All immunofluorescence images were acquired with either a 20X or a 60X objective on a 
confocal microscope (either Nikon A1R or Zeiss 710), with the exception of H&E-stained sections 
that were imaged with a 10X objective using an Infinity-2 camera (Lumenera Corporation) mounted 
on a Leica DM 2000 microscope (Leica Microsystems Canada). Image analysis was performed 
with ImageJ, using the “Subtract background” function to decrease non-specific background signal, 
the “Multi-point” function for cell counting, and the “Polygon selection” function for calculation of 
surface area.  
 
Western blot analysis 
Organs dissolved in RIPA buffer (containing 1X Roche Complete protease inhibitors) were 
sonicated on ice and centrifuged at 14,000 rpm for 15 minutes at 4°C, keeping the supernatants 
for western blot analysis. Equal volumes of samples were electrophoretically separated in an 18% 
sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE) and transferred to Immun-blot® PVDF 
membranes (Bio-Rad, Cat# 1620177). Membranes were subsequently incubated in blocking 
solution (5% skimmed milk and 0.1% Tween 20, in TBS), followed by incubation with either mouse 
anti-GDNF (Santa Cruz Biotechnology, Cat# sc-13147; 1:500 dilution factor) or rabbit anti-βTubulin 
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(Abcam, Cat# ab176560; 1:70 000 dilution factor) primary antibodies, and then relevant 
horseradish peroxydase-conjugated secondary antibodies, all diluted in blocking solution. Each 
incubation was for 60 min at room temperature, each time interspersed by 3 washes with blocking 
solution. Proteins were finally visualized using Immobilon western chemiluminescent HRP 
substrate (Millipore Sigma, Cat# WBKLS0050) and Fusion FX imaging system (Vilber). 
 
Ex vivo culture for time-lapse imaging 
Muscle strips were cultured in suspension as previously described for time-lapse imaging 
of embryonic guts (25), in DMEM/F12 medium (Wisent, Cat# 319-085-CL) supplemented with 10% 
FBS and 100IU/ml antibiotic-antimycotic with or without 5 µg/ml GDNF under standard culture 
conditions (37°C, 5% CO2). After 72h of culture, each petri dish was placed in a microscope 
incubation chamber (Okolab) for 10 hours under the same culture conditions, and image stacks 
(250μm-thick) of RFP-labelled extrinsic nerves and Schwann cells were acquired every 10 min, 
using a 20X objective on a Nikon A1R confocal unit as previously described (25).   
 
In vivo and ex vivo analysis of colonic motility 
For bead latency test, mice were anesthetized with 2% isoflurane and a 2mm glass bead 
(Sigma, Cat# 1.04014) was inserted into the distal colon with a probe over a distance of 0.5 cm 
from the anus. Each mouse was then isolated in its cage without access to food and water and 
monitored for the time required to expel the glass bead. For ex vivo analysis of contractility, muscle 
strips were initially stretched with a preload of 2 g of tension for 60 min, and contraction/relaxation 
of longitudinal muscles was then continuously recorded with a myograph (Narco Biosystems Inc., 
Model F-60) coupled to a computer equipped with the BIOPAC student Lab 4.0.2 software 
(BIOPAC Systems Inc.). Electrical field stimulation (EFS) was applied with a voltage stimulator 
(BIOPAC Systems Inc., Model BSL MP36/35) connected to electrodes, using parameters that 
activate enteric neurons without directly activating muscles (12 V, 20 Hz, 10s train duration, and 
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300µs stimulus pulse duration). This procedure was repeated 3 times, with 10 min washout periods 
between stimulations. To characterize the nitrergic and cholinergic components of EFS-induced 
contractile responses, N-nitro-L-arginine methyl ester (L-NAME; Sigma, Cat# N5751) and atropine 
(Sigma, Cat# A01132) were added to Krebs solution at a final concentration of 0.5µM and 1µM, 
respectively. The area under the curve (AUC) was measured during each EFS-induced response, 
and data were expressed in ΔAUC (corresponding to the difference between the AUC measured 
20s after stimulation minus the AUC measured 20s before stimulation).  
 
Ex vivo analysis of paracellular permeability 
Each Ussing chamber contained 5ml of DMEM/F12 medium (Wisent, Cat# 319-085-CL), 
which was maintained at 37ºC and continuously oxygenated (95% O2 / 5% CO2). After a 30 min 
equilibration period, 200µl of apical medium was replaced with 200µl of a 1mg/ml solution of FITC-
conjugated dextran 4 kDa (FD4; Sigma, Cat# 60842-46-8). Fluorescence intensity of basolateral 
aliquots of 150ul, reflecting paracellular transit from the luminal surface, was then measured every 
30 min over a period of 3 hours, using a fluorimeter (TECAN, Model Infinite M1000). Fluorescence 
intensity was finally converted in amount of FD4 by comparison to a standard curve, and the 
average value for the 3 hour period was used to calculate paracellular permeability, which was 
expressed in ng of FD4 per surface of mucosa area per min (ng/cm2/min). 
 
Microbiome analysis 
Mice were sacrificed at P20 and their feces were directly collected from the colon (3 fecal 
pellets per mouse).  Bacterial DNA was then extracted using the QIAamp® Fast DNA Stool Mini 
Kit (QIAGEN, Cat# 51604), and the V5-V6 region of the 16S rRNA gene was PCR amplified with a 
collection of previously described barcoded primers (47).  Raw sequences generated with an 
Illumina MiSeq sequencer were paired and processed using the MOTHUR pipeline (48), and the 
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BIOM package (49) was subsequently used to transfer biom files into R (50) for generating graphs 
of relative taxa abundance and beta diversity.  
 
 
Supplementary Figures and Tables 
  
Supplementary Figure 4.1: Set-up of GDNF therapy parameters in HolTg/Tg mice 
(A-B) Distribution of 10µl methylene blue enemas in the colon of P4 (A) and P8 (B) HolTg/Tg pups. 
(C) Impact of GDNF concentration on survival of HolTg/Tg pups that received 10µl enemas once 
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daily between P4-P8. Indicated amounts correspond to the total quantity of GDNF that was 
administered each day. (D) Impact of treatment time window (P4-P8 vs P8-P12), duration (1d, 5d 
or 10d; starting at P4) and frequency (once or twice a day, for 5 days) on the survival of HolTg/Tg 
pups treated with GDNF enemas (quantity of GDNF administered per single enema was kept 
constant at 10µg in 10µl). (E) Survival rate of HolTg/Tg pups that were administered 10µl enemas 
containing the indicated neurotrophic molecule (Noggin, Endothelin-3, or the serotonin receptor 
agonist RS67506; all at 1µg/µl final concentration) once daily between P4-P8. (F)  Impact of food 
consistency (regular chow vs gel diet) on survival of HolTg/Tg pups that received GDNF enemas 
(10µg in 10µl) on a daily basis between P4-P8. (G) Impact of co-administration of ascorbic acid 
(Vit.C; 100µM final concentration), serotonin (5-HT; 1µg/µl final concentration) and Endothelin-3 
(ET3; 1µg/µl final concentration) on survival of HolTg/Tg pups that received GDNF enemas (10µg in 
10µl) once daily between P4-P8. (H) Neuron density in the colon (expressed in % of surface area) 
and associated health status of P20 HolTg/Tg mice that received GDNF enemas (10µg in 10µl) on a 






Supplementary Figure 4.2: GDNF enemas do not rescue survival in RET hypomorph mouse 
model of HSCR 
(A) Treatment of pregnant dams with increasing doses of mycophenolate mofetil from E7.5 to E18.5 
increases penetrance of HSCR-like aganglionosis and the length of aganglionic bowel in the 
newborn Ret-/9 pups. A few Retwt/9 littermates (graphed as part of the control group) also exhibited 
aganglionosis.  (B) There is no survival difference for mice treated from P4-P8 with GDNF versus 
PBS for all mycophenolate mofetil concentrations. (Log-rank test and Gehan-Breslow-Wilcoxon 
test for all data sets P > 0.1). (C) Ret-/9 mice died during the P4-P8 treatment period with bowel 
distention. (D) Representative image of the distal colon of 125µg/mL mycophenolate-treated Ret-/9 
pups that died during the treatment period. This specific pup died at post-natal day 6 (as seen in 
C) even though myenteric neurons (HuC/D+) completely colonized the bowel (anal skin marked 




Supplementary Figure 4.3: Analysis of myenteric ganglion size and neuronal density in the 
colon of P20 HolTg/Tg and TashTTg/Tg mice that were treated or not with GDNF between P4-P8 
(A) Analysis of myenteric ganglion size in HolTg/Tg mice. (B) Analysis of neuronal density in 
TashTTg/Tg mice. The average neuronal density (color-coded) is indicated for each colon sub-region 
(represented by cylinders) along the length of the colon. Neuronal density is expressed as the 
percentage of area occupied by HuC/D+ cells in a single focal plane at the level of the myenteric 
plexus within the bowel wall (n=6 mice per group; 3 fields of view per sub-region). For each distal 
colon subregion, the neuronal density is also given as a numerical value. (C) Analysis of myenteric 





Supplementary Figure 4.4: Analysis of EdU incorporation in myenteric and submucosal 
ganglia of the colon from P20 WT and GDNF-treated HolTg/Tg mice that were administered 
EdU between P4-P8 
(A) Example of EdU incorporation in a z-stack projection of submucosal neurons (arrowheads) and 
glia (arrows) in the distal colon. Dashed outline marks area occupied by a single ganglion. Scale 
bar, 50 µm. (B) Quantitative analysis of EdU incorporation in submucosal neurons (HuC/D+) and 
glia (SOX10+) in mid and distal colon. Results are expressed as the number of EdU+ cells per mm2 
(n=3 WT and 3 GDNF-treated HolTg/Tg mice; 2-7 fields of view per animal; *P<0.05; one-way 
ANOVA with post-hoc Sidak’s test). (C) Quantitative analysis of EdU incorporation in myenteric (left 
panel) and submucosal (right panel) neurons (HuC/D+) and glia (SOX10+) in distal colon. Results 
are expressed in percentage of EdU+ cells per ganglion (n=3 WT and 3 GDNF-treated HolTg/Tg mice; 
2-7 fields of view per animal; ***P<0.001; ****P<0.0001; one-way ANOVA with post-hoc Sidak’s 





Supplementary Figure 4.5: Proportion of nitrergic and cholinergic myenteric neurons in the 
proximal and mid colon of WT, untreated HolTg/Tg or GDNF-treated HolTg/Tg mice at P20 
(A) Qualitative analysis of the proportion of nitrergic (left panel) and cholinergic (right panel) 
neurons. Scale bar, 50 µm. (B) Quantitative analysis of the proportion of nitrergic (left panels) and 
cholinergic (right panels) neurons (n=3 WT and 3 GDNF-treated HolTg/Tg mice; 3 fields of view per 
animal; *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001; one-way ANOVA with post-hoc Sidak’s test). 





Supplementary Figure 4.6: Supporting information for in vivo and ex vivo analyses of 
motility in the distal colon of WT, untreated HolTg/Tg or GDNF-treated HolTg/Tg mice at P20 
(A) Correlation between neuron density in distal colon and time for bead expulsion in GDNF-treated 
HolTg/Tg mice at P20 (in support of Figure 4.3D). (B) Examples of electric field-stimulated and drug-
modulated patterns of longitudinal smooth muscle contraction-relaxation in an organ bath equipped 
with a force transducer (in support of Figure 4.3E). In responsive tissues, electric field stimulation 
(EFS) triggers contractions of colonic muscles that can be slightly increased by L-NAME-mediated 
inhibition of nitrergic signaling, and robustly counteracted by atropine-mediated inhibition of 






Supplementary Figure 4.7: Analysis of smooth muscle thickness in the distal colon of WT, 
untreated HolTg/Tg or GDNF-treated HolTg/Tg mice at P20 
(A) Representative H&E-stained cross-sections of different colon segments, with smooth muscle 
thickness indicated by red brackets. Scale bar, 150 µm. (B) Average muscle thickness for each 
colon segment (n=6 mice per group; **P<0.01; ***P<0.001; one-way ANOVA with post-hoc Tukey’s 







Supplementary Figure 4.8: Analysis of GDNF distribution in multiple tissues of GDNF-
treated HolTg/Tg mice at P20 
Western bolt analysis of Tubulin-normalized levels of endogenous GDNF (eGDNF) and 
recombinant GDNF (rGDNF) in different tissues of P20 HolTg/Tg mice that received 10µg GDNF in 
10µL enemas once daily between P4-P8. The displayed blots are representative of observations 






Supplementary Figure 4.9: Time-course analysis of HisGDNF distribution and RET 
expression in colonic smooth muscles of P4-P8 HolTg/Tg mice treated with HisGDNF 
Immunofluorescence analysis of HisGDNF distribution and RET expression in distal colon 
muscularis of HisGDNF-treated HolTg/Tg mice. White arrowheads point to RET+ neurons that also 
stain positive for HisGDNF. All images show a single focal plane representative of observations 




Supplementary Figure 4.10: GDNF enemas trigger enteric neurogenesis without prolonging 
already extended survival of HSCR mouse models in Philadelphia  
(A-B) In both Montreal and Philadelphia, daily administration of HisGDNF  enemas (10µg HisGDNF 
in 10µL of PBS) between P4-P8 trigger enteric neurogenesis in both  Ednrbs-l/s-l (A) and HolTg/Tg (B) 
mice (in support of Figure 4.4C). Upper panels are representative images of immunolabeled distal 
colons (last cm) at P8 showing the presence of RET and HisGDNF double-positive myenteric 
neurons close to an extrinsic nerve fiber (dashed outlines; Scale bar, 50µm). Lower panels are 
quantitative analyses with results expressed in number of RET+ myenteric neurons per mm2. Each 
dot corresponds to a field of view, with color code meaning that samples were from the same animal 
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(n=3 for GDNF enemas; n=2 for untreated and PBS enemas; 4-8 fields of view per animal). (C-D) 
Untreated Ednrbs-l/s-l (C) and HolTg/Tg (D) mice live longer in Philadelphia than in Montreal. For many 
mice that were found dead, megacolon phenotype (distended feces-filled colon, as shown in insets) 
was visually confirmed (marked by red dots). In addition, some moribund mice were euthanized in 
order to prevent colon tissue alteration, thereby allowing to confirm distal aganglionosis by HuC-
TuJ1 double-immunofluorescence (marked by blue dots). (E-F) For both Ednrbs-l/s-l (E) and HolTg/Tg 
(F) mice, GDNF treatment in Montreal increases survival to rates seen in untreated mice in 
Philadelphia (P > 0.5 for GDNF-treated Ednrbs-l/s-l mice in Montreal versus untreated Ednrbs-l/s-l mice 
in Philadelphia; P > 0.7 for GDNF-treated HolTg/Tg mice in Montreal versus untreated HolTg/Tg mice 
in Philadelphia). GDNF treatment did not further enhance the survival advantage of Ednrbs-l/s-l and 
HolTg/Tg mice in Philadelphia (P > 0.9 for untreated Ednrbs-l/s-l mice in Philadelphia versus GDNF-
treated Ednrbs-l/s-l mice in Philadelphia; P > 0.5 for untreated HolTg/Tg mice in Philadelphia versus 







Supplementary Figure 4.11: Analysis of Schwann cell lineage-derived neurogenesis in 
myenteric and submucosal ganglia of Dhh-CreTg/+;R26YFP/+ and HolTg/Tg;Dhh-CreTg/+;R26YFP/+ 
mice at P20 
(A) Analysis of myenteric neurons (HuC/D+) and YFP expression in the proximal colon of Dhh-
CreTg/+;R26YFP/+ (Ctl) and HolTg/Tg;Dhh-CreTg/+;R26YFP/+ (HolTg/Tg) mice. Yellow arrowheads point to 
Schwann lineage-derived neurons. (B) Quantitative analyses of myenteric neurons (HuC/D+) that 
are YFP+ in the proximal and mid-colon of Dhh-CreTg/+;R26YFP/+ (Ctl) and HolTg/Tg;Dhh-
CreTg/+;R26YFP/+ (HolTg/Tg) mice (n=3 Ctl and 3 HolTg/Tg mice; 3 fields of view per animal; *P<0.05; 
one-way ANOVA with post-hoc Sidak’s test). (C) Analysis of submucosal neurons (HuC/D+) and 
YFP expression in the distal colon of HolTg/Tg;Dhh-CreTg/+;R26YFP/+ (HolTg/Tg) mice that were treated 
with GDNF between P4-P8. Neurons of either Schwann lineage (yellow arrowhead) or unknown 
(white arrowhead) origin are detected. (D) Analysis of RET-expressing myenteric neurons (HuC/D+) 
and YFP expression in the distal colon of HolTg/Tg;Dhh-CreTg/+;R26YFP/+ (HolTg/Tg) mice that were 
treated with GDNF between P4-P8. RET is expressed in a subset of neurons, regardless of 
Schwann lineage (RET+, filled yellow arrowhead; RET-, empty yellow arrowhead) or non-Schwann 
lineage (white arrowhead) origin. All displayed images are z-stack projections representative of 








Supplementary Figure 4.12: Analysis of neurogenesis and Schwann cell proliferation in 
distal colon explants from P4 HolTg/Tg mice and cultured in the presence or absence of GDNF 
for 96h 
(A-B) Representative images of HuC/D+ neurons (A), and EdU+ SOX10+ proliferating Schwann 
cells (arrows in B) in explants of distal colon from HolTg/Tg mice cultured in presence of GDNF and 
EdU (+GDNF) or EdU alone (ctl). The displayed images are single focal planes representative of 





Supplementary Figure 4.13: Marker analysis of GDNF-induced neurons in sigmoid colon 
explants prepared from HSCR patients and cultured in presence of GDNF for 96h  
Immunofluorescence analysis showing that human GDNF-induced neurons are closely associated 
with extrinsic nerves and express βIII-Tubulin (TuJ1), RET, PGP9.5 and PHOX2B (in support of 
Figure 4.5F). Arrowheads in middle panels point to round/ovoid nuclei of PGP9.5+ neurons. The 
displayed images are single focal planes representative of observations made from 3 human 




Supplementary Figure 4.14: GDNF-induced myenteric ganglia are self-sustaining until 
adulthood  
Immunofluorescence analysis of HuC/D and SOX10 expression in myenteric ganglia from distal 
colon of GDNF-treated HolTg/Tg mice at P56. The displayed image is a single focal plane 





Supplementary Figure 4.15: Schwann cells in the aganglionic distal colon of HolTg/Tg mice 
express NCAM but not RET 
Immunofluorescence analysis of NCAM and RET expression in extrinsic nerve fibers (delineated 
by dashed lines) from distal colon of untreated HolTg/Tg mice at P20. NCAM but not RET is 
expressed in SOX10+ Schwann cells and putative enteric glia/ENS progenitors (arrows). The 






Supplementary Figure 4.16: Schwann cells in the aganglionic distal colon of HolTg/Tg;Dhh-
CreTg/+;R26YFP/+ mice are not all YFP-labeled 
Immunofluorescence analysis of SOX10 and YFP expression in an extrinsic nerve fiber from distal 
colon of untreated HolTg/Tg;Dhh-CreTg/+;R26YFP/+mice at P8. A subset of SOX10+ Schwann cells are 
negative for YFP (arrows). The displayed images are single focal planes  representative of 





Supplementary Table 4.1. Rationale for selection of supplemental neurotrophic molecules 
 
  
Molecule Reason for selecting Reference 
Noggin NSE promoter-driven Noggin overexpression 
increases enteric neuron numbers in transgenic mice 
Chalazonitis et al., J 
Neurosci 2004 (51) 
Endothelin-3 Ex vivo culture of avian hindgut in presence of 
endothelin-3 increases ENS density 
Nagy and Goldstein, 
Dev Biol 2006 (52) 
RS67506 Systemic administration of the serotonin receptor (5-
HT4R) agonist RS67506 triggers enteric 
neurogenesis in adult mice 
Liu et al., J Neurosci 
2009 (53) 
Serotonin Serotonin (5-HT) enhances in vitro neuronal 
differentiation of murine enteric neural precursors 
Fiorica-Howells et al., J 
Neurosci 2000 (54) 
Vitamin C Ascorbic acid is needed for in vitro differentiation and 
maturation of human enteric neural precursors 




Supplementary Table 4.2. List of primary antibodies and dilution factors used for 
immunofluorescence 
Antibody Source Catalog number RRID reference Dilution 
6X His R&D systems MAB050 AB_357353 1:500 
CalR Swant, CG1 AB_10000342 1:500 
ChAT Millipore AB144P AB_2079751 1:100 
GFP Abcam Ab290 AB_303395 1:500 
HuC/D Molecular Probes A-21271 AB_221448 1:500 
HuC/D (ANNA-1) Gift from Vanda 
Lennon 
--- AB_2313944 1:2000 
Ki67 Abcam ab15580 AB_443209 1:500 
NCAM Abcam ab5032 AB_2291692 1:500 
NOS1 Santa Cruz 
Biotechnology 
sc-648 AB_630935 1:200 
PHOX2B R&D systems AF4940 --- 1:250 
RET R&D systems MAB718 AB_2232594 1:500 
SOX10 Santa Cruz 
Biotechnology 
sc-17342 AB_2195374 1:200 
SubP Abcam ab67006 AB_1143173 1:500 
TH Abcam ab137869 --- 1:500 
TUJ1 Covance MRB-435P AB_663339 1:1000 
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CHAPTER 5: THE EPIGENETIC REGULATOR BAP1 IS REQUIRED FOR 
MAINTENANCE OF POSTNATAL ENTERIC NERVOUS SYSTEM ANATOMY AND 
FUNCTION BUT NOT EMBRYONIC ENTERIC NERVOUS SYSTEM FORMATION 
This manuscript is being prepared for publication. In this chapter we present progress towards 
understanding the role of epigenetic regulator Bap1 in murine enteric nervous system development 
and postnatal function. Authors: Sabine Schneider, Jessica B. Anderson, Rebecca P. Bradley, 




Epigenetic regulatory mechanisms are underappreciated but likely critical for the development of 
the enteric nervous system. We decided to explore the role of the epigenetic regulator Bap1 in ENS 
development after a serendipitous discovery that embryonic Bap1 loss causes drastic bowel 
dysfunction and early death. Bap1 has well-defined roles in cancer genesis, however, its role in 
development is still barely understood. In this study, we report that deletion of Bap1 in enteric neural 
precursors does not affect enteric neural precursor migration or neonatal proximal small intestine 
motility and enteric neuron density. However, by postnatal day 15, in vitro and in vivo bowel motility 
as well as myenteric and submucosal enteric neuron density is significantly reduced in both small 
and large intestines. This loss of enteric neuron density can be partially explained by loss of 
neurons derived from Bap1-/- enteric neuron precursors. However, tamoxifen-induced postnatal 
deletion of Bap1 in most enteric neurons in either early life or adulthood does not cause obvious 
morbidity. We are now working on elucidating the mechanism through which embryonic Bap1 loss 







The enteric nervous system (ENS) is a complex network of neurons and glia that resides 
within the bowel wall. The ENS rivals the spinal cord in complexity, with more than 20 neuron 
subtypes and at least four glial subtypes forming the basis of repeating neural circuits along the 
length of the bowel (1–3). Enteric neural circuits regulate crucial bowel functions like fluid 
homeostasis across the epithelium, epithelial homeostasis, blood flow within the bowel wall, 
immune system activity, and coordinated smooth muscle contraction and relaxation (3–5). Due to 
its vital role in bowel health, dysfunction of the ENS has devastating consequences. Congenital or 
acquired defects in enteric nervous system function, also called enteric neuropathies, most notably 
disrupt the propulsive gut smooth muscle contractions. This causes abdominal distention, 
constipation, vomiting, pain, and in some cases sepsis and early death (6–8).  
The most severe congenital ENS defect, Hirschsprung disease, is caused by incomplete 
migration of enteric neuron precursors from the proximal to the distal end of the developing 
embryonic bowel (6, 9). Hirschsprung disease is thus characterized by a complete lack of enteric 
neurons at the distal end of the bowel. If the ENS forms along the entire length of the bowel, but 
there are no or only subtle anatomic abnormalities, the enteric neuropathy is called chronic 
intestinal pseudo-obstruction (CIPO). A number of causative gene mutations and genomic risk loci 
for Hirschsprung disease have been identified over the past few decades (9–12). Two examples 
that have been studied extensively are loss of EDNRB (13–18) and SOX10 (19–23), two 
monogenic causes of Hirschsprung disease. However, only a few genetic causes of neuropathic 
CIPO have been identified in humans (SOX10 (24), FLNA (25), SGOL1 (26), RAD21 (27), and 
mitochondrial genes POLG and TYMP (28)). Cumulatively, these genes only explain a small 
proportion of the total number of CIPO cases (29). A number of recent studies have advanced our 
understanding of gene expression in enteric neuron subtypes at different stages of ENS 
development ((22, 30–32) and Chapter 2) and greatly increased the number of possible candidate 
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CIPO risk loci. A handful of genes are now also known to affect enteric neuron subtype 
differentiation and function in mice (30, 31, 33–37).  
Neural crest precursors undergo drastic changes in cell identity during their migration and 
differentiation into the many cell types of the ENS. These changes include epithelial-to-
mesenchymal transition to become multipotent migratory neural crest precursors (38, 39), a 
transition to migratory multipotent enteric neural crest precursors that gives rise to immature enteric 
neurons and glia (40), and ultimately neural precursors make fate decisions to become specialized 
enteric neuron subtypes (31, 40). All of these processes require epigenetic reorganization of the 
chromatin landscape and coordinated transcriptional regulation of cell type and developmental 
stage-specific gene sets (41, 42).  
Epigenetic regulatory mechanisms are likely critical for the development of the ENS. For 
example, loss of Aebp2 and Ezh2, subunits of the epigenetic regulator complex polycomb repressor 
complex 2 (PRC2) in mouse enteric neuron precursors cause Hirschsprung Disease (43, 44). DNA 
Methyltransferase 3b (Dnmt3b), an enzyme necessary for the generation of important epigenetic 
marks, has also been implicated in ENS development (45). However, given the obvious importance 
of epigenetic mechanisms in ENS development, the dearth of knowledge about specific epigenetic 
mechanisms involved in ENS formation is surprising. We were thus intrigued by the serendipitous 
discovery that deletion of the epigenetic regulator Bap1 in the ENS leads to bowel dysfunction and 
early death in mice. Elucidating the role of Bap1 in enteric nervous system development and 
function will add to the critical fund of ENS biology knowledge needed to ultimately develop curative 
therapies for ENS-related human diseases like Hirschsprung disease and CIPO. 
BAP1 is a deubiquitinase and well-known tumor suppressor gene with diverse nuclear and 
cytoplasmic functions within the cell (46, 47). As a nuclear protein, BAP1 is involved in DNA 
replication fork elongation (48) and double-stranded DNA damage repair (49, 50). BAP1 also 
regulates gene expression. In association with other transcription factors, it can act as a 
transcriptional activator or repressor itself (51, 52), it can change the activity of other transcription 
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factors indirectly through its deubiquitinase activity (53, 54), and it can change gene expression 
patterns at a larger scale as an epigenetic regulator (55–57). In the cytoplasm, BAP1 regulates 
intrinsic apoptosis initiation through its deubiquitinase activity (46). However, BAP1’s role in 
development is not well understood. Global knock-out of Bap1 leads to early embryonic lethality in 
mice (52). In xenopus, Bap1 is required for lineage commitment of pluripotent cells to the germ 
layers and neural crest lineages (55). Intriguingly, loss of Bap1 in uveal melanoma cells causes 
downregulation of HSCR-associated genes Sox10 and Ednrb (58). Bap1 also has a role in 
regulating retinoic acid-induced gene expression (57, 59). Reduced retinoic acid signaling is a 
known cause of Hirschsprung disease (60–62). Therefore, we hypothesized that Bap1 knockout in 
the enteric nervous system would lead to disrupted migration of enteric neuron precursors resulting 
in Hirschsprung disease.  
To investigate the role of Bap1 in enteric nervous system development, we used two Cre 
recombinase driver mouse lines to conditionally delete Bap1 in different subsets of neural crest 
derivatives. In Bap1;Wnt1-Cre mice, Cre expression is regulated by the Wnt1 promoter and Bap1 
alleles are excised in all neural crest lineages early in neural crest development after embryonic 
day 8.5 (E8.5) (63). In Bap1;Tyr-Cre mice, Cre recombinase is expressed under the control of the 
tyrosinase promoter and Bap1 alleles are excised in the majority of migrating neural crest cells by 
E 10.5. However, in the adult ENS, only a subset of enteric neurons are still derived from Tyr-Cre 
lineage precursors (64). In this chapter, we present work towards anatomically and functionally 
defining the ENS defect caused by Bap1 loss as well as preliminary work towards understanding 







Studies adhere to ARRIVE (Animals in Research: Reporting In Vivo Experiments) 
guidelines (65). Mouse experiments were performed in accordance with Institutional Animal Care 
and Use Committee (IACUC) approval from Children’s Hospital of Philadelphia (IACUC#19-
001041). 
Animals 
Bap1tm1.1Geno mice (referred to as Bap1; RRID:MGI:5439652, C57BL/6) (66)  bred into 
Tg(Tyr-cre)1Gfk mice (referred to as Tyr-Cre; RRID:MGI:3580524, C57BL/6) were a kind gift from 
Dr. J. William Harbour at the University of Miami Miller School of Medicine. Hdac4tm2.1Eno mice 
(referred to as Hdac4; RRID: MGI:4418117, C57BL/6) were a kind gift from Dr. Kelly A. Hyndman 
at the University of Alabama at Birmingham. Rettm2(cre/ERT2)Ddg mice (referred to as Ret-
CreERT2; RRID:MGI:4437245, C57BL/6) were a kind gift from Dr. Jeffrey Milbrandt, Washington 
University. H2az2(Tg(Wnt1cre)11Rth mice (referred to as Wnt1-Cre; RRID:IMSR_JAX:003829, 
(C57BL/6J x CBA/J)F1) and Gt(ROSA)26Sortm9(CAGtdTomato)Hze mice (referred to as R26R-
TdTomato; RRID:IMSR_JAX:007909, C57BL/6) were obtained from The Jackson Laboratory (Bar 
Harbor, ME). Wnt1-Cre mice on a mixed background were bred into R26R-TdTomato mice on a 
pure C57BL/6J background and maintained on a mixed (C57BL/6J x CBA/J)F1xC57BL/6 
background. Wnt1-Cre mice were bred into Bap1 mice and maintained on a mixed (C57BL/6J x 
CBA/J)F1xC57BL/6 background. Bap1 mice were bred into Tyr-Cre and maintained on a pure 
C57BL/6 background. For specific experiments, Bap1;Tyr-Cre mice were bred into R26-TdTomato 
mice and maintained in a pure C57BL/6 background. Lastly, Hdac4 mice were bred into Bap1;Tyr-
Cre;R26-TdTomato mice and maintained on a pure C57BL/6 background. Ret-CreERT2 mice were 
bred to R26R-TdTomato and Bap1 mice and maintained on a pure C57BL/6 background. General 
animal husbandry information can be found in Supplementary Table 1. Genotyping was performed 
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with previously published and novel primers (Supplementary Table 3) and by Transnetyx 
(Cordova, TN) using tail or ear biopsies. Vaginal plug day was considered day E0.5. 
Tamoxifen treatment of Bap1;Ret-CreERT2;TdTomato mice 
Tamoxifen (20 mg/mL; Sigma, Cat#:T5648) was prepared by first dissolving tamoxifen in 
200 μL ethanol at 37°C and then adding 1800 μL sunflower oil (Sigma, Cat#:S5007). Adult 
Bap1;Ret-CreERT2;TdTomato were gavaged with 200 mg/kg tamoxifen once daily on 4 days in a 
5 day time window. Nursing dams (starting when litters are at postnatal day 1 to 3) were gavaged 
with 200 mg/kg tamoxifen once daily on 4 days in a 5 day time window. 
Whole Mount Immunofluorescence staining 
P0 mice were euthanized by decapitation. P15 mice were euthanized by cervical 
dislocation. Adult mice were euthanized with carbon dioxide (CO2, 3 minutes) followed by cervical 
dislocation. Full-length bowel was removed from the abdominal cavity, placed in 1x PBS, and 
opened along the mesenteric border. Bowel borders were pinned out serosa-side up to a Sylgard 
184 Elastomer (Ellsworth Adhesives, Cat#:184 SIL ELAST KIT 0.5KG) coated plate using insect 
pins (Fine Science Tools, Cat#:26002-20) and fixed for 20 minutes at RT in 4% paraformaldehyde 
(PFA; Thermo Fisher, Cat#:O4042-500). After fixation, the tissue was washed 3 times for 5 min 
each with 1x PBS and stored in 50% glycerol (Sigma, Cat#:G9012-2L)/50% 1x PBS (Quality 
Biological, Cat#:A611-E404-99) until use at 4°C (if up to a week) or -20°C (if stored longer than 
one week). When tissue samples were ready to be stained, they were rinsed 3 times for 5 min each 
in 1x PBS and blocked for 2 hours at RT in 5% normal donkey serum (Jackson ImmunoResearch 
Laboratories, Cat#:017-000-121) in 0.1-0.5% Triton X-100 (Sigma, Cat#:T8787) in PBS (0.1-0.5% 
PBST). HuC/D antibody (ANNA1) was incubated with tissue either for 3 hours at RT or overnight 
at 4°C. The tissue was then transferred into primary antibody after a single 5 min wash in 1x PBS 
at RT. Primary antibody (see Supplementary Table 2) in 5% normal donkey serum in 0.1-0.5% 
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PBST was incubated with tissue either for 3 hours at RT or overnight at 4°C. The tissue was then 
washed 3 times for 30min each in 1x PBS and transferred into secondary antibody (see 
Supplementary Table 2) in 5% normal donkey serum in 0.1-0.5% PBST for incubation at RT for 
60-90 min. The tissue was then washed 3 times for 30min each in 1x PBS and mounted in 50% 
glycerol/ 50% 1x PBS on microscope slides (Fisherbrand, Cat#:1255015) using cover slips 
(ThermoFisher, Cat#:125485P). All incubation and wash steps were performed on a benchtop 
rocker (Speed 2-4, Cole-Parmer, Cat#:S2035-CP-A). 
Immunohistochemistry for paraffin-embedded samples.  
Bowel was removed from mice at postnatal day 15, opened at the mesenteric border, and 
proximal small intestine, distal small intestine, and colon were stretched maximally and pinned out 
with insect pins. The tissue was fixed in 4% PFA (20 min, RT). The tissue was prepared for paraffin-
embedding by briefly washing the tissue in 1x DPBS and then leaving the tissue in 70% Ethanol 
for at least 3 hours at RT or overnight at 4°C. Pieces of 0.7 cm length were cut from the most 
proximal and most distal ends of both small intestine and colon.  
The tissue was dehydrated and pre-processed for paraffin-embedding using a Thermo 
Scientific Excelsior Es Processor: 4 stages of graded ethanol 80%, 90%, 100%, 100% (30 min 
each), then 3 stages of Xylene (30 min, 30 min, 45 min, Sigma, Cat#:EM-XX0060-4), then 3 stages 
of paraffin (45 min, 30 min, 30 min). Care was taken to embed the tissue in paraffin with as little 
horizontal or vertical curvature as possible. Tissue sections of 5μm were cut on a HM 355s Microm 
microtome so that the full 0.7 cm proximo-distal length of the tissue piece is visible in a single 
section. The tissue sections were then rehydrated (xylene - 3x 5 min, 100% ethanol - 5min, 5 min, 
95% ethanol - 5 min, 80% ethanol - 5 min, 70% ethanol - 5 min, dH2O - 5min) in preparation for 
immunohistochemical staining.  
For hematoxylin and eosin (H&E) staining, the tissue was first stained at hematoxylin 
(Harris Modified Method Hematoxylin Stains, Fisher, Cat#:SH30-500D - 7 min), then rinsed in tap 
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water for 5 min, differentiated in 1%  acid alcohol (1% concentrated HCl (VWR, Cat# 470301-260) 
in 70% ethanol, 23 sec), and blued in Scott’s tap water substitute concentrate (Scott’s tap water; 
Sigma, Cat#:S5134) for 5 min. The slides were then washed with running tap water a couple of 
times, dipped in 80% ethanol and directly afterwards transferred into alcoholic Eosin Y Solution 
(Sigma, Cat#:HT110116) for 60-90s. To finish, the slides were rinsed in fresh dH2O a couple of 
times, and then dehydrated (95% Ethanol > 1 min, 95% Ethanol -  2 min, 100% Ethanol - 2 min, 
Xylene - 2x 2 min) and mounted (Richard-Allan Scientific Cytoseal XYL, ThermoFisher, Cat#:8312-
4).  
For periodic acid-Schiff/Alcian blue (PAS/AB) staining, the sections were incubated with 
Alcian blue (pH2.5, RT, 6 min, Sigma, Cat#A5268), then washed in running tap water (2 min), 
rinsed in dH2O, treated with 0.5% periodic acid solution (RT, 5 min, Fisher, Cat#:A223-25), and 
again washed with dH2O. The slides were subsequently incubated with Schiff’s reagent (RT, 15 
min, Sigma, Cat#:3952016), washed with running tap water (5min), stained with hematoxylin (45 
sec - 1 min), washed again in running tap water (2 min), differentiated with acid alcohol (1% 
concentrated HCl in 70% ethanol; 22sec), then blued in Scott’s tap water (1min), and rinsed in 
running tap water a couple of times before dehydration  (95% Ethanol - 2x 2 min, 100% Ethanol - 
2 min, Xylene - 2x 2 min) and mounting (Richard-Allan Scientific Cytoseal XYL, ThermoFisher, 
Cat#:8312-4). 
Colon Bead Expulsion 
Adult mice (P95-P210) were anesthetized with 2 L/min carbogen with 2.5% (v/v) isoflurane 
for 1.5 minutes before start of the experiment, anesthesia was continued until completed bead 
insertion. A glass bead (3 mm, Sigma, Cat#:Z143928) lubricated with sunflower seed oil (Sigma, 
Cat#:S5007) was inserted 2 cm into the colon using a custom-made 3-mm rounded glass rod. Mice 
were placed in empty cages, and time to bead expulsion was recorded. Assay was repeated 3 
times per mouse with at least 48 hours between procedures. If a mouse regained consciousness 
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before bead insertion, mice were anesthetized for an additional 2-4min. If the bead insertion was 
met with increased resistance due to the presence of feces in the colon, the experiment was halted 
to allow the mouse to regain consciousness. After 10 minutes the bead insertion was attempted a 
second time. If there was still resistance, the experiment was not continued on that day and a new 
attempt was made 48 hours later. Mice were allowed to eat ad libitum before testing. 
FITC-Dextran small intestinal transit assay 
 P15 Tyr-Cre;Bap1 mice were gavaged with 70-100 μL of 10 mg/mL FITC-Dextran, MW 
70,000, (Sigma, Cat#:FD70S) dissolved in 2% methylcellulose (Sigma, Cat:#274429). Mice were 
kept in a normal cage environment for 90 min post gavage, but without access to their mother or 
food and water. The mice were then euthanized and the small intestine was cut into 12 segments 
of equal length. Colon was cut into 5 segments of equal length. The segments were each placed 
into individually labeled Eppendorf tubes containing 400 μL 1xPBS. Bowel segments in PBS were 
first minced with scissors and then vortexed for 40 sec until FITC was fully released from tissue. 
The samples were centrifuged (4000 xg, 10 min) and 100 μL of supernatant from each sample 
was transferred into a 96 well plate. Absolute fluorescence intensity in each well was measured 
with a Modulus II microplate Multimode Reader and a filter Cube with Excitation 490 nm and 
Emission 510-570 nm. Data is presented as percent fluorescence intensity ([fluorescence 
intensity measured in a specific bowel segment]/[sum of fluorescence intensities measured for all 
bowel segments] x100). Geometric mean is calculated as follows: i=119ixi. Where “i” refers to 
each of the 19 bowel segments (ordered from most proximal (stomach; segment 1) to most distal 
segment (distal colon; segment 19) and “x” refers to the measured fluorescence intensity in the 
corresponding segment.  
In vivo colon transit assay 
P15 Tyr-Cre;Bap1 mice were separated into individual opaque holding containers and 
placed in a dark, undisturbed location. The welfare of the mice was confirmed every hour. The 
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number of stool pellets in the container at the end of an 8 hour time period was counted and the 
presence of liquid diarrhea or feces-matted perianal fur was noted. 
In Vitro Organ Bath Experiments 
For Tyr-Cre;Bap1 mice at postnatal day 15 (P15), full-length colon was removed from the 
abdomen and immediately placed in a dish with warm (37°C), oxygenated (95% O2 and 5% CO2) 
Krebs-Ringers solution (118 mM NaCl (Sigma, Cat#:S6191), 4.6 mM KCl (Thermo Fisher Scientific, 
Cat#:BP366-500), 2.5 mM CaCl2 (Sigma, Cat#:C-7902), 1.2 mM MgSO4 (Sigma, Cat#:M-7506), 1 
mM NaH2PO4 (Sigma, Cat#:S0751), 25 mM NaHCO3 (Sigma, Cat#:BP328-500), 11 mM D-glucose 
(Sigma, Cat#:G7021, pH 7.4).  To remove stool from the bowel lumen, Krebs-Ringers solution was 
pushed into the bowel lumen through a 21-gauge needle (BD Biosciences, Cat#:BD305167). Care 
was taken to touch the epithelium as little as possible. After flushing, the entire colon was 
transferred to the organ bath (Hugo Sachs Elektronik - Harvard Apparatus, Cat#:D-79232) which 
was pre-filled with warm, oxygenated Krebs-Ringers solution flowing through the chamber at a rate 
of 9.189 mL/min. The colon was cannulated on both ends (Hugo Sachs Elektronik - Harvard 
Apparatus, Cat#:S#16105) and the tissue was secured to the cannula with thread. Intraluminal 
pressure was created and maintained with a liquid reservoir suspended level to the water surface 
in the bath. The height of the water column in the reservoir was maintained at 2cm above the 
surface of the water bath. The fluid reservoir was connected to the proximal colon and the distal 
colon was connected to an outflow tube that opened 1 cm above the fluid level in the chamber to 
facilitate continuous flow of the oxygenated Krebs-Ringers solution through the colon.   
For newborn (P0) Wnt1-Cre;Bap1 mice, the most proximal 3 cm of small bowel from P0 
Wnt1-Cre;Bap1 mice was removed from the mice and immediately placed in warm Krebs-Ringers 
solution. The small bowel was then transferred to the organ bath (Hugo Sachs Elektronik Harvard 
Apparatus, Cat#:D-79232) which was pre-filled with warm, oxygenated Krebs-Ringers solution 
flowing through the chamber at a rate of 9.189 mL/min. P0 proximal small bowel was cannulated 
262 
 
on the proximal end using a 10 μL pipette tip as a cannula (Fisher Scientific, Cat#:21-277-2A) and 
secured to the cannula using string. The distal end of the small bowel segment was pinned to 
sylgard through the mesentery. The cannula was connected to a 3 mL syringe via a 2 mm diameter 
plastic, L-shaped tube. Intraluminal pressure was created and maintained with a liquid reservoir 
suspended level to the height of the water in the bath with fluid levels maintained 1 cm above the 
surface level of the water bath. The fluid reservoir was connected only to the proximal bowel and 
allowed to freely flow out of the distal bowel, facilitating continuous flow of the warm, oxygenated 
Krebs-Ringers solution through the bowel.  
The bowel was equilibrated for 30 minutes. Video was recorded for 20 minutes. 
Tetrodotoxin (Abcam, Cat#:ab120054; 1mM stock in sodium citrate buffer [40mM citric acid 
monohydrate (EMD Millipore, Cat#:CX1725-1) and 60mM trisodium citrate dihydrate (Sigma, 
Cat#:C3434), pH 4.8]) was then added to the warm, oxygenated Krebs-Ringers solution at a final 
concentration of 1 μM. Video was recorded 20 minutes immediately following application.  
Video Imaging and data processing 
An E-PM1 Olympus digital camera was mounted on a dissecting microscope to video the 
bowel at 15 frames per second, 1,920 × 1,080 pixel resolution. The organ bath chamber was 
illuminated using the dissecting microscope’s light source, and contrast was provided between the 
bath and the bottom of the chamber by securing a piece of black paper to the bottom of the chamber 
(in the case of the P0 small bowel organ baths, beneath the sylgard). The files were converted from 
.MTS to .mp4 using VLC Media Player and spatiotemporal information was converted to matrices 
using a MATLab script created by Dr. Christina M. Wright 
(https://github.com/christinawright100/BowelSegmentation/commit/095850905504f6ac29c7311f5
6fd9bf089ad4574, commit ID 958509). The script first thresholds the image, then separates and 
distinguishes the bowel from the background. The thresholded image was used to determine bowel 
width across the bowel for the duration of the video to create a graph depicting bowel width over 
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time for each location along the proximo-distal axis of the bowel segment in question. CMCs 
(defined as a neurogenic contraction characterized by being repetitive and containing a defined 
peak point of contraction) were quantified by blinded trained laboratory personnel. 
Microscopy 
Images of whole mount immunofluorescence staining were acquired with a Zeiss LSM 710 
confocal microscope with a x20 (20x/0.8 air) Plan-Apochromat objective and Zeiss Zen software 
version 2.3 14.0.14.201 (Zeiss, Oberkochen, Germany). Images of Hematoxylin and Eosin as well 
as Periodic Acid-Schiff/Alcian Blue staining were acquired with a Leica DMC 2900 camera attached 
to a Leica DM 6000B epifluorescence microscope with an x20 (20x/0.7 air) HC Plan-Apochromat 
objective and Leica Application Suite X version 2.0.0.14332.2 (Leica Microsystems, Wetzlar, 
Germany). Confocal images show either single optical slices or maximum intensity z-projections 
as indicated in the figure legends. ImageJ (NIH) was used to color-adjust images. ImageJ or 
Inkscape (67); http://www.inkscape.org/) were used to crop images.  
 
Biological sample size and technical replicates.  
For H&E and PAS/AB immunohistochemistry, five slides per mouse for each bowel region were 
stained. Each slide held 3-5 consecutive sections separated by a minimum distance of 200 μm. 
Only one section was imaged per slide: the section with the highest number of “intact” villi or crypts 
(full-length epithelial crypts and/or villi with an uninterrupted epithelial monolayer). For proximal 
small intestine and distal colon, only fields of view containing at least one “intact” villus and/or crypt 
were imaged. For distal small intestine and proximal colon, the entire section was imaged and 
analyzed. 
For whole mount immunofluorescence staining of P0 and P15 mouse bowel, at least 4x 
randomly chosen full-thickness confocal Z-stacks at 20x magnification were acquired and 
analyzed as technical replicates for each individual bowel region. For P15 ENS quantifications, 
cells in the entire field of view were counted. For P0 ENS quantifications, cells in two randomly 
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chosen quadrants of the imaged field of view were counted. Quadrant choice was adjusted if 
tissue damage was identified. 
 
Statistics 
We used Prism 7.03 - 8 (GraphPad Software, San Diego, CA) for statistical analysis. A 
cutoff of p < 0.05 was considered significant. All data was tested for normality and appropriate tests 
were chosen. Statistical analysis was only attempted if the sample number in all comparison groups 
exceeded n=3.  
 
5.4 Results 
Loss of Bap1 in the enteric nervous system causes failure to thrive 
Bap1 fl/fl;Tyr-Cre+ (Tyr-Cre cKO) mice failed to thrive and died prematurely with a median 
survival of only 18 days (Figure 5.1A). A few Tyr-Cre cKO pups were able to live beyond day 40, 
however, only when they were left with parents and in the presence of soft, moist food. At birth, 
Tyr-Cre cKO pups could not be differentiated from their littermates (data not shown). However, Tyr-
Cre cKO pups gained weight more slowly (Figure 5.1B), stayed smaller than their littermates, and 
developed visibly distended abdomens towards the end of their lives (Figure 5.1C). At death, Tyr-
Cre cKO colon and distal small intestine were distended with accumulated feces (Figure 5.1D). 
This distention and accumulated feces developed with increasing age. At postnatal day 15 (P15), 
rare Tyr-Cre cKO pups still had a normal-appearing bowel with well-formed fecal pellets in the distal 
colon, but for most pups the proximal colon was already distended by accumulated feces (Figure 
5.1E-E’’). The colon of some Tyr-Cre cKO mice even became deformed by the accumulated feces 
within (Figure 5.1E-E’). By P20 and beyond, the vast majority of Tyr-Cre cKO mice presented with 
a deformed colon and accumulated feces throughout the colon (Figure 5.1E-E’). Accumulation of 
feces in the distal small intestine also increased with age. At P15, we observed distal small intestine 
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fecal aggregation and distention for 30.4% of Tyr-Cre cKO mice, but that percentage increased to 
89.9% beyond postnatal day 20 (Figure 5.1F). We also noticed white patches of abdominal fur for 
most Tyr-Cre cKO pups, indicating incomplete embryonic melanocyte migration (Figure 5.1G-H).  
 
Figure 5.1: Bap1 fl/fl; Tyr-Cre+ mice failed to thrive and died with massively dilated bowel.  
(A) Bap1 fl/fl;Tyr-Cre + (cKO) mice died early in life (median survival 20 days, n=30). Only mice left 
with parents and in the presence of softened, moist food lived beyond postnatal day 25 (P25). (B) 
cKO mice (n=111 measurements across all ages, 6.76 +/- 10.25 measurements per time point, 
R2=0.4861) gained weight more slowly than their heterozygous (Het, n=177 measurements across 
all ages, 10.50 +/- 15.58 measurements per time point, R2=0.8334) and wild-type (WT, n=168 
measurements across all ages, 11.06 +/- 15.49 measurements per time point, R2=0.8873) 
littermates. Graph shows simple regression with 95% confidence interval of mean weight per time 
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point with standard error of the mean (p = 0.001, Repeated Measures One-way ANOVA mixed 
effects model). (C) cKO mice (right) were smaller than their unaffected littermates (left). At P20, the 
representative cKO mouse also had a visibly distended abdomen (white arrows). (D) The colon 
and distal small intestine of cKO mice became severely distended due to aggregated feces later in 
life. The representative image of a cKO bowel was taken at P27. (E) cKO mice presented with 
abnormal colon phenotype beyond P15 (p<0.0001 comparing Het to cKO for both P15 and beyond 
P20, Binomial test). The severity of the observed bowel phenotype increased with age for cKO 
mice. At P15, the colons of the majority of cKO mice had a range of abnormal appearances (cKO: 
n=23, Het: n=19, WT: n=15), however, beyond P20 (>P20; cKO: n=9, Het: n=17, WT: n=20) most 
of the cKO mice presented with the most severe abnormal phenotype of aggregated feces with a 
deformed colon and a lack of formed fecal pellets (p=0.0142, Binomial test comparing P15 and 
>P20 cKO). (E’) An example of an unusual deformation (black arrowhead) in the mid-colon and 
accumulated, unformed feces in the proximal colon (white arrowhead) as well as distal small 
intestine (no arrow) in a P15. (E’’) A normal-appearing colon of a P15 WT pup shows well-formed 
stool pellets starting at the distal end of the proximal colon. (F) Feces also aggregated in the distal 
small intestine of cKO mice (P<0.0001 for both P15 and >P20, Binomial test) and distal small 
intestine involvement increased with age from 30.4%  at P15 to 88.9% for cKO mice >P20. 
(P<0.0001, Binomial test). Sample size at P15: cKO: n=23, Het: n=19, WT: n=15. Sample size for 
ages >P20: cKO: n=9, Het: n=17, WT: n=20. (G) Example of a spot of white fur on the abdomen of 
a P10 cKO pup (white arrow). This indicates incomplete melanocyte migration. (H) Melanocyte 
migration was incomplete for the majority of cKO mice as compared to WT mice (cKO: n=33, WT: 
n=76, Binomial test, P<0.00001). (A-H) cKO refers to Bap1 fl/fl;Tyr-Cre + genotype. (B,E-F) Het 
refers to Bap1 fl/wt; Tyr-Cre + genotype. (E,H) WT refers to Bap1 wt/wt;Tyr-Cre + genotype. (B) 
WT includes the genotypes Bap1 wt/wt; Tyr-Cre + genotype plus any mice not carrying a Cre allele. 
Data not significant unless otherwise indicated. ****p<0.0001 
Bowel motility is reduced in Bap1 conditional knockout mice 
To better understand the fecal stasis phenotype observed in the Tyr-Cre cKO mice, we 
decided to assess bowel motility in vivo and in vitro. We decided to focus our analysis on P15 mice. 
This is a time point where 83.3% of the Tyr-Cre cKO pups are still alive, but where a clearly 
abnormal bowel phenotype can already be observed in the vast majority of Tyr-Cre cKO pups 
(Figure 5.1A and E-F). We never observed gross abnormalities in the proximal small intestine like 
gas or fecal accumulation. However, in vivo bowel motility was significantly reduced in this part of 
the bowel based on slower transit of FITC Dextran dye along the proximal small intestine (Figure 
5.2A-B). Since fecal accumulation was most severe in the colon and was also first observed there, 
we assessed in vivo colon motility. We quantified the number of fecal pellets expelled within an 8 
hour time window by P15 Tyr-Cre cKO pups and control littermates. Unlike their littermates, all but 
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one Tyr-Cre cKO pup did not pass any fecal pellets in the 8 hour time window and if any feces were 
evident, it was watery diarrhea (Fig. 5.2C-D). The inability to pass stool could be explained by 
either a complete lack of colonic bowel motility or uncoordinated motility, where contractions can 
be observed but are unable to productively move stool pellets towards the anus. To differentiate 
between these possibilities, we took full-length colons from P15 mice, subjected them to constant 
intraluminal pressure in oxygenated Krebs-Ringers solution and recorded spontaneous contractility 
patterns. We observed repetitive contractions involving the whole colon with a defined peak point 
of contraction in all wild-type mice (Figure 5.2E). These contraction patterns matched the definition 
of “colonic motor complexes” (CMC) as proposed by Corsetti et al. (68). As expected for neurogenic 
contractions, these colonic motor complexes disappeared in the presence of the voltage-gated 
sodium channel inhibitor tetrodotoxin which blocks all neurotransmission (Supplementary Figure 
5.1A-B). In contrast, the majority of Tyr-Cre cKO mice had no neurogenic contractions (5/10, 
Figure 5.2F, Supplementary Figure 5.1C-D,F). We observed abnormal neurogenic contractions 
in three Tyr-Cre cKO mice (e.g. only retrograde propulsive contractions or very slow contractions 
involving only part of the colon, Supplementary Figure 5.1E-F). A single Tyr-Cre cKO colon 
exhibited both abnormal contractions as well as a single CMC. However, we also noted exclusively 
normal neurogenic motility for two of the Tyr-Cre cKO mice (Figure 5.2F). This is consistent with 
the observation that the bowel of some P15 mice still looks grossly normal and that a small number 
of cKO mice can still pass stool pellets. Overall, significantly fewer neurogenic colonic motility 
patterns were observed for Tyr-Cre cKO mice in vitro (Figure 5.2G). Dysfunction or loss of specific 
neuron subtypes could cause bowel dysmotility by causing imbalances in inhibitory and excitatory 
neuroeffector signaling to gut smooth muscle. This would result in tonic contraction or relaxation 
and abnormal motility of the affected gut segment (34). To assess this possibility, we assessed 
colon diameter before and after the addition of tetrodotoxin but could not detect a difference in 
either absolute colon diameter or percent change in bowel diameter before and after tetrodotoxin 




Figure 5.2: Proximal small intestine and colon motility were significantly reduced in Bap1 
fl/fl; Tyr-Cre+ mice at postnatal day 15. 
(A) Mean FITC fluorescence intensity (+/- standard error of the mean) measured along the full 
length of the bowel indicates that FITC-conjugated Dextrans traveled more slowly through the cKO 
(n=6, sex unknown) proximal small intestine as compared to Het (n=5, sex unknown) and WT (n=4, 
sex unknown) bowels at postnatal day 15 (P15).  (B) The geometric center of measured FITC 
fluorescence was more proximal for cKO mice than for Het and WT mice (P=0.0017, Kruskal-Wallis 
Test with Dunn’s Multiple Comparisons Test, cKO vs Het: P=0.0086, cKO vs WT: P=0.0452, cKO: 
n=6, 5.48 ± 1.21; Het: n=5, 8.47 ± 1.35; WT: n=4, 8.26 ± 0.33 (mean ± stdev)). (C) P15 cKO mice 
passed fewer stool pellets in an 8 hour time window than Het and WT mice (P=0.0001, Kruskal-
Wallis Test with Dunn’s Multiple Comparisons Test, cKO vs Het: P=0.0016, cKO vs WT: P=0.0004, 
cKO: n=9 (4F/3M/2 unknown), 0.11 ± 0.33; Het: n=9 (4F/5M), 3.33 ± 1.66; WT: n=10 (6F/4M), 3.90 
± 1.97 (mean ± stdev)). (D) The majority of P15 cKO mice had abnormal stool (diarrhea or no feces 
at all, P<0.0001, Binomial test comparing cKO and WT). (E-F) Representative kymographs 
depicting bowel width as a function of time and distance along the proximo-distal axis of the 
cannulated colon for P15 WT (E) and cKO (F) mice. (G) Fewer colonic motor complexes (CMC) 
were recorded for cKO as compared to Het and WT colons (P=0.0003, Kruskal-Wallis Test with 
Dunn’s Multiple Comparisons Test, Het vs cKO: P = 0.0065, WT vs. cKO: P=0.0003, cKO: n=10 (4 
females/ 6 males), 0.05 ± 0.10 CMC/min; Het: n=9 (6 females/ 3 males), 0.28 ± 0.12 CMC/min; 
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WT: n=9 (6 females/ 3 males), 0.34 ± 0.10 CMC/min (mean ± stdev)). (A-G) cKO refers to Bap1 
fl/fl;Tyr-Cre+ genotype and Het refers to Bap1 fl/wt; Tyr-Cre+ genotype. (A-B) WT includes Bap1 
wt/wt; Tyr-Cre + genotype plus any mice not carrying a Cre allele. (C-G) WT refers to Bap1 
wt/wt;Tyr-Cre + genotype. (B,C,G) Graphs show mean +/- standard deviation. Data not significant 
unless otherwise indicated. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 
Loss of Bap1 in the enteric nervous system alters bowel epithelium 
The deformed colon shape commonly observed in cTyr-Cre cKO mice beyond P15 (Figure 
5.1E-E’) led us to ask if the normally soft and flexible distal bowel wall had stiffened due to fibrosis 
and/or inflammatory infiltrates. Increased stiffness of the bowel wall also could directly affect bowel 
motility. To address this question, we first stained cross-sections of proximal and distal small 
intestine as well as proximal and distal colon with trichrome stain to visualize collagen-I deposition 
within the bowel wall. We did not observe any differences in Tyr-Cre cKO versus control bowels 
(Supplementary Figure 5.2A-H). We also did not see any inflammatory infiltrates within the bowel 
wall (Supplementary Figure 5.2A-H, I-J, O-R, A’-D’, and I’-J’). However, we noticed a possible 
reduction in goblet cells in Tyr-Cre cKO distal small intestine and proximal colon epithelium as 
compared to control epithelium (Supplementary Figure 5.2B-C versus F-G). Goblet cells produce 
mucus which lubricates stool and facilitates movement of the stool along the bowel. Mucus also 
forms an important protective layer between luminal contents and the epithelial layer and prevents 
access of potentially pathogenic bacteria to the epithelium (69). Thus, loss of goblet cells could 
increase susceptibility to sepsis and death. However, these preliminary observations were not 
confirmed. Proximal small intestine epithelium appeared grossly normal (Supplementary Figure 
5.2I-N), whereas distal small intestine epithelium was normal except for a significantly increased 
presence of relatively more immature goblet cells in Tyr-Cre cKO epithelial crypts that was no 
longer apparent in epithelial villi where mature epithelial cells are located (Supplementary Figure 
5.2O-Z). Tyr-Cre cKO epithelial crypts in proximal colon were deeper than in control mice and 
contained proportionally more goblet cells (Supplementary Figure 5.2A’-H’). No obvious 
differences in Tyr-Cre cKO versus control distal colon epithelium could be detected 
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(Supplementary Figure 5.2I’-L’). Overall, we were able to detect small differences in Tyr-Cre cKO 
epithelium in the distal bowel, however, the significance of these changes is unclear.  
Enteric neuron density along the length of the bowel is normal at birth but significantly 
reduced by postnatal day 15 in Bap1 conditional knock-out mice 
Bap1 is an epigenetic regulator with known roles in differentiation (55) and regulation of 
genes important for ENS precursor migration (58). Loss of Bap1 also affects fetal migration of 
melanocytes, another neural crest derivative (Figure 5.1G-H). Therefore, we hypothesized that 
loss of Bap1 in the ENS causes abnormal ENS anatomy. At P15, total myenteric and submucosal 
neuron density were significantly reduced throughout the bowel, including proximal small intestine, 
distal small intestine, proximal colon, and distal colon (Figure 5.3A-D,  and Supplementary 
Figures 5.3, 5.4A-B).  Since imbalance in enteric neuron subtypes can lead to abnormal enteric 
neural circuits and dysmotility, we also looked at the density of nitrergic neurons. Nitrergic neurons 
are an abundant and functionally important category of enteric neurons and include interneurons 
and inhibitory motor neurons (1). We found no difference in overall density of NOS1+ neurons in 
myenteric and submucosal plexi (Figure 5.3A-B,E-F, Supplementary Figures 5.3, 5.4C-D). 
However, nitrergic neuron numbers varied greatly between fields of view for both Tyr-Cre cKO and 
control mice. Thus we also assessed the ratio of nitrergic neurons to total neurons in each field of 
view and preliminary results suggest that nitrergic neurons are reduced proportionally to total 
neurons in both myenteric and submucosal plexi in all bowel regions assessed (Figure 5.3G-H and 
Supplementary Figure 5.4E-F). In Bap1;Tyr-Cre mice, only ~80% of migrating ENS precursor 
cells at day 11.5 of embryonic development (E11.5) are derived from Tyr-Cre lineage cells (64) and 
carry homozygous Bap1 null alleles. We thus hypothesized that ENS abnormalities would be much 
more severe in Bap1;Wnt1-Cre mice, a mouse model where 100% of the neonatal ENS is derived 






Figure 5.3: Preliminary analysis suggested that Bap1 fl/fl; Tyr-Cre+ mice at postnatal day 15 
had decreased total enteric neuron density and proportionally decreased nitrergic neuron 
density along the bowel. However, neonatal enteric neuron density was unaffected by Bap1 
loss.  
(A-B) Representative images of myenteric plexus showing enteric neurons (HUC/D+, green) and 
nitrergic neurons (NOS1+, magenta) in proximal small intestine for Control (A) and Bap1 fl/fl; Tyr-
Cre + (cKO; B) mice at postnatal day 15 (P15). (A) Single confocal optical slice. (B) Maximum 
intensity z-projection. (C-D) Quantification of total neuron density in Bap1;Tyr-Cre mice at postnatal 
day 15 showed decreased neuron density for cKO mice in both myenteric (A) and submucosal 
plexus (B) as compared to Control mice in all regions of the bowel (Student’s t-test; myenteric PSI: 
p < 0.0001, myenteric DSI: p= 0.0130, myenteric PCO: p = 0.0006, myenteric DCO: p = 0.0001, 
submucosal PSI: p < 0.0001, submucosal DSI: p = 0.0003, submucosal PCO: p = 0.0002, and 
submucosal DCO: p = 0.0003). (E-F) Preliminary analysis of nitrergic neuron (NOS1+) density in 
Bap1;Tyr-Cre mice at P15 suggests no significant decrease in NOS1+ neuron density in myenteric 
(E) and submucosal plexus (F) except for distal colon (DSI; Student’s t-test; myenteric PSI: p = 
0.02829, myenteric DSI: p= 0.6083, myenteric PCO: p = 0.8402, myenteric DCO: p = 0.0.0357, 
submucosal PSI: p = 0.0793, submucosal DSI: p = 0.2791, submucosal PCO: p = 0.0856, and 
submucosal DCO: p = 0.0011). (G-H) However, preliminary analysis of the proportion of nitrergic 
neurons in Bap1;Tyr-Cre mice at P15 suggests a proportional decrease of NOS1+ neuron density 
in myenteric plexus (G) in all bowel regions and submucosal plexus (H) in proximal small intestine 
(PSI; Student’s t-test; p = 0.1608). No conclusions can be drawn about submucosal plexus (H) in 
other bowel regions at this time. (I) Representative images of myenteric plexus showing myenteric 
enteric neurons (HUC/D+, magenta) and myenteric neurite network (TUJ1+, green) for neonatal 
(P0) Control and cKO Bap1;Wnt1-Cre mice along the bowel. All images are maximum intensity z-
projections. (J-K) Preliminary analysis of enteric neuron density in P0 Bap1;Wnt1-Cre mice 
indicates that there is no significant difference between Control and cKO mice in myenteric (G) and 
submucosal plexus (H; Student’s t-test; myenteric PSI: p = 0.2976, myenteric DSI: p= 0.6707, 
myenteric PCO: p = 0.2313, myenteric DCO: p = 0.3779, submucosal PSI: p = 0.1070, submucosal 
DSI: p = 0.2032, submucosal PCO: n too small for statistical analysis, and submucosal DCO: p = 
0.3877). (A) Control genotype is Bap1 wt/wt; Tyr-Cre + . (C-K) Control encompasses genotypes 
Bap1 wt/wt;Cre+ or any genotype without Cre allele plus Bap1 fl/wt;Cre +. cKO genotype is Bap1 
fl/fl;Cre +. (C-H,J-K) All data derived from mice with the following genotypes are visualized with 
green data points: Bap1 wt/wt;Cre + genotype or any genotype without Cre allele. PSI = proximal 
small intestine, DSI = distal small intestine, PCO = proximal colon, DCO = distal colon. (A-B) Scale 
bar = 50 μm. (I) Scale bar = 20 μm. All data represented as mean +/- standard deviation. *p<0.05, 
**p0.01, ***p<0.001, ****p<0.0001 
Surprisingly, when we compared the ENS of neonatal Bap1 fl/fl; Wnt1-Cre+ (Wnt1-Cre 
cKO) pups to that of control littermates, the ENS of cKO mice appeared unremarkable (Figure 
5.3I). When we quantified the density of enteric neurons in proximal small intestine, distal small 
intestine, proximal colon, and distal colon, we found  no differences between Wnt1-Cre cKO and 
control ENS (Figure 5.3J-K). This suggests that embryonic loss of Bap1 in the ENS does not affect 
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the development of a structurally normal way until birth. We hypothesized  that enteric neurons 
without functional BAP1 are possibly lost postnatally. Unfortunately, Wnt1-Cre cKO mice did not 
live beyond the first day of life due to cardiac abnormalities (data not shown), so we turned back to 
the Bap1;Tyr-Cre mouse model to interrogate this hypothesis. We noticed no obvious difference in 
the percentage of Tyr-Cre lineage (TDTOMATO fluorescent reporter- expressing) enteric neurons 
in P0 Tyr-Cre cKO mice as compared to control pups (Figure 5.4A-B, quantifications are ongoing). 
However, by P15, the percentage of Tyr-Cre lineage neurons was significantly lower in Tyr-Cre 
cKO myenteric plexus throughout the bowel as compared to wild-type myenteric plexus (Figure 
5.4C-E and Supplementary Figure 5.5). In the submucosal plexus, a significant reduction in 
TdTomato+ neurons could only be verified in distal colon (Figure 5.4F and Supplementary Figure 
5.5) where the overall number of enteric neuron numbers is also most severely reduced (Figure 
5.3D). This data supports the hypothesis that conditional loss of Bap1 allows the development of a 
normal ENS, but that enteric neurons are either lost postnatally or that there is significantly reduced 




Figure 5.4: Neonatal Bap1 fl/fl; Tyr-Cre+ mice appeared to have a normal complement of Tyr-
Cre lineage neurons, but lost neurons of the Tyr-Cre lineage by postnatal day 15.  
(A-B) The vast majority of enteric neurons (HUC/D+, green) of both Bap1 wt/wt; Tyr-Cre + (Control, 
A) and Bap1 fl/fl; Tyr-Cre + (cKO, B) mice at birth were derived from enteric neuron precursors of 
the Tyr-Cre lineage (TDTOMATO+, magenta). Images are representative confocal optical slices of 
distal small intestine myenteric plexus. (C-F) cKO mice preferentially lose Tyr-Cre lineage neurons 
by postnatal day 15 (P15). (C-D) Representative confocal optical slices of proximal colon myenteric 
plexus for Control (C) and cKO (D) mice. White arrows point to neurons (HUC/D+, green) that do 
not express TDTOMATO (magenta). (E) Quantification of the proportion of Tyr-Cre lineage neurons 
in the myenteric plexus of P15 Control and cKO mice showed a significant decrease in 
TDTOMATO+/ Tyr-Cre lineage neurons in all bowel regions (PSI: p = 0.013, DSI: p =  0.021, PCO: 
p = 0.028, DCO: p = 0.006; Student’s t-tests; Control = 2 females/ 2 males, cKO = 3 females/ 
1male). (F) Quantification of the proportion of Tyr-Cre lineage neurons in the submucosal plexus 
of P15 Control and cKO mice showed a significant decrease in TDTOMATO+/ Tyr-Cre lineage 
neurons in proximal small intestine only (PSI: p = 0.035, DSI: p = 0.263, PCO: 0.635, DCO: 0.362, 




Neonatal bowel motility is unchanged in Bap1 conditional knock-out mice 
We observed a progressive worsening of the bowel phenotype overall (Figure 5.1E-F and 
Figure 5.2) and some P15 mice were still gaining weight at a rate similar to their littermates (Figure 
5.1B) and had normal bowel motility (Figure 5.2C-D,G and Supplementary Figure 3F). Therefore, 
we wondered if the normal-appearing neonatal ENS is able to induce neurogenic motility patterns 
or if the neurons that are present are already functionally abnormal. We chose the Bap1;Wnt1-Cre 
mouse model to assess neonatal bowel motility since 100% of enteric neurons and glia carry the 
Bap1 null allele and any functional deficit should be more noticeable in these mice. We compared 
in vitro proximal small intestine motility in P0 Wnt1-Cre cKO mice with that of control littermates at 
birth and were unable to find a difference. As expected (71), we observed CMCs (low 
frequency/neurogenic contractions) in about half of both Wnt1-Cre cKO and control pups (Figure 
5.5A-E and Supplementary Figure 5.6A-D) and there was no difference in the frequency of 
observed CMCs (Figure 5.6F). We also assessed myogenic, high frequency contractions and 






Figure 5.5: Neonatal proximal small bowel motility in Bap1 fl/fl; Wnt1-Cre+ mice was normal. 
(A-D) Representative kymographs depicting bowel width as a function of time and distance along 
the proximo-distal axis of the cannulated proximal small intestine for Control (Ctrl; A-B) and cKO 
(C-D) neonatal (P0) mice. Low frequency (L.F.) contractions could be recorded for a subset of P0 
Ctrl and cKO pups (A and C; white arrows) while no L.F. contractions were detected for other Ctrl 
and cKO pups (B and D; Ctrl: n=10 [WT: 5 males/2 females and Het: 1 male/ 2 unknown], cKO: 6 
females/ 1 male/ 2 unknown). (E) The proportion of bowels where any L.F. contractions were 
recorded did not differ for P0 Ctrl (WT: contractions - 3 mice, no contractions - 4 mice, Het: 
contractions - 2 mice, no contractions - 1 mouse) and P0 cKO mice (contractions - 4 mice, no 
contractions - 5 mice). (F) The frequency of L.F. contractions did not differ for Ctrl and cKO 
neonates for which any L.F. contractions could be recorded (p=0.3368, Student’s t-test, Ctrl: : 0.18 
± 0.13, cKO: 0.11 ± 0.07  (mean ± stdev)). Data points derived from Het mice are marked by blue 
color. (A-F) WT refers to Bap1 wt/wt; Wnt1-Cre + or any genotype without the Wnt1-Cre transgene, 
Het refers to Bap1 fl/wt; Wnt1-Cre + genotype. cKO refers to Bap1 fl/fl; Wnt1-Cre + genotype. Data 
not significant unless otherwise indicated. 
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Postnatal loss of Bap1 in the ENS does not affect survival, weight gain or colon motility 
The ENS in Bap1 conditional knock-out mice appears to be structurally and functionally 
normal at birth, but enteric neurons, specifically of the Tyr-cre lineage are lost postnatally. These 
observations led us to ask if Bap1 has a primary role in the postnatal ENS maintenance with limited 
effects on prenatal ENS development. We thus deleted Bap1 in the postnatal ENS either at 8 weeks 
of age (adult) or between P1 and P7 (early life) in a Bap1;Ret-CreERT2 mouse model. Deletion of 
Bap1 in Bap1 fl/fl; Ret-CreERT2 + (Ret-CreERT2 cKO) adult mice or in early life did not affect 
overall survival of Ret-CreERT2 cKO mice, despite some toxicity-related lethality across genotypes 
due to the tamoxifen treatment early in life (Figure 5.6A-B). Loss of Bap1 caused a small increase 
in percent weight gain in Ret-CreERT2 cKO treated with tamoxifen in adulthood, but this increase 
in weight gain did not translate to a clear biologically meaningful increase in raw body weight (the 
weights of individual adult mice varied greatly at the beginning and end of experimental observation 
period. cKO: from 23.48g ± 2.96g to 24.49g ± 1.01g, Het: from 23.72g ± 3.41g to 24.77g ± 0.78g, 
and WT: from 20.73g ± 1.36g to 21.13g ± 0.74g). Weight gain of Ret-CreERT2 cKO mice was not 
affected by loss of Bap1 in early postnatal life (Figure 5.6C-D). Preliminary quantification of the 
proportion of TDTOMATO-expressing neurons in adult mice 1-12 weeks after tamoxifen treatment 
shows that most enteric neurons (myenteric plexus: 87.02 ± 6.15 across genotypes and 
submucosal plexus: 96.14 ± 4.62 across genotypes) have undergone Cre-mediated recombination 
and lost functional Bap1 alleles (Figure 6E-G). However, colon motility appears to be unaffected 
by postnatal loss of Bap1 irrespective of the timing of tamoxifen treatment (Figure 6H). These 
observations indicate either that prenatal Bap1 loss is required for the postnatal dysmotility 
phenotype and decrease in enteric neuron density, despite a functional, normal-appearing ENS at 
birth, or that loss of Bap1 in a small percentage of enteric neurons (1%-20%) is responsible for the 






Figure 5.6: Tamoxifen-induced postnatal loss of Bap1 in the ENS did not affect survival, 
bowel motility, and possibly post-treatment weight gain.  
(A) CRE-mediated excision of Bap1 allele in Bap1 fl/fl; Ret-CreERT2 + (cKO) mice at 8 weeks of 
age did not cause early lethality. Mice were followed for at least 90 days after tamoxifen treatment 
(cKO: 8 females/ 5 males, Het: 3 females/ 3 males, Control: 4F/1M). (B) Tamoxifen treatment 
between postnatal day 1 and day 7 (P1-P7) was lethal for a subset of mice, however, no meaningful 
difference in survival was observed for tamoxifen-treated cKO mice (cKO: 5 females/ 3 males/ 1 
not known, Het: 5 females/ 2 males, Control: 11 females/ 11 males/ 4 not known). (C) Tamoxifen-
treated adult cKO mice gained and maintained slightly more weight than Control and Het mice 
between 1 to 10 weeks after tamoxifen treatment with unclear biological significance (p=0.001, 
Repeated Measures One-way ANOVA mixed effects model with multiple comparisons, p = 0.025; 
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Control vs. cKO p = 0.016; Het vs. cKO, cKO: 3 females/ 5 males [112.2 ± 3.45], Het: 2 females/ 3 
males [109.3 ± 3.14], Control: 3 females [107.8 ± 3.64]). (D) cKO mice treated with tamoxifen 
between P1-P7 gained weight at the same rate as their Het and Control littermates (p=0.2076, 
Repeated Measures One-way ANOVA mixed effects model with multiple comparisons, cKO: 5 
females/ 2 males, Het: 3 females/ 2 males, Control: 6 females/ 10 males). (E) Proximal colon 
myenteric plexus in a cKO mouse 1 week after tamoxifen treatment contained some neurons that 
did not express TDTOMATO (white arrowheads). cKO mouse treated at 8 weeks of age. (F) 
Proximal colon submucosal plexus in a cKO mouse 1 week after tamoxifen treatment contained 
some neurons that did not express TDTOMATO (white arrowheads). cKO mouse treated at 8 
weeks of age. (G) Preliminary quantification of the proportion of TDTOMATO+ (magenta) enteric 
neurons (green) shows that tamoxifen treatment at 8 weeks of age led to CRE-mediated 
recombination in the vast majority of myenteric and submucosal neurons (Control: 2 males (1 week 
and 12 weeks after treatment), Het: 1 female (12 weeks after treatment), cKO: 1 male (1 week after 
treatment)) and that the proportion of Ret-CreERT2 lineage neurons remained constant. (H) Colon 
bead expulsion latency was normal for cKO mice that were treated with tamoxifen at 8 weeks of 
age (p = 0.8116, One-way ANOVA, cKO: 4 females/ 1 males, Het: 1 female/ 2 males, Control: 3 
females/ 1 males) and colon bead expulsion latency in cKO mice was likely unaffected by tamoxifen 
treatment between P1-P7 (cKO: 1 female, Het: 2 females, Control: 4 females, 2M). (E-F) Single 
confocal optical slice. (A-D, G) WT refers to Bap1 wt/wt; Ret wt/CreERT2 or any genotype without 
the CreERT2 knock-in allele. (A-H) Het refers to Bap1 fl/wt; Ret wt/CreERT2 genotype. cKO refers 
to Bap1 fl/fl; Ret wt/CreERT2 genotype. PSI = Proximal Small Intestine, DSI = Distal Small Intestine, 
PCO = Proximal Colon, and DCO = Distal Colon. (E-F) Scale bar = 20 μm. 
Summary  
Loss of Bap1 in enteric neural precursors did not affect neonatal enteric nervous system 
anatomy and function. However, density of Tyr-Cre lineage neurons and total neuron density were 
decreased by P15 in Tyr-Cre cKO mice along the entire length of the bowel. By P15, proximal small 
intestine and colon motility were decreased and Tyr-cre cKO mice failed to thrive and died early 
with greatly distended bowels due to accumulated feces. Postnatal loss of Bap1 in the vast majority 
of enteric neurons did not cause motility defects, affect weight gain or survival of RetCreERT2 cKO 
mice, indicating that prenatal loss of Bap1 in enteric neural precursors is required for postnatal 
neuron loss and bowel dysmotility or that postnatal loss of Bap1 in very specific neuron 




5.5 Discussion and Future Directions 
Loss of Bap1 does not cause Hirschsprung disease 
We initially expected that loss of Bap1 would lead to Hirschsprung disease. This hypothesis 
was supported by previous studies showing that Bap1 regulates neural crest lineage differentiation 
(55) and expression of genes important for enteric neural crest migration (58). We also observed 
early in this study that the majority of Tyr-Cre cKO mice had a patch of white abdominal fur, 
indicating incomplete embryonic melanocyte migration. Melanocytes are also a neural crest 
derivative and melanocyte migration defects are associated with Hirschsprung disease 
(Waardenburg-Shah syndrome (13, 17)). Hirschsprung disease can be caused by disruption of a 
number of processes, including enteric neural precursor proliferation, survival, and migration (9). 
Bap1’s role as a transcriptional and epigenetic regulator could affect all of these processes. Bap1 
loss could further impair enteric neural precursors differentiation into a full complement of neurons 
and glia. This could cause ENS structural abnormalities at birth even in the parts of the bowel 
colonized by enteric neural precursors (36, 72, 73).  
To our surprise, the ENS in Wnt1-Cre cKO mice appeared anatomically and functionally 
normal at birth. In neonatal Wnt1-Cre cKO mice, overall enteric neuron density was normal along 
the length of the bowel in both myenteric and submucosal plexi. Additionally, enteric neurons were 
arranged into enteric ganglia connected by Tuj1+ neurites. Despite the unexpected nature of this 
observation, the lack of an enteric neural precursor migration defect still needs to be interpreted 
with caution. Previous studies have shown that Cre-mediated recombination takes place at around 
E8.5-E9 in the Bap1;Wnt1-Cre mouse model (63) and before E10.5 for the Bap1;Tyr-cre mouse 
model (64). However, we do not know how long functional BAP1 protein is retained in migrating 
enteric neural precursors. It seems unlikely that the functionally and anatomically normal P0 ENS 
can be solely explained by lingering BAP1 protein that is still able to affect cell signaling until close 
to birth (more than 9 days after Cre excision in the case of Bap1;Tyr-Cre and more than 10 days 
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later in the case of Bap1;Wnt1-Cre). However, ENS migration is completed around E13.5 and the 
lack of an ENS migration defect could be due to BAP1 protein activity beyond the time point of Cre 
mediated recombination. We are currently staining embryonic bowel during enteric neuron 
precursor migration with BAP1 antibodies to visualize whether loss of BAP1 protein was already 
complete at this stage of development.  
Wnt1-Cre cKO in vitro proximal small intestine motility also seemed unaffected. Both the 
proportion of mice for which any neurally mediated contractions could be observed during the 
observation window and the frequency of recorded contractions was unchanged. These 
observations support the conclusion that Bap1 loss does not affect the intrauterine formation of the 
ENS. It should be noted, however, that assessing bowel motility in neonatal mice is complicated by 
the relative immaturity of the ENS at that age. Neurologically mediated neurogenic contractions 
can be observed in proximal small intestine as early as E18.5 (71), but at that same age, neurally 
mediated contractions are not yet present in the colon (74). The presence of a CMC with a “defined 
peak of contraction” in vitro cannot be directly equated with normal motility patterns that 
productively propagate a bolus of food towards the anus. To complete the characterization of 
neonatal bowel motility in cKO pups, we are currently assessing in vivo neonatal Wnt1-Cre cKO 
proximal small intestine motility with a FITC Dextran transit assay (analogous to Figure 5.2A-B).  
The ENS at P15 is abnormal in Bap1;Tyr-Cre mice 
 At P15, Tyr-Cre cKO myenteric and submucosal enteric neuron density was reduced along 
the length of the bowel. This decrease in enteric neuron numbers could be due to a reduction of all 
ENS neuron subtypes proportional to normal ENS subtype composition or a lack of specific cell 
populations with complete sparing of other cell types. The change in Tyr-Cre cKO enteric neuron 
density was also accompanied by in vivo and in vitro bowel dysmotility. Since loss of specific neuron 
subtypes in particular has been shown to cause dysmotility (30, 34), we decided to evaluate 
nitrergic (NOS1+) neuron density. Myenteric nitrergic neurons are functionally important since they 
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include interneurons and inhibitory motor neurons and, in combination with cholinergic enteric 
neurons, make up >95% of mouse myenteric plexus neurons (1). The data presented here is 
preliminary and only limited statistical conclusions could be reached, however, it appears that 
nitrergic neuron density was unchanged despite an overall decrease in neuron density. High 
variability in NOS1+ neuron numbers in individual fields of view across all genotypes was apparent. 
This variability made the proportion of NOS1+ neurons to total neurons easier to interpret than 
nitrergic neuron density since nitrergic neurons could be matched to total neuron numbers for each 
field of view. We are currently completing the quantification of nitrergic neuron density for the 
remainder of our P15 sample set.  
 As a next step, we will assess cholinergic enteric neuron density in P15 Tyr-Cre cKO mice. 
Cholinergic neurons comprise a large subset of submucosal neurons ~41% (75) and a subset of 
myenteric neurons that is mostly non-overlapping with nitrergic neurons (~70%) (76, 77). So far, 
we have focused exclusively on enteric neuron density at P0 and P15. However, neonatal enteric 
glial density as well as postnatal glial survival could also be affected by loss of Bap1. Loss or 
dysfunction of glia could even contribute to the observed functional deficit at P15  (78–80), albeit 
more subtly than enteric neuron dysfunction.  
Loss of Bap1 may lead to postnatal neuron loss 
A postnatal loss of enteric neurons could explain the observed anatomic and functional 
differences in neonatal versus P15 cKO mice. We observed a worsening of Tyr-Cre cKO mouse 
health over time. At birth, Tyr-Cre cKO mice were indistinguishable from their littermates in size 
and weight and then progressively fell behind their littermates in development and bowel motility 
defects could be detected in most cKO mice by P15. Interestingly, the rate of phenotype worsening 
was not uniform. Some Tyr-Cre cKO pups stopped gaining weight by P5 and died before P15. In 
contrast, some P15 Tyr-Cre cKO mice exhibited normal colon motility both in vivo and in vitro and 
rare Tyr-Cre cKO bowels were still free of aggregated feces as late as P20. 
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Loss of only Tyr-Cre lineage neurons in cKO mice would be sufficient to explain the overall 
loss of myenteric neurons in the myenteric plexus. However, the drastic loss of enteric neurons in 
the submucosal plexus does not correlate with the modest loss of Tyr-cre lineage neurons in 
proximal small intestine and a lack of statistically significant Tyr-Cre lineage neuron loss in all other 
bowel regions. This implies that the presence of Tyr-Cre lineage cells also affects the survival of 
other enteric neurons in the submucosa. 
Epithelial changes caused by loss of Bap1 are of unclear significance 
Loss of Bap1 caused subtle changes in distal small intestine and proximal colon epithelium. 
We decided to look at the epithelium after we noticed apparent qualitative changes in goblet cell 
density in Tyr-Cre cKO mice (see Supplementary Figure 5.1A-H). Assessing epithelial changes 
also made sense in the context of other observations: Tyr-Cre cKO mice sometimes started losing 
weight and developed diarrhea before any feces had started to accumulate in the distal bowel, 
which hinted at a possible loss of absorptive capacity for nutrients and water along the bowel. 
Enteric neurons and glia regulate epithelial turnover and epithelial barrier function (reviewed in 
Chapter 1) and loss of enteric neuron subtype signaling can affect epithelial wound healing 
capacity (81). The subtle changes we quantified in P15 Tyr-Cre cKO pups (e.g. deeper crypts with 
a proportional increase in goblet cells in proximal colon and a higher density of goblet cells in distal 
small intestinal crypts but not villi) could be caused directly by altered enteric neuron signaling to 
epithelial stem cells (82–85), but more likely, the epithelial changes were secondary to prolonged 
exposure to aggregated feces.  
Postnatal loss of Bap1 in most ENS cells does not cause obvious pathology 
Tamoxifen-induced Bap1 loss in most of the ENS does not seem to affect survival, bowel 
motility or biologically significant weight change. This could mean that prenatal Bap1 loss is 
necessary for the postnatal dysmotility phenotype and decrease in enteric neuron density, despite 
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a functional, normal-appearing ENS at birth. An alternative possibility is that the observed functional 
deficits in Bap1;Tyr-Cre mice are caused by loss of Bap1 in a small number of enteric neurons that 
do not express Ret (1-20% of total ENS neurons, see Figure 5.6G). We are currently in the process 
of completing in vivo small intestine and colon motility assays for Bap1;Ret-CreERT2 mice treated 
with tamoxifen in early life and adulthood to back up our preliminary observations. We are also 
quantifying enteric neuron density and Ret-CreERT2 lineage neuron density in Bap1;Ret-CreERT2 
mice treated with tamoxifen at early and later time points to see if enteric neuron survival is affected 
by postnatal loss of Bap1. If we can observe a decrease in enteric neuron density in Ret-CreERT2 
cKO mice compared to wild-type mice after tamoxifen treatment , this would indicate the fascinating 
possibility that the ENS can buffer a statistically significant loss of enteric neurons without any 
obvious morbidity and that the functional deficits observed in Tyr-Cre cKO mice are caused by 
dysfunction in a relatively small subset of neurons. 
Next steps - towards defining a mechanism 
Our next steps will focus on better understanding how Bap1 is causing postnatal enteric 
nervous system dysfunction. As a first step, we will look for apoptosis (cleaved caspase 3 staining) 
and evidence of double-stranded DNA breaks (stain tissue for phosphorylated histone 2AX) (86) in 
the ENS between P5 and P10. One of Bap1’s nuclear roles is  facilitating double-stranded DNA 
break repair (49, 50). Therefore, loss of Bap1 could cause accumulation of DNA damage resulting 
in ENS dysfunction and eventually loss of neurons. For example, ENS loss of Ercc1, an 
endonuclease complex subunit required for nucleotide excision repair, causes hypersensitivity to 
UV irradiation. In this mouse model, the ENS accumulates DNA damage, degenerates after 1 
month of age, and animals experience  massive colonic distention and death around 4-6 months 
of age (87). However, the timeline for ENS degeneration and survival in the Ercc1 cKO mouse 
model is very different from that in our mice (2-4 weeks for Bap1 versus 4-6 months for Ercc1), and 
Ercc1 loss only leads to this drastic phenotype when combined with UV radiation exposure. This 
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makes accumulation of DNA damage a less likely possibility, yet a possibility we need to exclude. 
It should also be noted that a lack of apoptotic markers in the postnatal Bap1;Tyr-Cre ENS would 
have to be interpreted with care and cannot exclude cell death since enteric neurons can employ 
cell death pathways that do not depend on effector caspase activation (88).  
We are also evaluating whether histone deacetylase 4 (Hdac4) regulation by Bap1 
contributes to the observed postnatal phenotype in the Bap1;Tyr-Cre cKO ENS. We were intrigued 
by the prominent regulatory interaction between Bap1 and Hdac4 in early xenopus development. 
Loss of both bap1 and hdac4 was able to rescue the prominent gastrulation and neurulation defects 
caused by bap1 loss alone. Deletion of other epigenetic regulators like the polycomb repressor 
complex 2 subunit ezh2 did not have any effect (55). We are currently in the process of breeding 
floxed Hdac4 alleles into the Bap1;Tyr-Cre mouse model to assess the effect of loss of both alleles 
on survival and bowel phenotype. Preliminary results suggest that Hdac4 loss by itself is insufficient 
to correct Bap1-induced postnatal ENS dysfunction (data not shown). 
Lastly, we are planning to compare single cell ENS transcriptomes from Bap1;Tyr-Cre cKO 
and wild-type mice at P5. We are planning to isolate Tyr-Cre lineage/TDTOMATO+ neurons and 
glia by FACS and assess changes in RNA expression due to Bap1 loss in comparable ENS cell 
types (89). This type of analysis can provide indirect evidence of epigenetic dysregulation through 
large numbers of dysregulated transcripts (56, 57) and may allow us to detect if any specific ENS 
cell types are most severely affected. 
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5.8 Supplementary Figures and Tables 
 
Supplementary Figure 5.1: Motility patterns observed at postnatal day 15 were neurogenic 
and often abnormal or absent in Bap1 fl/fl;Tyr-Cre+ mice.  
(A-D) Representative kymographs depicting bowel width as a function of time and distance along 
the proximo-distal axis of the cannulated colon for WT (Bap1 wt/wt; Tyr-cre+; A-B) and cKO (Bap1 
fl/fl; Tyr-Cre+; C-D) mice at postnatal day 15 (P15). (A-B) Colonic motor complexes (CMC) recorded 
for P15 WT mice (A; white arrows) disappeared in the presence of tetrodotoxin (TTX, B). (C-D) For 
some P15 cKO mice, no CMC was recorded (C) and this was also true in the presence of TTX (D). 
(E) Example kymograph for P15 cKO mouse shows regular but abnormal neurogenic propagating 
motility patterns. (F) Breakdown of the types of motility patterns observed for P15 cKO mice (n=10). 
(G) Colon width did not change significantly in the presence of TTX for either P15 WT or cKO mice 
(cKO: 2 males/1 female, WT: 2 females/1 male). (H) Percent change in colon width as compared 
to baseline also did not differ significantly for P15 WT and cKO mice (cKO: 2 males/ 1 females, 
WT: 2 females/ 1 male). (A-E) TTX = tetrodotoxin. (F-G) Graphs show mean +/- standard deviation. 






Supplementary Figure 5.2: Bap1 fl/fl; Tyr-Cre+ mice at postnatal day 15 had altered bowel 
epithelium.  
(A-H) Similar amounts of collagen in the bowel wall were observed in control (A-D) and cKO (E-H) 
proximal small intestine (A,E), distal small intestine (B,F), proximal colon (C,G), and distal colon 
(D,H). White arrows indicate trichrome stained collagen in submucosa (blue). Representative 
images shown. (I-J) Representative images of haematoxylin and eosin-stained proximal small 
intestine of control (I) and cKO (J) mice. Black arrowheads indicate villi that were included in the 
quantification. (K-O) No differences could be detected between control and cKO mice in proximal 
small intestine when comparing villus length (K), number of epithelial cells per villus (L), crypt length 
(M), and the number of epithelial cells per crypt (N). (O-P) Representative images of haematoxylin 
and eosin-stained distal small intestine of control (O) and cKO (P) mice. Black arrowheads indicate 
villi that were included in the quantification. (Q-R) Alcian Blue/Periodic Acid-Schiff staining was 
used to visualize goblet cells (dark purple spots within epithelium) in distal small intestine of control 
(Q) and cKO (R) mice. Black arrowheads indicate villi that were included in the quantification. (S-
V) No differences in villus length (S), number of epithelial cells per villus (T), crypt depth (U), and 
number of epithelial cells/crypt (V) could be verified when distal colon epithelium of control and cKO 
mice was compared. Comparison of average villus length trended towards shorter villi in cKO mice 
(S, p=0.0533). (W-X) No difference in goblet cell number per villus (W) or per villus epithelial cell 
number (X) could be found in control versus cKO mice. (Y-Z) cKO distal small intestinal crypts 
contain a significantly greater number of goblet cells, both when normalizing to crypt depth (Y, 
p=0.0317) or to crypt epithelial cell numbers (Z, p=0.0315). (A’-B’) Representative images of 
haematoxylin and eosin-stained proximal colon of control (A’) and cKO (B’) mice. Black arrowheads 
indicate villi that were included in the quantification. (C’-D’) Alcian Blue/Periodic Acid-Schiff staining 
visualized goblet cells (dark purple spots within epithelium) in proximal colon of control (C’) and 
cKO (D’) mice. Black arrowheads point towards villi that were included in the quantification. (E’) 
Proximal colon epithelial crypts were significantly deeper for cKO mice than control mice. (F’) 
However, epithelial cell number per crypt was not significantly different for control and cKO mice 
(p=0.0675). (G’) cKO mice had significantly greater numbers of goblet cells in proximal colon crypts 
(p=0.035). (H’) This increase in goblet cell number disappeared when normalized to the number of 
epithelial cells per crypt. (I’-J’)  Representative images of haematoxylin and eosin-stained distal 
colon of control (I’) and cKO (J’) mice. Black arrowheads indicate villi that were included in the 
quantification. (K’-L’) Distal colon crypt depth (K’) and number of epithelial cells per crypt (L’) were 
not significantly different for control and cKO mice. (A-D) Control refers to Bap1 wt/wt;Tyr-Cre+ 
genotype (n=1, 1 male) or Bap1 fl/wt; Tyr-Cre+ (n=4, 3 females/ 1 male). (E-H) cKO refers to Bap1 
fl/fl;Tyr-Cre+ genotype (n=4, 3 females/ 1 males). (I-O’) Control refers to Bap1 wt/wt;Tyr-Cre+ 
genotype (n=3, 2 females/ 1 male). (I-O’) cKO refers to Bap1fl/fl;Tyr-Cre + genotype (n=3, 2 
females/ 1 male). Data is presented as mean ± stdev. Unpaired t test was performed on all data 
sets to determine significance. Data not significant unless indicated otherwise. *p<0.05. (A-H) Scale 





Supplementary Figure 5.3: Bap1 fl/fl; Tyr-Cre + mice at postnatal day 15 had decreased total 
enteric neuron density along the bowel and nitrergic enteric neuron density appears 
proportionally decreased. 
(A-X) Representative images of myenteric plexus along the bowel for Bap1 wt/wt; Tyr-Cre+ 
(Control; A-C, G-I, M-O, S-U) and Bap1 fl/fl; Tyr-Cre + (cKO; D-F, J-L, P-R, V-X) mice at postnatal 
day 15. (D-F, J-L, P-R) Maximum intensity z-projections. All other images are single confocal optical 
slices. PSI = proximal small intestine, DSI = distal small intestine, PCO = proximal colon, DCO = 





Supplementary Figure 5.4: Preliminary analysis suggests Bap1 fl/fl; Tyr-Cre + mice had 
decreased total enteric neuron density along the bowel by postnatal day 15, but are born 
with normal neuron density. Nitrergic neurons may decrease proportionally to total neuron 
numbers.  
(A-B) Preliminary analysis of total neuron density in Bap1;Tyr-Cre mice at postnatal day 15 (P15) 
suggests decreased neuron density for cKO mice in both myenteric (A) and submucosal plexus (B) 
in all regions of the bowel (One-Way ANOVA with Tukey’s Multiple Comparisons Test; myenteric 
PSI: n too small for statistics, myenteric DSI: p= 0.0489, myenteric PCO: p = 0.0005, myenteric 
DCO: p = 0.0007; submucosal PSI/PCO/DCO: n too small for statistical analysis, submucosal DSI: 
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p = 0.0011). (C-D) Preliminary analysis of nitrergic neuron density (NOS1+) in P15 Bap1;Tyr-Cre 
mice indicates that there is no difference in NOS1+ neuron density between WT, Het, and cKO 
bowel in myenteric (C) and submucosal plexus (D) (all n too small for statistical analysis). (E-F) 
However, preliminary analysis of the proportion of nitrergic neurons in P15 Bap1;Tyr-Cre mice 
suggests a proportional decrease of NOS1+ neuron density in myenteric plexus (E) in all bowel 
regions (all n too small for statistical analysis). No conclusions can be drawn about submucosal 
plexus (H) at this time. (G-H) Preliminary analysis of total neuron density in Bap1;Wnt1-Cre mice 
at birth suggests no significant difference between WT, Het, and cKO mice in myenteric (G) and 
submucosal plexus (H; (all n too small for statistical analysis). (A-G) WT refers to Bap1 wt/wt; Tyr-
Cre + or any genotype without Cre allele, Het refers to Bap1 fl/wt; Tyr-Cre +, and cKO refers to 





Supplementary Figure 5.5: Bap1 fl/fl; Tyr-Cre+ mice lose neurons of the Tyr-Cre lineage by 
postnatal day 15.   
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(A-V’) Representative images showing enteric neurons (HUC/D+, green) and neurons of the Tyr-
Cre lineage (TDTOMATO+, magenta) in different bowel regions for Control (Bap1 wt/wt; Tyr-Cre+; 
D-F, J-L, P-R, V-X, B’-D’, H’-J’, N’-P’, and T’-V’) and cKO (Bap1 fl/fl; Tyr-Cre+; A-C, G-I, M-O, S-U, 
Y-A’, E’-G’, K’-M’, and Q’-S’) mice at postnatal day 15. (D-F, B’-D’, K’-P’) Maximum intensity z-
projections. All other images are single confocal optical slices. PSI= proximal small intestine, DSI 






Supplementary Figure 5.6: Neonatal proximal small intestine motility patterns observed in 
vitro are neurogenic and Bap1 fl/fl; Wnt1-Cre+ mice exhibited normal myogenic contraction 
frequency at birth.  
(A-D) Representative kymographs depicting bowel width as a function of time and distance along 
the proximo-distal axis of the cannulated proximal small intestine for neonatal control (Ctrl; A-B) 
and cKO (C-D) mice. (A-B) Low frequency (L.F.) contractions could be recorded for a subset of 
control mice (A; white arrows) and these L.F. contractions disappeared in the presence of 
tetrodotoxin (TTX, B). (C-D) Low frequency (L.F.) contractions could also be recorded for a subset 
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of cKO mice (C; white arrows) and these contractions also disappeared in the presence of 
tetrodotoxin (TTX, D). (E) Example Fourier transform of the recorded contractions that allows the 
identification of regularly-occurring myogenic higher frequency contractions (H.F. contractions; 
white arrow). (F) There was no difference in the frequency of myogenic H.F. contractions recorded 
for control and cKO neonates and the frequency of contractions was also unaffected by the 
presence of tetrodotoxin ([No TTX: Ctrl: WT 5 males/ 2 females and Het 1 male/2 unknown (11.38 
± 4.62), cKO: 6 females/ 1 male/ 2 unknown (19.97 ± 7.4)]. [+TTX: Ctrl: 2 male/ 1 unknown (13.30 
± 1.65), KO: 5 females (19.72 ± 8.74)]). Data points derived from Hets are marked by blue color. 
(A-F) WT refers to Bap1 wt/wt; Wnt1-Cre+ or any genotype without the Wnt1-Cre transgene. Het 
refers to Bap1 fl/wt; Wnt1-Cre+ genotype. cKO refers to Bap1 fl/fl; Wnt1-Cre+ genotype. (F) Data 
represented as mean ± standard deviation. Data not significant unless otherwise indicated. 
 
Supplementary Table 5.1: ARRIVE Guidelines - General animal husbandry information 
Location of Animal facility 
(types of experiments) 
Childrens’ Hospital of Philadelphia 
Facility Type Conventional: cages are opened at room air, face masks are 
not required when handling mice 
Facility Type Specific pathogen free, Pathogens detected in room within 
the past 2 years: MNV (mouse norovirus), Helicobacter not 
tested but likely present 
Bedding ¼ inch corncob (The Andersons, Product 4B) 
Cage type Lab Products (Seaford, DE) 75 sq. in. Ventilated. 
Cage cleaning/sterilization Standard tunnel washer 
Mouse diet 
Mouse Diet 5015 (Lab Diet), direct from manufacturer: not 
autoclaved, not irradiated 




Location of Animal facility 
(types of experiments) 
Childrens’ Hospital of Philadelphia 
Temperature 72°F +/- 2°F 
Humidity 30-70% depending on the day/season 
Water pH and quality Reverse Osmosis, pH~7, Edstrom automatic watering system 
Number of mice per cage 1-5 (20-30g) 
Cage Enrichment house/dome (Bioserve, S3174) and nestlet (Ancare) 
Mating strategy Continuous 
Age at weaning 19-20 days 
Access to food and water Continuous 
Animal welfare assessment Daily 





Supplementary Table 5.2: List of antibodies 
Antibody Concentration Catalog 
number 
Source 
Rabbit anti-NOS1 1:200 AB5380 Sigma; RRID:AB_91824 
ANNA-1 (HuC/D) N/A N/A Kind gift from Dr. V. Lennon, 
Mayo Clinic 
Chicken anti-GFP 1:500 GFP-1020 Aves Labs, RRID:AB_10000240 
Goat anti-SOX10 1:100 AF2864 R&D Systems, RRID:AB_442208 
Rabbit anti-Cleaved 
Caspase 3 
1:150 9661S Cell Signaling, RRID:AB_2341188 
Rabbit anti-H2AX 1:300 A300-081A Bethyl Laboratories, 
RRID:AB_203288 
Alexa Fluor goat anti-
human 647 




































1:200 ab102424 Abcam; RRID:AB_10710634 
DyLight donkey anti-
human 650 





Supplementary Table 5.3: List of PCR primers for mouse genotyping 
Gene 
(Strain) 
Primer Sequence Band size Genotyping 
solution 
Reference 
Bap1  F: 5'-AGC GTG CTT CTG 
AAC TGC AGC AAT GTG 
GAT-3’ 
R: 5’-TTC TGA AAG GGC 












F: 5'-TCA TAG AGG CGC 
AGA GTT CC-3' 
R: 5'-CTG AAC TTG TGG 
CCG TTT AC-3' 









F: 5’-GCA TTA CCG GTC 
GAT GCA ACG AGT GAT 
GAG-3’ 
R: 5’-GAG TGA ACG AAC 
CTG GTC GAA ATC AGT 
GCG-3’ 










Common F: 5'-AAA GTC 
GCT CTG AGT TGT TAT-3' 
Tg R: 5’-GCG AAG AGT 
TTG TCC TCA ACC-3’ 
WT R: 
5'-GGA GCG GGA GAA 











protocol (Stock No: 
007909) 
Hdac4 F: 5’-ATC TGC CCA CCA 
GAG TAT GTG-3’ 
R: 5’-CTT GTT GAG AAC 
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6.1 Abstract 
BACKGROUND & AIMS: Small, 2-dimensional sections routinely used for human pathology 
analysis provide limited information about bowel innervation. We developed a technique to image 
human enteric nervous system (ENS) and other intramural cells in 3 dimensions.  
METHODS: Using mouse and human colon tissues, we developed a method that combines tissue 
clearing, immunohistochemistry, confocal microscopy, and quantitative analysis of full-thickness 
bowel without sectioning to quantify ENS and other intramural cells in 3 dimensions.  
RESULTS: We provided 280 adult human colon confocal Z-stacks from persons without known 
bowel motility disorders. Most of our images were of myenteric ganglia, captured using a 20x 
objective lens. Full-thickness colon images, viewed with a 10x objective lens, were as large as 4 x 
5 mm2. Colon from 2 pediatric patients with Hirschsprung disease was used to show distal colon 
without enteric ganglia, as well as a transition zone and proximal pull-through resection margin 
where ENS was present. After testing a panel of antibodies with our method, we identified 16 
antibodies that bind to molecules in neurons, glia, interstitial cells of Cajal, and muscularis 
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macrophages. Quantitative analyses demonstrated myenteric plexus in 24.5% ± 2.4% of flattened 
colon Z-stack area. Myenteric ganglia occupied 34% ± 4% of myenteric plexus. Single myenteric 
ganglion volume averaged 3,527,678 ± 573,832 mm3 with 38,706 ± 5763 neuron/mm3 and 129,321 
± 25,356 glia/mm3. Images of large areas provided insight into why published values of ENS density 
vary up to 150- fold—ENS density varies greatly, across millimeters, so analyses of small numbers 
of thin sections from the same bowel region can produce varying results. Neuron subtype analysis 
revealed that approximately 56% of myenteric neurons stained with neuronal nitric oxide synthase 
antibody and approximately 33% of neurons produce and store acetylcholine. Transition zone 
regions from colon tissues of patients with Hirschsprung disease had ganglia in multiple layers and 
thick nerve fiber bundles without neurons. Submucosal neuron distribution varied among imaged 
colon regions.  
CONCLUSIONS: We developed a 3-dimensional imaging method for colon that provides more 
information about ENS structure than tissue sectioning. This approach could improve diagnosis for 
human bowel motility disorders and may be useful for other bowel diseases as well. 
 
6.2 Introduction 
The enteric nervous system (ENS) controls most aspects of bowel function and is thought 
to contain as many neurons as the spinal cord, with approximately 20 neuron and 4–7 glial cell 
types (1–4). ENS defects can cause debilitating or life-threatening bowel dysfunction, including 
diverse motility disorders. In many cases, human diseases are well-modeled by mouse mutations 
that cause striking changes in ENS anatomy (5,6). ENS structural defects are readily visualized in 
mice via whole-mount staining because murine bowel is thin. In contrast, human ENS is buried in 
opaque tissue, making visualization challenging, especially because ENS accounts for < 1:10,000 
cells in colon wall (our estimate). For this reason, human clinical pathology relies primarily on 
formalin-fixed paraffin-embedded thin sections to visualize ENS. However, even major ENS defects 
are difficult to appreciate in sectioned bowel (Supplementary Figure 6.1) and human quantitative 
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analyses provide highly variable results for “normal” colon neuron density (7–9). This variability in 
“normal” makes structural defects causing bowel motility disorders difficult to define. A few 
approaches demonstrated elaborate ENS structures in human bowel (10–17), but methods were 
not reproducible in our hands, technically challenging and time consuming, or failed to demonstrate 
ENS in large intact regions. We therefore sought to develop robust, highly reproducible methods to 
visualize cells controlling human colon motility. Our new approach provides 3-dimensional ENS 
views in large colon regions without sectioning, preserving associations with other bowel cells. This 
is important because bowel motility requires coordinated muscle contraction and relaxation18 
organized by enteric sensory neurons, interneurons, excitatory and inhibitory motor neuron 
(1,3,19,20), interstitial cells of Cajal (21), enteric glia, muscularis macrophages, platelet-derived 
growth factor receptor a-immunoreactive cells (or “fibroblast-like cells”), and enteroendocrine cells 
(1,3). Defining cell type–specific defects that affect bowel motility is most important for life-
threatening diseases like Hirschsprung disease (22,23), achalasia (24), gastroparesis (25), and 
chronic intestinal pseudo-obstruction (26), where improved imaging could provide new ideas about 
disease pathogenesis or treatment. First, however, we aimed to quantitatively define “normal” ENS 
anatomy. Here we provide 280 confocal Z-stacks and quantitative data from 14 human adult colons. 
We also visualized colon ENS from children with Hirschsprung disease, a birth defect where ENS 
is absent from distal bowel and a hypoganglionic “transition zone” separates aganglionic from 




Studies adhere to ARRIVE (Animals in Research: Reporting In Vivo Experiments) guidelines (27) 
and Institutional Animal Care and Use Committee at Children’s Hospital of Philadelphia (16-
001041). P0 Gfrα1 (MGI cat no. 3715269, RRID:MGI:3715269) (28) and wild-type littermate 
(C57BL/6) were analyzed (9–12 AM). Dam was fed Mouse Diet 5015* (LabDiet, St Louis, MO), not 
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fasted, housed on corncob (Product 4B; The Andersons, Maumee, OH) in Lab Products (Seaford, 
DE) caging. Human Tissue Colon was acquired with Children’s Hospital of Philadelphia Institutional 
Review Board (IRB 13-010357) and Perelman School of Medicine at University of Pennsylvania 
approval (IRB 804376) using Abramson Cancer Center Tumor Tissue Bank or pathology de-
identified tissue, providing limited clinical data. Jejunum and pancreas were from the Human 
Pancreas Analysis Program (IRB exempt).  
 
Human Colon Staining 
Detailed protocol is at protocols.io (dx.doi.org/10.17504/ protocols.io.wyeffte). 
 
Tissue Processing 
Adult colons remained at ambient temperature until arrival in pathology after routine 
hospital procedures. Transfer to sterile icecold 1X phosphate-buffered saline (PBS) occurred 61–
112 minutes after resection. Staff pathologists provided regions without recognized abnormalities. 
The laboratory received coded specimens in PBS on ice. While in PBS, fat was removed and tissue 
was pinned along edges (serosa up) to Sylgard 184 Silicone Elastomer (Dow, Midland, MI) using 
insect pins. We stretched while pinning, making the colon thin, flat, and uniform thickness. Pins 
were repositioned several times to stretch colon as muscles relaxed, increasing area 2.6-fold (N = 
3, SEM = 0.15) compared to unstretched colon. Pinned tissue was fixed (4% paraformaldehyde, 
4C overnight), transferred to PBS, and the edges with pin holes were trimmed. Full-thickness colon 
was cut with scissors. Most specimens were 1 x 1 cm2. Larger colonic specimens also stained 
adequately using this method (eg, 2 x 3 cm2 ). Stored tissue (4C, 50% PBS/50% glycerol/0.05% 
sodium azide) could be stained months later without obvious tissue degradation. Human jejunum, 
pancreas, and Hirschsprung colon were processed similar to adult colons. Hirschsprung colon was 
in ice-cold PBS 20–60 minutes after resection. Jejunum and pancreas from transplant donors were 
in Belzer UW solution (29) (NC0410019; Fisher Scientific, Waltham, MA) immediately after 
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resection and stored approximately 8 hours before fixation. 
 
Immunohistochemistry 
The 1 x 1 cm2 fixed colons were processed in 24-well VWR Culture Plates (nontreated), 2-
cm diameter (cat no. 10861-558). Reagent volumes were 500–1000 µL/well (enough to cover 
tissue). After washing (PBS, 3 x 5 minutes, room temperature), incubating to permeabilize and 
remove lipids (100% methanol, 1 hour, on ice), and treating with Dent’s bleach (5 mL 30% hydrogen 
peroxide, 5 mL dimethylsulfoxide, 20 mL 100% methanol) (30) (2 hours, room temperature) to 
permeabilize and quench auto-fluorescence, colon was washed (PBS, 3 x 5 minutes, room 
temperature), transferred to 2- mL Eppendorf tubes containing blocking solution (4% normal 
donkey serum, 0.5% Triton X-100, and 0.05% sodium azide/PBS) and incubated (3 days, 370C, 
New Brunswick Scientific I24 Incubator Shaker, 40–100 rpm). Then we incubated with 1–3 primary 
antibodies (Supplementary Table 6.1) in blocking solution on shaker (14 days, 370C, 40–100 rpm) 
using Parafilm-sealed tubes. Unbound primary antibody was removed (PBS/0.05% sodium azide, 
3 washes, 2 hours/wash, plus an overnight wash, on rocker). Secondary antibodies were in 
PBS/0.05% sodium azide (3 days, 370C, on rocker). Excess secondary was removed with 
PBS/0.05% sodium azide (3 washes, 2 hours/wash, plus additional wash overnight, room 
temperature, on rocker). Some tested antibodies did not work (Supplementary Table 6.2). 
 
Dehydration, Clearing, and Mounting After Immunohistochemistry 
Colon was dehydrated in 24-well dishes in graded methanol/PBS (approximately 500 
µL/well, extra if needed to cover, 30 minutes/wash: 50% methanol, 70% methanol, 80% methanol, 
95% methanol, 100% methanol x3, room temperature, on rocker). Dehydrated colon incubated in 
Murray’s Clear (2:1 benzyl benzoate: benzyl alcohol) (31) until completely translucent (15–30 






Zeiss LSM 710 confocal microscope (10x and 20x PlanApochromat objectives, Zeiss Zen 
software, version 2.3 14.0.14.201; Zeiss, Oberkochen, Germany) Z-axis increments were 4 mm 
(10x objective) or 1 mm (20x objective). Each image slice was 900 x 900 (10x) or 1200 x 1200 
pixels (20x). The 10x Z-stacks were stitched to cover large regions. Laserscanning operated under 
multitrack to sequentially acquire multichannel images. Each channel used 100% laser power. 
Excitation/long-pass emission filters were Alexa Fluor 647 (excitation: 633 nm, emission: 656- to 
755-nm filter), Alexa Fluor 594 (excitation: 561 nm, emission: 588- to 656-nm filter), and Alexa Fluor 
488 (excitation: 488 nm, emission: 493- to 584-nm filter). Tile scan and Zen stitching were used to 
assemble multifield images. ImageJ (Java 1.8), Imaris 9.0.2 (Bitplane AG, Zurich Switzerland), 
Adobe Photoshop CS6, and Inkscape (0.92.3) manipulation was limited to uniform contrast 
adjustment, cropping, rotating, stitching, assembling Z-stacks, and generating 3-dimensional 
projections and videos. 
 
Quantitative Analyses Employed Manual and Automated Features 
Imaris modules were Crop 3D, Image Processing, Thresholding, Background Subtraction, 
Surface, Manual Contour, Click Drawing Mode, and Detailed Statistics. ImageJ features were 
regions of interest, Polygon selection, Straight line tool, Measurements, Scale bar, Z-Project, Split 
channels, Merge channels, and Duplicate.  
 
Myenteric plexus 
Neurons (HuC/D+PHOX2B+) and glia (S100B+) were manually counted in ganglia using 
39 randomly selected colon regions (4 right, 5 fields/subject; 3 left, 5 fields/subject; 1 left, 4 fields). 
Two-dimensional ganglion areas were manually outlined in flattened Z-stacks (4 right, 4 left colon). 
Using similar manual outlining, we determined percent colon containing myenteric plexus (defined 
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as ganglia plus thick nerve fiber bundles connecting ganglia), and percent plexus occupied by 
ganglia (defined as regions with >2 myenteric neurons separated by < 1 cell diameter). For 3- 
dimensional analyses, individual ganglion volumes were determined by manually outlining at 5- to 
7-µm increments within 20x Z-stacks using Click Drawing mode (Surface Contour module; Imaris). 
Cell density within ganglia was determined by manually counting within defined volumes. 
 
Neuron subtypes 
Myenteric neurons (HuC/D+) expressing neuronal nitric oxide synthase (nNOS), choline 
acetyltransferase (ChAT), or vesicular acetylcholine transporter (VAChT) identified by triple-label 
immunohistochemistry were manually counted within Z-stacks (5 random fields/subject, 4 right, 4 
left, 40 total regions). Maximum neuron diameter was determined manually using ImageJ (6 
nNOS+/image, 6 ChAT+/image, five 20x images/subject; 4 right, 4 left; forty 20x images total, 240 
nNOS neurons, and 240 ChAT neurons). 
 
Submucosal plexus 
Ganglia location was defined in Z-stacks using ImageJ.  
 
Statistics 
We used Prism 7 (GraphPad Software, San Diego, CA), D’Agostino & Pearson, and 
Shapiro-Wilk normality tests with unpaired t tests to compare means. Volumes of manually 
contoured ganglia used Detailed Statistical Analysis (Imaris). Data are presented as mean ± SEM. 






Our goal was to establish highly reproducible, inexpensive, simple techniques to visualize 
human ENS in 3 dimensions to advance understanding of bowel motility disorders. We tried many 
published approaches to visualize human ENS (10–13,16,17,32–35), but human colon was 
incompletely penetrated by antibody, not transparent after clearing, or methods provided only 
limited views of ENS anatomy after meticulous challenging microdissection. Optimal Clearing, 
Staining, and Imaging To image ENS in full-thickness colon without perturbing cellular associations, 
we modified published methods (32,34) to enhance staining and translucency. Our approach 
worked routinely with 1 x 1 cm2 colon and can work with larger regions. We reasoned antibodies 
and light would penetrate better if colon was thin. We therefore pinned and repeatedly stretched 
colon before fixation to average thickness 800– 1000 µm (Figure 6.1A). We kept colon as flat and 
uniform as possible and avoided drying. We tried staining tissue that had not been stretched before 
fixation, but reagent penetration was poor, and folded tissue made image interpretation difficult. 
Methanol, Dent’s bleach, prolonged 370C incubation and shaking enhanced staining, but took 23 
days (Supplementary Figure 6.2). Murray’s Clear made tissue translucent, but fluorescence in 
Murray’s Clear declined over time so we imaged within 48 hours of immersion. Tissue area 
underwent shrinkage to 66.9% ± 6.6% of original area measured after fixation (Supplementary 
Figure 6.3), partially reversing stretching 
 
Imaging and Antibody Testing 
Colon was easily imaged to a depth of 1000 µm, allowing full-thickness reconstructions of 
stretched preparations. We identified antibodies binding nerve cell bodies (HuC/D), neuronal and 
some glial nuclei (PHOX2B), nerve fibers (TuJ1), nerve cell bodies and fibers (PGP9.5), enteric 
glia (S100β, SOX10), interstitial cells of Cajal (cKIT), muscularis macrophages (Iba1), and enteric 
neuron subsets (CHAT, VAChT, nNOS, neurofilament 200, neurofilament M, peripherin, calretinin, 
and somatostatin) (Figure 6.1B–Q). We generated 3-dimensional images of many cell types 
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thought to influence human colon motility and provide 280 adult colon Z-stacks (available at 
Blackfynn DOI:10.26275/pzek91wx). Our method also worked for human jejunum and pancreas 
(Supplementary Figure 6.4, Supplementary Videos 1 and 2). Quantitative analyses focused on 
adult human colon. 
 
Figure 6.1: Imaging cells controlling human colon motility 
(A) Strategy to image without sectioning. (B–G, J–Q) Human colon myenteric plexus visualized 
with 14 antibodies. (H, I) Longitudinal muscle interstitial cells of Cajal and muscularis macrophages 





Human Colon Enteric Nervous System in 3 Dimensions 
To examine normal human colon ENS structure, we analyzed specimens resected for varied clinical 
indications; all lacked identified motility disorders (Supplementary Table 4.3) and adult colon 
lacked obvious pathology. Three- dimensional imaging of HuC/D, PHOX2B, and S100β stained 
colon showed enteric neurons clustered into submucosal and myenteric ganglia connected by thick 
nerve fiber bundles (Supplementary Video 3). Myenteric ganglia appeared larger on average than 
submucosal ganglia. A few individual neuron cell bodies were within thick circular muscle of all 
colons (Supplementary Video 3). A rich network of fine nerve fibers and closely associated glia 
(S100β) was present within circular and longitudinal muscle, with neurites largely parallel to smooth 
muscle (Supplementary Video 3). Glia were also closely associated with neuronal soma in ganglia 
(Supplementary Video 4, Supplementary Figure 6.5) and nerve fibers were dense near bowel 
mucosa (Supplementary Video 3). 
 
Human Colon Myenteric Plexus 
To establish normal indices, full-thickness colon stained for HuC/D, PHOX2B, and S100β was 
imaged parallel to bowel surface (Figure 6.2A). Confocal Z-stacks were stitched to evaluate large 
regions (Figure 6.2A is 4 x 5 mm2 ). For quantitative analyses, we defined “myenteric plexus” as 
nerve fiber bundles (containing S100β+ glia) and embedded nerve soma (HuC/D+PHOX2B+). We 
defined “myenteric plexus ganglia” as regions within fiber bundles containing >2 adjacent neuron 
cell bodies. Using flattened Z-stacks, we determined percent colon containing myenteric plexus or 
ganglia (Figure 6.2B). Although myenteric plexus area was similar in left and right colon (left 26.5% 
± 2.5%, right 22.5% ± 4%; P = .4514), more myenteric plexus (left 43% ± 3.2%, right 26% ± 3.7%; 
P = .0113), and more image area (left 11.6%% ± 1.7%, right 5.3%% ± 0.1%; P = .0116) was 
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occupied by ganglia in left colon. Two-fold differences in density between left and right colon 
suggest region-specific normal ranges. 
 
Figure 6.2: Human colon myenteric plexus 2-dimensional analyses 
(A) Flattened Z-stack through myenteric plexus (10x objective, stitched fields, 4 x 5 mm2 ). Small 
clustered ganglia have HuC/D+ (green) and PHOX2B+ (blue) neurons. Nerve fibers are visualized 
via glial S100β (red). Myenteric plexus and ganglia within plexus were outlined manually (thin 
yellow lines). (B) Quantitative data from 4 x 5 mm2 images like (A). (C, D) Flattened Z-stack from 
colon myenteric ganglia (left [C] or right [D]) stained for HuC/D (green), S100β (red), and PHOX2B 
(blue) imaged with 20x objective. Table to right of each image shows quantitative data from that 
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specific Z-stack. (E) Quantitative data from 4 right colon, 5 fields/subject; 3 left colon, 5 fields/ 
subject; 1 left colon, 4 fields; total neurons counted: 1953 right colon, 2603 left colon; Total glia 
counted: 8021 right colon, 6423 left colon. Single ganglion areas are from 24 right and 19 left colon 
ganglia. Cells/mm2 within these ganglia are based on 5261 neurons and 16,915 glia. (F, G, H) 
Colon stained with HuC/D (green), S100β (red), and PHOX2B (blue) antibodies. PHOX2B+ nuclei 
include all myenteric neurons and glia within myenteric ganglia (G). Glia in longitudinal (F) and 
circular muscle (H) were not PHOX2B immunoreactive. (A) Scale bar: 1000 µm. (C, D) Scale bar: 
350 µm. (F–H) Scale bar: 50 µm. 
 
We next determined colon myenteric plexus neuronal and glial density by counting 
HuC/D+, PHOX2B+, and S100β+ cells (Figure 6.2C–E). We discovered all neurons and glia within 
myenteric ganglia or thick nerve fiber bundles had nuclear PHOX2B immunoreactivity (Figure 
6.2G). In contrast, glia in thin nerve fibers throughout muscle were not PHOX2B-immunoreactive 
(Figure 6.2F and H). Using 20X Z-stacks, we counted all stained cells in each image. Data are first 
presented based on 2-dimensional areas, ignoring Z-depth. Quantitative data adjacent to each 
image were from that specific Z-stack (Figure 6.2C-D). Areas containing neurons were considered 
“ganglia” and outlined (see thin yellow lines, Figure 6.2A). Mean density data are in Figure 6.2E. 
Although neuron density within myenteric ganglia was similar in left and right colon, neurons/mm2 
bowel was greater on left because ganglia occupy a larger percentage of bowel wall (left = 135 ± 
22, right 56 ± 8; P = .0179). In contrast, glial density was not statistically different in right vs left 
colon (glia/mm2 : left = 323 ± 68, right = 226 ± 28; P = .2329) or within myenteric ganglia (left = 
2875 ± 513, right = 4242 ± 536; P = .1151). Interestingly, within ganglia, ratio of glia to neurons was 
lower in left than right colon (left = 2.5 ± 0.2 glia/neuron, right = 4.2 ± 0.2; P = .0013). To define cell 
density within myenteric ganglia in 3 dimensions, we manually outlined and counted cells in Zstacks 
(Figure 6.3A-B). Quantitative data for 2 individual images are provided (Figure 6.3A-B). Pooled 
data indicate normal ranges for adult humans without known bowel motility disorders (Figure 6.3C). 
Estimates for large areas were generated by multiplying cell numbers within ganglia 
(counted at high magnification in 3-dimensional Z-stacks) by percent colon containing ganglia 
(measured at low magnification, Figure 6.2A). Using 5 regions/individual, cell density estimates 
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clustered within tight ranges (Figure 6.3N-O). Variation was greater between subjects with more 
variation in left vs right colon.  
 
Figure 6.3: Human colon myenteric plexus 2- and 3-dimensional analyses 
(A, B) Three-dimensional ganglia volumes (yellow regions) (Supplementary Videos 5 and 6 are 
from these regions). To right of each image are quantitative data from that specific region. (C) Cell 
density based on five 20x fields/subject, 8 subjects (4 left, 4 right colon)), 24 right and 19 left colon 
ganglia volumes, 5261 neurons and 16,915 glial cells. (D–M) Manual neuron and glia counts were 
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obtained after HuC/D (blue), S100β (green), and PHOX2B (red) staining. (D, I) Flattened Z-stacks. 
(E–H, J–M) Single slices and channels from Z-stack. (N, O) To estimate cell density over large 
regions we multiplied density within small regions (like Figure 6.2C) by percentage of bowel with 
myenteric plexus (using images like Figure 6.2A). We found little variability in cell density within 
ganglia, indicated by tight data clusters in individuals. Inter-individual differences primarily reflect 
percentage of bowel occupied by ganglia in each individual. (A, B, D, I) Scale bars: 100 µm. (E, F, 
G, H, J, K, L, M) Use (E) scale bar: 25 µm. 
 
We next asked how biopsy size impacts neuron density estimates, recognizing ENS is not 
uniformly distributed. To do this we divided a single 4 x 5 mm2 region into 20 x 1 mm2 zones and 
analyzed ganglion density in each zone (Figure 6.4A-B). If 1 mm2 is evaluated, widely divergent 
estimates of ganglion density (0–17%) occur, depending on zone evaluated. Using 4 mm2 areas, 
ganglion density estimates were more tightly clustered, but still ranged 3.5%– 11.4%. In contrast, 
narrow ranges were generated analyzing 9 mm2 regions. Thus, limited sampling causes diverse 
enteric neuron density estimates, with greater precision as area evaluated increases. 
 
 
Figure 6.4: Size of region evaluated affects estimated myenteric plexus neuron density 
(A) Flattened Z-stack (Figure 6.2A) was divided into 20 squares (1 mm2 each). We determined 
percentage of each square occupied by ganglia (regions with nerve cell bodies). (B) Estimates of 
percent colon occupied by ganglia using 1 x 1 mm2 , 2 x 2 mm2 , or 3 x 3 mm2 regions. Some 1 x 
1 mm2 regions have no myenteric plexus; others have up to 17% occupied by ganglia. As size of 
region evaluated increases, estimates of percent area occupied by ganglia become more uniform. 




Neuron Subtype Ratios 
Because most myenteric neurons express either nNOS or ChAT and VAChT (1,2,36–39), 
we defined ratios of these markers in human colon myenteric plexus using ChAT/nNOS/HuC/D 
(Figure 6.5A–H) or ChAT/VAChT/HuC/D staining (Figure 6.5K–Q). Using Z-stacks to 
unambiguously distinguish cytoplasmic staining from overlying neurites, we determined percent 
neurons (HuC/D+) expressing nNOS, ChAT, both or neither (40 samples, 3359 total neurons 
evaluated, Supplementary Table 6.4). In parallel, we compared ChAT to VAChT staining because 
murine data suggested ChAT staining is often weak. VAChT was considered “positive” in 1.62-fold 
more neurons than ChAT, but many VAChT+ cells had faint ChAT staining or high background 
(Figure 6.5O–Q, N = 1902 cells). We hypothesize ChAT alone (at least with this antibody) led to 
systematic cholinergic neuron undercounting. Supplementary Table 6.4 explains how we adjusted 
ChAT+ counts based on VAChT/ChAT data to establish “cholinergic” neuron counts (Figure 6.5I-
J). We scored approximately 50% of myenteric neurons as nNOS+/noncholinergic (Figure 6.5I-J), 
approximately 28% as cholinergic/nNOS negative, approximately 5% nNOS+/cholinergic, and 
approximately 16% as nNOS-/noncholinergic. Figure 6.5I shows inter-individual variability. 
Supplementary Figure 6.6 shows ChAT+ neuron diameters were 32% larger than nNOS+ 




Figure 6.5: Cholinergic/ nitrergic neuron ratios 
(A) Flattened Z-stack, human colon myenteric ganglion stained for HuC/D (red), nNOS (green), 
and ChAT (blue). (B–D) Channels for (A). (E–H) Sample neurons from (A): (E) ChAT+/ nNOS+, 
(F) ChAT+/ nNOS–, (G) ChAT+/ nNOS+, (H) neither ChAT nor nNOS positive. (I) Proportion of 
neuron classes (8 individuals). (J) Average neuron percentages in each class. (I, J) We initially 
evaluated 3360 HuC/D+ cells with ChAT and nNOS antibodies. Subsequent analysis of 
VAChT/ChAT/ HuC/D staining showed 1.62-fold more neurons would be identified as cholinergic 
using combined VAChT/ChAT staining compared to ChAT alone (N = 1902 HuC/D+ cells). 
“Cholinergic numbers” = “ChAT+ numbers” x 1.62. (K) Flattened Z-stack, human colon myenteric 
ganglion stained for ChAT (green), VAChT (red), and HuC/D (blue). (L–N) Channels for (K). (O–
Q) High magnification single confocal slice of neuron from box in (K). We scored this neuron as 
VAChT+. ChAT immunoreactivity alone was not well localized and ChAT background too high to 
score this cell as ChAT+ without VAChT staining. (A) Scale bar: 100 µm. (B–H, O–Q) Scale bars: 
25 µm. (K–N) Scale bars: 200 µm. Cell numbers evaluated are in Supplementary Table 6.4. 
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Submucosal Ganglion Location 
Additional parameters could be defined via 3-dimensional imaging. For example, human 
colon submucosal plexus was reported to be in 3 distinct layers (40), but our data suggest ganglia 
are scattered throughout submucosa, with considerable variability in patterns between evaluated 
specimens (Supplementary Figure 6.7). A subset may have ganglia in definable layers.  
 
Hirschsprung Disease 
To highlight clinical utility, we stained colon from children with Hirschsprung disease, a 
problem where enteric neurons are absent from distal bowel. Resected bowel from pull-through 
surgery should contain the entire distal aganglionic region, a hypoganglionic transition zone, and 
ideally normal ENS at proximal margins. This anatomy is difficult to appreciate in paraffin sections 
(Figure 6.6A). In contrast, our 3-dimensional method showed proximal resection margin had a rich 
ENS network (Figure 6.6C–H). Transition zone was relatively hypoganglionic, with unusual 
features like rows of neurons along nerve fibers (Figure 6.6B), myenteric ganglia in more than 1 
layer (Figure 6.7, slices 23, 29, 42, Supplementary Video 7), thick nerve fiber bundles without 
neurons (slice 50), and areas without ganglia (slice 144). As expected, distal aganglionic zone was 







Figure 6.6: Whole mount staining in Hirschsprung disease 
(A) Full-thickness colon approximately 4.5 mm from distal resection margin (H&E stained). (B– H) 
Two-month-old Hirschsprung colon stained for nNOS (green) and HuC/D (red). (B) Magnified 
region from transition zone with enteric neurons along nerve fibers. (C–H) Most proximal resection 
margin for Hirschsprung colon. (D–H) Z-stacks slices: (D) 49–97, (E) 95–96, (F) 118– 145, (G) 
165–176, (H) 208– 209. Scale bars: 500 µm. Supplementary Video 7 provides additional images 




Figure 6.7: Transition zone and distal aganglionic region of Hirschsprung pull through 
resections 
Full-thickness Z-stacks stained with HuC/D (red) and nNOS (green) antibodies. Identified single 
slices from Z-stacks in transition zone (left panel) and aganglionic region (right panel). Higher 





Human bowel was estimated to have approximately 500 million enteric neurons controlling 
most aspects of bowel function (2,3). Our data suggest colon alone has approximately 37 million 
enteric neurons (approximately 100 neurons/ mm2 x 1.4 m colon length x 0.15 m circumference 
(41) x 1,000,000 mm2 /m2 x 2.6-fold (stretching) x 0.67-fold (shrinkage with processing)). When 
ENS is missing or defective, profound bowel dysfunction may occur causing life-threatening 
problems like Hirschsprung disease (22) and neuropathic chronic intestinal pseudo-obstruction 
(26). ENS defects may also underlie achalasia (24) and gastroparesis (42), where selective nNOS 
neuron loss was reported. Furthermore, ENS can be damaged by toxins (eg, chemotherapy) (43–
45), systemic disease (diabetes, Parkinson disease) (46–49), inflammation due to infection (50,51), 
inflammatory bowel disease (52) or necrotizing enterocolitis (53), causing long-term dysmotility and 
visceral hypersensitivity (54). Unfortunately, until now it has been difficult to visualize human ENS 
in 3 dimensions. This technical problem limits our understanding of disease mechanisms because 
full-thickness tissue sections often appear “normal” unless changes are dramatic (eg, complete 
enteric neuron loss).  
Not surprisingly, most of what we know about ENS comes from animal models, in which 
bowel is thin and muscle is easily dissected from submucosa (5,6,55). In contrast, human bowel is 
thick (approximately 1000 µm in maximally stretched colon) and muscle layers are difficult to 
separate from submucosa or each other. For this reason, most human ENS analyses use thin 
cross-sections (eg, 5 µm), yielding limited data. We hypothesize this problem led to wide variation 
for “ganglia per 10 mm” (13.5-fold range in rectum) and neurons per ganglia (9-fold range in colon) 
previously reported (7). Swaminathan and Kapur (9) further identified an approximately 150-fold 
range for “mean number of ganglion cells per cm” in normal colon (9) and determined reproducible 
enteric neuron counts require >5 full-circumference sections (estimated at 1.25 mm2 = 5 sections x 
approximately 0.005-mm thick section x approximately 50 mm circumference in 8-week-old). Our 
data suggest 1 mm2 still yields quite variable neuron density estimates in adult colon and that >9 
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mm2 provides more reliable data. Additional problems arise when evaluating human ENS anatomy 
using thin sections. ENS organization is difficult to appreciate, so dramatic changes can be missed. 
Nerve fiber bundle orientation is impossible to discern in sections and small nerve fibers are difficult 
to see, so changes in neurite density or organization are not appreciated. Decades of mouse work 
suggest 3-dimensional imaging provides much greater insight into disease mechanisms and is 
essential to see many ENS defects (eg, Supplementary Figure 6.1). Thus, robust 3-dimensional 
methods to visualize human ENS may provide new insight into bowel motility disorders. A few prior 
studies demonstrated human ENS in 3 dimensions. Myenteric plexus has been visualized by 
meticulous “fiber by fiber” removal of longitudinal muscle to expose ENS (13,39,56). We tried this, 
but found it difficult to uncover even small regions, and only cells exposed by dissection could be 
imaged. Three-dimensional human ENS images were also generated by optical clearing and 
immunohistochemistry using 300-µm sections (10–12), but we had difficulty replicating this 
approach, even with significant effort, and few quantitative data were provided from those images. 
To overcome these problems, we spent years optimizing clearing and antibody staining for 
human colon. Our goal was to establish methods that worked well, were easy, and did not require 
special skill (like microdissection). In addition, we wanted to visualize cells that control bowel 
motility in 3 dimensions without sectioning that disrupts cellular connections. For this approach to 
be useful, we need a large library of publicly available images from people without known bowel 
motility disorders and we need rigorous quantitative data for “normal” ENS anatomy. Our strategy 
accomplished many of these goals. 
Our approach makes colon completely translucent. Large bowel pieces were stained and 
imaged without sectioning. Confocal imaging permitted visualization of stained cells from serosa to 
mucosa. Identified antibodies stain neurons, glia, interstitial cells of Cajal, muscularis 
macrophages, neuron subtypes, and nerve fibers. As expected, some antibodies did not work with 
our method. We provide 280 three-dimensional Z-stacks of stained adult human colon, highlighting 
how much we miss with traditional tissue sectioning. We performed substantial quantitative 
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analyses to define “normal” adult human colon ENS anatomy. Finally, we show images of 
Hirschsprung disease colon. This is clinically relevant because “transition zone pull through” is 
thought to commonly cause Hirschsprung disease postoperative morbidity (22), although 
prolonged processing needed with our approach means it cannot be used for intraoperative 
decision making. Methods are also applicable to human jejunum and pancreas. 
Several observations are worth highlighting. We estimate enteric neurons are < 0.01% of 
total human colon cells. Myenteric and submucosal plexus resembles ENS in other species, but 
differences in ENS anatomy between species (57,58) means we need human ENS normal values. 
Irregular ganglia spacing probably explains dramatic variability in reported enteric neuron densities 
(7,9) because some thin sections include large ganglia and others lack neurons. Within myenteric 
ganglia, neuron density was fairly uniform (SEM < 25% of mean neurons/mm3 ) and adult human 
colon had on average 137 ± 20 neurons/myenteric ganglion (Figure 6.3C: 38,706 neurons/mm3 x 
0.0035278 mm3 / ganglion = 137 neurons/ganglion). Uniformity of neuron density within myenteric 
ganglia contrasts with the 1.65-fold difference in ganglion density within myenteric plexus of right 
vs left colon (P = .0113). These differences highlight the need to establish region-specific normal 
ranges for most parameters, although variable ganglion density might simply reflect differences in 
proximal vs distal colon distensibility. 
Enteric glia are much more abundant than neurons, even within myenteric ganglia. Our 
estimates of glial index (glia to neuron ratio) within ganglia (2.5 left; 4.2 right colon) are lower than 
prior estimates (5.9–7) (56), but S100β does not label all glia (59,60). Furthermore, 3 left colons 
were from people with diverticulitis where S100β-labeled enteric glia loss was reported (61). One 
novel observation was that PHOX2B-immunoreactive nuclei included S100β+ glia and HuC/D+ 
neurons, but PHOX2B was not detected in enteric glia outside ganglia. Murine data also showed 
PHOX2B in adult enteric neurons and glia, although mouse images suggest PHOX2B in glia within 
and outside ganglia (62). These data suggest PHOX2B, a gene mutated in some people with 
Hirschsprung disease (22), might influence human enteric glial diversity. 
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We began to define neuron subtype ratios in human colon myenteric plexus because 
human intestinal motility disorders may result from quantitative or qualitative ENS defects 
(5,8,22,26,63,64) and nitric oxide–producing enteric neurons are particularly susceptible to injury 
(65). Because most myenteric neurons produce either nitric oxide or acetylcholine (2), we focused 
on these subgroups. We found little between-subject variability in noncholinergic nNOS+ neuron 
prevalence (approximately 50% of myenteric neurons) similar to prior reports indicating 43%–54% 
of human myenteric neurons were ChAT–/nNOS+ (Supplementary Table 6.5) (36–39,66–69). 
Also consistent with past studies reporting 3%–10% of human colon myenteric neurons produce 
nNOS and ChAT, we scored 4%–6% of myenteric neurons as nNOS+/cholinergic. We differed 
substantially from prior studies reporting 36%–56% of human colon myenteric neurons were 
ChAT+/nNOS– and 2%–7% ChAT–/nNOS– (37–39). Despite using ChAT and VAChT, we scored 
fewer myenteric neurons as cholinergic/ nNOS– (approximately 28%) and more as noncholinergic/ 
nNOS– (14%–19%). We suspect the differences are technical (eg, less robust staining with this 
ChAT antibody using our method). We note, however, that neuron subtype ratios vary between 
mouse strains and are influenced by diet (70–75) and human subtype ratios are impacted by age 
(66), diabetes (67), and inflammation (69), so biological variability between subjects is plausible. 
Clearly, more remains to be done to define human enteric neuron subtype ratios. 
Finally, we include many images from distal Hirschsprung disease colon. Although 
additional studies are needed to define transition zone and “normal” infant ENS, 3-dimensional 
imaging should facilitate development of intraoperative strategies to avoid transition zone pull 
through. For example, once transition zone characteristics are well-defined, methods like confocal 
laser endomicroscopy (76) could be used in the operating room to visualize ENS anatomy. Biopsies 
could also be evaluated 3-dimensionally in children treated initially by ostomy because they 
undergo pull-through surgery months later.  
Our study has limitations. Subjects were 28–80 years old, with the exception of 2 infants 
with Hirschsprung disease. Colons were resected for clinical indications. Although we tried to 
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evaluate only pathology-free regions, diverticulitis-associated inflammation could affect ENS. Exact 
colon regions are not known (ie, “left” might mean splenic flexure or sigmoid). Specimens were 
randomly oriented so we cannot distinguish proximal from distal and do not know location along 
the circumferential colon axis. 
Finally, technical obstacles should be noted. Staining takes several weeks, so our method 
cannot be used intraoperatively. Fluorophores fade after immersion in Murray’s Clear, so efficient 
confocal imaging is required. Threedimensional imaging takes hours without light sheet 
microscopy, limiting size of samples that can be imaged. Tissues may dry during prolonged imaging 
and Murray’s Clear dissolves some plastics. Finally, not all tested antibodies worked well. 
Nonetheless, our work lays the foundation for future research and suggests new directions for 
human ENS analyses. We can now visualize human ENS in 3 dimensions in large colon areas with 
minimal dissection and no sectioning. Our images make it easy to understand why previously 
reported enteric neuron density estimates vary up to 150-fold. We hope this method will be widely 
adopted for defining ENS anatomy in adults and children with life-threatening bowel motility 
disorders where current diagnostic strategies seem most inadequate. We invite others to help us 
perform quantitative analysis using our images. 
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6.9 Supplementary Figures and Tables 
 
 
Supplementary Figure 6.1: ENS is difficult to appreciate in bowel sections 
(A) Full-thickness human colon. H&E-stained (5-mm paraffin) section, the most common method 
to evaluate bowel pathology. (B, F, J) Rich ENS networks in P0 wild-type mouse stomach (B), 
small bowel (F), and colon (J) are easily seen after TuJ1 (blue)/PHOX2B (green) whole-mount 
immunohistochemistry. (E, I, M) P0 GFRα1–/– mice have few enteric neurons in stomach (E) and 
only extrinsic nerve fibers in small bowel (I) and colon (M) seen by whole-mount TuJ1 
(blue)/PHOX2B (green) immunohistochemistry. (C, D, G, H, K, L) ENS is difficult to appreciate in 
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H&E-stained 5-mm sections from P0 wild-type stomach (C Q14 ), small bowel (G), or colon (K). 
ENS loss is difficult to appreciate in P0 GFRα1–/– stomach (D), small bowel (H), or colon (L) 5-mm 
sections even though magnification is approximately 5–7x higher in sections than whole mounts. 








Supplementary Figure 6.2: Tissue processing 
A single fixed piece of full-thickness human colon on selected days: tissue is opaque on day 1, but 





Supplementary Figure 6.3: Change in tissue area during processing 
(A) Before images show fixed stretched colon. After images show tissue ready for imaging. (B) 
Quantitative analysis shows tissue area after processing is 0.67-fold smaller area compared to 
fixed tissue before processing. The reduction in tissue area during processing partially 
compensates for the increase in tissue area as we stretch colon before fixation. Because colon 




Supplementary Figure 6.4: Human jejunum and human pancreas tissue clearing, 
immunohistochemistry, and 3-dimensional imaging  
Using our method optimized for colon, we stained 1 piece of human jejunum (top panels) and 1 






Supplementary Figure 6.5 
Large (5.5 x 2.5 mm2 ) confocal images. (A, B) Flattened Z-stacks of human colon myenteric (A) 
and submucosal plexus (B) stained with HuC/D (green), PHOX2B (blue), and S100β (red) 





Supplementary Figure 6.6: Largest neuron soma diameter 
(A, J) Flattened Z-stack, single human myenteric ganglion from left (A) or right colon (J) stained 
for HuC/D (red), nNOS (green), and ChAT (blue). (B–I, K–R) Higher magnification images. (B–E) 
nNOS+/ChAT– neurons from dotted line boxed region in (A). (F–I) ChAT+/nNOS– neuron from 
solid line boxed region in (A). (K–N) nNOS+/ChAT– neurons from dotted line boxed region in (J). 
(O–R) ChAT+/nNOS– neuron from solid line boxed region in (J). (S) Longest neuron diameter (N 




Supplementary Figure 6.7: Quantitative analysis of relative location for ganglia within 
submucosa 
Analysis is based on fullthickness 10X Z-stacks from 6 human colon specimens (A–C right colon; 
D–F left colon) stained with antibodies to HuC/D, PHOX2B, and S100b. Because submucosal 
thickness varied between specimens, we set inner margin of circular smooth muscle (CSM) at 0% 
and crypt base to 100%. Each dot shows the relative location of a single submucosal ganglion. 
Bars show positions of all Z-stack slices where submucosal ganglia were present (defined as >2 
neuron cell bodies). Area analyzed = 3.6 mm2 per sample. 
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Supplementary Table 6.2: Antibodies that did not work well with our tissue clearing 3-











Supplementary Table 6.4: Myenteric neuron subtypes in human colon based on 3359 cells 






Supplemental Table 6.5. Previously published data about human colon myenteric neuron 
subtypes 
Neuron subtype percentages Demographics 
and colon region 
Comment Ref 
ChAT +/nNOS-                                      52% 
nNOS +/ChAT-                                      43% 
Neither nNOS nor ChAT                       4% 
ChAT+/nNOS+                                       6% 
nNOS/VIP                                              19% 
nNOS without VIP                                29% 
-Ascending colon 
-5 male/8 female 
-Cancer surgery 
-Median age 76 
years 
-Age range 55-86 
years 
--Excluded IBS 





includes data for DiI 




ChAT+/nNOS-                                       48% 
nNOS+ /ChAT-                                       43% 
ChAT+/nNOS+                                         4% 





-2 sigmoid colon 
-5 male/5 female 
-Cancer surgery 
-Median age 68 
years 
-Age range 52-83 
years 
Myenteric neurons 





     ChAT+/nNOS- (ascending)              41% 
                               (transverse)             51% 
                               (descending)            48% 
     nNOS+/ChAT- (ascending)              51% 
                               (transverse)             43% 
                               (descending)            44% 
     ChAT+/nNOS+                                  3-4% 
     ChAT-/nNOS-                                   2-4% 
Slow transit constipation 
     ChAT+/nNOS- (ascending)              36% 
                               (transverse)            38 % 
                               (descending)            42% 
     nNOS+/ChAT- (ascending)              54% 
                               (transverse)             52% 
                               (descending)            49% 
     ChAT+/nNOS+                                  3-5% 
     ChAT-/nNOS-                                   4-5% 
-Control  
     Colon cancer 
surgery 
     7 male/5 
female 
     Median age 64 
years  
     Age range 49-
82 years 
-Colon resection 
for slow transit 
constipation (4 
females) 





Analysis of ENS in slow 
transit constipation 
 





Neuron subtype percentages Demographics 
and colon region 
Comment Ref 
ChAT+                                                      71% 
nNOS+                                                     42% 
 
-1.3 HuC/D+ neurons/mm/10 years 
           Starting at about 10 neuron/mm 
           for youngest 
-1.1 ChAT+ neurons/mm/10 years 
          Starting at about 7 neurons/mm  
          for youngest 





-9 male/7 female 
-Cancer surgery 




declined by >50% over 
interval evaluated, but 







Neuron counts not reported 
 
ChAT immunoreactive area is about 50% 
lower in diabetic than in control 
 
nNOS immunoreactive area is about 80% 
lower in diabetic than in control 






-Cancer or polyp 
surgery 
-Mean age 62 to 
65 years 
-Age distribution 
not clear. SEM (?) 
~ 2 for ages 
9% of control and 18% 
of diabetics had 
constipation 
67 
Distal colon, < 1 year old 
      NADPH diaphorase+                       39%                         
Proximal and distal colon, > 70 year old 
     NADPH diaphorase+                        25% 
-3 male/1 female 
(4-12 months) 
-1 male/3 female 
(48-58 years) 





anus praeter  
  
Control: 
     ChAT+                                                 35% 
Ulcerative colitis 
     ChAT+                                                 33% 
-2 male/6 female 
control 
-Control age 43 
to 82 years 
-3 male/7 female 
UC 
Comparing control to 
ulcerative colitis (UC) 
ENS 




Neuron subtype percentages Demographics 
and colon region 
Comment Ref 
-UC age 22 to 68 
years 
Descending colon 
     ChAT+                                                 56% 
     nNOS+                                                43% 
     ChAT+/nNOS+                                    9% 
     ChAT-/nNOS-                                      7% 
Rectum 
     ChAT+                                                 55% 
     nNOS+                                                48% 
     ChAT+/nNOS+                                   10% 






-Median age 63 
years 






DiI = (1,1¢- didodecyl 3,3,3¢,3¢-indocarbocyanine perchlorate), a lipophilic dye for membrane 
tracing. 
IBS = Irritable bowel syndrome 





Supplementary Videos 1-9 can be viewed at https://www.gastrojournal.org/article/S0016-
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